association_info.ancestry	association_info.doi	association_info.gwas_catalog_id	association_info.neg_log_pval	association_info.otg_id	association_info.pubmed_id	association_info.url	gold_standard_info.evidence.class	gold_standard_info.evidence.confidence	gold_standard_info.evidence.curated_by	gold_standard_info.evidence.description	gold_standard_info.evidence.pubmed_id	gold_standard_info.evidence.source	gold_standard_info.gene_id	gold_standard_info.highest_confidence	metadata.comments	metadata.date_added	metadata.reviewed_by	metadata.set_label	metadata.submitted_by	metadata.tags	sentinel_variant.alleles.alternative	sentinel_variant.alleles.reference	sentinel_variant.locus_GRCh37.chromosome	sentinel_variant.locus_GRCh37.position	sentinel_variant.locus_GRCh38.chromosome	sentinel_variant.locus_GRCh38.position	sentinel_variant.rsid	trait_info.ontology	trait_info.reported_trait_name	trait_info.standard_trait_name
EUR		GCST000324	23.699	GCST000324_3	19185284		expert curated	High	Eric Fauman	BCO1 (previously referred to as BCMO1) encodes beta-carotene oxygenase 1 which uses a molecule of oxygen to produce two molecules of retinol from beta-carotene.  Enzyme deficiency results in accumulation of beta-carotene.	11401432		ENSG00000135697	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	16	81264597	16	81230992	rs6564851	HMDB0000561	Carotenoid and tocopherol levels (beta-carotene)	B-Carotene
unknown		GCST000386	323.301	GCST000386	19414484		expert curated	High	Eric Fauman	UGT1A1 encodes an enzyme with bilirubin glucuronidating activity.  Bilirubin is derived from biliverdin.	01898728		ENSG00000242366	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	2	234672639	2	233763993	rs6742078	HMDB0000054	Bilirubin levels	Bilirubin
ASW|EUR		GCST000388	8.046	GCST000388	19419973		expert curated	High	Eric Fauman	G6PD encodes the glucose-6-phosphate dehydrogenase, an enzyme critical to red blood cell metabolism.  G6PD deficiency results in accumulation of bilirubin, a breakdown product of heme.	11445808		ENSG00000160211	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	C	X	153554404	X	154326058	rs766420	HMDB0000054	Bilirubin levels	Bilirubin
EUR		GCST000493	65.046	GCST000493_3	19798445		expert curated	High	Eric Fauman	SGPP1 encodes a sphingosine-1-phosphate phosphatase which dephosphorylates sphingosine-1-phosphate to sphingosine which can then be incorporated into sphingomyelin.	10859351		ENSG00000126821	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	14	64235556	14	63768838	rs7157785	HMDB0012097	Sphingolipid levels (SM 14:0Mol%)	sphingomyelin 14âˆ¶0 molar percentage
EUR		GCST000568	217.046	GCST000568	20081858		expert curated	High	Eric Fauman	G6PC2 encodes a pancreas-specific glucose-6-phosphatase. This enzyme influences the fasting glucose set point for basal insulin secretion.	23274894		ENSG00000152254	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	2	169763148	2	168906638	rs560887	HMDB0000122	Fasting glucose-related traits (FPG)	D-Glucose
EUR		GCST000697	108.699	GCST000697	20541252		expert curated	High	Eric Fauman	GC encodes the vitamin D binding protein which transports multiple forms of vitamin D	00049052		ENSG00000145321	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	4	72608383	4	71742666	rs2282679	HMDB0001438	Vitamin D insufficiency	25-Hydroxyvitamin D2
EUR		GCST000697	19.523	GCST000697	20541252		expert curated	High	Eric Fauman	CYP2R1 encodes the vitamin D 25-hydroxylase which produces the detected metabolite.	12867411		ENSG00000186104	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	11	14914878	11	14893332	rs10741657	HMDB0001438	Vitamin D insufficiency	25-Hydroxyvitamin D2
EUR		GCST000697	26.699	GCST000697	20541252		expert curated	High	Eric Fauman	DHCR7 encodes 7-dehydrocholesterol reductase, which acts on 7-dehydrocholesterol, a precursor of vitamin D.	10807690		ENSG00000172893	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	11	71167449	11	71456403	rs12785878	HMDB0001438	Vitamin D insufficiency	25-Hydroxyvitamin D2
EUR		GCST000703	27.0	GCST000703	20558539		expert curated	High	Eric Fauman	ALPL encodes the liver alkaline phosphatase.  Loss of function of alkaline phosphatase causes hypophosphatasia.	03174660		ENSG00000162551	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	1	21823292	1	21496799	rs1697421	HMDB0001315	Phosphorus levels	Phosphorus
EUR		GCST000703	8.398	GCST000703	20558539		expert curated	High	Eric Fauman	FGF23 encodes a fibroblast growth factor which regulates phosphate levels through multiple mechanisms, including regulation of levels of kidney phosphate transporters	15863037		ENSG00000118972	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	T	12	4606168	12	4497002	rs2970818	HMDB0001315	Phosphorus levels	Phosphorus
EUR		GCST000756	35.699	GCST000756	20700443		expert curated	High	Eric Fauman	MUC1 encodes a mucin protein which forms a mucosal layer in intestines and kidney and may regulate absorption of magnesium	01983814		ENSG00000185499	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	1	155162067	1	155192276	rs4072037	HMDB0000547	Magnesium levels	Magneseium
EUR		GCST000756	14.097	GCST000756	20700443		expert curated	High	Eric Fauman	TRPM6 encodes a cation transporter with demonstrated activity toward magnesium.	14576148		ENSG00000119121	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	9	77499796	9	74884880	rs11144134	HMDB0000547	Magnesium levels	Magnesium
EUR		GCST000925	17.523	GCST000925_3	21203500		expert curated	High	Eric Fauman	FUT8 encodes a fucosyltransferase that catalyzes the transfer of fucose to complex glycopeptides.	00985526		ENSG00000033170	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	14	65758642	14	65291924	rs7159888	EFO_0004999	N-glycan levels (DG1)	N-glycan measurement
EUR		GCST001049	51.222	GCST001049	21502573		expert curated	High	Eric Fauman	F3 encodes coagulation factor 3, also known as tissue factor, which is involved in the initiation of the clotting cascade, which eventually results in the production of fibrin.  The D-dimer metabolite is a degredation product of fibrin clots.	12223078		ENSG00000117525	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	1	95053353	1	94587797	rs12029080	EFO_0004507	D-dimer levels	D dimer measurement
EUR		GCST001049	13.699	GCST001049	21502573		expert curated	High	Eric Fauman	F5 encodes coagulation factor 5, an essential element of the clotting cascade, which eventually results in the production of fibrin.  The D-dimer metabolite is a degredation product of fibrin clots.	25231258		ENSG00000198734	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	1	169477574	1	169508336	rs6687813	EFO_0004507	D-dimer levels	D dimer measurement
EUR		GCST001142	10.0	GCST001142	21729881		expert curated	High	Eric Fauman	CYP4F2 encodes a cytochrome P450 with a special role in the production of Vitamin E	11997390		ENSG00000186115	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	19	15990431	19	15879621	rs2108622	HMDB0001893	Vitamin E levels	Alpha-Tocopherol
EUR		GCST001179	43.0	GCST001179	21829377		expert curated	High	Eric Fauman	ELOVL2 encodes a long chain fatty acid elongase.  The coenzyme A derivative of DPA (22:5n3) is both a product and a substrate for the enzyme. 	12371743		ENSG00000197977	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	6	10982973	6	10982740	rs3734398	HMDB0006528	Phospholipid levels (plasma) (DPA)	Docosapentaenoic acid
EUR		GCST001216	14.155	GCST001216	21878437		expert curated	High	Eric Fauman	RBP4 encodes a retinol-binding protein that transports retinol in the blood. 	02444024		ENSG00000138207	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	10	95348182	10	93588425	rs10882272	HMDB0000305	Retinol levels	Vitamin A
EUR		GCST001216	13.222	GCST001216	21878437		expert curated	High	Eric Fauman	TTR encodes a thyroid hormone-binding protein which transports thryroxine and retinol.	04607556		ENSG00000118271	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	18	29187279	18	31607316	rs1667255	HMDB0000305	Retinol levels	Vitamin A
EUR		GCST001217	14.301	GCST001217_23	21886157		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	AHR encodes the aromatic hydrocarbon receptor, a transcription factor which activates CYP1A1 and CYP1A2.  These enzymes metabolize caffeine.|AHR encodes the aromatic hydrocarbon receptor, a transcription factor which activates CYP1A1 and CYP1A2.  These enzymes metabolize caffeine.	10605936|08095225		ENSG00000106546	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	7	17309279	7	17269655	rs12670403	HMDB0001847|HMDB0003072	Metabolic traits (caffeine/quinate + 3 other traits)	Caffeine / Quinic acid
EUR		GCST001217	12.155	GCST001217_30	21886157		expert curated	High	Eric Fauman	NT5E encodes the ecto-5'-nucleotidase which can generate inosine	06271180		ENSG00000135318	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	6	86117129	6	85407411	rs494562	HMDB0000195	Metabolic traits (inosine + 1 other trait)	Inosine
EUR		GCST001264	41.0	GCST001264_2	21998597		expert curated	High	Eric Fauman	SHBG encodes the sex-hormone binding globulin which binds which binds to and transports testosterone.	07626508		ENSG00000129214	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	17	7521915	17	7618597	rs12150660	HMDB0000234	Testosterone levels (Testosterone)	Testosterone
EUR		GCST001391	21.523	GCST001391_3	22286219		expert curated	High	Eric Fauman	SLC1A4 encodes a neutral amino acid transporter with demonstrated activity for alanine, serine, cysteine and threonine.  2-aminobutyrate is structurally similar to these amino acids.	07896285		ENSG00000115902	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	2	65220910	2	64993776	rs2160387	HMDB0000161|HMDB0000883	Metabolite levels (Ala, Val)	L-Alanine / L-Valine
EUR		GCST001391	16.699	GCST001391_10	22286219		expert curated	High	Eric Fauman	TAT encodes tyrosine aminotransferase which converts tyrosine to 4-hydroxyphenylpyruvate.  Enzyme deficiency in this enzyme causes tyrosine build up.	01973834		ENSG00000198650	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	A	16	71634811	16	71600908	rs4788815	HMDB0000159|HMDB0000158	Metabolite levels (Phe, Tyr)	L-Phenylalanine / L-Tyrosine
EUR		GCST001392	11.097	GCST001392_5	22286219		expert curated	High	Eric Fauman	CPT1A encodes a carnitine O-palmitoyltransferase which acts the CoA version of the free fatty acid metabolite detected here	01865762		ENSG00000110090	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	11	68562328	11	68794860	rs2229738	HMDB0000673	Lipid metabolism phenotypes (LA/PUFA)	Linoleic acid
EUR		GCST001414	9.097	GCST001414_2	22359512		expert curated	High	Eric Fauman	AGPAT1 encodes 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha, an enzyme which produces phosphatidic acid.	17707131		ENSG00000204310	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	6	32136547	6	32168770	rs1061808	HMDB0008031|HMDB0008003	Phospholipid levels (plasma) (proportions (PC 32âˆ¶0/PC 34âˆ¶1))	similar to Phosphatidylcholine(18:0/14:0)|Phosphatidylcholine(16:1/18:0)
EUR		GCST001413	18.699	GCST001413	22359512		expert curated	High	Eric Fauman	ATP10D encodes a phospholipid flippase.  Closely related gene family members have demonstrated activity versus phosphatidylcholine.	25947375		ENSG00000145246	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	4	47551863	4	47549846	rs13106975	EFO_0004622 	Sphingolipid levels (levels)	sphingolipid measurement
SAS		GCST001421	8.523	GCST001421	22383894		expert curated	High	Eric Fauman	AS3MT encodes arsenite methyltransferase which acts on methylarsonite to produce dimethylarsinate (also known as cacodylate)	20621156		ENSG00000214435	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	10	104623578	10	102863821	rs9527	HMDB0011625	Arsenic metabolism  (DMA%)	Dimethylarsinate
EAS		GCST001608	62.523	GCST001608	22797727		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	SLC22A12 encodes the URAT1 transporter, a kidney urate reuptake transporter.  The nearby gene SLC22A11 encodes the hOAT4 transporter which primarily transports steroid molecules and has only very weak affinity for urea.|SLC22A12 encodes the URAT1 transporter, a kidney urate reuptake transporter.  The nearby gene SLC22A11 encodes the hOAT4 transporter which primarily transports steroid molecules and has only very weak affinity for urea.	12024214|27105641		ENSG00000197891	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	T	11	64464085	11	64696613	rs504915	HMDB0000294	Renal function-related traits (urea)	Urea
EAS		GCST001608	17.155	GCST001608	22797727		expert curated	High	Eric Fauman	SLC14A2 encodes a urea transporter expressed in kidney.	11502588		ENSG00000132874	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	18	43187130	18	45607165	rs7227483	HMDB0000294	Renal function-related traits (BUN)	Urea
EUR			17.068		22885924		expert curated	High	Eric Fauman	SLC2A2 encodes a glucose transporter (GLUT2)	02479026		ENSG00000163581	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	3	170713290	3	170995501	rs1280	HMDB0000122	MAGIC Fasting Glucose GWAS/Metabochip 2012	D-Glucose
EUR			7.757		22885924		expert curated	High	Eric Fauman	IGF2BP2 encodes a protein which binds insulin-like growth factor 2 mRNA.  	09891060		ENSG00000073792	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	3	185513392	3	185795604	rs7651090	HMDB0000122	MAGIC Fasting Glucose GWAS/Metabochip 2012	D-Glucose
EUR			14.991		22885924		expert curated	High	Eric Fauman	PCSK1 encodes a protease which is involved in maturation of insulin	01843283		ENSG00000175426	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	5	95539448	5	96203744	rs4869272	HMDB0000122	MAGIC Fasting Glucose GWAS/Metabochip 2012	D-Glucose
EUR			98.541		22885924		expert curated	High	Eric Fauman	GCK encodes glucokinase which directly phosphorylates glucose and thus contributes to glucose homeostasis	01871135		ENSG00000106633	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	7	44231886	7	44192287	rs6975024	HMDB0000122	MAGIC Fasting Glucose GWAS/Metabochip 2012	D-Glucose
EUR			214.971		22885924		expert curated	High	Eric Fauman	MTNR1B encodes a melatonin receptor.  Melatonin stimulates glucose uptake.	16842543		ENSG00000134640	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	C	11	92708710	11	92975544	rs10830963	HMDB0000122	MAGIC Fasting Glucose GWAS/Metabochip 2012	D-Glucose
EUR			14.876		22885924		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	PDX1 encodes a pancreas-specific transcription factor which induces expression of insulin and SLC2A2 (GLUT2)  which each influence glucose levels|PDX1 encodes a pancreas-specific transcription factor which induces expression of insulin and SLC2A2 (GLUT2)  which each influence glucose levels	07901001|08923459		ENSG00000139515	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	13	28487599	13	27913462	rs11619319	HMDB0000122	MAGIC Fasting Glucose GWAS/Metabochip 2012	D-Glucose
EUR		GCST001791	29.0	GCST001791	23263486		expert curated	High	Eric Fauman	PDZK1 encodes a protein that binds to and regulates the activity of URAT1 (encoded by SLC22A12), which is a urate transporter.	15304510		ENSG00000174827	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	1	145723739	1	145711327	rs1471633	HMDB0000289	Urate levels	Uric acid
EUR		GCST001791	700.0	GCST001791	23263486		expert curated	High	Eric Fauman	SLC2A9 encodes a urate transporter.	18327257		ENSG00000109667	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	4	9944052	4	9942428	rs12498742	HMDB0000289	Urate levels	Uric acid
EUR		GCST001791	134.0	GCST001791	23263486		expert curated	High	Eric Fauman	ABCG2 encodes a urate transporter.	19506252		ENSG00000118777	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	4	89052323	4	88131171	rs2231142	HMDB0000289	Urate levels	Uric acid
EUR		GCST001840	8.523	GCST001840	23362303		expert curated	High	Eric Fauman	LPGAT1 encodes a lysophosphatidylglycerol acyltransferase which transfers long-chain acyl-CoAs to lysophosphatidylglycerol with a demonstrated preference for stearoyl-CoA.	15485873		ENSG00000123684	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	T	1	211918244	1	211744902	rs11119805	HMDB0000827	Stearic acid (18:0) plasma levels	Stearic acid
EUR		GCST001856	31.097	GCST001856_4	23408906		expert curated	High	Eric Fauman	DIO1 encodes an iodothyronine deiodinase which deiodinates of thyroxine (T4) to produce the biologically active hormone T3	01400883		ENSG00000211452	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	1	54375570	1	53909897	rs2235544	HMDB0000248	Thyroid hormone levels (FT4: free thyroxine)	Thyroxine
EUR		GCST001856	10.699	GCST001856_4	23408906		expert curated	High	Eric Fauman	FOXE1 encodes a transcription factor expressed specifically in thyroid gland, the source of the thyroxine (FT4 thyroid hormone)	09214635		ENSG00000178919	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	9	100591463	9	97829181	rs7045138	HMDB0000248	Thyroid hormone levels (FT4: free thyroxine)	Thyroxine
EUR		GCST001856	13.699	GCST001856_4	23408906		expert curated	High	Eric Fauman	LHX3 encodes pituitary-specific transcription factor which is critical for pituitary gland development.  The pituitary gland produces thyroid stimulating hormone which directs the thyroid gland to produce thyroxine (T4).	08638120		ENSG00000107187	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	9	139089679	9	136197833	rs7860634	HMDB0000248	Thyroid hormone levels (FT4: free thyroxine)	Thyroxine
AFR|EAS|EUR|ZZ1		GCST001914	7.523	GCST001914	23518928		expert curated	High	Eric Fauman	TSPYL5 induces CYP19A1 expression, which in turn encodes a key enzyme involved in the biosynthesis of estradiol.	23518928		ENSG00000180543	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	8	98282189	8	97269961	rs1864729	HMDB0000151	Estradiol plasma levels (breast cancer)	Estradiol
EUR		GCST002041	19.523	GCST002041	23720494		expert curated	High	Eric Fauman	SELENBP1 encodes a selenium-binding protein.  The Arabidopsis ortholog (61% identity) has been shown to bind copper.	25274629		ENSG00000143416	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	1	151344741	1	151372265	rs2769264	HMDB0000657	Blood trace element (Cu levels)	Copper
ASW		GCST002043	9.222	GCST002043	23726366		expert curated	High	Eric Fauman	CD36 encodes a platelet glycoprotein which binds HDL	09867808		ENSG00000135218	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	7	80340622	7	80711306	rs2366858	EFO_0004612	HDL cholesterol (AA)	high density lipoprotein cholesterol measurement
EUR			32.18		23823483		expert curated	High	Eric Fauman	DMGDH encodes dimethylglycine dehydrogenase which takes dimethlyglycine as a substrate.  Enzyme deficiency results in excess dimethlyglycine.	10102904		ENSG00000132837	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	5	78330227	5	79034404	rs248386	HMDB0000092	Dimethlyglycine	Dimethlyglycine
EUR			9.854		23823483		expert curated	High	Eric Fauman	AGA encodes the enzyme aspartylglucosaminidase which generates asparagine from N-acetylglucosamines.  Deficiency results in an accumulation of asparagine-linked glycopeptides.	01281977		ENSG00000038002	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	4	178361051	4	177439897	rs4690522	HMDB0000168	Asparagine	L-Asparagine
EUR			9.119		23823483		expert curated	High	Eric Fauman	UMPS encodes uridine monophosphate synthetase, the enzyme which converts orotic acid to uridine.  Enzyme deficiency results in accumulation of orotic acid.	06893554		ENSG00000114491	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	3	124451064	3	124732217	rs9844948	HMDB0000226	Orotic acid	Orotic acid
EUR			19.886		23823483		expert curated	High	Eric Fauman	SERPINA7 encodes the thyroxine-binding globulin protein.	03094014		ENSG00000123561	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	X	105276609	X	106032618	rs7883218	HMDB0000248	Thyroxine	Thyroxine
EUR		GCST002087	103.398	GCST002087	23824729		expert curated	High	Eric Fauman	MTHFR encodes methylenetetrahydrolate reductase, an enzyme that catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the methyl donor in the conversion of homocysteine to methionine.  Defects in MTHFR lead to homocysteinuria.	05057914		ENSG00000177000	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	1	11856378	1	11796321	rs1801133	HMDB0000742	Homocysteine levels	Homocysteine
EUR		GCST002087	8.699	GCST002087	23824729		expert curated	High	Eric Fauman	MMACHC encodes a cobalamin-binding protein.  Defects in MMACHC are a known cause of homocystinuria.	16311595		ENSG00000132763	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	1	45978675	1	45513003	rs4660306	HMDB0000742	Homocysteine levels	Homocysteine
EUR		GCST002087	9.699	GCST002087	23824729		expert curated	High	Eric Fauman	MTR encodes 5-methyltetrahydrofolate-homocysteine methyltransferase.  The enzyme acts on homocysteine to produce methionine	02407589		ENSG00000116984	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	1	237048676	1	236885376	rs2275565	HMDB0000742	Homocysteine levels	Homocysteine
EUR		GCST002087	9.699	GCST002087	23824729		expert curated	High	Eric Fauman	MUT is a cobalamin-dependent enzyme.  Cobalamin is also needed in a reaction taking the homocysteine as a substrate	07901104		ENSG00000146085	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	6	49382193	6	49414480	rs9369898	HMDB0000742	Homocysteine levels	Homocysteine
EUR		GCST002087	19.699	GCST002087	23824729		expert curated	High	Eric Fauman	FOLH1B encodes a liver-enriched polyglutamylfolate hydrolase which will influence folate availability for the conversion of homocysteine to methionine	09816319		ENSG00000134612	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	11	89148372	11	89415204	rs7130284	HMDB0000742	Homocysteine levels	Homocysteine
EUR		GCST002087	42.699	GCST002087	23824729		expert curated	High	Eric Fauman	DPEP1 encodes a dipeptidase that acts on glutathione, which is a downstream product of homocysteine metabolism. Glutathione and homocysteine levels have been shown to be negatively correlated.	06122685		ENSG00000015413	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	16	89708096	16	89641688	rs154657	HMDB0000742	Homocysteine levels	Homocysteine
EUR		GCST002196	45.0	GCST002196	24047826		expert curated	High	Eric Fauman	GATM encodes glycine amidinotransferase.  This enzyme produces the Homoarginine when using lysine as a substrate.	23010440		ENSG00000171766	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	15	45652703	15	45360505	rs1153858	HMDB0000670	Homoarginine levels	Homo-L-arginine
EAS		GCST002195	30.155	GCST002195_2	24049095		expert curated	High	Eric Fauman	CYP19A1 encodes aromatase which produces estradiol (the measured analyte) from testosterone.	04153532		ENSG00000137869	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	15	51524292	15	51232095	rs2414095	HMDB0000151	Hormone measurements (Oestradiol)	Estradiol
EUR		GCST002201	10.097	GCST002201	24068962		expert curated	High	Eric Fauman	TRPM8 encodes a calcium-permeable channel activated by menthol and cold.	11882888		ENSG00000144481	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	C	2	234264848	2	233356202	rs1550532	HMDB0000464	Calcium levels	Calcium
EUR		GCST002201	85.046	GCST002201	24068962		expert curated	High	Eric Fauman	CASR encodes the calcium sensing receptor, a GPCR which binds calcium and regulates parathyroid hormone secretion which in turn regulates circulating levels of calcium.	11013439		ENSG00000036828	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	3	122003757	3	122284910	rs1801725	HMDB0000464	Calcium levels	Calcium
EUR		GCST002201	8.097	GCST002201	24068962		expert curated	High	Eric Fauman	GUSB encodes a glucuronidase which induces the opening of the calcium-specific kidney-specific channel, TRPV5.	18495742		ENSG00000169919	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	7	65271197	7	65806210	rs17711722	HMDB0000464	Calcium levels	Calcium
EUR		GCST002201	11.046	GCST002201	24068962		expert curated	High	Eric Fauman	CYP24A1 encodes the 1,25-dihydroxyvitamin D(3) 24-hydroxylase which produces the biologically active form of vitamin D, which regulates calcium levels.	09333115		ENSG00000019186	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	20	52774427	20	54157888	rs1570669	HMDB0000464	Calcium levels	Calcium
AFR|EAS|EUR|SAS		GCST002221	27.153	GCST002221	24097068		expert curated	High	Eric Fauman	IRF2BP2 encodes a protein which binds to the interferon regulatory factor 2 transcription factor.  This transcription factor is essential for the activation of the ABCA1 cholesterol transporter.	26195219		ENSG00000168264	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	1	234853406	1	234717659	rs558971	HMDB0000067	Total Cholesterol	Cholesterol
EUR		GCST002221	11.398	GCST002221	24097068		expert curated	High	Eric Fauman	ABCB11 encodes a transporter for taurocholate, a bile acid derived from cholesterol	01862084		ENSG00000073734	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	2	169830155	2	168973645	rs2287623	HMDB0000067	Cholesterol, total	Cholesterol
AFR|EAS|EUR|SAS		GCST002221	16.075	GCST002221	24097068		expert curated	High	Eric Fauman	PPARG encodes a transcription factor that upreguates ABCA1 among other proteins involved in lipid metabolism.	11135616		ENSG00000132170	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	3	12267648	3	12226148	rs7616006	HMDB0000067	Total Cholesterol	Cholesterol
AFR|EAS|EUR|SAS		GCST002221	16.141	GCST002221	24097068		expert curated	High	Eric Fauman	LPA encodes the lipoprotein(a) protein, a constituent of the lipoprotein(a) particle, a carrier of cholesterol.	24977982		ENSG00000198670	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	6	161010118	6	160589086	rs10455872	HMDB0000067	Total Cholesterol	Cholesterol
AFR|EAS|EUR|SAS		GCST002221	22.952	GCST002221	24097068		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	CYP7A1 encodes a cytochrome P450 which is the rate limiting step in the conversion of cholesterol to bile acids.  CYP7A1 deficiency results in excess cholesterol.|CYP7A1 encodes a cytochrome P450 which is the rate limiting step in the conversion of cholesterol to bile acids.  CYP7A1 deficiency results in excess cholesterol.	02993784|12093894		ENSG00000167910	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	8	59393273	8	58480714	rs4738684	HMDB0000067	Total Cholesterol	Cholesterol
AFR|EAS|EUR|SAS		GCST002221	9.176	GCST002221	24097068		expert curated	High	Eric Fauman	VLDLR encodes the very low density lipoprotein receptor 	08294473		ENSG00000147852	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	9	2640759	9	2640759	rs3780181	HMDB0000067	Total Cholesterol	Cholesterol
AFR|EAS|EUR|SAS		GCST002221	8.006	GCST002221	24097068		expert curated	High	Eric Fauman	PPARA encodes a transcription factor which regulates expression of HDL apolipoproteins	09808609		ENSG00000186951	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	22	46627603	22	46231706	rs4253772	HMDB0000067	Total Cholesterol	Cholesterol
AFR|EAS|EUR|SAS		GCST002223	7.744	GCST002223	24097068		expert curated	High	Eric Fauman	NAXE (formerly APOA1BP) encodes an APOA1 binding protein which promotes cholesterol efflux into high density lipoprotein (HDL) particles.	23719382		ENSG00000163382	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	1	156700651	1	156730859	rs12145743	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	40.454	GCST002223	24097068		expert curated	High	Eric Fauman	GALNT2 encodes an acetylgalactosaminyltransferase which glycosylates the APOC3 protein, which in turn inhibits the lipoprotein lipase (LPL) enzyme which hydrolyzes triglycerides from triglyceride-containing lipoproteins, leading to the generation of HDL	22152306		ENSG00000143641	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	1	230295691	1	230159944	rs4846914	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	8.663	GCST002223	24097068		expert curated	High	Eric Fauman	GPIHBP1 encodes the glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1, a receptor for the HDL.	12496272		ENSG00000182851	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	8	144303418	8	143221248	rs10087900	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	64.825	GCST002223	24097068		expert curated	High	Eric Fauman	ABCA1 encodes a cholesterol transporter.  Deficiency results in reduced HDL.	10431237		ENSG00000165029	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	9	107664301	9	104902020	rs1883025	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	37.481	GCST002223	24097068		expert curated	High	Eric Fauman	NR1H3 encodes the LXR-alpha nuclear hormone receptor.  This transcription factor upreguates ABCA1, a cholesterol transporter with a direct impact on HDL levels.	11090131		ENSG00000025434	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	11	47333685	11	47312134	rs3847502	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	7.951	GCST002223	24097068		expert curated	High	Eric Fauman	DGAT2 encodes a diacylglycerol O-acyltransferase which produces triglycerides from diaglycerides.	11481335		ENSG00000062282	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	11	75455021	11	75743976	rs499974	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	19.604	GCST002223	24097068		expert curated	High	Eric Fauman	MVK encodes mevalonate kinase which synthesizes a precursor to cholesterol.	02153681		ENSG00000110921	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	12	109950144	12	109512339	rs2241210	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	32.135	GCST002223	24097068		expert curated	High	Eric Fauman	SCARB1 encodes a scavanger receptor which can act as an HDL receptor.	08560269		ENSG00000073060	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	12	125259888	12	124775342	rs838876	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	8.019	GCST002223	24097068		expert curated	High	Eric Fauman	AKT1 encodes a protein kinase which activates SREBP which induces transcription of enzymes involved in cholesterol biosynthesis.	16007182		ENSG00000142208	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	14	105277209	14	104810872	rs4983559	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
EUR		GCST002223	188.0	GCST002223	24097068		expert curated	High	Eric Fauman	LIPC encodes hepatic triglyceride lipase which hydrolyses triglycerides.  The enzyme plays a key role in regulating levels of HDL.	07417375		ENSG00000166035	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	15	58683366	15	58391167	rs1532085	EFO_0004612	HDL cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	801.939	GCST002223	24097068		expert curated	High	Eric Fauman	CETP encodes the cholesterol ester transfer protein which acts on high density lipoprotein (HDL).  Deficiency of this enzyme results in increased HDL. 	02586614		ENSG00000087237	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	16	56989590	16	56955678	rs247616	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
EUR		GCST002223	53.097	GCST002223	24097068		expert curated	High	Eric Fauman	LCAT encodes lecithin-cholesterol acyltransferase which travels with HDL, esterifying cholesterol to cholesterol ester for incorporation into the HDL particles for transport back to the liver.	04868699		ENSG00000213398	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	16	67928042	16	67894139	rs16942887	EFO_0004612	HDL cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	19.264	GCST002223	24097068		expert curated	High	Eric Fauman	STARD3 encodes the StAR-related lipid transfer protein 3 which promotes export of cholesterol to HDL	25014273		ENSG00000131748	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	GT	G	17	37821435	17	39665182	rs113612868	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	65.746	GCST002223	24097068		expert curated	High	Eric Fauman	LIPG encodes endothelial lipase which acts on HDL.  Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo	12569161		ENSG00000101670	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	18	47167214	18	49640844	rs4939883	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002223	33.785	GCST002223	24097068		expert curated	High	Eric Fauman	HNF4A drives expression of many cholesterol related genes including HMGCR	21071704		ENSG00000101076	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	20	43042364	20	44413724	rs1800961	EFO_0004612	HDL Cholesterol	high density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	16.519	GCST002222	24097068		expert curated	High	Eric Fauman	LDLRAP1 encodes an adapter protein which binds to the LDL receptor.  Mutations in this gene cause a form of familial hypercholesterolemia.	15166224		ENSG00000157978	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	1	25768937	1	25442446	rs10903129	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	142.067	GCST002222	24097068		expert curated	High	Eric Fauman	PCSK9 encodes a protein that binds to the LDLR receptor, promoting its degradation and thus influencing circulating LDL cholesterol levels.  Rare gain of function mutations result in greatly elevated LDL cholesterol levels.	12730697		ENSG00000169174	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	1	55505647	1	55039974	rs11591147	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	271.788	GCST002222	24097068		expert curated	High	Eric Fauman	SORT1 encodes sortilin, a receptor with a role in VLDL secretion from the liver	20686566		ENSG00000134243	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	1	109818530	1	109275908	rs646776	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	182.023	GCST002222	24097068		expert curated	High	Eric Fauman	APOB encodes apolipoprotein B, a major component of LDL particles.  Defects in APOB can lead to familial hypercholesterolemia.	00052771		ENSG00000084674	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	2	21263900	2	21041028	rs1367117	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	11.77	GCST002222	24097068		expert curated	High	Eric Fauman	INSIG2 encodes a protein that plays a key role in regulating the SREBP cleavage-activating protein (SCAP), thus providing a means for feedback regulation of cholesterol synthesis over a wide range of sterol concentrations.	12242332		ENSG00000125629	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	2	118835841	2	118078265	rs10490626	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	77.108	GCST002222	24097068		expert curated	High	Eric Fauman	HMGCR encodes HMG-CoA reductase, the rate-limiting enzyme for cholesterol biosynthesis	01967820		ENSG00000113161	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	5	74656539	5	75360714	rs12916	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	16.68	GCST002222	24097068		expert curated	High	Eric Fauman	MYLIP encodes an E3 ubiquitin ligase which ubiquitinates the low density lipoprotein receptor (LDLR), which promotes the degradation of LDLR, influencing the circulating levels of LDL-cholesterol.	19520913		ENSG00000007944	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	6	16127407	6	16127176	rs3757354	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	20.716	GCST002222	24097068		expert curated	High	Eric Fauman	NPC1L1 encodes a transporter for cholesterol in the intestine.	14976318		ENSG00000015520	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	7	44582331	7	44542732	rs2073547	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
EUR		GCST002222	40.398	GCST002222	24097068		expert curated	High	Eric Fauman	HP encodes haptoglobin which binds to ApoA-I, the primary protein component of HDL.	23420675		ENSG00000257017	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	16	72108093	16	72074194	rs2000999	EFO_0004611	LDL cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	11.008	GCST002222	24097068		expert curated	High	Eric Fauman	ApoH increases the enzymic activity of lipoprotein lipase (LPL) in the presence of apoC-II by 45.7 percent [ 7417307].  a small molecule inhibitor of PKC alpha, HBDDE, show minimal inhibition of cholesterol accumulation while a small molecule inhibitor of PKC beta, LY333513, could completely account for the inhibition of cholesterol accumulation by the classical group PKC isoenzyme [16930534]	07417307		ENSG00000091583	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	17	64210580	17	66214462	rs1801689	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
AFR|EAS|EUR|SAS		GCST002222	261.415	GCST002222	24097068		expert curated	High	Eric Fauman	LDLR encodes the LDL receptor.	00226968		ENSG00000130164	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	19	11202306	19	11091630	rs6511720	EFO_0004611	LDL Cholesterol	low density lipoprotein cholesterol measurement
Caucasian		GCST002219	81.456	GCST002219	24097068		expert curated	High	Eric Fauman	ANGPTL3 encodes a protein that regulates triglyceride clearance by reducing the activity of lipoprotein lipase (LPL).	22063269		ENSG00000132855	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	1	63133930	1	62668259	rs4587594	EFO_0004530	Triglycerides	triglyceride measurement
Caucasian		GCST002219	11.795	GCST002219	24097068		expert curated	High	Eric Fauman	LRPAP1 encodes a protein which binds the LDL-receptor-related protein and the VLDL receptor affecting distribution of lipoprotein particles.	07538675		ENSG00000163956	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	4	3473139	4	3471412	rs6831256	EFO_0004530	Triglycerides	triglyceride measurement
Caucasian		GCST002219	7.676	GCST002219	24097068		expert curated	High	Eric Fauman	CAV1 encodes caveolin-1, a scaffolding protein.  Very rare CAV1 frameshift mutations appear to be associated with atypical lipodystrophy and hypertriglyceridemia.	18237401		ENSG00000105974	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	7	116358044	7	116717990	rs38855	EFO_0004530	Triglycerides	triglyceride measurement
Caucasian		GCST002219	198.74	GCST002219	24097068		expert curated	High	Eric Fauman	LPL encodes the lipoprotein lipase which hydrolyzes triglycerides.  LPL deficiency results in accumulation of triglycerides.	13712364		ENSG00000175445	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	8	19844222	8	19986711	rs12678919	EFO_0004530	Triglycerides	triglyceride measurement
Caucasian		GCST002219	112.652	GCST002219	24097068		expert curated	High	Eric Fauman	TRIB1 regulates hepatic lipogenesis.	26517927		ENSG00000173334	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	8	126482621	8	125470379	rs2954022	EFO_0004530	Triglycerides	triglyceride measurement
EUR		GCST002242	40.0	GCST002242	24159190		expert curated	High	Eric Fauman	DDAH1 encodes dimethylarginine dimethylaminohydrolase which acts directly on dimethylarginine.	07608105		ENSG00000153904	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	1	85797110	1	85331427	rs28489187	HMDB0001539	Serum dimethylarginine levels (asymmetric)	Asymmetric dimethylarginine
EUR			36.538		24507774		expert curated	High	Eric Fauman	ANGPTL4 regulates TG clearance by reducing the activity of LPL	16081640		ENSG00000167772	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	19	8429323	19	8364439	rs116843064	EFO_0004530	Triglycerides	triglyceride measurement
EUR		GCST002549	15.699	GCST002549_7	24528284		expert curated	High	Eric Fauman	CYP2C19 encodes a cytochrome P450 which acts on xenobiotics including the selective serotonin reuptake inhibitor citalopram.	08451774		ENSG00000165841	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	10	96681846	10	94922089	rs1074145	HMDB0060576|HMDB0005038	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DCT/S-CT ratio)	Desmethylcitalopram / Citalopram
EUR		GCST002549	15.699	GCST002549_8	24528284		expert curated	High	Eric Fauman	CYP2D6 encodes a cytochrome P450 which acts on many xenobiotics including the conversion of desmethylcitalopram to didesmethylcitalopram (DDCT)	08451774		ENSG00000100197	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	22	42526694	22	42130692	rs1065852	HMDB0060472	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DDCT concentration)	Didemethylcitalopram
AMR|EUR		GCST002364	35.523	GCST002364_35	24586186		expert curated	High	Eric Fauman	FUT2 encodes a galactoside 2-alpha-L-fucosyltransferase, which adds fucose moeities to various proteins.	07876235		ENSG00000176920	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	19	49228272	19	48725015	rs2287921	HMDB0000174	Urinary metabolites (H-NMR features) (5.2125, Fucose)	L-Fucose
AMR|EUR		GCST002364	33.0	GCST002364_9	24586186		expert curated	High	Eric Fauman	SLC7A9 encodes an amino acid transporter which can transport a range of amino acids including lysine	24107421		ENSG00000021488	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	19	33364628	19	32873722	rs8101881	HMDB0000182	Urinary metabolites (H-NMR features) (1.7325, Lysine)	L-Lysine
ASW		GCST002388	15.046	GCST002388_14	24625756		expert curated	High	Eric Fauman	ACY3 encodes an aminoacylase which preferentially deacetylates N-acetylaromatic amino acids including N-acetyl-L-phenylalanine.	14656720		ENSG00000132744	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	11	67421341	11	67653870	rs12288023	HMDB0000512	Serum metabolite levels (N-acetylphenylalanine)	N-Acetyl-L-phenylalanine
ASW		GCST002388	29.523	GCST002388_18	24625756		expert curated	High	Eric Fauman	TREH encodes trehalase which hydrolyses the disaccharide trehalose.	09427547		ENSG00000118094	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	11	118549582	11	118678873	rs507080	HMDB0000975	Serum metabolite levels (Trehalose)	Trehalose
AFR|EUR		GCST002391	12.155	GCST002391	24651765		expert curated	High	Eric Fauman	ALDH1L1 encodes a multifunctional enzyme which includes 10-formyltetrahydrofolate dehydrogenase activity.  The gene thus plays a key role in one carbon metabolism.	07702556		ENSG00000144908	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	3	125906179	3	126187336	rs10934753	HMDB0000742	Plasma homocysteine levels (post-methionine load test)	Homocysteine
AFR|EUR		GCST002391	62.699	GCST002391	24651765		expert curated	High	Eric Fauman	GNMT encodes an enzyme which produces S-adenosylhomocysteine.  S-adenosylhomocysteine can be converted to homocysteine by the enzyme S-adenosylhomocysteine hydrolase	10843803		ENSG00000124713	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	6	42925803	6	42958065	rs9296404	HMDB0000742	Plasma homocysteine levels (post-methionine load test)	Homocysteine
AFR|EUR		GCST002391	25.523	GCST002391	24651765		expert curated	High	Eric Fauman	CBS encodes the cystathionine beta-synthase which acts on homocysteine to produce cystathionine	16545978		ENSG00000160200	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	21	44488033	21	43067923	rs234714	HMDB0000742	Plasma homocysteine levels (post-methionine load test)	Homocysteine
EUR		GCST002443	11.0	GCST002443_34	24816252		expert curated	High	Eric Fauman	ADHFE1 encodes the hydroxyacid-oxoacid transhydrogenase which catalyzes the oxidation of 4-hydroxybutanoic acid to 4-oxobutanoic acid, while reducing 2-oxoglutarate to 2-hydroxyglutarate.	16616524		ENSG00000147576	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	8	67360725	8	66448490	rs1030420	HMDB0000337	Blood metabolite levels (X-04499--3,4-dihydroxybutyrate)	(S)-3,4-Dihydroxybutyric acid
EUR		GCST002443	25.222	GCST002442_19	24816252		expert curated	High	Eric Fauman	F12 encodes coagulation factor XII, a protease which activates kallikrein which releases bradykinin from kininogen.	03521732		ENSG00000131187	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	5	176842474	5	177415473	rs2731672	HMDB0004246	Blood metabolite ratios (X-12038/bradykinin, des-arg(9))	/ Bradykinin
EUR		GCST002443	60.0	GCST002443_9	24816252		expert curated	High	Eric Fauman	NAT2 encodes an N-acetyltransferase which can produce methylxanthine as a downstream metabolite of caffeine.	10744128		ENSG00000156006	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	8	18272438	8	18414928	rs4921914	HMDB0010738	Blood metabolite levels (1-methylxanthine)	1-methylxanthine
EUR		GCST002443	22.699	GCST002443_71	24816252		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	ALOX12 encodes arachidonate 12-lipoxygenase, which catalyzes the regio-selective addition of oxygen into arachidonic acid, generating 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE).  12R-HPETE is rapidly reduced to the corresponding 12S-hydroxy compound, 12-HETE.|ALOX12 encodes arachidonate 12-lipoxygenase, which catalyzes the regio-selective addition of oxygen into arachidonic acid, generating 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE).  12R-HPETE is rapidly reduced to the corresponding 12S-hydroxy compound, 12-HETE.	04215079|02377602		ENSG00000108839	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	C	17	6915401	17	7012082	rs2271316	HMDB0006111	Blood metabolite levels (X-12441--12-hydroxyeicosatetraenoate (12-HETE))	12-HETE
EUR		GCST002443	7.77	GCST002443_2	24816252		expert curated	High	Eric Fauman	PEMT encodes the phosphatidylethanolamine N-methyltransferase which converts phosphatidylethanolamine to phosphatidylcholine.	09370326		ENSG00000133027	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	17	17422768	17	17519454	rs748196	HMDB0061699	1-arachidonoylglycerophosphocholine - M33228	2-Arachidonoylglycerophosphocholine
EUR		GCST002443	11.751	GCST002443_99	24816252		expert curated	High	Eric Fauman	HAO2 encodes a 2-hydroxyacid oxidase which catalyzes the oxidation of L-alpha-hydroxy acids; alpha-hydroxyisovalerate or a related metabolite may be a potential substrate	10777549		ENSG00000116882	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	1	119952776	1	119410153	rs12141041	HMDB0000407	alpha-hydroxyisovalerate - M33937	2-Hydroxy-3-methylbutyric acid
EUR		GCST002443	30.0	GCST002443_99	24816252		expert curated	High	Eric Fauman	LDHA encodes lactate dehydrogenase.  In addition to producing pyruvate from lactate, this enzyme can produce the observed metabolite from the keto acid 3-methyl-2-oxobutanoate	26014429		ENSG00000134333	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	11	18325146	11	18303599	rs2403254	HMDB0000407	Blood metabolite levels (alpha-hydroxyisovalerate)	2-Hydroxy-3-methylbutyric acid
EUR		GCST002443	10.155	GCST002443_69	24816252		expert curated	High	Eric Fauman	IDO1 and IDO2 encode the two indoleamine 2,3-dioxygenase isozymes.  Both enzymes take tryptophan and tryptophan-related metabolites as substrates, but IDO1 is more active [18282734].  IDO1 has known activity against 5-hydroxy-tryptophan [10833386].  Common polymorphisms in IDO2 ablate activity but have no effect on this endpoint [17671174]	10833386		ENSG00000131203	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	A	8	39823145	8	39965626	rs2160860	HMDB0000472	Blood metabolite levels (X-12100--hydroxytryptophan)	5-Hydroxy-L-tryptophan
EUR		GCST002443	10.699	GCST002443_49	24816252		expert curated	High	Eric Fauman	UGT3A1 encodes a UDP glycosyltransferase.  This enzyme has demonstrated activity against the bile acid ursodeoxycholic acid.  The metabolite detected here is structurally related to the bile acids.	18981171		ENSG00000145626	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	5	35968000	5	35967898	rs10491431	HMDB0094650	Blood metabolite levels (X-11445--5-alpha-pregnan-3beta,20alpha-disulfate)	5alpha-pregnan-3beta,20alpha-diol disulfate
EUR		GCST002443	37.398	GCST002443_83	24816252		expert curated	High	Eric Fauman	ECI2 encodes the enoyl-CoA delta isomerase 2, which is known to act on octenoyl-CoA and could possibly act on decenoyl-CoA as well.	10419495		ENSG00000198721	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	6	4146198	6	4145964	rs9392556	HMDB0013205	Blood metabolite levels (X-13435, a 10:1 acylcarnitine)	9-Decenoylcarnitine
EUR		GCST002443	20.097	GCST002443_70	24816252		expert curated	High	Eric Fauman	GADL1 encodes the glutamate decarboxylase-like protein 1 which produces beta-alanine, a component of the dipeptide carnosine	23038267		ENSG00000144644	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	3	30753573	3	30712081	rs6804368	HMDB0012881	Blood metabolite levels (X-12244--N-acetylcarnosine)	Acetylcarnosine
EUR		GCST002443	37.523	GCST002443_100	24816252		expert curated	High	Eric Fauman	AKR1C4 encodes a 3 alpha-hydroxysteroid dehydrogenase (HSD) isoform, which is expressed in the liver and acts on androsterone.   The nearby paralogous gene AKR1C3 is expressed in prostate and mammary gland and the encoded enzyme does not act on androsterone. 	15026176		ENSG00000198610	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	10	5256272	10	5214309	rs17134585	HMDB0002759|HMDB0062657	Blood metabolite ratios (androsterone sulfate/epiandrosterone sulfate)	Androsterone sulfate / Epiandrosterone Sulfate
EUR		GCST002443	360.699	GCST002442_26	24816252		expert curated	High	Eric Fauman	FADS1 encodes a delta-5 desaturase, which converts dihomo-linolenate (20:3n6) to arachidonate (20:4n6).	10601301		ENSG00000149485	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	C	11	61571348	11	61803876	rs174548	HMDB0060102|HMDB0002925	Blood metabolite ratios (arachidonate (20:4n6)/dihomo-linolenate (20:3n3 or n6))	Arachidonate / 8,11,14-Eicosatrienoic acid
EUR		GCST002443	28.699	GCST002442_26	24816252		expert curated	High	Eric Fauman	MBOAT7 encodes a lysophosphatidylinositol acyltransferase that has specificity for arachidonoyl-CoA as an acyl donor. Arachidonate is readily converted to arachidonoyl-CoA. Thus the associated ratio is closely linked to the substrate/product pair for this enzyme. The associated ratio is closely linked to the substrate/product pair for this enzyme.	18094042		ENSG00000125505	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	19	54676433	19	54172738	rs2576452	HMDB0060102|HMDB0061690	Blood metabolite ratios (arachidonate (20:4n6)/1-arachidonoylglycerophosphoinositol)	Arachidonate|1-Arachidonoylglycerophosphoinositol
EUR		GCST002443	37.0	GCST002442_28	24816252		expert curated	High	Eric Fauman	ACE encodes an angiotensin-converting enzyme.  This carboxypeptidase can generate aspartylphenylalanine from cholecystokinin-8.	02554881		ENSG00000159640	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	17	61566031	17	63488670	rs4343	HMDB0000706	Blood metabolite ratios (aspartylphenylalanine/X-14450--phenylalanylleucine)	Aspartylphenylalanine / 
EUR		GCST002443	19.0	GCST002443_104	24816252		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	BHMT encodes a betaine-homocysteine methyltransferase which converts betaine to dimethylglycine.  Conversely, the homologous enzyme encoded by the nearby BHMT2 gene cannot use betaine.|BHMT encodes a betaine-homocysteine methyltransferase which converts betaine to dimethylglycine.  Conversely, the homologous enzyme encoded by the nearby BHMT2 gene cannot use betaine.	06746658|18230605		ENSG00000145692	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	5	78346769	5	79050946	rs16876394	HMDB0000043	Blood metabolite levels (betaine)	Betaine
EUR		GCST002443	12.097	GCST002443_104	24816252		expert curated	High	Eric Fauman	SLC6A12 encodes a sodium- and chloride-dependent betaine transporter.	08198549		ENSG00000111181	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	T	12	320920	12	211754	rs499368	HMDB0000043	Blood metabolite levels (betaine)	Betaine
EUR		GCST002443	12.222	GCST002443_109	24816252		expert curated	High	Eric Fauman	KNG1 includes the coding sequence for the bradykinin peptide.	02989293		ENSG00000113889	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	3	186454180	3	186736391	rs5030062	HMDB0004246	Blood metabolite levels (bradykinin, des-arg(9))	Bradykinin
EUR		GCST002443	47.398	GCST002443_109	24816252		expert curated	High	Eric Fauman	KLKB1 encodes kallikrein, a serine protease which releases bradykinin from kininogen.	08662673		ENSG00000164344	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	4	187174683	4	186253529	rs4253311	HMDB0004246	Blood metabolite levels (bradykinin, des-arg(9))	Bradykinin
EUR		GCST002443	629.523	GCST002443_110	24816252		expert curated	High	Eric Fauman	ACADS encodes the short chain acyl-CoA dehydrogenase which takes butyrl-CoA as a substrate.   Butyryl-CoA and butyrylcarnitine readily interconvert.  	03597357		ENSG00000122971	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	12	121160615	12	120722812	rs2066938	HMDB0002013	Blood metabolite levels (butyrylcarnitine)	Butyrylcarnitine
EUR		GCST002443	7.657	GCST002443_25	24816252		expert curated	High	Eric Fauman	CFH encodes complement factor H which binds complement factor 3.  The detected analyte is a peptide fragment of complement factor 3.	06219696		ENSG00000000971	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	1	196682346	1	196713216	rs7535263	EFO_0004983	HWESASXX - M32836	C3f, complement C3 derived peptide
EUR		GCST002443	11.752	GCST002443_25	24816252		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	ANPEP encodes Aminopeptidase N, which is a broad specificity aminopeptidase.  HWESASXX, a peptide derived from C3 complement is a possible substrate.|ANPEP encodes Aminopeptidase N, which is a broad specificity aminopeptidase.  HWESASXX, a peptide derived from C3 complement is a possible substrate.	07957888|09647737		ENSG00000166825	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	15	90345335	15	89802104	rs2007084	EFO_0004983	HWESASXX - M32836	C3f, complement C3 derived peptide
EUR		GCST002443	10.097	GCST002443_115	24816252		expert curated	High	Eric Fauman	ALDH18A1 encodes delta-1-pyrroline-5-carboxylate synthetase which catalyzes a step in the de novo production of ornithine which is subsequently converted to citrulline.  Mutations in ALDH18A1 cause hypocitrullinemia.	11092761		ENSG00000059573	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	10	97395962	10	95636205	rs56322409	HMDB0000904	Blood metabolite levels (citrulline)	Citrulline
EUR		GCST002443	44.0	GCST002442_17	24816252		expert curated	High	Eric Fauman	SRD5A2 encodes the type II steroid 5 alpha-reductase enzyme best known for converting testosterone to dihydrotestosterone.  The metabolites represented by the ratio detected here are also steroid molecules differing in reduction at carbon 5.  The enzyme has known activity against corticosterone.	07734398		ENSG00000049319	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	T	2	31810974	2	31585905	rs559555	HMDB0010320	Blood metabolite ratios (X-11444/X-12844) (X-11444 is tentatively identified by Metabolon as urocortisol glucuronide or cortolone glucuronide and X-12844 is tentatively identified as tetrahydrocortisone glucuronide)	cortolone glucuronide
EUR		GCST002443	12.699	GCST002443_117	24816252		expert curated	High	Eric Fauman	GGT1 encodes gamma-glutamyltransferase 1 which catalyzes the transfer of the glutamyl moiety of glutathione to a number of different amino acids and can take the analyte reported here (the cysteine-glutathione mixed disulfide) as a substrate. 	06130452		ENSG00000100031	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	22	25002081	22	24606114	rs2330809	HMDB0000656	Blood metabolite levels (cysteine-glutathione disulfide)	Cysteineglutathione disulfide
EUR		GCST002443	37.061	GCST002443_118	24816252		expert curated	High	Eric Fauman	ETFDH encodes a mitochondrial electron transfer flavoprotein dehydrogenase which is essential for electron transfer from the short-, medium- and long-chain acyl-CoA dehydrogenases.  Mutations in ETFDH lead to multiple acyl-CoA dehydrogenase deficiency, which is characterized by elevated short-, medium- and long-chain acyl carnitines.	17412732		ENSG00000171503	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	4	159630817	4	158709665	rs8396	HMDB0000651	decanoylcarnitine - M33941	Decanoylcarnitine
EUR		GCST002443	11.699	GCST002443_124	24816252		expert curated	High	Eric Fauman	AKR1A1 encodes an aldehyde reductase which can catalyze the production of erythritol	04402936		ENSG00000117448	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	1	46990681	1	46525009	rs7542172	HMDB0002994	Blood metabolite levels (erythritol)	erythritol
EUR		GCST002443	13.398	GCST002442	24816252		expert curated	High	Eric Fauman	SLC27A2 encodes a very-long-chain acyl-CoA synthetase which activates fatty acids by forming their coenzyme A derivatives.	10198260		ENSG00000140284	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	15	50477138	15	50184941	rs1365505	HMDB0034286	Blood metabolite ratios (10-undecenoate (11:1n1)/X-11438)	Ethyl 10-undecenoate / 
EUR		GCST002443	36.046	GCST002442_4	24816252		expert curated	High	Eric Fauman	ABO encodes a glycosyltransferase that determines the blood group.  ABO blood group contributes to von Willebrand Factor levels perhaps by protecting it from susceptibility to ADAMTS13-mediated proteolysis.  As part of the coagulation cascade, von Willebrand Factor effects rates of fibrinogen cleavage.	17894864		ENSG00000175164	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	9	136154304	9	133278860	rs649129	EFO_0004623	Blood metabolite ratios (ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR)	Fibrinopeptide A
EUR		GCST002443	27.553	GCST002443_128	24816252		expert curated	High	Eric Fauman	CPT2 encodes carnitine palmitoyltransferase II, which catalyzes the transfer of palmitate and related metabolites from carnitine to coenzyme A in the mitochondrial inner membrane.	09654057		ENSG00000157184	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	1	53695882	1	53230210	rs13375749	HMDB13130	Blood metabolite levels (glutaroyl carnitine)	Glutarylcarnitine
EUR		GCST002443	44.222	GCST002443_128	24816252		expert curated	High	Eric Fauman	GCDH encodes a glutaryl-CoA dehydrogenase which catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA.	03081514		ENSG00000105607	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	19	13010520	19	12899706	rs8012	HMDB13130	Blood metabolite levels (glutaroyl carnitine)	Glutarylcarnitine
EUR		GCST002443	16.0	GCST002443_135	24816252		expert curated	High	Eric Fauman	MCCC1 encodes methylcrotonoyl-CoA carboxylase 1 which catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in the breakdown of leucine.  An alternate fate of 3-methylcrotonyl-CoA is 3-hydroxyisovaleryl-CoA.  3-Methylcrotonyl-CoA carboxylase deficiency has been associated with elevated urinary 3-hydroxyisovalerylcarnitine levels.	19339287		ENSG00000078070	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	3	182755209	3	183037421	rs2270968	HMDB0062555	Blood metabolite levels (hydroxyisovaleroyl carnitine)	hydroxyisovaleroyl carnitine
EUR		GCST002443	15.699	GCST002443_136	24816252		expert curated	High	Eric Fauman	GMPR encodes guanosine monophosphate reducatase which converts guanosine monophosphate to inosine monophosphate which can subsequently be converted to hypoxanthine by the enzyme purine-nucleoside phosphorylase.	00218932		ENSG00000137198	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	6	16288192	6	16287961	rs6459467	HMDB0000157	Blood metabolite levels (hypoxanthine)	Hypoxanthine
EUR		GCST002443	9.795	GCST002443_137	24816252		expert curated	High	Eric Fauman	DDC encodes dopa decarboxylase which converts tryptophan to tryptamine, which can be further metabolized to indoleacetic acid.	13610897		ENSG00000132437	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	A	7	50610379	7	50542681	rs7809234	HMDB0000197	indoleacetate - M27513	Indoleacetic acid
EUR		GCST002443	12.0	GCST002443_137	24816252		expert curated	High	Eric Fauman	CCBL1 encodes a kyneurenine aminotransferase, also known as hKAT-1, which can convert tryptophan to indolepyruvate.  Indolepyruvate is then converted to indolelactate. 	15606768		ENSG00000171097	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	9	131572027	9	128809748	rs15676	HMDB0000671	Blood metabolite levels (indolelactate)	Indolelactic acid
EUR		GCST002443	48.303	GCST002443_140	24816252		expert curated	High	Eric Fauman	SLC22A1 encodes OCT1, an organic cation transporter with activity towards acylcarnitine.	28942964		ENSG00000175003	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	C	6	160564476	6	160143444	rs662138	HMDB0062556	isobutyrylcarnitine - M33441	isobutyrylcarnitine
EUR		GCST002443	12.449	GCST002443_140	24816252		expert curated	High	Eric Fauman	ETFA encodes a mitochondrial-specific electron transfer flavoprotein.  Enzyme deficiency results in urinary excretion of isobutyric acid and isobutyrylglycine; the urinary levels of these metabolites should reflect plasma levels of the analyte reported here, isobutyrylcarnitine.	07360517		ENSG00000140374	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	15	77030792	15	76738451	rs2404602	HMDB0062556	isobutyrylcarnitine - M33441	isobutyrylcarnitine
EUR		GCST002443	7.343	GCST002443_17	24816252		expert curated	High	Eric Fauman	SUCLA2 encodes a subunit of succinyl-CoA synthetase a key enzyme in the Krebs cycle.  SUCLA2 deficiency results in elevated urinary excretion of leucine degradation products downstream of the analyte detected here (specifically 3-hydroxyisovaleric acid and 3-methylglutaconic acid).	19666145		ENSG00000136143	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	13	48459901	13	47885766	rs4941615	HMDB0000695	4-methyl-2-oxopentanoate - M22116	Ketoleucine
EUR		GCST002443	171.699	GCST002442_23	24816252		expert curated	High	Eric Fauman	ACADM encodes an acyl-CoA dehydrogenase with a preference for medium chain length acyl-CoAs.  Acyl-CoAs are converted to acyl-carnitines for circulation which are then detected in the plasma.	03597357		ENSG00000117054	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	1	76161889	1	75696204	rs4949874	HMDB0000201|HMDB0000705	Blood metabolite ratios (acetylcarnitine/hexanoylcarnitine)	L-Acetylcarnitine|Hexanoylcarnitine
EUR		GCST002443	8.831	GCST002443_102	24816252		expert curated	High	Eric Fauman	ASRGL1 encodes an asparaginase which hydrolyzes asparagine to produce aspartate.	24768817		ENSG00000162174	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	11	62176943	11	62409471	rs3017098	HMDB0000168	asparagine - M34283	L-Asparagine
EUR		GCST002443	40.806	GCST002443_102	24816252		expert curated	High	Eric Fauman	ASPG encodes an asparaginase homolog which which can hydrolyse asparagine to form aspartic acid	09575212		ENSG00000166183	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	14	104608068	14	104141731	rs2011069	HMDB0000168	asparagine - M34283	L-Asparagine
EUR		GCST002443	25.046	GCST002443_142	24816252		expert curated	High	Eric Fauman	SLC7A5 encodes LAT1 which mediates tryptophan/kynurenine exchange.	17896864		ENSG00000103257	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	16	87878822	16	87845216	rs8051149	HMDB0000684	Blood metabolite levels (kynurenine)	L-Kynurenine
EUR		GCST002443	26.155	GCST002443_161	24816252		expert curated	High	Eric Fauman	PHGDH encodes a phosphoglycerate dehydrogenase which catalyses the first and rate-limiting step in serine biosynthesis.	16589713		ENSG00000092621	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	1	120209755	1	119667132	rs1163251	HMDB0000187	Blood metabolite levels (serine)	L-Serine
EUR		GCST002443	11.046	GCST002443_167	24816252		expert curated	High	Eric Fauman	TDO2 encodes tryptophan 2,3-dioxygenase which acts on tryptophan.	08666386		ENSG00000151790	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	4	156808288	4	155887136	rs13122250	HMDB0000929	Blood metabolite levels (tryptophan)	L-Tryptophan
EUR		GCST002443	50.523	GCST002442_46	24816252		expert curated	High	Eric Fauman	SLC22A5 encodes the OCTN2 protein, which is the primary transporter reponsible for carnitine homeostasis.	20648231		ENSG00000197375	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	5	131665378	5	132329685	rs272889	HMDB0000883|HMDB0000688	Blood metabolite ratios (valine/isovalerylcarnitine)	L-Valine / Isovalerylcarnitine
EUR		GCST002443	37.398	GCST002442_37	24816252		expert curated	High	Eric Fauman	THEM4 is a broad range acyl-CoA thioesterase with a preference for medium and long chain acyl-CoAs. [19453107].  X-12442 has been identified as 5,8-tetradecadienoate.	19453107		ENSG00000159445	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	1	151930645	1	151958169	rs6693388	HMDB0000673|HMDB0000560	Blood metabolite ratios (linoleate (18:2n6)/X-12442--5,8-tetradecadienoate)	Linoleic acid / 5,8-Tetradecadienoic acid
EUR		GCST002443	13.097	GCST002443_59	24816252		expert curated	High	Eric Fauman	FMO3 encodes a flavin containing monooxygenase which can act on S-allyl-cysteine and methionine. Methylcysteine is a plausible substrate.  This isozyme prefers smaller substrates and shows highest expression in liver.	18775983		ENSG00000007933	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	G	1	171080615	1	171111474	rs7061710	HMDB0002108	Blood metabolite levels (X-11786--methylcysteine)	Methylcysteine
EUR		GCST002443	13.301	GCST002443_148	24816252		expert curated	High	Eric Fauman	ISYNA1 encodes an inositol-3-phosphate synthase, which converts d-glucose 6-phosphate to 1-d-myo-inositol 3-phosphate.	15024000		ENSG00000105655	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	19	18618867	19	18508057	rs4808136	HMDB0000211	Blood metabolite levels (myo-inositol)	myo-Inositol
EUR		GCST002443	115.0	GCST002442_40	24816252		expert curated	High	Eric Fauman	SCD encodes a stearyl-CoA desaturase which acts on medium chain-length acyl-CoAs to bring about the delta 9 desaturation of various fatty acids, such as the conversion of myristate (14:0) to myristoleate (14:1n5).	00008453		ENSG00000099194	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	10	102075479	10	100315722	rs603424	HMDB0000806|HMDB0002000	Blood metabolite ratios (myristate (14:0)/myristoleate (14:1n5))	Myristic acid / Myristoleic acid
EUR		GCST002443	13.523	GCST002443_31	24816252		expert curated	High	Eric Fauman	AOC1 encodes an amine oxidase which deaminates N1-acetylspermidine to produce N-[3-(2-oxopyrrolidin-1-yl)propyl]acetamide (also known as acisoga).  	12072962		ENSG00000002726	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	7	150543721	7	150846633	rs1005390	HMDB0061384	Blood metabolite levels (X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide)	N-(3-acetamidopropyl)pyrrolidin-2-one
EUR		GCST002443	12.523	GCST002443_32	24816252		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	PAOX encodes an N1-acetylspermidine oxidase.  The detected analyte is a downstream metabolite of N1-acetylspermidine.  |PAOX encodes an N1-acetylspermidine oxidase.  The detected analyte is a downstream metabolite of N1-acetylspermidine.  	12660232|03558558		ENSG00000148832	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	A	10	135197336	10	133383832	rs11101730	HMDB0061384	Blood metabolite levels (X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide)	N-(3-acetamidopropyl)pyrrolidin-2-one
EUR		GCST002443	497.301	GCST002442_10	24816252		expert curated	High	Eric Fauman	NAT8 shows sequence similarity to N-acetyltransferases.  N-acetylornithine may be a product or related to a product.  Ornithine itself is part of the urea cycle and myoinositol levels are altered in patients with urea cycle disorders.	18662894		ENSG00000144035	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	2	73868328	2	73641201	rs13538	HMDB0003357|HMDB0000211	Blood metabolite ratios (N-acetylornithine/myo-inositol)	N-Acetylornithine / myo-Inositol
EUR		GCST002443	11.222	GCST002443_68	24816252		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	ACMSD encodes alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, the key enzyme regulating de novo synthesis of nicitinamide adenine dinucleotide (NAD) from tryptophan.  The metabolite in question, N1-methyl-3-pyridone-4-carboxamide, is an endproduct of NAD degradation.|ACMSD encodes alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, the key enzyme regulating de novo synthesis of nicitinamide adenine dinucleotide (NAD) from tryptophan.  The metabolite in question, N1-methyl-3-pyridone-4-carboxamide, is an endproduct of NAD degradation.	16807375|12694300		ENSG00000153086	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	2	135631400	2	134873830	rs6430553	HMDB0004194	Blood metabolite levels (X-12095--N1-methyl-3-pyridone-4-carboxamide)	N1-Methyl-4-pyridone-3-carboxamide
EUR		GCST002443	134.0	GCST002443_82	24816252		expert curated	High	Eric Fauman	ACADL encodes Long-chain acyl-CoA dehydrogenase which has activity against a variety of medium and long chain acyl-CoAs .  Intracellular acyl-CoAs are converted to acyl-carnitines for circulation.	10832093		ENSG00000115361	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	2	210874246	2	210009522	rs3738934	HMDB0013288	Blood metabolite levels (X-13431--nonanoylcarnitine)	Nonanoylcarnitine
EUR		GCST002443	177.301	GCST002443_58	24816252		expert curated	High	Eric Fauman	COMT encodes the catechol-O-methyltransferase which can methylate ascorbate to produce O-methylascorbate.	07129800		ENSG00000093010	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	22	19951271	22	19963748	rs4680	HMDB0000044	Blood metabolite levels (X-11593--O-methylascorbate)	O-methylascorbate
EUR		GCST002443	17.155	GCST002443_44	24816252		expert curated	High	Eric Fauman	ARSA encodes the arylsulfatase A, which can act on L-tyrosine O-sulfate.	00033715		ENSG00000100299	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	22	51063477	22	50625049	rs6151429	HMDB0000158	Blood metabolite levels (X-11423--O-sulfo-L-tyrosine)	O-Sulfotyrosine
EUR		GCST002443	10.097	GCST002443_154	24816252		expert curated	High	Eric Fauman	SLC5A6 encodes a solute transporter with demonstrated activity for pantothenate	09516450		ENSG00000138074	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	2	27424636	2	27201768	rs1395	HMDB0000210	Blood metabolite levels (pantothenate)	Pantothenic acid
EUR		GCST002443	23.523	GCST002442_42	24816252		expert curated	High	Eric Fauman	GOT2 encodes the enzyme aspartate aminotransferase which can take each of the aromatic amino acids as substrates. In particular, GOT2 catalyzes the conversion of phenylalanine to phenylpyruvate which is then converted to phenyllactate.	04623131		ENSG00000125166	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	16	58829790	16	58795886	rs12709013	HMDB0000779|HMDB0000159	Blood metabolite ratios (phenyllactate (PLA)/phenylalanine)	Phenyllactic acid / L-Phenylalanine
EUR		GCST002443	22.046	GCST002442_43	24816252		expert curated	High	Eric Fauman	TKT encodes transkelolase, an enzyme with a prefererence for D-erythrose 4-phosphate as a substrate.	09924800		ENSG00000163931	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	3	53282188	3	53248172	rs4687717	HMDB0001429|HMDB0000613	Blood metabolite ratios (phosphate/erythronate)	Phosphate / Erythronic acid
EUR		GCST002443	42.046	GCST002442_44	24816252		expert curated	High	Eric Fauman	IVD encodes isovaleryl-CoA dehydrogenase which acts on isovaleryl-CoA in the third step of leucine catabolism.  Isovaleryl-CoA is converted to isovalerylcarnitine for circulation.	03597357		ENSG00000128928	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	15	40703211	15	40411012	rs9635324	HMDB0000824|HMDB0000688	Blood metabolite ratios (propionylcarnitine/isovalerylcarnitine)	Propionylcarnitine / Isovalerylcarnitine
EUR		GCST002443	109.222	GCST002443_22	24816252		expert curated	High	Eric Fauman	OPLAH encodes 5-oxoprolinase which catalyzes the ATP-dependent hydrolysis of 5-oxoproline to glutamic acid	09233839		ENSG00000178814	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	8	145155408	8	144100505	rs12550729	HMDB0000267	Blood metabolite levels (5-oxoproline)	Pyroglutamic acid
EUR		GCST002443	190.523	GCST002442_15	24816252		expert curated	High	Eric Fauman	SULT2A1 encodes a bile salt sulfotransferase which can catalyze the sulfation of steroids and bile acids.	08575776		ENSG00000105398	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	19	48385057	19	47881800	rs2547231	HMDB03818	Blood metabolite ratios (X-11440/4-androsten-3beta,17beta-diol disulfate 2)	similar to 5-Androstenediol
EUR		GCST002443	10.155	GCST002443_164	24816252		expert curated	High	Eric Fauman	SUCLG2 encodes the beta subunit of succinate-CoA ligase which acts on succinate-CoA.  Acyl-CoAs and acyl-carnitines are readily interconverted.	18392745		ENSG00000172340	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	3	67416322	3	67365898	rs17806888	HMDB0061717	Blood metabolite levels (succinylcarnitine)	Succinylcarnitine
EUR		GCST002443	85.097	GCST002442	24816252		expert curated	High	Eric Fauman	CYP4A11 encodes a fatty acid omega-hydroxylase.  X-11438 may be a hydroxylated tridecenoic acid (C13:1(OH)) so may represent a product.	10860550		ENSG00000187048	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	1	47331966	1	46866294	rs6678639	HMDB33724|HMDB0035881	Blood metabolite ratios (10-undecenoate (11:1n1)/X-11438)	Undecylenic acid / 11-Hydroxy-9-tridecenoic acid
EUR		GCST002443	7.467	GCST002443_170	24816252		expert curated	High	Eric Fauman	CDA encodes cytidine deaminase which deaminates cytidine, producing uridine.	08422236		ENSG00000158825	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	1	20915172	1	20588679	rs532545	HMDB0000296	uridine - M00606	Uridine
EUR		GCST002443	7.724	GCST002443_170	24816252		expert curated	High	Eric Fauman	UPP1 encodes uridine phosphorylase which catalyzes the interconversion of uridine and uracil.	07488099		ENSG00000183696	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	7	48102911	7	48063314	rs2686796	HMDB0000296	uridine - M00606	Uridine
EUR		GCST002443	15.398	GCST002443_170	24816252		expert curated	High	Eric Fauman	TYMP encodes thymidine phosphorylase, which catalyzes the phosphorolysis of thymidine and deoxyuridine.   These pyrimidines are metabolically linked to uridine.	07284378		ENSG00000025708	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	22	50971752	22	50533323	rs131794	HMDB0000296	Blood metabolite levels (uridine)	Uridine
AFR|EUR		GCST002559	12.699	GCST002559_2	25147783		expert curated	High	Eric Fauman	CUBN encodes cubilin, a protein involved in the uptake of vitamin B12 (cobalamin).  CUBN deficiency results in reduced levels of cobalamin.	09478979		ENSG00000107611	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	10	17156151	10	17114152	rs1801222	HMDB0002174	Vitamin B levels in ischemic stroke (Vitamin B12)	Cobalamin
EAS		GCST002586	11.719	GCST002586	25187374		expert curated	High	Eric Fauman	FOXA2 encodes a transcription factor that impacts the expression of many genes (i.e., GCK, SLC2A2) previously related to the glucose levels.	11875061		ENSG00000125798	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	20	22581268	20	22600630	rs6048216	HMDB0000122	Fasting plasma glucose (East Asian)	D-Glucose
EUR		GCST002623	18.398	GCST002623	25245031		expert curated	High	Eric Fauman	ARG1 encodes an arginase which hydrolyzes arginine.  Enzyme deficiency causes argininemia.	03540966		ENSG00000118520	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	6	131924689	6	131603549	rs2248551	HMDB0000517	L-arginine levels	L-Arginine
AMR|ASW|EUR|JPT|ZZ2		GCST002652	154.699	GCST002652	25293881		expert curated	High	Eric Fauman	UGT2B10 encodes a UDP glucuronosyltransferase which glucuronidates cotinine to produce cotinine glucuronide	17576790		ENSG00000109181	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	4	69673553	4	68807835	rs34100980	HMDB0001013	Cotinine glucuronidation	Cotinine glucuronide
EUR		GCST002679	19.177	GCST002679	25352340		expert curated	High	Eric Fauman	TF encodes transferrin, a key transporter for iron.	01809186		ENSG00000091513	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	3	133477701	3	133758857	rs8177240	HMDB0015531	Iron|serum	Iron
EUR		GCST002679	96.565	GCST002679	25352340		expert curated	High	Eric Fauman	HFE encodes the hereditary hemochromatosis protein which binds transferrin receptor which binds transferrin which binds iron	09465039		ENSG00000010704	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	6	26093141	6	26092913	rs1800562	HMDB0015531	Iron|serum	Iron
EUR		GCST002679	18.0	GCST002679	25352340		expert curated	High	Eric Fauman	TFR2 encodes a receptor for transferrin which binds iron	10409623		ENSG00000106327	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	7	100235970	7	100638347	rs7385804	HMDB0015531	Iron status biomarkers (iron levels)	Iron
EUR		GCST002679	139.0	GCST002679	25352340		expert curated	High	Eric Fauman	TMPRSS6 encodes a protease which regulates levels of hepcidin which regulates iron levels	25588876		ENSG00000187045	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	22	37462936	22	37066896	rs855791	HMDB0015531	Iron status biomarkers (iron levels)	Iron
EUR		GCST002690	39.577	GCST002690	25378659		expert curated	High	Eric Fauman	CERS4 encodes a ceramide synthase which produces ceramides from sphingosine and a long chain acyl CoA, derived from long chain free fatty acids.	12912983		ENSG00000090661	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	19	8281635	19	8216751	rs2100944	HMDB0002212	FA 20:0|plasma	Arachidic acid
unknown		GCST002712	48.523	GCST002712_9	25500335		expert curated	High	Eric Fauman	LPCAT3 encodes a lysophosphatidylcholine acyltransferase which takes the CoA version of oleic acid to convert lysophosphatidylcholine to phosphatidylcholine.	18781350		ENSG00000111684	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	12	7075882	12	6966719	rs2110073	HMDB0000207	Red blood cell fatty acid levels (OA)	Oleic Acid
unknown		GCST002831	13.398	GCST002831	25820613		expert curated	High	Eric Fauman	ALAD encodes aminolevulinate dehydratase, an enzyme which binds to lead.	01713045		ENSG00000148218	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	9	116151191	9	113388911	rs1805313	HMDB0004628	Lead levels in blood	Lead
unknown		GCST002932	13.658	GCST002932	26025379		expert curated	High	Eric Fauman	SLC30A10 encodes a transporter with specificity for manganese.	25319704		ENSG00000196660	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	1	220080028	1	219906686	rs1776029	HMDB0001333	Manganese|plasma	Manganese
EUR		GCST002964	31.699	GCST002964_2	26068415		expert curated	High	Eric Fauman	SPTLC3 encodes a subunit of serine palmitoyltransferase, which catalyzes the first step in de novo sphingolipid biosynthesis.	17023427		ENSG00000172296	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	20	12959398	20	12978750	rs4814176	HMDB0013469	Sphingolipid levels (Hydroxysphingomyeline C24:1)	Hydroxysphingomyeline C24:1
EUR		GCST002961	80.82	GCST002961_2	26068415		expert curated	High	Eric Fauman	SLC16A9 encodes a carnitine efflux transporter.	21886157		ENSG00000165449	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	10	61469538	10	59709780	rs1171614	HMDB0000062	C0	L-Carnitine
EUR		GCST002966	58.523	GCST002966_4	26068415		expert curated	High	Eric Fauman	PRODH encodes proline dehydrogenase which catalyzes the first step in proline degradation	16874462		ENSG00000100033	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	22	18959684	22	18972171	rs2540641	HMDB0000162	Blood metabolite levels (proline)	L-Proline
EUR		GCST002966	17.353	GCST002966_5	26068415		expert curated	High	Eric Fauman	PSPH encodes phosphoserine phosphatase which produces serine	16589713		ENSG00000146733	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	7	56079094	7	56011401	rs4947534	HMDB0000187	Ser	L-Serine
EUR		GCST002966	12.552	GCST002965_33	26068415		expert curated	High	Eric Fauman	MFSD2A encodes a lysophosphotidylcholine transporter.	24828044		ENSG00000168389	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	G	1	40403370	1	39937698	rs7529794	HMDB0010382	lysoPC a C16:0	LysoPC(16:0)
EUR		GCST002966	9.39	GCST002965_13	26068415		expert curated	High	Eric Fauman	AGPS encodes the alkylglycerone phosphate synthase which generates ether phospholipids such as the metabolite detected here.	10215861		ENSG00000018510	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	2	178370631	2	177505903	rs7582179	HMDB0013456	PC ae C44:5	PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))
EUR		GCST002966	10.475	GCST002965_13	26068415		expert curated	High	Eric Fauman	ACSL1 encodes a long-chain fatty-acid-coenzyme A ligase which produces acyl-CoAs.  These in turn can be used in the synthesis of plasmalogens, e.g., via LPCAT4	08584017		ENSG00000151726	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	4	185773811	4	184852657	rs7700133	HMDB0013456	PC ae C44:5	PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))
EUR		GCST002966	10.419	GCST002965_2	26068415		expert curated	High	Eric Fauman	ABHD3 encodes a phospholipase with demonstrated activity against PC(32:2), specifically the PC(14:0/18:2) stereoisomer.	21926997		ENSG00000158201	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	18	19263128	18	21683167	rs7343008	HMDB0007874	PC aa C32:2	Phosphatidyl choline PC(14:0/18:2(9Z,12Z)) is a specific example  
EUR		GCST003119	251.625	GCST003119_11	26352407		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	AGXT2 encodes an alanine-glyoxylate aminotransferase, an enzyme which can take 3-aminoisobutyrate as a substrate.|AGXT2 encodes an alanine-glyoxylate aminotransferase, an enzyme which can take 3-aminoisobutyrate as a substrate.	08427875|05773299		ENSG00000113492	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	5	35037115	5	35037010	rs37369	HMDB0003911	3-aminoisobutyrate|urine	3-Aminoisobutanoic acid
EUR		GCST003119	17.159		26352407		expert curated	High	Eric Fauman	AGXT encodes alanine-glyoxylate aminotransferase.  When acting on valine, rather than alanine, as a substrate, the enzyme will produce alpha-ketoisovaleric acid as a product (see EC code EC 2.6.1.66).  The mouse and rat orthologs have demonstrated activity on valine.	00629740		ENSG00000172482	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	2	241837452	2	240898035	rs6748734	HMDB0000019	alpha-ketoisovalerate|urine	alpha-Ketoisovaleric acid
EUR		GCST003119	59.074	GCST003119_14	26352407		expert curated	High	Eric Fauman	SLC6A20 encodes a transporter for N-methylglycine, proline and other specific amino acids.	15632147		ENSG00000163817	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	G	3	45814094	3	45772602	rs17279437	HMDB0000092|HMDB0000161	N,N-dimethylglycine/alanine|urine	Dimethylglycine / L-Alanine
EUR		GCST003119	27.146		26352407		expert curated	High	Eric Fauman	ETNPPL encodes the ethanolamine-phosphate phospho-lyase which acts on the phosphorylated form of ethanolamine.  AGXT2L1 is a common synonym for this gene.	22241472		ENSG00000164089	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	4	109705967	4	108784811	rs56043887	HMDB0000149	ethanolamine|urine	Ethanolamine
EUR		GCST003119	14.68	GCST003119_16	26352407		expert curated	High	Eric Fauman	SLC36A2 encodes the a proton-coupled amino acid transporter, which is specific for glycine and proline.	19033659		ENSG00000186335	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	5	150698806	5	151319245	rs3846710	HMDB0000123|HMDB0000094	glycine/citrate|urine	Glycine / Citric acid
EUR		GCST003119	13.53	GCST003119_17	26352407		expert curated	High	Eric Fauman	XYLB encodes a xylulokinase homolog which phosphorylates D-xylulose, a precursor of glycolate	09783918		ENSG00000093217	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	3	38395562	3	38354071	rs3132440	HMDB0000115	glycolate|urine	Glycolic acid
EUR		GCST003119	261.126	GCST002443_168	26352407		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	SLC6A19 encodes a neutral amino acid transporter which can act on tyrosine.  The nearby paralog, SLC6A18, is specific for glycine.|SLC6A19 encodes a neutral amino acid transporter which can act on tyrosine.  The nearby paralog, SLC6A18, is specific for glycine.	15044460|15804236		ENSG00000174358	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	5	1183560	5	1183445	rs11750211	HMDB0000158	tyrosine|urine	L-Tyrosine
EUR		GCST003119	65.034	GCST002443_148	26352407		expert curated	High	Eric Fauman	SLC5A11 encodes a sodium/myo-inositol transporter (SMIT2) which can also transport scyllo-inostiol.	21887366		ENSG00000158865	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	16	25002600	16	24991279	rs17702912	HMDB0000211	myo-inositol|urine	myo-Inositol
EUR		GCST003119	15.845	GCST003666_3	26352407		expert curated	High	Eric Fauman	SLC13A3 encodes a high affinity succinate transporter enriched in kidney tissue.	10794676		ENSG00000158296	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	20	45261041	20	46632402	rs941206	HMDB0000254|HMDB0000094	sucinate/citrate|urine	Succinic acid / Citric acid
EUR		GCST006879	36.131	GCST006879_4	26401656		expert curated	High	Eric Fauman	SLC22A16 encodes transporter specific for carnitine	12089149		ENSG00000004809	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	6	110760008	6	110438805	rs12210538	EFO_0005059 	total acylcarnitine	acylcarnitine measurement
EUR		GCST006879	11.622	GCST006879_5	26401656		expert curated	High	Eric Fauman	GPT encodes alanine aminotransferase which takes alanine as a substrate and produces glutamate which is one step removed from aspartate.	09119391		ENSG00000167701	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	8	145701453	8	144476070	rs750472	HMDB0000161|HMDB0000168	metabolite ratio (Ala/Asp)	L-Alanine / L-Asparagine
EUR		GCST006879	82.375	GCST006879_17	26401656		expert curated	High	Eric Fauman	CRAT encodes carnitine O-acetyltransferase, which catalyzes the interconversion of short chain acylcarnitines and acyl-coenzyme A derivatives. 	02351134		ENSG00000095321	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	9	131865027	9	129102748	rs746872	HMDB0013133	Methylmalonylcarnitine	Methylmalonylcarnitine
EUR		GCST006879	7.269	GCST006879_2	26401656		expert curated	High	Eric Fauman	HLCS encodes a biotin apo-protein ligase which attaches biotin to four biotin-dependent enymes, including enzymes involved in branched chain amino acid catabolism.  Holocarboxylase synthetase deficiency results in increased levels of 3-Hydroxyisovalerylcarnitine.	19201116		ENSG00000159267	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	21	38336834	21	36964534	rs1571700	HMDB0061189	2-Hydroxyisovalerylcarnitine	Similar to 3-Hydroxyisovalerylcarnitine
FIN			85.239		26407342		expert curated	High	Eric Fauman	CYP2A6 encodes a cytochrome P450 which is the primary enzyme responsible for the conversion of nicotine to cotinine.	08937855		ENSG00000255974	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	19	41353107	19	40847202	rs56113850	HMDB0001390|HMDB0001046	Nicotine Metabolite Ratio	ratio of Hydroxycotinine to Cotinine
EUR		GCST003666	17.319	GCST003666_3	27005778		expert curated	High	Eric Fauman	SLC13A5 encodes NaCT, a sodium-coupled citrate transporter.	16973915		ENSG00000141485	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	17	6595398	17	6692079	rs172642	HMDB0000094	Citrate	Citric acid
EUR		GCST003666	21.886	GCST003666_3	27005778		expert curated	High	Eric Fauman	SLC25A1 encodes the mitochondrial-localized tricarboxylate transporter of citrate.	02804096		ENSG00000100075	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	22	19161935	22	19174422	rs2040771	HMDB0000094	Citrate	Citric acid
EUR		GCST003666	300.0	GCST003666_7	27005778		expert curated	High	Eric Fauman	CPS1 encodes a mitochondrial carbamoyl phosphate synthetase which takes ammonia as a substrate.   Glycine and ammonia are interconverted via the glycine cleavage complex.	18941301		ENSG00000021826	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	2	211540507	2	210675783	rs1047891	HMDB0000123	Glycine	Glycine
EUR		GCST003666	39.432	GCST003666_7	27005778		expert curated	High	Eric Fauman	GLDC encodes glycine dehydrogenase which takes glycine as a substrate.  GLDC deficiency causes excess of glycine.	04585091		ENSG00000178445	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	TA	T	9	5877295	9	5877295	rs140348140	HMDB0000123	Glycine	Glycine
EUR		GCST003666	12.523	GCST003666_7	27005778		expert curated	High	Eric Fauman	GCSH encodes the glycine cleavage system H protein which is involved in the degradation of glycine.  GCSH deficiency leads to excess plasma glycine.	18941301		ENSG00000140905	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	16	81065282	16	81031677	rs10083777	HMDB0000123	Glycine	Glycine
EUR		GCST003665	10.495	GCST003665_10	27005778		expert curated	High	Eric Fauman	APOA2 encodes apolipoprotein A-II, a major component of HDL particles	24089247		ENSG00000158874	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	1	161190250	1	161220460	rs4503368	EFO_0004612	XL.HDL.PL	high density lipoprotein cholesterol measurement
EUR		GCST003665	54.585	GCST003665	27005778		expert curated	High	Eric Fauman	PLTP encodes phospholipid transfer protein which acts directly on HDL particles.	08664337		ENSG00000100979	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	T	20	44551855	20	45923216	rs6073958	EFO_0004612	S.HDL.P	high density lipoprotein cholesterol measurement
EUR		GCST003666	12.215	GCST003666	27005778		expert curated|expert curated	High|High	Eric Fauman|Eric Fauman	SLC38A4 encodes a liver-enriched amino acid transporter (ATA3) with affinity for most cationic and neutral amino acids including alanine.|SLC38A4 encodes a liver-enriched amino acid transporter (ATA3) with affinity for most cationic and neutral amino acids including alanine.	11342143|11118514		ENSG00000139209	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	12	47201814	12	46808031	rs4554975	HMDB0000161	Alanine	L-Alanine
EUR		GCST003666	69.481	GCST003666_6	27005778		expert curated	High	Eric Fauman	GLS2 encodes the mitochondrial phosphate-activated glutaminase which catalyzes the hydrolysis of glutamine to glutamate and ammonia.	10620514		ENSG00000135423	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	12	56865338	12	56471554	rs2657879	HMDB0000641	Glutamine	L-Glutamine
EUR		GCST003666	14.137	GCST003666_10	27005778		expert curated	High	Eric Fauman	HAL encodes histidine ammonia-lyase which catalyzes the first step in the degradation of histidine to glutamate.	13018112		ENSG00000084110	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	12	96314795	12	95921017	rs7954638	HMDB0000177	Metabolite levels (small molecules and protein measures) (Histidine)	L-Histidine
EUR		GCST003666	14.602	GCST003666_11	27005778		expert curated	High	Eric Fauman	PAH encodes the enzyme phenylalanine hydroxylase which is the rate-limiting step in phenylalanine catabolism.	04150152		ENSG00000171759	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	A	12	103242396	12	102848618	rs1718309	HMDB0000159	Phenylalanine	L-Phenylalanine
EUR		GCST003666	23.854	GCST003666_13	27005778		expert curated	High	Eric Fauman	SLC16A10 encodes the T?type amino acid transporter?1 (TAT1); this transporter transports tryptophan, tyrosine and phenylalanine	11827462		ENSG00000112394	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	A	C	6	111543944	6	111222741	rs14399	HMDB0000158	Tyrosine	L-Tyrosine
EUR		GCST003666	34.77	GCST003666_15	27005778		expert curated	High	Eric Fauman	PPM1K encodes a phosphatase called PP2Cm for the branched-chain keto acid dehydrogenase (BCKD) complex.  BCKD catalyzes an essential step in the catabolism of valine and the other branched chain amino acids.	19411760		ENSG00000163644	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	C	A	4	89206230	4	88285078	rs9637599	HMDB0000883	Valine	L-Valine
EUR		GCST003666	10.678	GCST003666_12	27005778		expert curated	High	Eric Fauman	PDPR encodes a component of the pyruvate dehydrogenase complex (PDC) which converts pyruvate into acetyl-CoA.	09395502		ENSG00000090857	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	T	C	16	69979271	16	69945368	rs74249229	HMDB0000243	Pyruvate	Pyruvic acid
EUR		GCST003665	99.866	GCST003217	28334899		expert curated	High	Eric Fauman	MLXIPL encodes the carbohydrate-responsive element-binding protein, a transcription factor for multiple lipogenic enzymes.	16890538		ENSG00000009950	High		2019-05-17	Ed Mountjoy	ProGeM	Eric Fauman	metabolite|mQTL	G	T	7	72863249	7	73448919	rs17145738	EFO_0004530	Triglycerides	triglyceride measurement
European=341215		GCST007798	10.221848749616356	GCST007798	30929738		drug	Low	Ed Mountjoy	PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000171608 at this locus (355116bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171608	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	1	9356676	1	9296617		EFO_0000270	Asthma	asthma
European, Other=1157		GCST001476	7.301029995663981	GCST001476_7	22491018		drug	Low	Ed Mountjoy	PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000171608 at this locus (302833bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171608	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	1	9408959	1	9348900		EFO_0000685	Response to tocilizumab in rheumatoid arthritis [CSJC , EA, RF-]	rheumatoid arthritis
European=488|African American or Afro-Caribbean=111|Hispanic or Latin American=60|Other=56		GCST004250	8.0	GCST004250_2	28090653		drug	Low	Ed Mountjoy	CAMPATH-1 antigen inhibitor drug ALEMTUZUMAB is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000169442 at this locus (491379bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169442	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	1	27138393	1	26811902		EFO_0000220	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) [AA]	acute lymphoblastic leukemia
Other=1097|NR=150064		GCST003048	8.522878745280337	GCST003048	26198764		drug	Low	Ed Mountjoy	Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (419487bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196517	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	1	44037685	1	43572014		EFO_0000692	Schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	12.0	GCST004946	28991256		drug	Low	Ed Mountjoy	Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196517	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	1	44097530	1	43631859		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	8.397940008672037	GCST007201_2	30285260		drug	Low	Ed Mountjoy	Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196517	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	1	44097530	1	43631859		EFO_0000692	Schizophrenia [EA]	schizophrenia
European=105318		GCST006803	11.0	GCST006803	29483656		drug	Low	Ed Mountjoy	Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196517	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	1	44097530	1	43631859		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	10.0	GCST007201	30285260		drug	Low	Ed Mountjoy	Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196517	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	1	44097530	1	43631859		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	9.522878745280337	GCST002539	25056061		drug	Low	Ed Mountjoy	Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196517	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	1	44100084	1	43634413		EFO_0000692	Schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	9.397940008672037	GCST004521	28540026		drug	Low	Ed Mountjoy	Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196517	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	1	44100084	1	43634413		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=139274		GCST004988	7.530472520812986	GCST004988	29059683		drug	Low	Ed Mountjoy	Anandamide amidohydrolase inhibitor drug ACETAMINOPHEN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000117480 at this locus (259073bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000117480	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	1	46600917	1	46135245		EFO_0000305	Breast cancer	breast carcinoma
European=361141			28.214189147749966	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	1	55487346	1	55021673		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=361141			28.214189147749966	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	1	55487346	1	55021673		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=361141			28.214189147749966	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	1	55487346	1	55021673		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=406276	10.1038/s41588-018-0184-y		11.88941028970075	SAIGE_272_11			drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	1	55489542	1	55023869		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
European=408961	10.1038/s41588-018-0184-y		12.71669877129645	SAIGE_272			drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	1	55489542	1	55023869		Orphanet_309005	Disorders of lipoid metabolism	Disorder of lipid metabolism
European=406276	10.1038/s41588-018-0184-y		11.88941028970075	SAIGE_272_11			drug	Low	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	1	55489542	1	55023869		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
European=408961	10.1038/s41588-018-0184-y		12.71669877129645	SAIGE_272			drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	1	55489542	1	55023869		Orphanet_309005	Disorders of lipoid metabolism	Disorder of lipid metabolism
European=408878	10.1038/s41588-018-0184-y		12.79860287567955	SAIGE_272_1			drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (15680bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	1	55489542	1	55023869		EFO_0003774	Hyperlipidemia	hyperlipidemia
European=406276	10.1038/s41588-018-0184-y		11.88941028970075	SAIGE_272_11			drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	1	55489542	1	55023869		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	7.698970004336019	GCST003116	26343387		drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (9183bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	1	55496039	1	55030366		EFO_0000378	Coronary artery disease	coronary artery disease
European=408878	10.1038/s41588-018-0184-y		23.57186520597121	SAIGE_272_1			drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	1	55505647	1	55039974		EFO_0003774	Hyperlipidemia	hyperlipidemia
European=406276	10.1038/s41588-018-0184-y		20.25103713874384	SAIGE_272_11			drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	1	55505647	1	55039974		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
NR=250736		GCST005196	24.69897000433602	GCST005196	29212778		drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		EFO_0000378	Coronary artery disease	coronary artery disease
European=408458	10.1038/s41588-018-0184-y		11.844663962534938	SAIGE_411			drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		EFO_0000378	Ischemic heart disease	coronary artery disease
European=406276	10.1038/s41588-018-0184-y		20.25103713874384	SAIGE_272_11			drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
European=406276	10.1038/s41588-018-0184-y		20.25103713874384	SAIGE_272_11			drug	Low	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	1	55505647	1	55039974		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
European=459000		GCST007072	11.0	GCST007072	30595370		drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			64.89219328560758	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	1	55505647	1	55039974		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European, NR=63731		GCST004787	9.522878745280337	GCST004787	28714975		drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		EFO_0000378	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	coronary artery disease
European=361141			64.89219328560758	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	1	55505647	1	55039974		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
NR=296525		GCST005194	21.731656086048936	GCST005194	29212778		drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		EFO_0000378	Coronary artery disease	coronary artery disease
NR=547261		GCST005195	17.82390874094432	GCST005195	29212778		drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		EFO_0000378	Coronary artery disease	coronary artery disease
European=408961	10.1038/s41588-018-0184-y		23.614393726401687	SAIGE_272			drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		Orphanet_309005	Disorders of lipoid metabolism	Disorder of lipid metabolism
European=408961	10.1038/s41588-018-0184-y		23.614393726401687	SAIGE_272			drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	1	55505647	1	55039974		Orphanet_309005	Disorders of lipoid metabolism	Disorder of lipid metabolism
European=361141			64.89219328560758	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55505647	1	55039974		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=459000		GCST007072	11.0	GCST007072	30595370		drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	1	55505647	1	55039974		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			14.0	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	55521313	1	55055640		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=361141			14.0	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	1	55521313	1	55055640		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=361141			14.0	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169174	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	1	55521313	1	55055640		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=406276	10.1038/s41588-018-0184-y		7.812479279163537	SAIGE_272_11			drug	Low	Ed Mountjoy	Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (14882bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132855	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	1	63048277	1	62582606		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
European=361141			24.119709018294724	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (49271bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132855	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	TC	T	1	63121101	1	62655430		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=6889		GCST001957	8.698970004336019	GCST001957	23563609		drug	Medium	Ed Mountjoy	Leptin receptor agonist drug METRELEPTIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000116678 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000116678	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	1	65979280	1	65513597		EFO_0001073	Obesity (early onset extreme)	obesity
European=26621		GCST001198	9.426548177964515	GCST001198	21833088		drug	Low	Ed Mountjoy	Sphingosine 1-phosphate receptor Edg-1 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000170989	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	1	101407519	1	100941963		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=26621		GCST001198	9.426548177964515	GCST001198	21833088		drug	Low	Ed Mountjoy	Sphingosine 1-phosphate receptor Edg-1 agonist drug PONESIMOD is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000170989	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	1	101407519	1	100941963		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=33394		GCST005527	14.221848749616356	GCST005527	23143594		drug	Low	Ed Mountjoy	T-cell surface antigen CD2 inhibitor drug SIPLIZUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000116824	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	1	117287354	1	116744732		EFO_0000676	Psoriasis	psoriasis
European=33394		GCST005527	14.221848749616356	GCST005527	23143594		drug	High	Ed Mountjoy	T-cell surface antigen CD2 inhibitor drug ALEFACEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000116824	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	1	117287354	1	116744732		EFO_0000676	Psoriasis	psoriasis
Other=1097|NR=150064		GCST003048	9.397940008672037	GCST003048	26198764		drug	Medium	Ed Mountjoy	Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	HG1287_PATCH	150745909	1	150059494		EFO_0000692	Schizophrenia	schizophrenia
European=105318		GCST006803	9.154901959985743	GCST006803	29483656		drug	Medium	Ed Mountjoy	Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	HG1287_PATCH	150745909	1	150059494		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	9.397940008672037	GCST002539	25056061		drug	Medium	Ed Mountjoy	Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	HG1287_PATCH	150745909	1	150059494		EFO_0000692	Schizophrenia	schizophrenia
NR=150064|European=70017		GCST007257	10.301029995663981	GCST007257	30626913		drug	Medium	Ed Mountjoy	Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (225954bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	1	150115974	1	150143798		EFO_0000692	Broad depression or schizophrenia	schizophrenia
NR=150064|European=70017		GCST007257	10.301029995663981	GCST007257	30626913		drug	Medium	Ed Mountjoy	Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000159164 at this locus (225954bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	1	150115974	1	150143798		EFO_0003761	Broad depression or schizophrenia	unipolar depression
European=140254		GCST006085	11.0	GCST006085	29892016		drug	Medium	Ed Mountjoy	Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000143387	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	1	150658287	1	150685811		EFO_0001663	Prostate cancer	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	10.221848749616356	GCST002606_3	25217961		drug	Medium	Ed Mountjoy	Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000143387	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	1	150658287	1	150685811		EFO_0001663	Prostate cancer [EA]	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	8.522878745280337	GCST002606	25217961		drug	Medium	Ed Mountjoy	Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000143387	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	1	150658287	1	150685811		EFO_0001663	Prostate cancer	prostate carcinoma
European=459000		GCST007072	9.096910013008056	GCST007072	30595370		drug	High	Ed Mountjoy	Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169418 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169418	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	1	153662423	1	153689947		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			10.209025579976215	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169418 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169418	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	1	153662423	1	153689947		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=22647|East Asian=3117		GCST005529	14.698970004336019	GCST005529_3	23749187		drug	Medium	Ed Mountjoy	Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	1	154426264	1	154453788		EFO_0003898	Ankylosing spondylitis [EA]	ankylosing spondylitis
European=86475		GCST005537	17.045757490560675	GCST005537	26974007		drug	Medium	Ed Mountjoy	Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	1	154426264	1	154453788		EFO_0003898	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ankylosing spondylitis
European=22647|East Asian=3117		GCST005529	12.522878745280337	GCST005529	23749187		drug	Low	Ed Mountjoy	Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	1	154426264	1	154453788		EFO_0003898	Ankylosing spondylitis	ankylosing spondylitis
European=22647|East Asian=3117		GCST005529	14.698970004336019	GCST005529_3	23749187		drug	Low	Ed Mountjoy	Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	1	154426264	1	154453788		EFO_0003898	Ankylosing spondylitis [EA]	ankylosing spondylitis
European=86475		GCST005537	17.045757490560675	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	1	154426264	1	154453788		EFO_0003898	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ankylosing spondylitis
European=22647|East Asian=3117		GCST005529	12.522878745280337	GCST005529	23749187		drug	Medium	Ed Mountjoy	Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	1	154426264	1	154453788		EFO_0003898	Ankylosing spondylitis	ankylosing spondylitis
European=58284|East Asian=22515		GCST002318	8.397940008672037	GCST002318	24390342		drug	High	Ed Mountjoy	Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	1	154426970	1	154454494		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=47580		GCST005569	7.8807441107220635	GCST005569	23143596		drug	High	Ed Mountjoy	Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	1	154426970	1	154454494		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	8.522878745280337	GCST006959	30423114		drug	High	Ed Mountjoy	Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160712	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	1	154426970	1	154454494		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=140254		GCST006085	8.0	GCST006085	29892016		drug	Low	Ed Mountjoy	Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160752	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	1	154834183	1	154861707		EFO_0001663	Prostate cancer	prostate carcinoma
European=22548		GCST001942	7.698970004336019	GCST001942	23535732		drug	Low	Ed Mountjoy	Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160752	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	1	154834183	1	154861707		EFO_0001663	Prostate cancer	prostate carcinoma
European=86475		GCST005537	9.522878745280337	GCST005537	26974007		drug	Medium	Ed Mountjoy	Farnesyl diphosphate synthase inhibitor drug PAMIDRONIC ACID is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000160752 at this locus (150834bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160752	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	1	155130391	1	155157915		EFO_0003898	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ankylosing spondylitis
European=139274		GCST004988	10.316502682320188	GCST004988	29059683		drug	Medium	Ed Mountjoy	Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160752	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	1	155148781	1	155176305		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	10.316502682320188	GCST004988	29059683		drug	Medium	Ed Mountjoy	Farnesyl diphosphate synthase inhibitor drug ALENDRONIC ACID is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160752	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	1	155148781	1	155176305		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	10.316502682320188	GCST004988	29059683		drug	Low	Ed Mountjoy	Mucin-1 other drug HUHMFG1 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000185499 at this locus (9520bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000185499	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	1	155148781	1	155176305		EFO_0000305	Breast cancer	breast carcinoma
European=360527			33.801755413771765	NEALE2_6152_7		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198734	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	1	169467654	1	169498416		EFO_0003827	Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	pulmonary embolism
European=361141			34.79160702064111	NEALE2_20002_1093		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198734	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	1	169467654	1	169498416		EFO_0003827	Pulmonary embolism +/- dvt | non-cancer illness code, self-reported	pulmonary embolism
European=258962		GCST003390	136.39794000867204	GCST003390	26908601		drug	Low	Ed Mountjoy	Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198734	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	1	169519049	1	169549811		EFO_0003827	Thrombosis	pulmonary embolism
European=361141			7.340779989063745	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (452003bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000117586	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	1	172700868	1	172731728		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=341215		GCST007798	11.154901959985743	GCST007798	30929738		drug	Low	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (21377bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000117586	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	1	173131493	1	173162354		EFO_0000270	Asthma	asthma
European=157242		GCST003987	7.522878745280337	GCST003987	27182965		drug	Low	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (834bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000117586	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	1	173152036	1	173182897		EFO_0000270	Asthma	asthma
European=361141			8.202546175019036	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000117586	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	1	173170618	1	173201479		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=360527			8.11264155329629	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000117586	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	1	173170618	1	173201479		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=455221		GCST007093	8.0	GCST007093	30664745		drug	Low	Ed Mountjoy	Antithrombin-III activator drug HEPARIN SODIUM is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000117601 at this locus (305887bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000117601	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	TAAAAAAAAAAAAAAAAA	1	174192402	1	174223264		EFO_0002506	Osteoarthritis	osteoarthritis
European=20883		GCST003044	8.37190434327122	GCST003044	26192919		drug	Medium	Ed Mountjoy	Cyclooxygenase-2 inhibitor drug CELECOXIB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000073756 at this locus (225905bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000073756	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	1	186875459	1	186906327		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=1030836		GCST006414	19.006828394969236	GCST006414	30061737		drug	Low	Ed Mountjoy	Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	1	203026214	1	203057086		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	24.221848749616356	GCST006061	29892015		drug	Low	Ed Mountjoy	Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	1	203026214	1	203057086		EFO_0000275	Atrial fibrillation	atrial fibrillation
East Asian=36792		GCST004373	10.045757490560675	GCST004373	28416822		drug	Low	Ed Mountjoy	Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33191bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	1	203026591	1	203057463		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=395739	10.1038/s41588-018-0184-y		9.97061622231479	SAIGE_427_2			drug	Low	Ed Mountjoy	Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	1	203028711	1	203059583		EFO_0000275	Atrial fibrillation and flutter	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	18.0	GCST006061_3	29892015		drug	Low	Ed Mountjoy	Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	1	203028711	1	203059583		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
East Asian=4372		GCST004352	8.698970004336019	GCST004352	28460022		drug	Low	Ed Mountjoy	Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (24876bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	1	203034906	1	203065778		EFO_0000275	Early onset atrial fibrillation	atrial fibrillation
European=360527			9.949848472659069	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	1	203091274	1	203122146		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=341215		GCST007798	10.045757490560675	GCST007798	30929738		drug	Low	Ed Mountjoy	Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	1	203093201	1	203124073		EFO_0000270	Asthma	asthma
European=157242		GCST003987	8.0	GCST003987	27182965		drug	Low	Ed Mountjoy	Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	1	203100504	1	203131376		EFO_0000270	Asthma	asthma
European=361141			9.000392345087638	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163485	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	TA	T	1	203103205	1	203134077		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=361141			8.172660456455034	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Potassium channel subfamily K member 2 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000082482 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082482	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	TATA	1	215304685	1	215131342		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=139274		GCST004988	8.408601448718752	GCST004988	29059683		drug	Low	Ed Mountjoy	Estrogen-related receptor gamma antagonist drug AFIMOXIFENE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000196482 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196482	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	1	217220574	1	217047232		EFO_0000305	Breast cancer	breast carcinoma
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	8.154901959985743	GCST007692	30804561		drug	High	Ed Mountjoy	Muscarinic acetylcholine receptor M3 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000133019	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	1	239901006	1	239737706		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	8.154901959985743	GCST007692	30804561		drug	Low	Ed Mountjoy	Muscarinic acetylcholine receptor M3 antagonist drug AZD8683 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000133019	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	1	239901006	1	239737706		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European=88583		GCST007505	7.698970004336019	GCST007505	30429480		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000134460 at this locus (268502bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	10	5784151	10	5742188		EFO_0000389	Nevus count or cutaneous melanoma	skin melanoma
European=20883		GCST003044	12.095825631715837	GCST003044	26192919		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	10	6081230	10	6039267		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=4421		GCST004290	9.0	GCST004290	28445677		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	10	6092346	10	6050383		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=360527			14.096910013008056	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6093139	10	6051176		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=341215		GCST007798	17.69897000433602	GCST007798	30929738		drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6093139	10	6051176		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		8.749579997691106	SAIGE_495			drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6093139	10	6051176		EFO_0000270	Asthma	asthma
European=361141			13.823908740944319	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6093139	10	6051176		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=86475		GCST005537	15.0	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=16179		GCST001394	8.301029995663981	GCST001394	22293688		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6094697	10	6052734		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European, NR=40266		GCST004132	7.702896349850744	GCST004132	28067908		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0000384	Crohn's disease	Crohn's disease
European=86475		GCST005537	15.0	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
European=29652		GCST005536	38.54606892809315	GCST005536	25751624		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=16179		GCST001394	8.301029995663981	GCST001394	22293688		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=102453		GCST007563	11.397940008672037	GCST007563	29785011		drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0000270	Allergic disease (asthma, hay fever or eczema)	asthma
European=29652		GCST005536	38.54606892809315	GCST005536	25751624		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6094697	10	6052734		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=20883		GCST003044	12.496209316942819	GCST003044	26192919		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=116538		GCST007564	10.698970004336019	GCST007564	29785011		drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6094697	10	6052734		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=19102		GCST001191	38.0	GCST001191	21829393		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	10	6097283	10	6055320		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=19102		GCST001191	38.0	GCST001191	21829393		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	10	6097283	10	6055320		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=16753		GCST003097	8.221848749616356	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6098949	10	6056986		EFO_0000384	Pediatric autoimmune diseases	Crohn's disease
European=16753		GCST003097	8.221848749616356	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6098949	10	6056986		EFO_0001359	Pediatric autoimmune diseases	insulin-dependent diabetes mellitus
European=16753		GCST003097	8.221848749616356	GCST003097	26301688		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6098949	10	6056986		EFO_0001359	Pediatric autoimmune diseases	insulin-dependent diabetes mellitus
European=16753		GCST003097	8.221848749616356	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6098949	10	6056986		EFO_0002690	Pediatric autoimmune diseases	systemic lupus erythematosus
European=16753		GCST003097	8.221848749616356	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6098949	10	6056986		EFO_0000729	Pediatric autoimmune diseases	ulcerative colitis
European=38582		GCST005531	22.11861534322943	GCST005531	24076602		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	10	6099045	10	6057082		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=26621		GCST001198	8.68909437062386	GCST001198	21833088		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	10	6101713	10	6059750		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=21389		GCST000879	8.522878745280337	GCST000879	21102463		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6102012	10	6060049		EFO_0000384	Crohn's disease	Crohn's disease
European=5224		GCST000062	7.522878745280337	GCST000062	17660530		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6102012	10	6060049		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=17698		GCST001341	7.3979400086720375	GCST001341	22190364		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6102012	10	6060049		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=29652		GCST005536	22.81702340982209	GCST005536	25751624		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	10	6106552	10	6064589		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=29652		GCST005536	22.81702340982209	GCST005536	25751624		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	10	6106552	10	6064589		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=38582		GCST005531	20.443697499232712	GCST005531	24076602		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (16953bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	10	6121286	10	6079323		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=15283		GCST003566	8.397940008672037	GCST003566	27386562		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (18336bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	10	6122669	10	6080706		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=16559		GCST000392	13.0	GCST000392	19430480		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6123495	10	6081532		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=16559		GCST000392	13.0	GCST000392	19430480		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6123495	10	6081532		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=38582		GCST005531	17.190440285364733	GCST005531	24076602		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (19925bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6124257	10	6082294		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=29652		GCST005536	8.257205214388867	GCST005536	25751624		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6129643	10	6087680		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=29652		GCST005536	8.257205214388867	GCST005536	25751624		drug	Medium	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	10	6129643	10	6087680		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=27432		GCST003045	8.018482423811946	GCST003045	26192919		drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (71834bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	6176166	10	6134203		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European=8207		GCST000258	8.397940008672037	GCST000258	18978792		drug	Low	Ed Mountjoy	Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	10	6390450	10	6348488		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=8207		GCST000258	8.397940008672037	GCST000258	18978792		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000134460	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	6390450	10	6348488		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=18264|African American or Afro-Caribbean=5422|Hispanic or Latin American=3888		GCST005752	9.154901959985743	GCST005752	28714469		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (327251bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	10	49974656	10	48766611		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=5420		GCST003599	8.698970004336019	GCST003599	26663301		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	50025396	10	48817351		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=14267		GCST003155	10.065299598284575	GCST003155	26502338		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	50025396	10	48817351		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=5057|European=10995		GCST003622	10.045757490560675	GCST003622_3	27399966		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	50025396	10	48817351		EFO_0002690	Systemic lupus erythematosus [EA]	systemic lupus erythematosus
European=14267		GCST003156	10.065299598284575	GCST003156	26502338		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	50025396	10	48817351		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=1798		GCST000592	11.096910013008056	GCST000592	20169177		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	50025396	10	48817351		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=5050		GCST001795	8.096910013008056	GCST001795	23273568		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (395547bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	50042951	10	48834906		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=18264		GCST007400	8.0	GCST007400	28714469		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (454572bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	50101977	10	48893932		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=2252		GCST000507	11.154901959985743	GCST000507	19838193		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (471650bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000107643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	50119054	10	48911009		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=86475		GCST005537	10.522878745280337	GCST005537	26974007		drug	Low	Ed Mountjoy	Cytochrome P450 26A1 inhibitor drug TALAROZOLE is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000095596 at this locus (401233bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000095596	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	10	94432000	10	92672243		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=22548		GCST001942	9.301029995663981	GCST001942	23535732		drug	Medium	Ed Mountjoy	Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000148795	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	10	104414221	10	102654464		EFO_0001663	Prostate cancer	prostate carcinoma
European=22548		GCST001942	9.301029995663981	GCST001942	23535732		drug	Medium	Ed Mountjoy	Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000148795	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	10	104414221	10	102654464		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	15.221848749616356	GCST006085	29892016		drug	Medium	Ed Mountjoy	Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000148795	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	10	104414221	10	102654464		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	15.221848749616356	GCST006085	29892016		drug	Medium	Ed Mountjoy	Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000148795	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	10	104414221	10	102654464		EFO_0001663	Prostate cancer	prostate carcinoma
European=361141			8.399595651036623	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug NADOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (80138bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	10	115723678	10	113963919		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
East Asian=50792		GCST007707	8.698970004336019	GCST007707	30487518		drug	High	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug ACEBUTOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (61988bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	10	115741828	10	113982069		EFO_0000537	Hypertension [East Asian]	hypertension
European=91102|African American or Afro-Caribbean=21417|Asian unspecified=12365|Hispanic or Latin American=8471		GCST006434	19.69897000433602	GCST006434_9	29912962		drug	Low	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11754bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	115792062	10	114032303		EFO_0004329	Systolic blood pressure x alcohol consumption interaction (2df test) [EA]	alcohol drinking
European=91110|African American or Afro-Caribbean=21416|Asian unspecified=12365|Hispanic or Latin American=8470		GCST006167	9.698970004336019	GCST006167_9	29912962		drug	Low	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	115792787	10	114033028		EFO_0004329	Mean arterial pressure x alcohol consumption interaction (2df test) [EA]	alcohol drinking
European=361141			21.73008330295326	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug METOPROLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (11029bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	10	115792787	10	114033028		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=91099|African American or Afro-Caribbean=21416|Asian unspecified=12365|Hispanic or Latin American=8471		GCST006166	22.096910013008056	GCST006166_8	29912962		drug	Low	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	115792787	10	114033028		EFO_0004329	Diastolic blood pressure x alcohol consumption interaction (2df test) [EA]	alcohol drinking
European=408089	10.1038/s41588-018-0184-y		14.522878745280337	SAIGE_401_1			drug	High	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	10	115805056	10	114045297		EFO_0000537	Essential hypertension	hypertension
European=408343	10.1038/s41588-018-0184-y		14.397940008672037	SAIGE_401			drug	High	Ed Mountjoy	Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	10	115805056	10	114045297		EFO_0000537	Hypertension	hypertension
European=459000		GCST007072	23.221848749616356	GCST007072	30595370		drug	High	Ed Mountjoy	Beta-1 adrenergic receptor agonist drug DOPAMINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000043591 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000043591	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	10	115805056	10	114045297		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=22627		GCST001937	7.698970004336019	GCST001937	23535729		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	123093901	10	121334387		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	8.096910013008056	GCST004950	25751625		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	123093901	10	121334387		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	11.680685695909489	GCST004988	29059683		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143858bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	GT	G	10	123093991	10	121334477		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	43.678815972697684	GCST004988	29059683		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	A	10	123331467	10	121571953		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	190.37059040089727	GCST004988	29059683		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	A	10	123331690	10	121572176		EFO_0000305	Breast cancer	breast carcinoma
European=123671		GCST003588	34.096910013008056	GCST003588_2	27197191		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	123334930	10	121575416		EFO_0000305	Cancer (pleiotropy) [subset analysis]	breast carcinoma
European=123671		GCST003588	34.096910013008056	GCST003588_2	27197191		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	123334930	10	121575416		EFO_0005842	Cancer (pleiotropy) [subset analysis]	colorectal cancer
European=123671		GCST003588	34.096910013008056	GCST003588_2	27197191		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	123334930	10	121575416		EFO_0001075	Cancer (pleiotropy) [subset analysis]	ovarian carcinoma
European=8556		GCST000678	30.397940008672037	GCST000678	20453838		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123337335	10	121577821		EFO_0000305	Breast cancer	breast carcinoma
European=2287		GCST000365	9.698970004336019	GCST000365	19330030		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123337335	10	121577821		EFO_0000305	Breast cancer	breast carcinoma
European=22627		GCST001937	169.69897000433602	GCST001937	23535729		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123337335	10	121577821		EFO_0000305	Breast cancer	breast carcinoma
East Asian=13905		GCST003520	10.522878745280337	GCST003520	27354352		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123337335	10	121577821		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	163.22184874961636	GCST004950	25751625		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123337335	10	121577821		EFO_0000305	Breast cancer	breast carcinoma
European=330828			30.844827992822484	NEALE2_20110_5		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123338975	10	121579461		EFO_0000305	Breast cancer | illnesses of mother	breast carcinoma
East Asian=4741		GCST002234	12.0	GCST002234	24143190		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	10	123340311	10	121580797		EFO_0000305	Breast cancer	breast carcinoma
East Asian=4741		GCST002234	12.0	GCST002234	24143190		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	123340311	10	121580797		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	321.65300282934044	GCST004988	29059683		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	GC	10	123340431	10	121580917		EFO_0000305	Breast cancer	breast carcinoma
European=279478			14.096910013008056	NEALE2_20111_5		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	10	123343909	10	121584395		EFO_0000305	Breast cancer | illnesses of siblings	breast carcinoma
European=1703		GCST000846	8.0	GCST000846	21060860		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	123346116	10	121586602		EFO_0000305	Breast cancer in BRCA2 mutation carriers	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		71.26440110030182	SAIGE_174			drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	10	123346116	10	121586602		EFO_0000305	Breast cancer	breast carcinoma
European=6346		GCST000952	30.0	GCST000952	21263130		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123346190	10	121586676		EFO_0000305	Breast cancer	breast carcinoma
East Asian=13905		GCST003520	8.221848749616356	GCST003520	27354352		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123346190	10	121586676		EFO_0000305	Breast cancer	breast carcinoma
European=8428		GCST000811	12.698970004336019	GCST000811	20872241		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123346190	10	121586676		EFO_0000305	Breast cancer	breast carcinoma
European=2287		GCST000036	10.0	GCST000036	17529973		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123346190	10	121586676		EFO_0000305	Breast cancer	breast carcinoma
European=6225		GCST002346	26.522878745280337	GCST002346	24493630		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	10	123348662	10	121589148		EFO_0000305	Breast cancer (early onset)	breast carcinoma
European=139274		GCST004988	36.13804762507855	GCST004988	29059683		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	A	10	123349324	10	121589810		EFO_0000305	Breast cancer	breast carcinoma
European=359981			13.229147988357855	NEALE2_2453		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	10	123350216	10	121590702		EFO_0000311	Cancer diagnosed by doctor	cancer
European=8211		GCST007302	13.698970004336019	GCST007302	23544012		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	10	123351324	10	121591810		EFO_0000305	Breast cancer in BRCA2 mutation carriers	breast carcinoma
European=5452		GCST003823	10.301029995663981	GCST003823	27764800		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	123352220	10	121592706		EFO_0000305	Estrogen receptor status in HER2 negative breast cancer	breast carcinoma
European=754		GCST000035	75.69897000433602	GCST000035	17529967		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123352317	10	121592803		EFO_0000305	Breast cancer	breast carcinoma
East Asian=13905		GCST003520	7.698970004336019	GCST003520	27354352		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	10	123352317	10	121592803		EFO_0000305	Breast cancer	breast carcinoma
European=8727		GCST003821	11.221848749616356	GCST003821	27764800		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	10	123353869	10	121594355		EFO_0000305	Estrogen receptor status in breast cancer	breast carcinoma
European=139274		GCST004988	13.173925197299173	GCST004988	29059683		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000066468	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	10	123357561	10	121598047		EFO_0000305	Breast cancer	breast carcinoma
European=408089	10.1038/s41588-018-0184-y		15.0	SAIGE_401_1			drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	11	1873232	11	1852002		EFO_0000537	Essential hypertension	hypertension
European=408343	10.1038/s41588-018-0184-y		15.0	SAIGE_401			drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	11	1873232	11	1852002		EFO_0000537	Hypertension	hypertension
European=361141			16.29810490633703	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (308214bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	1876945	11	1855715		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
East Asian=50792		GCST007707	8.0	GCST007707_2	30487518		drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (298091bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	11	1887068	11	1865838		EFO_0000537	Hypertension [Japanese]	hypertension
European=361141			26.22452645095722	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	1888614	11	1867384		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=408089	10.1038/s41588-018-0184-y		19.518557371497696	SAIGE_401_1			drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	1888614	11	1867384		EFO_0000537	Essential hypertension	hypertension
European=408343	10.1038/s41588-018-0184-y		19.619788758288394	SAIGE_401			drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	1888614	11	1867384		EFO_0000537	Hypertension	hypertension
East Asian=50792		GCST007707	15.397940008672037	GCST007707	30487518		drug	Low	Ed Mountjoy	Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (286496bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180176	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	11	1898664	11	1877434		EFO_0000537	Hypertension [East Asian]	hypertension
European=139274		GCST004988	37.01300446027562	GCST004988	29059683		drug	Low	Ed Mountjoy	Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (251679bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167244	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	1898664	11	1877434		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	8.045757490560675	GCST003845	27117709		drug	Low	Ed Mountjoy	Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (248245bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167244	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	1902097	11	1880867		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	12.698970004336019	GCST004950	25751625		drug	Low	Ed Mountjoy	Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167244	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	1909006	11	1887776		EFO_0000305	Breast cancer	breast carcinoma
European=22627		GCST001937	10.698970004336019	GCST001937	23535729		drug	Low	Ed Mountjoy	Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167244	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	1909006	11	1887776		EFO_0000305	Breast cancer	breast carcinoma
European=754		GCST000035	8.522878745280337	GCST000035	17529967		drug	Low	Ed Mountjoy	Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167244	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	1909006	11	1887776		EFO_0000305	Breast cancer	breast carcinoma
European=407701	10.1038/s41588-018-0184-y		9.896196279044043	SAIGE_250_2			drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408404	11	17386857		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	10.494850021680094	GCST005047	22885922		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	10.522878745280337	GCST002352	24509480		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	19.69897000433602	GCST006867	30054458		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	13.096910013008056	GCST004894_2	28869590		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	20.0	GCST004894	28869590		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	21.30102999566398	GCST007518	29632382		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007517	16.397940008672037	GCST007517	29632382		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=4862		GCST000025	10.301029995663981	GCST000025_2	17463249		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes [DGI+FUSION+WTCCC]	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	21.69897000433602	GCST007516	29632382		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=2931		GCST000028	10.154901959985743	GCST000028	17463246		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=4862		GCST000277	9.0	GCST000277	19056611		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes [non-obese]	type II diabetes mellitus
European=2335		GCST000024	10.154901959985743	GCST000024_2	17463248		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes [DGI+FUSION+WTCCC]	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	21.221848749616356	GCST007515	29632382		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	11.698970004336019	GCST007077	30595370		drug	Low	Ed Mountjoy	Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (943bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187486	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	17411821	11	17390274		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=361141			13.853871964321762	NEALE2_20002_1093		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (34991bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	11	46705739	11	46684189		EFO_0003827	Pulmonary embolism +/- dvt | non-cancer illness code, self-reported	pulmonary embolism
European=120158		GCST004256	8.096910013008056	GCST004256_2	28373160		drug	Medium	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	46760756	11	46739206		EFO_0004286	Venous thromboembolism [Conditioned on rs1799963]	venous thromboembolism
European=120158		GCST004256	8.096910013008056	GCST004256_2	28373160		drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46760756	11	46739206		EFO_0004286	Venous thromboembolism [Conditioned on rs1799963]	venous thromboembolism
European=404271	10.1038/s41588-018-0184-y		12.829738284605043	SAIGE_459_9			drug	High	Ed Mountjoy	Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0000319	Circulatory disease nec	cardiovascular system disease
European=258962		GCST003390	24.0	GCST003390	26908601		drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0000712	Thrombosis	cerebrovascular accident
European=120158		GCST004256	12.301029995663981	GCST004256	28373160		drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0004286	Venous thromboembolism	venous thromboembolism
European=404449	10.1038/s41588-018-0184-y		12.882728704344236	SAIGE_459			drug	High	Ed Mountjoy	Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0000319	Other disorders of circulatory system	cardiovascular system disease
European=404449	10.1038/s41588-018-0184-y		12.882728704344236	SAIGE_459			drug	Medium	Ed Mountjoy	Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	46761055	11	46739505		EFO_0000319	Other disorders of circulatory system	cardiovascular system disease
European=258962		GCST003390	24.0	GCST003390	26908601		drug	Medium	Ed Mountjoy	Thrombin inhibitor drug ARGATROBAN is Phase III for the indiciation HP_0002140 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	46761055	11	46739505		HP_0002140	Thrombosis	Ischemic stroke
European=360527			19.56919957537582	NEALE2_6152_5		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0003907	Blood clot in the leg (dvt) | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	deep vein thrombosis
European=60139		GCST002808	8.698970004336019	GCST002808	25772935		drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0004286	Venous thromboembolism	venous thromboembolism
European=258962		GCST003390	24.0	GCST003390	26908601		drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0004286	Thrombosis	venous thromboembolism
European=120158		GCST004256	12.301029995663981	GCST004256	28373160		drug	Medium	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	46761055	11	46739505		EFO_0004286	Venous thromboembolism	venous thromboembolism
European=258962		GCST003390	24.0	GCST003390	26908601		drug	High	Ed Mountjoy	Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0003907	Thrombosis	deep vein thrombosis
European=404271	10.1038/s41588-018-0184-y		12.829738284605043	SAIGE_459_9			drug	Medium	Ed Mountjoy	Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	46761055	11	46739505		EFO_0000319	Circulatory disease nec	cardiovascular system disease
European=60139		GCST002808	8.698970004336019	GCST002808	25772935		drug	Medium	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	46761055	11	46739505		EFO_0004286	Venous thromboembolism	venous thromboembolism
European=258962		GCST003390	24.0	GCST003390	26908601		drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0003827	Thrombosis	pulmonary embolism
European=361141			20.081541349622885	NEALE2_20002_1094		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0003907	Deep venous thrombosis (dvt) | non-cancer illness code, self-reported	deep vein thrombosis
European=360527			12.362510270487489	NEALE2_6152_7		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	46761055	11	46739505		EFO_0003827	Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	pulmonary embolism
European=258962		GCST003390	24.0	GCST003390	26908601		drug	Medium	Ed Mountjoy	Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180210	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	46761055	11	46739505		EFO_0004286	Thrombosis	venous thromboembolism
European=360527			8.413929430513312	NEALE2_6152_9		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	G protein-coupled receptor 44 antagonist drug SETIPIPRANT is Phase III for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183134	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	60793648	11	61026176		EFO_0003956	Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	seasonal allergic rhinitis
European=360527			8.413929430513312	NEALE2_6152_9		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	G protein-coupled receptor 44 antagonist drug QAV680 is Phase II for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183134	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	60793648	11	61026176		EFO_0003956	Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	seasonal allergic rhinitis
European=1951		GCST001737	26.0	GCST001737_2	23144326		drug	Low	Ed Mountjoy	Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168539	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	62186542	11	62419070		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [CC16]	chronic obstructive pulmonary disease
European=1951		GCST001737	26.0	GCST001737_2	23144326		drug	Low	Ed Mountjoy	Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168539	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	11	62186542	11	62419070		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [CC16]	chronic obstructive pulmonary disease
European=1951		GCST001737	13.698970004336019	GCST001737_2	23144326		drug	Low	Ed Mountjoy	Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168539	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	11	62197427	11	62429955		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [CC16]	chronic obstructive pulmonary disease
European=1951		GCST001737	13.698970004336019	GCST001737_2	23144326		drug	Low	Ed Mountjoy	Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168539	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	11	62197427	11	62429955		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [CC16]	chronic obstructive pulmonary disease
European=1951		GCST001737	9.0	GCST001737_2	23144326		drug	Low	Ed Mountjoy	Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168539	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	62199817	11	62432345		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [CC16]	chronic obstructive pulmonary disease
European=1951		GCST001737	9.0	GCST001737_2	23144326		drug	Low	Ed Mountjoy	Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168539	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	11	62199817	11	62432345		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [CC16]	chronic obstructive pulmonary disease
European=408393	10.1038/s41588-018-0184-y		7.543633966870957	SAIGE_274_1			drug	Low	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	64334114	11	64566642		EFO_0004274	Gout	gout
European=408393	10.1038/s41588-018-0184-y		7.543633966870957	SAIGE_274_1			drug	High	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	64334114	11	64566642		EFO_0004274	Gout	gout
European=408393	10.1038/s41588-018-0184-y		7.543633966870957	SAIGE_274_1			drug	High	Ed Mountjoy	Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168065	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	64334114	11	64566642		EFO_0004274	Gout	gout
European=361141			15.066630665946775	NEALE2_20002_1466		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (9456bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168065	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	11	64349802	11	64582330		EFO_0004274	Gout | non-cancer illness code, self-reported	gout
European=361141			15.066630665946775	NEALE2_20002_1466		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	11	64349802	11	64582330		EFO_0004274	Gout | non-cancer illness code, self-reported	gout
European=361141			15.066630665946775	NEALE2_20002_1466		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug SULFINPYRAZONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	11	64349802	11	64582330		EFO_0004274	Gout | non-cancer illness code, self-reported	gout
European=361141			23.07433525192862	NEALE2_20002_1466		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	11	64352063	11	64584591		EFO_0004274	Gout | non-cancer illness code, self-reported	gout
European=361141			23.07433525192862	NEALE2_20002_1466		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	64352063	11	64584591		EFO_0004274	Gout | non-cancer illness code, self-reported	gout
European=361141			23.07433525192862	NEALE2_20002_1466		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (11717bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168065	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	11	64352063	11	64584591		EFO_0004274	Gout | non-cancer illness code, self-reported	gout
East Asian=2158		GCST003925	10.301029995663981	GCST003925_2	27899376		drug	High	Ed Mountjoy	Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168065	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	64435906	11	64668434		EFO_0004274	Gout [Japanese]	gout
East Asian=1832		GCST003926	9.045757490560675	GCST003926	27899376		drug	Low	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	64435906	11	64668434		EFO_0004274	Renal underexcretion gout	gout
East Asian=1832		GCST003926	9.045757490560675	GCST003926	27899376		drug	High	Ed Mountjoy	Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168065	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	64435906	11	64668434		EFO_0004274	Renal underexcretion gout	gout
East Asian=2158		GCST003925	10.301029995663981	GCST003925_2	27899376		drug	Low	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	64435906	11	64668434		EFO_0004274	Gout [Japanese]	gout
East Asian=1832		GCST003926	9.045757490560675	GCST003926	27899376		drug	High	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	64435906	11	64668434		EFO_0004274	Renal underexcretion gout	gout
East Asian=2158		GCST003925	10.301029995663981	GCST003925_2	27899376		drug	High	Ed Mountjoy	Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197891	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	64435906	11	64668434		EFO_0004274	Gout [Japanese]	gout
European=688809		GCST006477	9.0	GCST006477	29942085		drug	Low	Ed Mountjoy	Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168959	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	88695846	11	88962678		EFO_0003761	Depression	unipolar depression
NR=361315|European=446238		GCST007342	24.522878745280337	GCST007342	30718901		drug	Low	Ed Mountjoy	Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168959	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	88744425	11	89011257		EFO_0003761	Depression	unipolar depression
European=322580		GCST005902	10.171997842193115	GCST005902	29662059		drug	Low	Ed Mountjoy	Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000168959	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	88748162	11	89014994		EFO_0003761	Depression (broad)	unipolar depression
East Asian=50792		GCST007707	12.0	GCST007707	30487518		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (318127bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	100582228	11	100711497		EFO_0000537	Hypertension [East Asian]	hypertension
East Asian=50792		GCST007707	9.301029995663981	GCST007707_2	30487518		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	11	100593538	11	100722807		EFO_0000537	Hypertension [Japanese]	hypertension
European, NR=58918|European=458554		GCST007611	46.69897000433602	GCST007611	30940143		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug MEGESTROL ACETATE is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000082175 at this locus (306817bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	11	100593538	11	100722807		EFO_0000341	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	chronic obstructive pulmonary disease
European=69395		GCST001238	10.301029995663981	GCST001238	21909115		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	11	100593538	11	100722807		EFO_0000537	Hypertension	hypertension
European, NR=58918|European=458554		GCST007611	46.69897000433602	GCST007611	30940143		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	11	100593538	11	100722807		EFO_0000537	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	hypertension
European=408458	10.1038/s41588-018-0184-y		8.14206473528057	SAIGE_411			drug	Low	Ed Mountjoy	Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (306817bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	11	100593538	11	100722807		EFO_0000378	Ischemic heart disease	coronary artery disease
European=459000		GCST007072	39.096910013008056	GCST007072	30595370		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000082175 at this locus (289809bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	11	100610546	11	100739815		EFO_0000319	Cardiovascular disease	cardiovascular system disease
NR=547261		GCST005195	9.55284196865778	GCST005195	29212778		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (289809bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	11	100610546	11	100739815		EFO_0000378	Coronary artery disease	coronary artery disease
European=408089	10.1038/s41588-018-0184-y		20.34008379993015	SAIGE_401_1			drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	11	100610546	11	100739815		EFO_0000537	Essential hypertension	hypertension
European=408343	10.1038/s41588-018-0184-y		20.27490547891853	SAIGE_401			drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	11	100610546	11	100739815		EFO_0000537	Hypertension	hypertension
European=361141			38.813874644838485	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	11	100610546	11	100739815		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
NR=250736		GCST005196	8.522878745280337	GCST005196	29212778		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (275756bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	100624599	11	100753868		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	10.168322150808534	GCST005194	29212778		drug	Low	Ed Mountjoy	Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (268448bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000082175	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	11	100631908	11	100761177		EFO_0000378	Coronary artery disease	coronary artery disease
NR=574		GCST002665	43.69897000433602	GCST002665_5	25340798		drug	Medium	Ed Mountjoy	Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137745 at this locus (96747bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137745	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	11	102716980	11	102846249		EFO_0000249	Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]	Alzheimer's disease
NR=574		GCST002665	43.69897000433602	GCST002665_5	25340798		drug	Medium	Ed Mountjoy	Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000118113 at this locus (119199bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000118113	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	11	102716980	11	102846249		EFO_0000249	Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]	Alzheimer's disease
NR=574		GCST002665	43.69897000433602	GCST002665_5	25340798		drug	Medium	Ed Mountjoy	Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000196611 at this locus (48090bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196611	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	11	102716980	11	102846249		EFO_0000249	Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]	Alzheimer's disease
NR=574		GCST002665	43.69897000433602	GCST002665_5	25340798		drug	Low	Ed Mountjoy	Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137673 at this locus (315500bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137673	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	11	102716980	11	102846249		EFO_0000249	Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]	Alzheimer's disease
European=7100|African American or Afro-Caribbean=2570		GCST002350	8.522878745280337	GCST002350	24621683		drug	Low	Ed Mountjoy	Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137673 at this locus (319465bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137673	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	102720945	11	102850214		EFO_0000341	Chronic obstructive pulmonary disease (severe)	chronic obstructive pulmonary disease
European=7100|African American or Afro-Caribbean=2570		GCST002350	8.522878745280337	GCST002350	24621683		drug	High	Ed Mountjoy	Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000196611 at this locus (52055bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196611	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	102720945	11	102850214		EFO_0000341	Chronic obstructive pulmonary disease (severe)	chronic obstructive pulmonary disease
European=7100|African American or Afro-Caribbean=2570		GCST002350	8.522878745280337	GCST002350	24621683		drug	High	Ed Mountjoy	Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137745 at this locus (92782bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137745	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	102720945	11	102850214		EFO_0000341	Chronic obstructive pulmonary disease (severe)	chronic obstructive pulmonary disease
European=7100|African American or Afro-Caribbean=2570		GCST002350	8.522878745280337	GCST002350	24621683		drug	Medium	Ed Mountjoy	Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000118113 at this locus (123164bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000118113	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	102720945	11	102850214		EFO_0000341	Chronic obstructive pulmonary disease (severe)	chronic obstructive pulmonary disease
European=459000		GCST007072	7.522878745280337	GCST007072	30595370		drug	Low	Ed Mountjoy	Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196611 at this locus (284087bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196611	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	11	102952976	11	103082247		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=459000		GCST007072	7.522878745280337	GCST007072	30595370		drug	Low	Ed Mountjoy	Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000118113 at this locus (355197bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000118113	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	11	102952976	11	103082247		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=459000		GCST007072	7.522878745280337	GCST007072	30595370		drug	Medium	Ed Mountjoy	Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000137745 at this locus (126515bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137745	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	11	102952976	11	103082247		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=348219		GCST006478	9.0	GCST006478	29942085		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug PALIPERIDONE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	11	112827715	11	112956992		EFO_0005230	Worry	anxiety
European=348219		GCST006478	9.0	GCST006478	29942085		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug QUETIAPINE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	11	112827715	11	112956992		EFO_0005230	Worry	anxiety
European=357957		GCST006475	8.487182241435127	GCST006475	29942085		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug CLOZAPINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	HG305_PATCH	112849719	11	112978997		EFO_0003761	Depressed affect	unipolar depression
European=357957		GCST006475	8.487182241435127	GCST006475	29942085		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug ILOPERIDONE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	HG305_PATCH	112849719	11	112978997		EFO_0003761	Depressed affect	unipolar depression
European=357957		GCST006475	8.487182241435127	GCST006475	29942085		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	HG305_PATCH	112849719	11	112978997		EFO_0004247	Depressed affect	mood disorder
European=357957		GCST006475	8.487182241435127	GCST006475	29942085		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	HG305_PATCH	112849719	11	112978997		EFO_0004247	Depressed affect	mood disorder
East Asian=45528		GCST007201	7.698970004336019	GCST007201	30285260		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	HG305_PATCH	113215923	11	113345201		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	7.698970004336019	GCST007201	30285260		drug	High	Ed Mountjoy	Dopamine D2 receptor modulator drug CARIPRAZINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	HG305_PATCH	113215923	11	113345201		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	7.698970004336019	GCST007201	30285260		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug TRIMIPRAMINE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	HG305_PATCH	113215923	11	113345201		EFO_0000692	Schizophrenia	schizophrenia
European=348219		GCST006478	9.0	GCST006478	29942085		drug	High	Ed Mountjoy	Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	11	113364647	11	113493925		EFO_0005230	Worry	anxiety
European=348219		GCST006478	9.0	GCST006478	29942085		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug BROMPERIDOL is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	11	113364647	11	113493925		EFO_0005230	Worry	anxiety
NR=361315|European=446238		GCST007342	38.39794000867204	GCST007342	30718901		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (474846bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113370758	11	113500036		EFO_0003761	Depression	unipolar depression
NR=361315|European=446238		GCST007342	38.39794000867204	GCST007342	30718901		drug	High	Ed Mountjoy	Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113370758	11	113500036		EFO_0003761	Depression	unipolar depression
NR=361315|European=446238		GCST007342	38.39794000867204	GCST007342	30718901		drug	Medium	Ed Mountjoy	Dopamine D2 receptor modulator drug CARIPRAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	11	113370758	11	113500036		EFO_0003761	Depression	unipolar depression
European=357957		GCST006475	12.761953896871205	GCST006475	29942085		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (459256bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	11	113386347	11	113515625		EFO_0003761	Depressed affect	unipolar depression
European=357957		GCST006475	12.761953896871205	GCST006475	29942085		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	11	113386347	11	113515625		EFO_0004247	Depressed affect	mood disorder
European=357957		GCST006475	12.761953896871205	GCST006475	29942085		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug PERPHENAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	11	113386347	11	113515625		EFO_0003761	Depressed affect	unipolar depression
European=357957		GCST006475	12.761953896871205	GCST006475	29942085		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	11	113386347	11	113515625		EFO_0004247	Depressed affect	mood disorder
European=357957		GCST006475	12.761953896871205	GCST006475	29942085		drug	High	Ed Mountjoy	Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	11	113386347	11	113515625		EFO_0003761	Depressed affect	unipolar depression
East Asian=26026|European=82315		GCST004946	10.301029995663981	GCST004946	28991256		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	10.301029995663981	GCST004946	28991256		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	10.522878745280337	GCST002539	25056061		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	10.522878745280337	GCST002539	25056061		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	10.0	GCST007201	30285260		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
Other=1097|NR=150064		GCST003048	9.698970004336019	GCST003048	26198764		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	10.301029995663981	GCST004946	28991256		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	9.301029995663981	GCST007201_2	30285260		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia [EA]	schizophrenia
East Asian=45528		GCST007201	9.301029995663981	GCST007201_2	30285260		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia [EA]	schizophrenia
East Asian=45528		GCST007201	10.0	GCST007201	30285260		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	10.0	GCST007201	30285260		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	10.301029995663981	GCST004946	28991256		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	10.522878745280337	GCST002539	25056061		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=105318		GCST006803	11.698970004336019	GCST006803	29483656		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	9.301029995663981	GCST007201_2	30285260		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia [EA]	schizophrenia
Other=1097|NR=150064		GCST003048	9.698970004336019	GCST003048	26198764		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
Other=1097|NR=150064		GCST003048	9.698970004336019	GCST003048	26198764		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	9.301029995663981	GCST007201_2	30285260		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia [EA]	schizophrenia
Other=1097|NR=150064		GCST003048	9.698970004336019	GCST003048	26198764		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=105318		GCST006803	11.698970004336019	GCST006803	29483656		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	10.522878745280337	GCST002539	25056061		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	10.522878745280337	GCST002539	25056061		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	10.0	GCST007201	30285260		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=105318		GCST006803	11.698970004336019	GCST006803	29483656		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	10.301029995663981	GCST004946	28991256		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
Other=1097|NR=150064		GCST003048	9.698970004336019	GCST003048	26198764		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	9.301029995663981	GCST007201_2	30285260		drug	Medium	Ed Mountjoy	Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia [EA]	schizophrenia
European=105318		GCST006803	11.698970004336019	GCST006803	29483656		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	10.0	GCST007201	30285260		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=105318		GCST006803	11.698970004336019	GCST006803	29483656		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	11	113392994	11	113522272		EFO_0000692	Schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	8.301029995663981	GCST004521	28540026		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	11	113412443	11	113541721		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	8.301029995663981	GCST004521	28540026		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	11	113412443	11	113541721		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	8.301029995663981	GCST004521	28540026		drug	High	Ed Mountjoy	Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003756 and targets the gene ENSG00000149295 at this locus (66031bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	11	113412443	11	113541721		EFO_0003756	Autism spectrum disorder or schizophrenia	autism spectrum disorder
European=13574|NR=2380		GCST004521	8.301029995663981	GCST004521	28540026		drug	High	Ed Mountjoy	Dopamine D2 receptor antagonist drug ASENAPINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	11	113412443	11	113541721		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	8.301029995663981	GCST004521	28540026		drug	Medium	Ed Mountjoy	Dopamine D2 receptor partial agonist drug BIFEPRUNOX is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	11	113412443	11	113541721		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	8.301029995663981	GCST004521	28540026		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	11	113412443	11	113541721		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.522878745280337	GCST002606_3	25217961		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113807181	11	113936459		EFO_0001663	Prostate cancer [EA]	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.301029995663981	GCST002606	25217961		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113807181	11	113936459		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	14.397940008672037	GCST006085	29892016		drug	Low	Ed Mountjoy	Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000149295	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113807181	11	113936459		EFO_0001663	Prostate cancer	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.522878745280337	GCST002606_3	25217961		drug	High	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113807181	11	113936459		EFO_0001663	Prostate cancer [EA]	prostate carcinoma
European=140254		GCST006085	14.397940008672037	GCST006085	29892016		drug	High	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113807181	11	113936459		EFO_0001663	Prostate cancer	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.301029995663981	GCST002606	25217961		drug	High	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	113807181	11	113936459		EFO_0001663	Prostate cancer	prostate carcinoma
European=9799		GCST003227	10.221848749616356	GCST003227	26424050		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	114030799	11	114160077		EFO_0000326	Non-glioblastoma glioma	central nervous system cancer
European=24009		GCST004348	11.301029995663981	GCST004348	28346443		drug	Low	Ed Mountjoy	Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	114030799	11	114160077		EFO_0000326	Non-glioblastoma glioma	central nervous system cancer
European=5548		GCST000439	8.0	GCST000439	19578367		drug	Low	Ed Mountjoy	T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198851	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	118477367	11	118606652		EFO_0000326	Glioma	central nervous system cancer
European=11582		GCST001058	10.301029995663981	GCST001058	21531791		drug	Low	Ed Mountjoy	T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198851	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	11	118477367	11	118606652		EFO_0000326	Glioma	central nervous system cancer
European=9799		GCST003227	24.397940008672037	GCST003227	26424050		drug	Low	Ed Mountjoy	T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198851	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	11	118480115	11	118609400		EFO_0000326	Non-glioblastoma glioma	central nervous system cancer
European=24009		GCST004348	42.221848749616356	GCST004348	28346443		drug	Low	Ed Mountjoy	T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198851	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	11	118480115	11	118609400		EFO_0000326	Non-glioblastoma glioma	central nervous system cancer
European=11582		GCST003228	15.698970004336019	GCST003228	26424050		drug	Low	Ed Mountjoy	T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198851	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	11	118480115	11	118609400		EFO_0000326	Glioma	central nervous system cancer
European=30659		GCST004347	15.0	GCST004347	28346443		drug	Low	Ed Mountjoy	T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198851	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	11	118480115	11	118609400		EFO_0000326	Glioma	central nervous system cancer
European=38053		GCST000987	12.0	GCST000987	21383967		drug	Low	Ed Mountjoy	T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000198851 at this locus (424897bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198851	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	11	118611781	11	118741072		EFO_0000540	Celiac disease or Rheumatoid arthritis	immune system disease
European=459000		GCST007072	12.096910013008056	GCST007072	30595370		drug	Low	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug MILRINONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (361012bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	12	20161168	12	20008234		EFO_0000319	Cardiovascular disease	cardiovascular system disease
NR=250736		GCST005196	13.096910013008056	GCST005196	29212778		drug	Low	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	20220033	12	20067099		EFO_0000378	Coronary artery disease	coronary artery disease
NR=547261		GCST005195	8.2839966563652	GCST005195	29212778		drug	Low	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	20220033	12	20067099		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	13.537602002101044	GCST005194	29212778		drug	Low	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	20220033	12	20067099		EFO_0000378	Coronary artery disease	coronary artery disease
European=459000		GCST007072	8.698970004336019	GCST007072	30595370		drug	Medium	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (161851bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	12	20360328	12	20207394		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=440328|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20687|Asian unspecified=555|Hispanic or Latin American=1247		GCST005843	7.301029995663981	GCST005843	29531354		drug	High	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	12	20577593	12	20424659		HP_0002140	Ischemic stroke	Ischemic stroke
European=440328|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20687|Asian unspecified=555|Hispanic or Latin American=1247		GCST005843	7.301029995663981	GCST005843	29531354		drug	High	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	12	20577593	12	20424659		HP_0002140	Ischemic stroke	Ischemic stroke
European=17565|African American or Afro-Caribbean=375|South Asian=4710		GCST003322	7.522878745280337	GCST003322_2	26732560		drug	Low	Ed Mountjoy	Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (486296bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172572	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	12	21323611	12	21170677		HP_0002140	Ischemic stroke (large artery atherosclerosis) [EA]	Ischemic stroke
European=361141			8.267891037697892	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	12	48186563	12	47792780		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=361141			8.267891037697892	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	12	48186563	12	47792780		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=360838		GCST005038	10.941953769604718	GCST005038	29083406		drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase II for the indiciation EFO_0003785 and targets the gene ENSG00000111424 at this locus (39448bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	12	48195873	12	47802090		EFO_0003785	Allergic disease (asthma, hay fever or eczema)	allergy
European, NR=58918|European=458554		GCST007611	10.154901959985743	GCST007611	30940143		drug	High	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	48204499	12	47810716		EFO_0000537	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	hypertension
European, NR=58918|European=458554		GCST007611	10.154901959985743	GCST007611	30940143		drug	High	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000111424 at this locus (30821bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	48204499	12	47810716		EFO_0000341	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	chronic obstructive pulmonary disease
European, NR=58918|European=458554		GCST007611	10.154901959985743	GCST007611	30940143		drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	12	48204499	12	47810716		EFO_0000537	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	hypertension
European=86475		GCST005537	8.221848749616356	GCST005537	26974007		drug	Medium	Ed Mountjoy	Vitamin D receptor agonist drug PEFCALCITOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	12	48208368	12	47814585		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=86475		GCST005537	8.221848749616356	GCST005537	26974007		drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug DOXERCALCIFEROL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	12	48208368	12	47814585		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=86475		GCST005537	8.221848749616356	GCST005537	26974007		drug	Medium	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000111424 at this locus (26953bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	12	48208368	12	47814585		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=86475		GCST005537	8.221848749616356	GCST005537	26974007		drug	High	Ed Mountjoy	Vitamin D receptor agonist drug CALCITRIOL is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	12	48208368	12	47814585		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=86475		GCST005537	8.221848749616356	GCST005537	26974007		drug	High	Ed Mountjoy	Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000111424 at this locus (26953bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	12	48208368	12	47814585		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
European=361141			12.517126416391246	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	12	48254353	12	47860570		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=459000		GCST007072	9.301029995663981	GCST007072	30595370		drug	Medium	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	12	48254353	12	47860570		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			12.517126416391246	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	12	48254353	12	47860570		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=2062		GCST007843	11.522878745280337	GCST007843	30891314		drug	High	Ed Mountjoy	Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000111424 at this locus (78926bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	12	48415757	12	48021974		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	8.698970004336019	GCST002606	25217961		drug	Medium	Ed Mountjoy	Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	12	48419618	12	48025835		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	10.698970004336019	GCST006085	29892016		drug	Medium	Ed Mountjoy	Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	12	48419618	12	48025835		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	10.698970004336019	GCST006085	29892016		drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	12	48419618	12	48025835		EFO_0001663	Prostate cancer	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.3979400086720375	GCST002606_3	25217961		drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	12	48419618	12	48025835		EFO_0001663	Prostate cancer [EA]	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	8.698970004336019	GCST002606	25217961		drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	12	48419618	12	48025835		EFO_0001663	Prostate cancer	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.3979400086720375	GCST002606_3	25217961		drug	Medium	Ed Mountjoy	Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	12	48419618	12	48025835		EFO_0001663	Prostate cancer [EA]	prostate carcinoma
European=459000		GCST007072	9.301029995663981	GCST007072	30595370		drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (260223bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	12	48597053	12	48203270		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			9.53863955699212	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	A	12	48615283	12	48221500		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=361141			9.53863955699212	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111424	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	12	48615283	12	48221500		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=58284|East Asian=22515		GCST002318	10.0	GCST002318	24390342		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	12	56394954	12	56001170		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=58284|East Asian=22515		GCST002318	7.698970004336019	GCST002318_2	24390342		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	12	56394954	12	56001170		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	9.0	GCST006959	30423114		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	12	56394954	12	56001170		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=16753		GCST003097	8.397940008672037	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	12	56396768	12	56002984		EFO_0000384	Pediatric autoimmune diseases	Crohn's disease
European=16753		GCST003097	8.397940008672037	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000110944 at this locus (331190bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	12	56396768	12	56002984		EFO_0000729	Pediatric autoimmune diseases	ulcerative colitis
European=16753		GCST003097	8.397940008672037	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	12	56396768	12	56002984		EFO_0000676	Pediatric autoimmune diseases	psoriasis
European=16753		GCST003097	8.397940008672037	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	12	56396768	12	56002984		EFO_0000676	Pediatric autoimmune diseases	psoriasis
European=16753		GCST003097	8.397940008672037	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug BRAZIKUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	12	56396768	12	56002984		EFO_0000384	Pediatric autoimmune diseases	Crohn's disease
European=2759		GCST000322	9.0	GCST000322	19169254		drug	High	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	12	56737973	12	56344189		EFO_0000676	Psoriasis	psoriasis
European=12244		GCST002738	9.221848749616356	GCST002738	25574825		drug	Medium	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	12	56737973	12	56344189		EFO_0000676	Psoriasis	psoriasis
European=12244		GCST002738	9.221848749616356	GCST002738	25574825		drug	High	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	12	56737973	12	56344189		EFO_0000676	Psoriasis	psoriasis
European=2759		GCST000322	9.0	GCST000322	19169254		drug	Medium	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	12	56737973	12	56344189		EFO_0000676	Psoriasis	psoriasis
East Asian=5134|European=8682		GCST002874	11.301029995663981	GCST002874	25903422		drug	Medium	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	12	56740682	12	56346898		EFO_0000676	Psoriasis	psoriasis
East Asian=5134|European=8682		GCST002874	10.0	GCST002874_8	25903422		drug	High	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	56740682	12	56346898		EFO_0000676	Psoriasis [EA]	psoriasis
East Asian=5134|European=8682		GCST002874	11.301029995663981	GCST002874	25903422		drug	High	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	56740682	12	56346898		EFO_0000676	Psoriasis	psoriasis
East Asian=5134|European=8682		GCST002874	10.0	GCST002874_8	25903422		drug	Medium	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	12	56740682	12	56346898		EFO_0000676	Psoriasis [EA]	psoriasis
European=287323		GCST004346	24.397940008672037	GCST004346	28537254		drug	High	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	12	56741228	12	56347444		EFO_0000676	Psoriasis	psoriasis
European=287323		GCST004346	24.397940008672037	GCST004346	28537254		drug	Medium	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	12	56741228	12	56347444		EFO_0000676	Psoriasis	psoriasis
European=18190		GCST002740	11.698970004336019	GCST002740_4	25574825		drug	High	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	12	56744276	12	56350492		EFO_0000676	Inflammatory skin disease [Psoriasis]	psoriasis
European=18190		GCST002740	11.698970004336019	GCST002740_4	25574825		drug	Medium	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	12	56744276	12	56350492		EFO_0000676	Inflammatory skin disease [Psoriasis]	psoriasis
European=8941		GCST003268	14.397940008672037	GCST003268	26626624		drug	High	Ed Mountjoy	Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000110944 at this locus (16011bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000110944	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	12	56750204	12	56356420		EFO_1001494	Psoriasis vulgaris	psoriasis vulgaris
European=58284|East Asian=22515		GCST002318	8.154901959985743	GCST002318_2	24390342		drug	Low	Ed Mountjoy	MAP kinase-activated protein kinase 5 inhibitor drug GLPG-0259 is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000089022 at this locus (446244bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000089022	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	12	111833788	12	111395984		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
East Asian=314		GCST002293	7.301029995663981	GCST002293	24277619		drug	High	Ed Mountjoy	Aldehyde dehydrogenase inhibitor drug DISULFIRAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000111275 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000111275	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	12	112241766	12	111803962		EFO_0003829	Alcohol dependence	alcohol dependence
NR=7046|European=7320|NR, Hispanic or Latin American, African unspecified, Asian unspecified=636		GCST002991	10.045757490560675	GCST002991	26098869		drug	Medium	Ed Mountjoy	Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122025	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	13	28476978	13	27902841		EFO_0002618	Pancreatic cancer	pancreatic carcinoma
NR=7046|European=7320|NR, Hispanic or Latin American, African unspecified, Asian unspecified=636		GCST002991	10.045757490560675	GCST002991	26098869		drug	Low	Ed Mountjoy	Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122025	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	13	28476978	13	27902841		EFO_0002618	Pancreatic cancer	pancreatic carcinoma
European=21536		GCST005434	13.301029995663981	GCST005434	29422604		drug	Medium	Ed Mountjoy	Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122025	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	13	28493997	13	27919860		EFO_0002618	Pancreatic cancer	pancreatic carcinoma
European=21536		GCST005434	13.301029995663981	GCST005434	29422604		drug	Low	Ed Mountjoy	Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122025	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	13	28493997	13	27919860		EFO_0002618	Pancreatic cancer	pancreatic carcinoma
European=6785		GCST002553	8.698970004336019	GCST002553	25086665		drug	Medium	Ed Mountjoy	Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122025	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	13	28493997	13	27919860		EFO_0002618	Pancreatic cancer	pancreatic carcinoma
European=6785		GCST002553	8.698970004336019	GCST002553	25086665		drug	Low	Ed Mountjoy	Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122025	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	13	28493997	13	27919860		EFO_0002618	Pancreatic cancer	pancreatic carcinoma
European=459000		GCST007072	11.698970004336019	GCST007072	30595370		drug	High	Ed Mountjoy	Relaxin receptor 2 activator drug SERELAXIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000133105 at this locus (67851bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000133105	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	13	32245813	13	31671676		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			11.549904924128398	NEALE2_20002_1309		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 11 inhibitor drug DENOSUMAB is Phase IV for the indiciation EFO_0003882 and targets the gene ENSG00000120659 at this locus (184727bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000120659	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	13	42952145	13	42378009		EFO_0003882	Osteoporosis | non-cancer illness code, self-reported	osteoporosis
NR=250736		GCST005196	11.096910013008056	GCST005196	29212778		drug	Medium	Ed Mountjoy	Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	13	113631780	13	112977466		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	11.085445301482366	GCST005194	29212778		drug	Medium	Ed Mountjoy	Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	13	113631780	13	112977466		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	11.096910013008056	GCST005196	29212778		drug	Medium	Ed Mountjoy	Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	13	113631780	13	112977466		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	11.085445301482366	GCST005194	29212778		drug	Medium	Ed Mountjoy	Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	13	113631780	13	112977466		EFO_0000378	Coronary artery disease	coronary artery disease
European=8071		GCST001209	7.698970004336019	GCST001209	21871595		drug	High	Ed Mountjoy	Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000126218 at this locus (82619bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	13	113694509	13	113040195		EFO_0002506	Osteoarthritis	osteoarthritis
European=1030836		GCST006414	7.860750782428393	GCST006414	30061737		drug	Low	Ed Mountjoy	Coagulation factor X inhibitor drug BETRIXABAN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	13	113872712	13	113218398		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	7.860750782428393	GCST006414	30061737		drug	High	Ed Mountjoy	Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	13	113872712	13	113218398		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	7.860750782428393	GCST006414	30061737		drug	Medium	Ed Mountjoy	Coagulation factor X inhibitor drug IDRAPARINUX is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000126218	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	13	113872712	13	113218398		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=140254		GCST006085	7.698970004336019	GCST006085	29892016		drug	Low	Ed Mountjoy	26S proteosome inhibitor drug CARFILZOMIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000100804 at this locus (180104bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100804	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	14	23305649	14	22836440		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	7.698970004336019	GCST006085	29892016		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000258643 at this locus (470396bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258643	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	14	23305649	14	22836440		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	7.698970004336019	GCST006085	29892016		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000129473 at this locus (462350bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000129473	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	14	23305649	14	22836440		EFO_0001663	Prostate cancer	prostate carcinoma
African American or Afro-Caribbean=1452|European=2358|Hispanic or Latin American=1313		GCST001912	11.045757490560675	GCST001912	23512250		drug	Medium	Ed Mountjoy	26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (80894bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100804	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	14	23585333	14	23116124		EFO_0000220	Acute lymphoblastic leukemia (childhood)	acute lymphoblastic leukemia
European=4735|Hispanic or Latin American=10533|African American or Afro-Caribbean=3972		GCST005315	12.154901959985743	GCST005315	29348612		drug	Medium	Ed Mountjoy	26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100804	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	14	23589057	14	23119848		EFO_0000220	Acute lymphoblastic leukemia (childhood)	acute lymphoblastic leukemia
European=893		GCST001320	7.698970004336019	GCST001320_3	22076464		drug	Medium	Ed Mountjoy	26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100804	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	14	23589057	14	23119848		EFO_0000220	Acute lymphoblastic leukemia (childhood) [ETV6-RUNX1 positive]	acute lymphoblastic leukemia
European=6381		GCST002158	16.0	GCST002158	23996088		drug	Low	Ed Mountjoy	26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100804	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	14	23589057	14	23119848		EFO_0000094	Acute lymphoblastic leukemia (B-cell precursor)	B-cell acute lymphoblastic leukemia
European=893		GCST001320	9.397940008672037	GCST001320	22076464		drug	Medium	Ed Mountjoy	26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100804	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	14	23589057	14	23119848		EFO_0000220	Acute lymphoblastic leukemia (childhood)	acute lymphoblastic leukemia
European=17051		GCST005832	13.301029995663981	GCST005832	29632299		drug	Low	Ed Mountjoy	26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100804	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	14	23589057	14	23119848		EFO_0000094	Acute lymphoblastic leukemia in childhood (B cell precursor)	B-cell acute lymphoblastic leukemia
European=480359		GCST005839	9.096910013008056	GCST005839	29700475		drug	High	Ed Mountjoy	Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000140009	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	14	64686207	14	64219489		EFO_0003761	Depression	unipolar depression
East Asian=7394		GCST003148	9.221848749616356	GCST003148	26443449		drug	Medium	Ed Mountjoy	Estrogen receptor beta modulator drug ESTRAMUSTINE PHOSPHATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000140009 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000140009	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	14	64693912	14	64227194		EFO_0001663	Prostate cancer	prostate carcinoma
NR=361315|European=446238		GCST007342	11.397940008672037	GCST007342	30718901		drug	High	Ed Mountjoy	Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000140009	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	14	64697037	14	64230319		EFO_0003761	Depression	unipolar depression
European=408961	10.1038/s41588-018-0184-y		9.172630726946174	SAIGE_366			drug	Low	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0001059 and targets the gene ENSG00000182256 at this locus (443188bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000182256	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	15	28230318	15	27985172		EFO_0001059	Cataract	cataract
European=11756		GCST003524	12.301029995663981	GCST003524	27135401		drug	Medium	Ed Mountjoy	Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137869	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	15	51537806	15	51245609		EFO_1001512	Endometrial cancer	endometrial carcinoma
European=121885		GCST006464	13.522878745280337	GCST006464	30093612		drug	Medium	Ed Mountjoy	Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137869	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	15	51553909	15	51261712		EFO_1001512	Endometrial cancer	endometrial carcinoma
European=54884		GCST006465	9.698970004336019	GCST006465	30093612		drug	Medium	Ed Mountjoy	Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137869	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	15	51553909	15	51261712		EFO_1001512	Endometrial cancer (endometrioid histology)	endometrial carcinoma
European=20926|African American or Afro-Caribbean=2895		GCST000675	8.0	GCST000675_2	20445134		drug	High	Ed Mountjoy	Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000074410 at this locus (63881bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000074410	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	15	63737925	15	63445726		EFO_0003144	Heart failure [EA]	heart failure
European, NR=58918|European=458969		GCST007656	12.0	GCST007656	30940143		drug	Low	Ed Mountjoy	Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000074410 at this locus (314720bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000074410	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	15	63988765	15	63696566		EFO_0000341	Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)	chronic obstructive pulmonary disease
European=59133		GCST001499	16.522878745280337	GCST001499	22544366		drug	High	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	15	73652174	15	73359833		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=59133		GCST001499	16.522878745280337	GCST001499	22544366		drug	Medium	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	15	73652174	15	73359833		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	35.32039042822024	GCST006414	30061737		drug	Medium	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	15	73667255	15	73374914		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	35.32039042822024	GCST006414	30061737		drug	High	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	15	73667255	15	73374914		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	26.69897000433602	GCST006061_3	29892015		drug	Medium	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	15	73667255	15	73374914		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	26.69897000433602	GCST006061_3	29892015		drug	High	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	15	73667255	15	73374914		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=395739	10.1038/s41588-018-0184-y		14.522878745280337	SAIGE_427_2			drug	Medium	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	15	73668046	15	73375705		EFO_0000275	Atrial fibrillation and flutter	atrial fibrillation
European=395739	10.1038/s41588-018-0184-y		14.522878745280337	SAIGE_427_2			drug	High	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	15	73668046	15	73375705		EFO_0000275	Atrial fibrillation and flutter	atrial fibrillation
European=118755		GCST004297	11.096910013008056	GCST004297	28416818		drug	Medium	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	15	73669006	15	73376665		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=118755		GCST004297	11.096910013008056	GCST004297	28416818		drug	High	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	15	73669006	15	73376665		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	27.0	GCST006061	29892015		drug	Medium	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	15	73677264	15	73384923		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	27.0	GCST006061	29892015		drug	High	Ed Mountjoy	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138622	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	15	73677264	15	73384923		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=13574|NR=2380		GCST004521	8.698970004336019	GCST004521	28540026		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	16	9900057	16	9806200		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	8.698970004336019	GCST004521	28540026		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0003756 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	16	9900057	16	9806200		EFO_0003756	Autism spectrum disorder or schizophrenia	autism spectrum disorder
European=105318		GCST006803	8.221848749616356	GCST006803	29483656		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	16	9900057	16	9806200		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	7.698970004336019	GCST007201	30285260		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	16	9946319	16	9852462		EFO_0000692	Schizophrenia	schizophrenia
Other=1097|NR=150064		GCST003048	8.698970004336019	GCST003048	26198764		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	16	9946319	16	9852462		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	8.221848749616356	GCST007201_2	30285260		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	16	9946319	16	9852462		EFO_0000692	Schizophrenia [EA]	schizophrenia
European=82315|East Asian=5219		GCST002539	8.0	GCST002539	25056061		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	16	9946319	16	9852462		EFO_0000692	Schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	8.522878745280337	GCST004946	28991256		drug	Low	Ed Mountjoy	Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183454	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	16	9946319	16	9852462		EFO_0000692	Schizophrenia	schizophrenia
European=28835		GCST007797	8.301029995663981	GCST007797	30929738		drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	27349168	16	27337847		EFO_0000270	Asthma onset (childhood vs adult)	asthma
European=361141			11.676747899828312	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	27349168	16	27337847		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=459000		GCST007076	15.301029995663981	GCST007076	30595370		drug	Low	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase II for the indiciation EFO_0000684 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	27349168	16	27337847		EFO_0000684	Respiratory diseases	respiratory system disease
European=360527			12.204815410317575	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	27349168	16	27337847		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=401837	10.1038/s41588-018-0184-y		9.97061622231479	SAIGE_495			drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	16	27349438	16	27338117		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		8.866461091629782	SAIGE_495			drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	16	27355849	16	27344528		EFO_0000270	Asthma	asthma
European=341215		GCST007798	19.397940008672037	GCST007798	30929738		drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	16	27369502	16	27358181		EFO_0000270	Asthma	asthma
European=361141			12.795880017344075	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	16	27371424	16	27360103		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=360527			13.721246399047171	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	16	27371424	16	27360103		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=459000		GCST007075	8.096910013008056	GCST007075	30595370		drug	High	Ed Mountjoy	Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase IV for the indiciation HP_0000964 and targets the gene ENSG00000077238 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000077238	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	16	27371539	16	27360218		HP_0000964	Eczema	Eczema
European=86475		GCST005537	29.397940008672037	GCST005537	26974007		drug	Low	Ed Mountjoy	Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (312964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000005844	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	GT	16	30171015	16	30159694		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
East Asian=2252		GCST000507	7.522878745280337	GCST000507	19838193		drug	Low	Ed Mountjoy	Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000005844 at this locus (108362bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000005844	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	30642867	16	30631546		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=33394		GCST005527	7.607581136972331	GCST005527	23143594		drug	Low	Ed Mountjoy	Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (269751bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000005844	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	16	30804257	16	30792936		EFO_0000676	Psoriasis	psoriasis
NR=4377		GCST000834	9.045757490560675	GCST000834	20953189		drug	Low	Ed Mountjoy	Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (408120bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000005844	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	16	30942625	16	30931304		EFO_0000676	Psoriasis	psoriasis
European=86475		GCST005537	10.0	GCST005537	26974007		drug	Low	Ed Mountjoy	Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (436435bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000005844	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	16	30970941	16	30959620		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
East Asian=5134|European=8682		GCST002874	7.698970004336019	GCST002874	25903422		drug	Low	Ed Mountjoy	Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (466304bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000005844	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	16	31000809	16	30989488		EFO_0000676	Psoriasis	psoriasis
European=287323		GCST004346	15.0	GCST004346	28537254		drug	Low	Ed Mountjoy	Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (486572bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000005844	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	16	31021078	16	31009757		EFO_0000676	Psoriasis	psoriasis
European=361141			9.289274371510311	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Sodium/glucose cotransporter 2 inhibitor drug DAPAGLIFLOZIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000140675 at this locus (345181bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000140675	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	16	31149142	16	31137821		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=459000		GCST007072	12.0	GCST007072	30595370		drug	Low	Ed Mountjoy	Sodium/glucose cotransporter 2 inhibitor drug EMPAGLIFLOZIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000140675 at this locus (345181bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000140675	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	16	31149142	16	31137821		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=22161		GCST001003	8.045757490560675	GCST001003	21386085		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	16	56988044	16	56954132		EFO_0000195	Metabolic syndrome	metabolic syndrome
European=22161		GCST001007	16.0	GCST001007_4	21386085		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	16	56988044	16	56954132		EFO_0000195	Metabolic syndrome (bivariate traits) [HDLC-WC]	metabolic syndrome
European=9618		GCST004045	149.0	GCST004045	27790247		drug	Medium	Ed Mountjoy	Cholesteryl ester transfer protein inhibitor drug ANACETRAPIB is Phase III for the indiciation EFO_0001645 and targets the gene ENSG00000087237 at this locus (5120bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087237	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	16	56990716	16	56956804		EFO_0001645	Age-related diseases, mortality and associated endophenotypes	coronary heart disease
European=9618		GCST004045	149.0	GCST004045	27790247		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000070915 at this locus (40954bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	16	56990716	16	56956804		EFO_0000400	Age-related diseases, mortality and associated endophenotypes	diabetes mellitus
European=9618		GCST004045	149.0	GCST004045	27790247		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000070915 at this locus (40954bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	16	56990716	16	56956804		EFO_0003144	Age-related diseases, mortality and associated endophenotypes	heart failure
European=10564		GCST001436	59.045757490560675	GCST001436_2	22399527		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (40954bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	16	56990716	16	56956804		EFO_0000195	Metabolic syndrome [HDL]	metabolic syndrome
European=22161		GCST001007	12.522878745280337	GCST001007_2	21386085		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	16	56993324	16	56959412		EFO_0000195	Metabolic syndrome (bivariate traits) [BP-HDLC]	metabolic syndrome
South Asian=2554		GCST000753	48.0	GCST000753_3	20694148		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	16	56993324	16	56959412		EFO_0000195	Metabolic syndrome [HDL]	metabolic syndrome
European=22161		GCST001007	11.154901959985743	GCST001007_3	21386085		drug	High	Ed Mountjoy	Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (52971bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000070915	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	16	57002732	16	56968820		EFO_0000195	Metabolic syndrome (bivariate traits) [HDLC-GLUC]	metabolic syndrome
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.522878745280337	GCST002606	25217961		drug	Low	Ed Mountjoy	Dihydroorotate dehydrogenase inhibitor drug LEFLUNOMIDE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000102967 at this locus (351162bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000102967	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	16	71691329	16	71657426		EFO_0001663	Prostate cancer	prostate carcinoma
European=455221		GCST007093	9.698970004336019	GCST007093	30664745		drug	Low	Ed Mountjoy	Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0002506 and targets the gene ENSG00000258947 at this locus (283436bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	16	89704365	16	89637957		EFO_0002506	Osteoarthritis	osteoarthritis
European=361141			33.803837637410474	NEALE2_20001_1059		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89736157	16	89669749		EFO_0000756	Malignant melanoma | cancer code, self-reported	melanoma
European=61457		GCST003327	20.0	GCST003327_3	26829030		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	16	89736157	16	89669749		EFO_0000707	Squamous cell carcinoma [adjusted for rs4268748]	squamous cell carcinoma
European=361141			33.803837637410474	NEALE2_20001_1059		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	89736157	16	89669749		EFO_0000756	Malignant melanoma | cancer code, self-reported	melanoma
European=61457		GCST003327	20.0	GCST003327_3	26829030		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	89736157	16	89669749		EFO_0000707	Squamous cell carcinoma [adjusted for rs4268748]	squamous cell carcinoma
European=10422		GCST001267	26.522878745280337	GCST001267	21983787		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=291407		GCST004142	26.522878745280337	GCST004142	28212542		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=291407		GCST004142	26.522878745280337	GCST004142	28212542		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=6122		GCST002514	8.698970004336019	GCST002514	24980573		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=5456		GCST000437	26.522878745280337	GCST000437	19578364		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=5456		GCST000437	26.522878745280337	GCST000437	19578364		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=10422		GCST001267	26.522878745280337	GCST001267	21983787		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=6122		GCST002514	8.698970004336019	GCST002514	24980573		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	16	89755903	16	89689495		EFO_0000756	Melanoma	melanoma
European=58607			11.396639075651619	NEALE2_40009		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	16	89846677	16	89780269		EFO_0000311	Reported occurrences of cancer	cancer
European=88583		GCST007505	44.69897000433602	GCST007505	30429480		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	16	89846677	16	89780269		EFO_0000389	Nevus count or cutaneous melanoma	skin melanoma
European=58607			11.396639075651619	NEALE2_40009		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	16	89846677	16	89780269		EFO_0000311	Reported occurrences of cancer	cancer
European=88583		GCST007505	44.69897000433602	GCST007505	30429480		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	16	89846677	16	89780269		EFO_0000389	Nevus count or cutaneous melanoma	skin melanoma
European=58607			11.396639075651619	NEALE2_40009		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	16	89846677	16	89780269		EFO_0000311	Reported occurrences of cancer	cancer
European=361141			12.303643611266669	NEALE2_20001_1059		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	16	89951527	16	89885119		EFO_0000756	Malignant melanoma | cancer code, self-reported	melanoma
European=361141			12.303643611266669	NEALE2_20001_1059		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	16	89951527	16	89885119		EFO_0000756	Malignant melanoma | cancer code, self-reported	melanoma
European=406033	10.1038/s41588-018-0184-y		14.698970004336019	SAIGE_702_1			drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0002496 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89986117	16	89919709		EFO_0002496	Actinic keratosis	actinic keratosis
European=397762	10.1038/s41588-018-0184-y		28.661543506395397	SAIGE_172_11			drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89986117	16	89919709		EFO_0000389	Melanomas of skin	skin melanoma
European=291407		GCST004142	36.39794000867204	GCST004142	28212542		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	89986117	16	89919709		EFO_0000756	Melanoma	melanoma
European=291407		GCST004142	36.39794000867204	GCST004142	28212542		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89986117	16	89919709		EFO_0000756	Melanoma	melanoma
European=287137		GCST003655	38.045757490560675	GCST003655	27424798		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_1001927 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89986117	16	89919709		EFO_1001927	Cutaneous squamous cell carcinoma	cutaneous squamous cell carcinoma
European=397762	10.1038/s41588-018-0184-y		28.661543506395397	SAIGE_172_11			drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	89986117	16	89919709		EFO_0000389	Melanomas of skin	skin melanoma
European=397762	10.1038/s41588-018-0184-y		28.661543506395397	SAIGE_172_1			drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	89986117	16	89919709		EFO_0000389	Melanomas of skin, dx or hx	skin melanoma
European=397762	10.1038/s41588-018-0184-y		28.661543506395397	SAIGE_172_1			drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89986117	16	89919709		EFO_0000389	Melanomas of skin, dx or hx	skin melanoma
European=397762	10.1038/s41588-018-0184-y		9.339134521996131	SAIGE_172_11			drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	89990843	16	89924435		EFO_0000389	Melanomas of skin	skin melanoma
European=397762	10.1038/s41588-018-0184-y		9.339134521996131	SAIGE_172_11			drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89990843	16	89924435		EFO_0000389	Melanomas of skin	skin melanoma
European=397762	10.1038/s41588-018-0184-y		9.339134521996131	SAIGE_172_1			drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	16	89990843	16	89924435		EFO_0000389	Melanomas of skin, dx or hx	skin melanoma
European=397762	10.1038/s41588-018-0184-y		9.339134521996131	SAIGE_172_1			drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	16	89990843	16	89924435		EFO_0000389	Melanomas of skin, dx or hx	skin melanoma
European=359981			12.515700160653214	NEALE2_2453		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	16	90024206	16	89957798		EFO_0000311	Cancer diagnosed by doctor	cancer
European=359981			12.515700160653214	NEALE2_2453		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	16	90024206	16	89957798		EFO_0000311	Cancer diagnosed by doctor	cancer
European=359981			12.515700160653214	NEALE2_2453		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	16	90024206	16	89957798		EFO_0000311	Cancer diagnosed by doctor	cancer
European=61457		GCST003327	43.69897000433602	GCST003327	26829030		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	16	90026512	16	89960104		EFO_0000707	Squamous cell carcinoma	squamous cell carcinoma
European=61457		GCST003327	43.69897000433602	GCST003327	26829030		drug	High	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	16	90026512	16	89960104		EFO_0000707	Squamous cell carcinoma	squamous cell carcinoma
European=13550		GCST003422	8.698970004336019	GCST003422	26908436		drug	High	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	16	90027626	16	89961218		EFO_0000707	Squamous cell carcinoma	squamous cell carcinoma
European=13550		GCST003422	8.698970004336019	GCST003422	26908436		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	A	16	90027626	16	89961218		EFO_0000707	Squamous cell carcinoma	squamous cell carcinoma
European=291407		GCST004142	21.221848749616356	GCST004142	28212542		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	16	90066936	16	90000528		EFO_0000756	Melanoma	melanoma
European=5456		GCST000437	21.221848749616356	GCST000437	19578364		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	16	90066936	16	90000528		EFO_0000756	Melanoma	melanoma
European=291407		GCST004142	21.221848749616356	GCST004142	28212542		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	16	90066936	16	90000528		EFO_0000756	Melanoma	melanoma
European=5456		GCST000437	21.221848749616356	GCST000437	19578364		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000258947	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	16	90066936	16	90000528		EFO_0000756	Melanoma	melanoma
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	10.096910013008056	GCST007515	29632382		drug	Low	Ed Mountjoy	Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	17	3947644	17	4044350		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	10.096910013008056	GCST007515	29632382		drug	Low	Ed Mountjoy	Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	17	3947644	17	4044350		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	10.045757490560675	GCST007517	29632382		drug	Low	Ed Mountjoy	Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	17	3953102	17	4049808		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	8.096910013008056	GCST007518	29632382		drug	Low	Ed Mountjoy	Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	17	3953102	17	4049808		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007518	8.096910013008056	GCST007518	29632382		drug	Low	Ed Mountjoy	Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	17	3953102	17	4049808		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007517	10.045757490560675	GCST007517	29632382		drug	Low	Ed Mountjoy	Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	17	3953102	17	4049808		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=361141			8.644381843915278	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000196689 at this locus (467788bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	17	3980493	17	4077199		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=655666|South Asian=3650		GCST006867	13.397940008672037	GCST006867	30054458		drug	Low	Ed Mountjoy	Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	17	3985864	17	4082570		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	13.397940008672037	GCST006867	30054458		drug	Low	Ed Mountjoy	Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196689	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	17	3985864	17	4082570		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=5704		GCST001364	10.045757490560675	GCST001364	22197929		drug	Low	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000161955	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	17	7462969	17	7559652		EFO_0004194	IgA nephropathy	IGA glomerulonephritis
East Asian=5704		GCST001364	9.397940008672037	GCST001364	22197929		drug	Low	Ed Mountjoy	Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (26251bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000161955	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	17	7491177	17	7587859		EFO_0004194	IgA nephropathy	IGA glomerulonephritis
European=86475		GCST005537	20.30102999566398	GCST005537	26974007		drug	Low	Ed Mountjoy	Eotaxin inhibitor drug BERTILIMUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000172156 at this locus (42141bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000172156	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	17	32570547	17	34243528		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
East Asian=4392		GCST002082	9.045757490560675	GCST002082	23817570		drug	Low	Ed Mountjoy	DNA topoisomerase II alpha inhibitor drug DOXORUBICIN is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000131747 at this locus (493430bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000131747	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	17	38051348	17	39895095		EFO_0001061	Cervical cancer [Matched]	cervical carcinoma
East Asian=4392		GCST002082	9.045757490560675	GCST002082	23817570		drug	Low	Ed Mountjoy	Receptor protein-tyrosine kinase erbB-2 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000141736 at this locus (164669bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000141736	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	17	38051348	17	39895095		EFO_0001061	Cervical cancer [Matched]	cervical carcinoma
European=4735|Hispanic or Latin American=10533|African American or Afro-Caribbean=3972		GCST005315	9.0	GCST005315	29348612		drug	Low	Ed Mountjoy	DNA topoisomerase II alpha inhibitor drug ETOPOSIDE PHOSPHATE is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000131747	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	17	38066240	17	39909987		EFO_0000220	Acute lymphoblastic leukemia (childhood)	acute lymphoblastic leukemia
European=4735|Hispanic or Latin American=10533|African American or Afro-Caribbean=3972		GCST005315	9.0	GCST005315	29348612		drug	Low	Ed Mountjoy	DNA topoisomerase II alpha inhibitor drug DAUNORUBICIN is Phase IV for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000131747	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	17	38066240	17	39909987		EFO_0000220	Acute lymphoblastic leukemia (childhood)	acute lymphoblastic leukemia
European=359241			12.11747546204512	NEALE2_2463		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (37925bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167941	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	CT	17	41793182	17	43715814		EFO_0003931	Fractured/broken bones in last 5 years	bone fracture
European=426795		GCST006980	40.30102999566398	GCST006980	30598549		drug	Low	Ed Mountjoy	Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (32252bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167941	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	17	41798855	17	43721487		EFO_0003931	Fractures	bone fracture
East Asian=800|European=264173		GCST006423	24.522878745280337	GCST006423	30158200		drug	Low	Ed Mountjoy	Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (4268bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167941	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	17	41826839	17	43749471		EFO_0003931	Fractures	bone fracture
NR=171776		GCST005835	10.522878745280337	GCST005835	29559929		drug	Low	Ed Mountjoy	Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (297425bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000120088	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	17	43564222	17	45486856		EFO_0003761	Remission after SSRI treatment in MDD or neuroticism	unipolar depression
European=357957		GCST006475	21.624885315307775	GCST006475	29942085		drug	Low	Ed Mountjoy	Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (5007bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000120088	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	17	43856639	17	45779273		EFO_0003761	Depressed affect	unipolar depression
European=38582		GCST005531	15.265200170411154	GCST005531	24076602		drug	Low	Ed Mountjoy	Carbonic anhydrase IV inhibitor drug TOPIRAMATE is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000167434 at this locus (410546bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167434	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	17	57816757	17	59739396		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=459000		GCST007072	24.154901959985743	GCST007072	30595370		drug	High	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug FOSINOPRIL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000159640 at this locus (5504bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	17	61548918	17	63471557		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=459000		GCST007072	24.154901959985743	GCST007072	30595370		drug	Low	Ed Mountjoy	Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000007314 at this locus (466997bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000007314	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	17	61548918	17	63471557		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			19.50811606596098	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug CAPTOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	17	61548948	17	63471587		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=361141			19.50811606596098	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	17	61548948	17	63471587		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=361141			19.50811606596098	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Sodium channel protein type IV alpha subunit blocker drug BUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (466967bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000007314	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	17	61548948	17	63471587		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=408343	10.1038/s41588-018-0184-y		10.26440110030182	SAIGE_401			drug	High	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	17	61556298	17	63478937		EFO_0000537	Hypertension	hypertension
European=408343	10.1038/s41588-018-0184-y		10.26440110030182	SAIGE_401			drug	Medium	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	17	61556298	17	63478937		EFO_0000537	Hypertension	hypertension
European=408343	10.1038/s41588-018-0184-y		10.26440110030182	SAIGE_401			drug	Low	Ed Mountjoy	Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000007314	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	17	61556298	17	63478937		EFO_0000537	Hypertension	hypertension
European=408089	10.1038/s41588-018-0184-y		10.172630726946174	SAIGE_401_1			drug	Medium	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	17	61556298	17	63478937		EFO_0000537	Essential hypertension	hypertension
European=408089	10.1038/s41588-018-0184-y		10.172630726946174	SAIGE_401_1			drug	High	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	17	61556298	17	63478937		EFO_0000537	Essential hypertension	hypertension
European=408089	10.1038/s41588-018-0184-y		10.172630726946174	SAIGE_401_1			drug	Low	Ed Mountjoy	Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000007314	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	17	61556298	17	63478937		EFO_0000537	Essential hypertension	hypertension
European=655666|South Asian=3650		GCST006867	7.3979400086720375	GCST006867	30054458		drug	Medium	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	17	61687600	17	63610240		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.3979400086720375	GCST006867	30054458		drug	Medium	Ed Mountjoy	Angiotensin-converting enzyme inhibitor drug PERINDOPRIL is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000159640	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	17	61687600	17	63610240		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.3979400086720375	GCST006867	30054458		drug	Low	Ed Mountjoy	Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000007314 at this locus (328315bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000007314	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	17	61687600	17	63610240		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
NR=250736		GCST005196	10.096910013008056	GCST005196	29212778		drug	Low	Ed Mountjoy	Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (336814bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000007314	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	17	62387091	17	64309731		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	10.20210951694165	GCST005194	29212778		drug	Low	Ed Mountjoy	Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (351688bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000007314	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	17	62401965	17	64324605		EFO_0000378	Coronary artery disease	coronary artery disease
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	10.0	GCST006061	29892015		drug	Medium	Ed Mountjoy	Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (160996bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000123700	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	17	68337185	17	70341044		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	8.522878745280337	GCST006061_3	29892015		drug	Medium	Ed Mountjoy	Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000123700	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	17	68347338	17	70351197		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	8.522878745280337	GCST006061_3	29892015		drug	Medium	Ed Mountjoy	Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000123700	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	17	68347338	17	70351197		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
East Asian=9299|European=45790		GCST006048	7.522878745280337	GCST006048	24532676		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000176014	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	18	12797694	18	12797695		EFO_0000685	Rheumatoid arthritis (ACPA-positive)	rheumatoid arthritis
East Asian=20965		GCST001454	7.698970004336019	GCST001454	22446963		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000176014	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	18	12797694	18	12797695		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
East Asian=4075		GCST001674	10.698970004336019	GCST001674	22960999		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000176014	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	18	12821593	18	12821594		EFO_0000707	Esophageal cancer (squamous cell)	squamous cell carcinoma
East Asian=4075		GCST001674	10.698970004336019	GCST001674	22960999		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000176014	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	18	12821593	18	12821594		EFO_0000707	Esophageal cancer (squamous cell)	squamous cell carcinoma
East Asian=4075		GCST001674	10.698970004336019	GCST001674	22960999		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0002916 and targets the gene ENSG00000176014 at this locus (477275bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000176014	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	18	12821593	18	12821594		EFO_0002916	Esophageal cancer (squamous cell)	esophageal carcinoma
European=2258		GCST000663	10.221848749616356	GCST000663	20421936		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (226313bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	18	57811982	18	60144750		EFO_0001073	Obesity (early onset extreme)	obesity
European=204498		GCST001953	35.69897000433602	GCST001953_4	23563607		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187873bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	18	57850422	18	60183189		EFO_0001073	Obesity [Obesity class I]	obesity
European=2796		GCST000317	7.698970004336019	GCST000317_3	19151714		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	18	57851097	18	60183864		EFO_0001073	Obesity [children]	obesity
European=2796		GCST000317	14.301029995663981	GCST000317	19151714		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	18	57851097	18	60183864		EFO_0001073	Obesity	obesity
European=2796		GCST000317	8.397940008672037	GCST000317_2	19151714		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	18	57851097	18	60183864		EFO_0001073	Obesity [adults]	obesity
European=204498		GCST001953	26.69897000433602	GCST001953_5	23563607		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (186533bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	18	57851763	18	60184530		EFO_0001073	Obesity [Overweight]	obesity
European=408792	10.1038/s41588-018-0184-y		11.251037138743838	SAIGE_278_1			drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	18	57852587	18	60185354		EFO_0001073	Obesity	obesity
European=6889		GCST001957	13.045757490560675	GCST001957	23563609		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	18	57852587	18	60185354		EFO_0001073	Obesity (early onset extreme)	obesity
European=408961	10.1038/s41588-018-0184-y		11.126098402135538	SAIGE_278			drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	18	57852587	18	60185354		EFO_0001073	Overweight, obesity and other hyperalimentation	obesity
European=204498		GCST001953	21.522878745280337	GCST001953_3	23563607		drug	Medium	Ed Mountjoy	Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185347bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000166603	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	18	57852948	18	60185715		EFO_0001073	Obesity [Obesity class II]	obesity
European=10486		GCST002643	9.096910013008056	GCST002643	25279986		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase II for the indiciation EFO_0000096 and targets the gene ENSG00000171791 at this locus (7369bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	18	60783211	18	63115978		EFO_0000096	Follicular lymphoma	neoplasm of mature B-cells
European=17691		GCST004146	10.698970004336019	GCST004146	28165464		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	18	60788745	18	63121512		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=17691		GCST004146	10.698970004336019	GCST004146	28165464		drug	High	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	18	60788745	18	63121512		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=10767		GCST003468	10.397940008672037	GCST003468	26956414		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	18	60793494	18	63126261		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=10767		GCST003468	10.397940008672037	GCST003468	26956414		drug	High	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	18	60793494	18	63126261		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=8400		GCST002073	11.522878745280337	GCST002073	23770605		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	18	60793549	18	63126316		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=8400		GCST002073	11.522878745280337	GCST002073	23770605		drug	High	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	18	60793549	18	63126316		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=8400		GCST002073	10.096910013008056	GCST002073	23770605		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	18	60793921	18	63126688		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=8400		GCST002073	10.096910013008056	GCST002073	23770605		drug	High	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	18	60793921	18	63126688		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=140254		GCST006085	8.0	GCST006085	29892016		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	CT	C	18	60961193	18	63293960		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	8.0	GCST006085	29892016		drug	Low	Ed Mountjoy	Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	CT	18	60961193	18	63293960		EFO_0001663	Prostate cancer	prostate carcinoma
European=33976		GCST003219	7.522878745280337	GCST003219_2	26691988		drug	Medium	Ed Mountjoy	Complement factor D inhibitor drug LAMPALIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000197766 at this locus (167810bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197766	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	19	1031438	19	1031439		EFO_0001365	Advanced age-related macular degeneration [EA]	age-related macular degeneration
European=17691		GCST004146	7.301029995663981	GCST004146	28165464		drug	Low	Ed Mountjoy	Elongation factor 2 inhibitor drug DENILEUKIN DIFTITOX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000167658 at this locus (83658bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167658	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	19	4069119	19	4069121		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=1043		GCST005934	8.522878745280337	GCST005934	29884837		drug	Low	Ed Mountjoy	Insulin receptor inhibitor drug LINSITINIB is Phase II for the indiciation EFO_0006859 and targets the gene ENSG00000171105 at this locus (340047bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171105	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	19	7699347	19	7634461		EFO_0006859	Neuropathic pain in head and neck cancer	head and neck malignant neoplasia
European=86475		GCST005537	21.69897000433602	GCST005537	26974007		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (169080bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	19	10427721	19	10317045		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=287323		GCST004346	42.52287874528034	GCST004346	28537254		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	19	10463118	19	10352442		EFO_0000676	Psoriasis	psoriasis
European=361141			11.517984423549288	NEALE2_20002_1453		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	19	10463118	19	10352442		EFO_0000676	Psoriasis | non-cancer illness code, self-reported	psoriasis
European=33394		GCST005527	13.045757490560675	GCST005527	23143594		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	19	10463118	19	10352442		EFO_0000676	Psoriasis	psoriasis
European=7353		GCST000833	10.397940008672037	GCST000833	20953190		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (126826bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	19	10469975	19	10359299		EFO_0000676	Psoriasis	psoriasis
European=7353		GCST000833	8.397940008672037	GCST000833	20953190		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (123868bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	19	10472933	19	10362257		EFO_0000676	Psoriasis	psoriasis
European=18190		GCST002740	13.522878745280337	GCST002740_4	25574825		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (18959bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	19	10577843	19	10467167		EFO_0000676	Inflammatory skin disease [Psoriasis]	psoriasis
European=38582		GCST005531	9.019088062223156	GCST005531	24076602		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase IV for the indiciation EFO_0003885 and targets the gene ENSG00000079999 at this locus (127936bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	19	10742170	19	10631494		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=38582		GCST005531	9.019088062223156	GCST005531	24076602		drug	Medium	Ed Mountjoy	Sphingosine 1-phosphate receptor Edg-8 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000180739 at this locus (113564bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180739	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	19	10742170	19	10631494		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=33394		GCST005527	9.378437388797577	GCST005527	23143594		drug	Medium	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (203859bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	19	10818092	19	10707416		EFO_0000676	Psoriasis	psoriasis
European=287323		GCST004346	9.698970004336019	GCST004346	28537254		drug	Low	Ed Mountjoy	Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (271972bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000079999	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	19	10886206	19	10775530		EFO_0000676	Psoriasis	psoriasis
European=6042		GCST000340	8.698970004336019	GCST000340	19198609		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	19	11163601	19	11052925		EFO_0000612	Myocardial infarction (early onset)	myocardial infarction
NR=123388		GCST002287	11.522878745280337	GCST002287	24262325		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (324283bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	19	11163601	19	11052925		EFO_0000712	Coronary artery disease or ischemic stroke	cerebrovascular accident
European=6042		GCST000340	8.698970004336019	GCST000340	19198609		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	19	11163601	19	11052925		EFO_0000612	Myocardial infarction (early onset)	myocardial infarction
European=446696|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20695|Asian unspecified=698|Hispanic or Latin American=1557		GCST005838	7.522878745280337	GCST005838	29531354		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (312949bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	19	11174935	19	11064259		EFO_0000712	Stroke	cerebrovascular accident
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	7.522878745280337	GCST003117	26343387		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	19	11188153	19	11077477		EFO_0000612	Myocardial infarction	myocardial infarction
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	7.522878745280337	GCST003117	26343387		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	19	11188153	19	11077477		EFO_0000612	Myocardial infarction	myocardial infarction
European=388806	10.1038/s41588-018-0184-y		8.777283528852417	SAIGE_411_2			drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	19	11188164	19	11077488		EFO_0000612	Myocardial infarction	myocardial infarction
European=388806	10.1038/s41588-018-0184-y		8.777283528852417	SAIGE_411_2			drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	19	11188164	19	11077488		EFO_0000612	Myocardial infarction	myocardial infarction
NR=296525		GCST005194	35.71175077442801	GCST005194	29212778		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	19	11188247	19	11077571		EFO_0000378	Coronary artery disease	coronary artery disease
European=408458	10.1038/s41588-018-0184-y		12.602059991327963	SAIGE_411			drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	19	11188247	19	11077571		EFO_0000378	Ischemic heart disease	coronary artery disease
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	14.397940008672037	GCST003116	26343387		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	19	11188247	19	11077571		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	40.30102999566398	GCST005196	29212778		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	19	11202306	19	11091630		EFO_0000378	Coronary artery disease	coronary artery disease
European, NR=63731		GCST004787	21.096910013008056	GCST004787	28714975		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	19	11202306	19	11091630		EFO_0000378	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	coronary artery disease
NR=547261		GCST005195	23.4089353929735	GCST005195	29212778		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	19	11202306	19	11091630		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	7.705313375720557	GCST005194	29212778		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (263618bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	19	11224265	19	11113589		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	7.698970004336019	GCST005196	29212778		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (184329bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	19	11303554	19	11192878		EFO_0000378	Coronary artery disease	coronary artery disease
European=87827		GCST005077	8.154901959985743	GCST005077	29058716		drug	Medium	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000187266 at this locus (64180bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	19	11423703	19	11313027		EFO_0000305	Breast cancer	breast carcinoma
NR=547261		GCST005195	8.2518119729938	GCST005195	29212778		drug	Low	Ed Mountjoy	Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (1963bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000187266	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	19	11496981	19	11386305		EFO_0000378	Coronary artery disease	coronary artery disease
European=66756		GCST004744	9.045757490560675	GCST004744	28604730		drug	Low	Ed Mountjoy	Tyrosine-protein kinase receptor UFO inhibitor drug R428 is Phase II for the indiciation EFO_0000571 and targets the gene ENSG00000167601 at this locus (372022bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000167601	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	19	41353107	19	40847202		EFO_0000571	Lung adenocarcinoma	lung adenocarcinoma
European=140254		GCST006085	8.045757490560675	GCST006085	29892016		drug	Low	Ed Mountjoy	Sodium/potassium-transporting ATPase inhibitor drug DIGOXIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000105409 at this locus (199298bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000105409	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	19	42700947	19	42196795		EFO_0001663	Prostate cancer	prostate carcinoma
European=22548		GCST001942	7.522878745280337	GCST001942	23535732		drug	Low	Ed Mountjoy	Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (462229bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115758	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	10117868	2	9977740		EFO_0001663	Prostate cancer	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.698970004336019	GCST002606_3	25217961		drug	Low	Ed Mountjoy	Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115758	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	10710730	2	10570604		EFO_0001663	Prostate cancer [EA]	prostate carcinoma
European=140254		GCST006085	16.221848749616356	GCST006085	29892016		drug	Low	Ed Mountjoy	Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115758	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	10710730	2	10570604		EFO_0001663	Prostate cancer	prostate carcinoma
European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080		GCST002606	7.522878745280337	GCST002606	25217961		drug	Low	Ed Mountjoy	Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115758	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	10710730	2	10570604		EFO_0001663	Prostate cancer	prostate carcinoma
European=241704		GCST004483	16.0	GCST004483	27363682		drug	Low	Ed Mountjoy	DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (47687bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000119772	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	25613146	2	25390277		EFO_0001378	Multiple myeloma	multiple myeloma
European=14421		GCST004099	9.221848749616356	GCST004099	28112199		drug	Low	Ed Mountjoy	DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (63979bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000119772	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	2	25629438	2	25406569		EFO_0001378	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)	multiple myeloma
European=14421		GCST004099	9.221848749616356	GCST004099	28112199		drug	Low	Ed Mountjoy	DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000119772 at this locus (63979bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000119772	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	2	25629438	2	25406569		EFO_0000095	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)	chronic lymphocytic leukemia
European=408089	10.1038/s41588-018-0184-y		35.59516628338006	SAIGE_401_1			drug	High	Ed Mountjoy	Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171303	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	26914364	2	26691496		EFO_0000537	Essential hypertension	hypertension
European=361141			39.522019692388156	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171303	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	26914364	2	26691496		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
East Asian=50792		GCST007707	13.301029995663981	GCST007707_2	30487518		drug	High	Ed Mountjoy	Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171303	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	2	26920025	2	26697157		EFO_0000537	Hypertension [Japanese]	hypertension
European=408343	10.1038/s41588-018-0184-y		35.37263414340727	SAIGE_401			drug	High	Ed Mountjoy	Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171303	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	2	26923568	2	26700700		EFO_0000537	Hypertension	hypertension
East Asian=50792		GCST007707	17.69897000433602	GCST007707	30487518		drug	High	Ed Mountjoy	Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171303	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	26930411	2	26707543		EFO_0000537	Hypertension [East Asian]	hypertension
European=17500		GCST003983	14.698970004336019	GCST003983	27182965		drug	High	Ed Mountjoy	Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000277893	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	31805826	2	31580756		EFO_0004191	Male-pattern baldness	androgenetic alopecia
European=43590		GCST005116	25.69897000433602	GCST005116	29146897		drug	Low	Ed Mountjoy	Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (375418bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000277893	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	2	32181424	2	31956355		EFO_0004191	Male-pattern baldness	androgenetic alopecia
East Asian=5255		GCST001634	8.397940008672037	GCST001634	22885925		drug	Low	Ed Mountjoy	Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138039	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	48978159	2	48751020		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=1639		GCST000914	20.096910013008056	GCST000914	21151128		drug	High	Ed Mountjoy	Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138039	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	2	48978159	2	48751020		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=5255		GCST001634	8.397940008672037	GCST001634	22885925		drug	Medium	Ed Mountjoy	Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000170820	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	2	48978159	2	48751020		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=5255		GCST001634	8.397940008672037	GCST001634	22885925		drug	High	Ed Mountjoy	Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138039	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	2	48978159	2	48751020		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=1639		GCST000914	20.096910013008056	GCST000914	21151128		drug	Low	Ed Mountjoy	Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138039	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	48978159	2	48751020		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=1639		GCST000914	20.096910013008056	GCST000914	21151128		drug	Medium	Ed Mountjoy	Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000170820	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	2	48978159	2	48751020		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=5255		GCST001634	12.0	GCST001634	22885925		drug	Medium	Ed Mountjoy	Luteinizing hormone/Choriogonadotropin receptor agonist drug LH (MENOTROPINS) is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138039	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	49201612	2	48974473		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=5255		GCST001634	12.0	GCST001634	22885925		drug	Low	Ed Mountjoy	Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138039	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	49201612	2	48974473		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
East Asian=5255		GCST001634	12.0	GCST001634	22885925		drug	High	Ed Mountjoy	Follicle stimulating hormone receptor agonist drug HUMAN FSH is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000170820	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	49201612	2	48974473		EFO_0000660	Polycystic ovary syndrome	polycystic ovary syndrome
European=407052	10.1038/s41588-018-0184-y		7.52432881167557	SAIGE_420_2			drug	Medium	Ed Mountjoy	Interleukin-1 beta inhibitor drug RILONACEPT is Phase III for the indiciation EFO_0007427 and targets the gene ENSG00000125538 at this locus (15088bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000125538	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	2	113609568	2	112851991		EFO_0007427	Pericarditis	pericarditis
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	7.698970004336019	GCST007692	30804561		drug	Low	Ed Mountjoy	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000115159 at this locus (278767bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115159	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	157013035	2	156156523		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
NR=361315|European=446238		GCST007342	17.522878745280337	GCST007342	30718901		drug	Medium	Ed Mountjoy	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115159	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	157111313	2	156254801		EFO_0003761	Depression	unipolar depression
European=480359		GCST005839	7.698970004336019	GCST005839	29700475		drug	Medium	Ed Mountjoy	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115159	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	157111313	2	156254801		EFO_0003761	Depression	unipolar depression
European=357957		GCST006475	7.4889191544608815	GCST006475	29942085		drug	Medium	Ed Mountjoy	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (134654bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115159	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	2	157157148	2	156300636		EFO_0003761	Depressed affect	unipolar depression
European=361141			8.54284051026846	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (367302bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	2	162481453	2	161624943		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=408343	10.1038/s41588-018-0184-y		7.732828271596986	SAIGE_401			drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	2	162583504	2	161726994		EFO_0000537	Hypertension	hypertension
European=408089	10.1038/s41588-018-0184-y		7.580044251510242	SAIGE_401_1			drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	2	162583504	2	161726994		EFO_0000537	Essential hypertension	hypertension
European=82315|East Asian=5219		GCST002539	7.301029995663981	GCST002539	25056061		drug	High	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug LINAGLIPTIN is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000197635 at this locus (2901bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	2	162845855	2	161989345		EFO_0000692	Schizophrenia	schizophrenia
European=86475		GCST005537	12.522878745280337	GCST005537	26974007		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	163110536	2	162254026		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=18190		GCST002740	11.698970004336019	GCST002740_4	25574825		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	163110536	2	162254026		EFO_0000676	Inflammatory skin disease [Psoriasis]	psoriasis
European=29652		GCST005536	17.418639958543828	GCST005536	25751624		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	2	163110536	2	162254026		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=29652		GCST005536	17.418639958543828	GCST005536	25751624		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	2	163110536	2	162254026		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=33394		GCST005527	7.709543459425466	GCST005527	23143594		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	163124051	2	162267541		EFO_0000676	Psoriasis	psoriasis
European=19102		GCST001191	13.698970004336019	GCST001191	21829393		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	163124051	2	162267541		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
East Asian=5134|European=8682		GCST002874	8.0	GCST002874	25903422		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	163124051	2	162267541		EFO_0000676	Psoriasis	psoriasis
European=5000		GCST000038	10.698970004336019	GCST000038	17554260		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	163124051	2	162267541		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=16559		GCST000392	8.154901959985743	GCST000392	19430480		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	2	163124051	2	162267541		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=16559		GCST000392	8.154901959985743	GCST000392	19430480		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	2	163124051	2	162267541		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=5000		GCST000038	10.698970004336019	GCST000038	17554260		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	2	163124051	2	162267541		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=19102		GCST001191	13.698970004336019	GCST001191	21829393		drug	Medium	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	2	163124051	2	162267541		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
East Asian=5134|European=8682		GCST002874	10.522878745280337	GCST002874_5	25903422		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	163128824	2	162272314		EFO_0000676	Psoriasis [EA, conditional on rs1990760]	psoriasis
East Asian=5134|European=8682		GCST002874	18.0	GCST002874_9	25903422		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	163128824	2	162272314		EFO_0000676	Psoriasis [conditional on rs1990760]	psoriasis
European=287323		GCST004346	24.0	GCST004346	28537254		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (237021bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	2	163167746	2	162311236		EFO_0000676	Psoriasis	psoriasis
European=12244		GCST002738	8.522878745280337	GCST002738	25574825		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	163260691	2	162404181		EFO_0000676	Psoriasis	psoriasis
European=7353		GCST000833	13.0	GCST000833	20953190		drug	Low	Ed Mountjoy	Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000197635	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	163260691	2	162404181		EFO_0000676	Psoriasis	psoriasis
European, NR=40266		GCST004132	10.012333735073724	GCST004132	28067908		drug	High	Ed Mountjoy	Integrin alpha-4/beta-1 inhibitor drug NATALIZUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000115232 at this locus (13578bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000115232	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	2	182308352	2	181443625		EFO_0000384	Crohn's disease	Crohn's disease
East Asian=4325		GCST001457	13.045757490560675	GCST001457	22452962		drug	Low	Ed Mountjoy	Receptor protein-tyrosine kinase erbB-4 inhibitor drug BMS-690514 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000178568 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000178568	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	213296863	2	212432139		EFO_0000305	Breast cancer	breast carcinoma
European, NR=58918|European=458969		GCST007656	8.698970004336019	GCST007656	30940143		drug	Low	Ed Mountjoy	Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (360196bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163464	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	218667372	2	217802649		EFO_0000341	Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)	chronic obstructive pulmonary disease
European, NR=58918|European=458969		GCST007656	8.698970004336019	GCST007656	30940143		drug	Low	Ed Mountjoy	Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (322641bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180871	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	2	218667372	2	217802649		EFO_0000341	Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)	chronic obstructive pulmonary disease
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	11.522878745280337	GCST007692	30804561		drug	Low	Ed Mountjoy	Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (344415bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163464	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	218683154	2	217818431		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	11.522878745280337	GCST007692	30804561		drug	Low	Ed Mountjoy	Interleukin-8 receptor B antagonist drug DANIRIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (306858bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180871	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	218683154	2	217818431		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European=139274		GCST004988	9.466355021201236	GCST004988	29059683		drug	Low	Ed Mountjoy	Interleukin-8 receptor A modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000163464 at this locus (304113bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163464	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	218723455	2	217858732		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	9.466355021201236	GCST004988	29059683		drug	Low	Ed Mountjoy	Interleukin-8 receptor B modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000180871 at this locus (266557bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180871	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	218723455	2	217858732		EFO_0000305	Breast cancer	breast carcinoma
European=27432		GCST003045	8.682610761959468	GCST003045	26192919		drug	Low	Ed Mountjoy	Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180871	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	219010146	2	218145423		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European=86475		GCST005537	10.698970004336019	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180871	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	219010146	2	218145423		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=26405		GCST000964	8.056505484093897	GCST000964	21297633		drug	Low	Ed Mountjoy	Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180871	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	219010146	2	218145423		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=86475		GCST005537	10.698970004336019	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000180871 at this locus (8173bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000180871	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	219010146	2	218145423		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=86475		GCST005537	10.698970004336019	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000163464 at this locus (17422bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163464	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	219010146	2	218145423		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=17691		GCST004146	11.045757490560675	GCST004146	28165464		drug	Low	Ed Mountjoy	Programmed cell death protein 1 inhibitor drug NIVOLUMAB is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000188389 at this locus (494386bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000188389	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	2	242294913	2	241355498		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=140254		GCST006085	14.0	GCST006085	29892016		drug	Low	Ed Mountjoy	Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000188389	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	242382864	2	241443449		EFO_0001663	Prostate cancer	prostate carcinoma
European=22548		GCST001942	8.301029995663981	GCST001942	23535732		drug	Low	Ed Mountjoy	Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000188389	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	2	242382864	2	241443449		EFO_0001663	Prostate cancer	prostate carcinoma
European=16559		GCST000392	11.0	GCST000392	19430480		drug	Medium	Ed Mountjoy	FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000088832	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	20	1610551	20	1629905		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=16559		GCST000392	11.0	GCST000392	19430480		drug	Medium	Ed Mountjoy	FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000088832	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	20	1610551	20	1629905		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=29652		GCST005536	9.526299949462304	GCST005536	25751624		drug	Medium	Ed Mountjoy	FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000088832	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	20	1616206	20	1635560		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=29652		GCST005536	9.526299949462304	GCST005536	25751624		drug	Medium	Ed Mountjoy	FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000088832	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	20	1616206	20	1635560		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=20883		GCST003044	54.01739783478714	GCST003044	26192919		drug	Low	Ed Mountjoy	FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000088832	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	20	1682037	20	1701391		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=27432		GCST003045	41.87573133737034	GCST003045	26192919		drug	Low	Ed Mountjoy	FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000088832 at this locus (308219bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000088832	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	20	1682037	20	1701391		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European=20883		GCST003044	54.01739783478714	GCST003044	26192919		drug	Low	Ed Mountjoy	FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000088832	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	20	1682037	20	1701391		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=89677		GCST007236	7.4634655452861525	GCST007236	25751625		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (408100bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	20	44229447	20	45600808		EFO_0000305	Breast cancer	breast carcinoma
European, NR=40266		GCST004132	10.576918041702768	GCST004132	28067908		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (2636bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	20	44634912	20	46006273		EFO_0000384	Crohn's disease	Crohn's disease
European=89677		GCST007236	7.402641632544848	GCST007236	25751625		drug	Medium	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (48698bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	20	44693897	20	46065258		EFO_0000305	Breast cancer	breast carcinoma
European=43327		GCST005568	9.0	GCST005568	23143596		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (89110bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	20	44734310	20	46105671		EFO_0000685	Rheumatoid arthritis (ACPA-positive)	rheumatoid arthritis
European=20883		GCST003044	11.569280112136719	GCST003044	26192919		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (94996bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	20	44740196	20	46111557		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=86475		GCST005537	11.397940008672037	GCST005537	26974007		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000100985 at this locus (101782bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	20	44746982	20	46118343		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=86475		GCST005537	11.397940008672037	GCST005537	26974007		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (101782bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	20	44746982	20	46118343		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
East Asian=9299|European=45790		GCST006048	12.698970004336019	GCST006048	24532676		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (101782bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	20	44746982	20	46118343		EFO_0000685	Rheumatoid arthritis (ACPA-positive)	rheumatoid arthritis
European=25708		GCST000679	8.244874758392445	GCST000679	20453842		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	20	44747947	20	46119308		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=15853		GCST000232	8.096910013008056	GCST000232	18794853		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	20	44747947	20	46119308		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=43327		GCST005568	10.045757490560675	GCST005568	23143596		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	20	44747947	20	46119308		EFO_0000685	Rheumatoid arthritis (ACPA-positive)	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	13.522878745280337	GCST006959	30423114		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	20	44749251	20	46120612		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=58284|East Asian=22515		GCST002318	17.397940008672037	GCST002318	24390342		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	20	44749251	20	46120612		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	13.397940008672037	GCST006959_3	30423114		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	20	44749251	20	46120612		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
European=58284|East Asian=22515		GCST002318	16.0	GCST002318_2	24390342		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	20	44749251	20	46120612		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
European=89677		GCST007236	7.61253898367965	GCST007236	25751625		drug	Medium	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (229958bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	20	44875157	20	46246518		EFO_0000305	Breast cancer	breast carcinoma
European=89677		GCST007236	7.818633826857316	GCST007236	25751625		drug	Low	Ed Mountjoy	Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (391013bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100985	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	20	45036213	20	46407574		EFO_0000305	Breast cancer	breast carcinoma
European=89677		GCST007236	8.34338536184194	GCST007236	25751625		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug TRASTUZUMAB EMTANSINE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	20	57367899	20	58792844		EFO_0000305	Breast cancer	breast carcinoma
European=89677		GCST007236	8.34338536184194	GCST007236	25751625		drug	Low	Ed Mountjoy	Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	20	57367899	20	58792844		EFO_0000305	Breast cancer	breast carcinoma
East Asian=70506		GCST007552	7.698970004336019	GCST007552	30529582		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000101162 at this locus (119118bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	20	57475191	20	58900136		EFO_0005842	Colorectal cancer	colorectal cancer
European=89677		GCST007236	7.5130894413060085	GCST007236	25751625		drug	Low	Ed Mountjoy	Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	20	57659124	20	59084069		EFO_0000305	Breast cancer	breast carcinoma
European=89677		GCST007236	7.5130894413060085	GCST007236	25751625		drug	High	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	20	57659124	20	59084069		EFO_0000305	Breast cancer	breast carcinoma
NR=296525		GCST005194	9.099086932262331	GCST005194	29212778		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000101162 at this locus (112317bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	20	57714025	20	59138970		EFO_0000378	Coronary artery disease	coronary artery disease
European=86475		GCST005537	11.397940008672037	GCST005537	26974007		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000101162 at this locus (222600bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	20	57824309	20	59249254		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=89677		GCST007236	7.339507340775082	GCST007236	25751625		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	20	57971104	20	59396049		EFO_0000305	Breast cancer	breast carcinoma
European=89677		GCST007236	7.339507340775082	GCST007236	25751625		drug	Low	Ed Mountjoy	Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101162	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	20	57971104	20	59396049		EFO_0000305	Breast cancer	breast carcinoma
European=140254		GCST006085	17.522878745280337	GCST006085	29892016		drug	Low	Ed Mountjoy	Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101213	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	20	62362563	20	63731211		EFO_0001663	Prostate cancer	prostate carcinoma
European=22548		GCST001942	15.397940008672037	GCST001942	23535732		drug	Low	Ed Mountjoy	Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000101213	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	20	62362563	20	63731211		EFO_0001663	Prostate cancer	prostate carcinoma
European=58284|East Asian=22515		GCST002318	7.522878745280337	GCST002318_2	24390342		drug	Low	Ed Mountjoy	Interferon-alpha/beta receptor alpha chain antagonist drug ANIFROLUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000142166 at this locus (32118bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142166	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	21	34764288	21	33391982		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
European, NR=63731		GCST004787	9.154901959985743	GCST004787	28714975		drug	Medium	Ed Mountjoy	Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000128271	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	22	24658858	22	24262890		EFO_0000378	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	coronary artery disease
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	9.698970004336019	GCST003116_2	26343387		drug	Medium	Ed Mountjoy	Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000128271	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	22	24658858	22	24262890		EFO_0000378	Coronary artery disease [additive model]	coronary artery disease
NR=250736		GCST005196	9.045757490560675	GCST005196	29212778		drug	Medium	Ed Mountjoy	Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (151677bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000128271	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	22	24662171	22	24266203		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	8.428291168191313	GCST005194	29212778		drug	Medium	Ed Mountjoy	Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (141129bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000128271	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	22	24672718	22	24276750		EFO_0000378	Coronary artery disease	coronary artery disease
European, NR=40266		GCST004132	7.7544873321858505	GCST004132	28067908		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100385 at this locus (263382bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100385	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	22	37258503	22	36862461		EFO_0000384	Crohn's disease	Crohn's disease
European=29652		GCST005536	7.748198311221298	GCST005536	25751624		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (16018bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100385	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	22	37587111	22	37191071		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
European=8207		GCST000258	7.698970004336019	GCST000258	18978792		drug	Low	Ed Mountjoy	Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (20224bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000100385	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	22	37591318	22	37195278		EFO_0001359	Type 1 diabetes	insulin-dependent diabetes mellitus
NR=237		GCST004105	7.3979400086720375	GCST004105	28044437		drug	Medium	Ed Mountjoy	Interleukin-5 receptor subunit alpha inhibitor drug BENRALIZUMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000091181 at this locus (122868bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091181	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	3	2985142	3	2943458		EFO_0000341	Body mass index (change over time) in chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European=459000		GCST007072	10.0	GCST007072	30595370		drug	Medium	Ed Mountjoy	Histamine H1 receptor agonist drug TOLAZOLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196639 at this locus (203935bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196639	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	3	11508965	3	11467491		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=688809		GCST006477	7.301029995663981	GCST006477	29942085		drug	Low	Ed Mountjoy	Histamine H1 receptor antagonist drug HYDROXYZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196639	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	3	11590751	3	11549277		EFO_0003761	Depression	unipolar depression
European=688809		GCST006477	7.301029995663981	GCST006477	29942085		drug	Low	Ed Mountjoy	Histamine H1 receptor agonist drug BETAHISTINE is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196639	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	3	11590751	3	11549277		EFO_0003761	Depression	unipolar depression
European=688809		GCST006477	7.301029995663981	GCST006477	29942085		drug	Low	Ed Mountjoy	Histamine H1 receptor antagonist drug DIBENZEPIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196639	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	3	11590751	3	11549277		EFO_0003761	Depression	unipolar depression
European=459000		GCST007077	11.0	GCST007077	30595370		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	3	12329783	3	12288284		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=360192			7.5486127463375	NEALE2_2443		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug PIOGLITAZONE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	3	12329783	3	12288284		EFO_0000400	Diabetes diagnosed by doctor	diabetes mellitus
European=459000		GCST007077	11.0	GCST007077	30595370		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	12329783	3	12288284		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	11.0	GCST007077	30595370		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	3	12329783	3	12288284		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=360192			7.5486127463375	NEALE2_2443		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	3	12329783	3	12288284		EFO_0000400	Diabetes diagnosed by doctor	diabetes mellitus
European=69033		GCST005047	8.795880017344075	GCST005047	22885922		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	12392272	3	12350773		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	8.795880017344075	GCST005047	22885922		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	3	12392272	3	12350773		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	8.795880017344075	GCST005047	22885922		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	3	12392272	3	12350773		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	11.301029995663981	GCST007517	29632382		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	13.698970004336019	GCST004894_2	28869590		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	18.522878745280337	GCST007516	29632382		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007518	16.0	GCST007518	29632382		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	9.221848749616356	GCST002352	24509480		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	13.698970004336019	GCST004894_2	28869590		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	18.522878745280337	GCST007516	29632382		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	18.69897000433602	GCST004894	28869590		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	9.221848749616356	GCST002352	24509480		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	9.221848749616356	GCST002352	24509480		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	17.0	GCST007515	29632382		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	11.301029995663981	GCST007517	29632382		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	18.522878745280337	GCST007516	29632382		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	17.0	GCST007515	29632382		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	18.69897000433602	GCST004894	28869590		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	16.0	GCST007518	29632382		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007517	11.301029995663981	GCST007517	29632382		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	18.69897000433602	GCST004894	28869590		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	13.698970004336019	GCST004894_2	28869590		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=298957		GCST007518	16.0	GCST007518	29632382		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	17.0	GCST007515	29632382		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	23.69897000433602	GCST006867	30054458		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	3	12394840	3	12353341		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	23.69897000433602	GCST006867	30054458		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	3	12394840	3	12353341		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	23.69897000433602	GCST006867	30054458		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	12394840	3	12353341		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	15.357832365595055	GCST005413	29358691		drug	Low	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	3	12396913	3	12355414		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	15.357832365595055	GCST005413	29358691		drug	High	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	3	12396913	3	12355414		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	15.357832365595055	GCST005413	29358691		drug	Medium	Ed Mountjoy	Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000132170	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	3	12396913	3	12355414		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	7.698970004336019	GCST006061_3	29892015		drug	Medium	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	3	38634142	3	38592651		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	7.698970004336019	GCST006061_3	29892015		drug	Low	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	3	38634142	3	38592651		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	7.698970004336019	GCST006061_3	29892015		drug	High	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	3	38634142	3	38592651		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=1030836		GCST006414	15.12010167566999	GCST006414	30061737		drug	High	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	3	38710315	3	38668824		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	15.12010167566999	GCST006414	30061737		drug	Medium	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	3	38710315	3	38668824		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	13.154901959985743	GCST006061_3	29892015		drug	Low	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	3	38710315	3	38668824		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	13.154901959985743	GCST006061_3	29892015		drug	High	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	3	38710315	3	38668824		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	13.154901959985743	GCST006061_3	29892015		drug	Medium	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	3	38710315	3	38668824		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=1030836		GCST006414	15.12010167566999	GCST006414	30061737		drug	Low	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	3	38710315	3	38668824		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=395739	10.1038/s41588-018-0184-y		7.87942606879415	SAIGE_427_2			drug	Medium	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	3	38766675	3	38725184		EFO_0000275	Atrial fibrillation and flutter	atrial fibrillation
European=395739	10.1038/s41588-018-0184-y		7.87942606879415	SAIGE_427_2			drug	High	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	3	38766675	3	38725184		EFO_0000275	Atrial fibrillation and flutter	atrial fibrillation
European=395739	10.1038/s41588-018-0184-y		7.87942606879415	SAIGE_427_2			drug	Low	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	38766675	3	38725184		EFO_0000275	Atrial fibrillation and flutter	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	17.397940008672037	GCST006061	29892015		drug	Medium	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	14.221848749616356	GCST006061_3	29892015		drug	Medium	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=1030836		GCST006414	19.619607839942972	GCST006414	30061737		drug	Low	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	19.619607839942972	GCST006414	30061737		drug	Medium	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	14.221848749616356	GCST006061_3	29892015		drug	Low	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	17.397940008672037	GCST006061	29892015		drug	Low	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	14.221848749616356	GCST006061_3	29892015		drug	High	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=1030836		GCST006414	19.619607839942972	GCST006414	30061737		drug	High	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	17.397940008672037	GCST006061	29892015		drug	High	Ed Mountjoy	Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000183873	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	3	38771925	3	38730434		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=361141			10.553695886048077	NEALE2_20002_1456		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (247604bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000173585	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	3	46192270	3	46150778		EFO_0001060	Malabsorption/coeliac disease | non-cancer illness code, self-reported	celiac disease
European=23649|South Asian=620		GCST005523	8.045757490560675	GCST005523_7	22057235		drug	Low	Ed Mountjoy	C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (261019bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000173585	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	46205686	3	46164194		EFO_0001060	Celiac disease [conditioned on rs2097282]	celiac disease
European=15283		GCST000612	10.597222930389652	GCST000612	20190752		drug	Low	Ed Mountjoy	C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (290535bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000173585	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	46235201	3	46193709		EFO_0001060	Celiac disease	celiac disease
European=4634		GCST002520	7.3979400086720375	GCST002520	24999842		drug	Low	Ed Mountjoy	C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (337078bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000173585	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	46281744	3	46240253		EFO_0001060	Celiac disease	celiac disease
European=23649|South Asian=620		GCST005523	20.0	GCST005523	22057235		drug	Low	Ed Mountjoy	C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (433359bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000173585	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	46378025	3	46336534		EFO_0001060	Celiac disease	celiac disease
European=86475		GCST005537	7.698970004336019	GCST005537	26974007		drug	Low	Ed Mountjoy	C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000121807 at this locus (26239bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121807	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	46428658	3	46387167		EFO_0004268	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	sclerosing cholangitis
European=86475		GCST005537	7.698970004336019	GCST005537	26974007		drug	Low	Ed Mountjoy	C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000160791 at this locus (10962bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	46428658	3	46387167		EFO_0004268	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	sclerosing cholangitis
European=86475		GCST005537	7.698970004336019	GCST005537	26974007		drug	Low	Ed Mountjoy	C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000173585 at this locus (483992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000173585	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	3	46428658	3	46387167		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
European=86475		GCST005537	7.698970004336019	GCST005537	26974007		drug	Low	Ed Mountjoy	C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000173585 at this locus (483992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000173585	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	46428658	3	46387167		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=6315		GCST003183	18.69897000433602	GCST003183	26553974		drug	Low	Ed Mountjoy	C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000121807 at this locus (49262bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121807	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	46451680	3	46410189		EFO_0000180	Setpoint viral load in HIV-1 infection	HIV-1 infection
European=6315		GCST003183	18.69897000433602	GCST003183	26553974		drug	Low	Ed Mountjoy	C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160791	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	46451680	3	46410189		EFO_0000180	Setpoint viral load in HIV-1 infection	HIV-1 infection
European=6315		GCST003183	18.69897000433602	GCST003183	26553974		drug	High	Ed Mountjoy	C-C chemokine receptor type 5 antagonist drug MARAVIROC is Phase IV for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000160791	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	3	46451680	3	46410189		EFO_0000180	Setpoint viral load in HIV-1 infection	HIV-1 infection
European=13574|NR=2380		GCST004521	7.3979400086720375	GCST004521	28540026		drug	Medium	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (220268bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	3	52268866	3	52234850		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
Other=1097|NR=150064		GCST003048	8.522878745280337	GCST003048	26198764		drug	Medium	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (201667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	3	52287468	3	52253452		EFO_0000692	Schizophrenia	schizophrenia
European=398213	10.1038/s41588-018-0184-y		7.847711655616943	SAIGE_740_1			drug	Medium	Ed Mountjoy	Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (196795bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000239732	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	3	52456973	3	52422957		EFO_0002506	Osteoarthritis; localized	osteoarthritis
East Asian=45528		GCST007201	12.698970004336019	GCST007201	30285260		drug	Medium	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	3	52628056	3	52594040		EFO_0000692	Schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	12.301029995663981	GCST004946	28991256		drug	Medium	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	3	52628056	3	52594040		EFO_0000692	Schizophrenia	schizophrenia
European=18419		GCST001592	8.301029995663981	GCST001592	22763110		drug	Low	Ed Mountjoy	Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (461126bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000239732	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	3	52721305	3	52687289		EFO_0002506	Osteoarthritis	osteoarthritis
European=417596		GCST007092	9.698970004336019	GCST007092	30664745		drug	Low	Ed Mountjoy	Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase II for the indiciation EFO_0004616 and targets the gene ENSG00000239732 at this locus (468625bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000239732	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	3	52728804	3	52694788		EFO_0004616	Osteoarthritis of the hip or knee	osteoarthritis, knee
NR, African American or Afro-Caribbean, European, African unspecified, Asian unspecified, Other=48070		GCST002254	7.522878745280337	GCST002254	24166486		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (288821bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	3	52815905	3	52781889		EFO_0000692	Schizophrenia, schizoaffective disorder or bipolar disorder	schizophrenia
European=61220		GCST001877	11.522878745280337	GCST001877	23453885		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	3	52833219	3	52799203		EFO_0000692	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	schizophrenia
NR=150064|European=70017		GCST007257	10.698970004336019	GCST007257	30626913		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	3	52833219	3	52799203		EFO_0000692	Broad depression or schizophrenia	schizophrenia
European=105318		GCST006803	11.0	GCST006803	29483656		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	3	52833805	3	52799789		EFO_0000692	Schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	11.522878745280337	GCST004521	28540026		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	3	52833805	3	52799789		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
East Asian=45528		GCST007201	10.0	GCST007201_2	30285260		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	3	52833805	3	52799789		EFO_0000692	Schizophrenia [EA]	schizophrenia
European=11244|NR=20899		GCST002149	8.0	GCST002149	23974872		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (311318bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	3	52838402	3	52804386		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	10.397940008672037	GCST002539	25056061		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	3	52845105	3	52811089		EFO_0000692	Schizophrenia	schizophrenia
Other=1097|NR=150064		GCST003048	10.698970004336019	GCST003048	26198764		drug	Low	Ed Mountjoy	Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000010322	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	3	52845105	3	52811089		EFO_0000692	Schizophrenia	schizophrenia
East Asian=5158		GCST004302	12.522878745280337	GCST004302	28425483		drug	High	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (93052bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	3	119150089	3	119431242		EFO_1001486	Primary biliary cholangitis	primary biliary cirrhosis
European=18264|African American or Afro-Caribbean=5422|Hispanic or Latin American=3888		GCST005752	11.0	GCST005752	28714469		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (68758bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	119174383	3	119455536		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=13239		GCST003129	14.397940008672037	GCST003129	26394269		drug	High	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	3	119219934	3	119501087		EFO_1001486	Primary biliary cholangitis	primary biliary cirrhosis
European=26621		GCST001198	8.96738123914928	GCST001198	21833088		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (23206bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	3	119219934	3	119501087		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=11375		GCST005581	15.16526148109616	GCST005581	22961000		drug	High	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	3	119219934	3	119501087		EFO_1001486	Primary biliary cirrhosis	primary biliary cirrhosis
East Asian=3574		GCST007036	8.221848749616356	GCST007036	30643196		drug	High	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	3	119219934	3	119501087		EFO_1001486	Primary biliary cholangitis	primary biliary cirrhosis
European=18264		GCST007400	9.0	GCST007400	28714469		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (20684bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	3	119222456	3	119503609		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=38582		GCST005531	14.397940008672037	GCST005531	24076602		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	3	119244593	3	119525746		EFO_0003885	Multiple sclerosis	multiple sclerosis
East Asian=5050		GCST001795	15.522878745280337	GCST001795	23273568		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	3	119260944	3	119542097		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=5050		GCST002845	7.301029995663981	GCST002845	25862617		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000121594	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	3	119272391	3	119553544		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=38582		GCST005531	14.154901959985743	GCST005531	24076602		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (230632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000114013	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	3	121543577	3	121824730		EFO_0003885	Multiple sclerosis	multiple sclerosis
NR=215725		GCST007124	7.3979400086720375	GCST007124	26920376		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (113546bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000114013	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	3	121660664	3	121941817		EFO_0003885	Multiple sclerosis and HDL levels (pleiotropy)	multiple sclerosis
European=341215		GCST007798	8.154901959985743	GCST007798	30929738		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000114013 at this locus (58039bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000114013	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	3	121716171	3	121997324		EFO_0000270	Asthma	asthma
European=15283		GCST003566	9.0	GCST003566	27386562		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (4687bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000114013	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	3	121769522	3	122050675		EFO_0003885	Multiple sclerosis	multiple sclerosis
NR=3599|Hispanic or Latin American=1956|European=17698		GCST003340	7.301029995663981	GCST003340	26819262		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000114013	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	3	121770539	3	122051692		EFO_0003885	Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis	multiple sclerosis
European=38582		GCST005531	12.273272790973428	GCST005531	24076602		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000114013	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	3	121770539	3	122051692		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=26621		GCST001198	8.811915626285062	GCST001198	21833088		drug	Low	Ed Mountjoy	T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000114013	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	3	121796768	3	122077921		EFO_0003885	Multiple sclerosis	multiple sclerosis
European=41199		GCST000639	11.0	GCST000639	20348956		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000068078	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	1734239	4	1732512		EFO_0000292	Urinary bladder cancer	bladder carcinoma
European=6206		GCST002240	24.154901959985743	GCST002240	24163127		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000068078	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	1734239	4	1732512		EFO_0000292	Bladder cancer	bladder carcinoma
European=8652		GCST000842	12.397940008672037	GCST000842	20972438		drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000068078	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	1734239	4	1732512		EFO_0000292	Bladder cancer	bladder carcinoma
European=361141			7.692944898477948	NEALE2_20001_1035		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (25584bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000068078	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	1769436	4	1767709		EFO_0000292	Bladder cancer | cancer code, self-reported	bladder carcinoma
African American or Afro-Caribbean=1541|European=1436		GCST004955	7.522878745280337	GCST004955	28990359		drug	Low	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug LORAZEPAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	4	45547068	4	45545051		EFO_0003829	Risky sexual behaviors in alcohol dependence [AA]	alcohol dependence
African American or Afro-Caribbean=1541|European=1436		GCST004955	7.522878745280337	GCST004955	28990359		drug	Low	Ed Mountjoy	GABA-A receptor; anion channel allosteric antagonist drug FLUMAZENIL is Phase II for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	4	45547068	4	45545051		EFO_0003829	Risky sexual behaviors in alcohol dependence [AA]	alcohol dependence
African American or Afro-Caribbean=1541|European=1436		GCST004955	7.522878745280337	GCST004955	28990359		drug	Low	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug CHLORDIAZEPOXIDE is Phase III for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	4	45547068	4	45545051		EFO_0003829	Risky sexual behaviors in alcohol dependence [AA]	alcohol dependence
European=3524		GCST003427	9.0	GCST003427	26830138		drug	Low	Ed Mountjoy	GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000163285 at this locus (288042bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	46414112	4	46412095		EFO_0000249	Alzheimer disease and age of onset [between families]	Alzheimer's disease
European=3524		GCST003427	9.0	GCST003427	26830138		drug	Low	Ed Mountjoy	GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151834	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	46414112	4	46412095		EFO_0000249	Alzheimer disease and age of onset [between families]	Alzheimer's disease
European=26405		GCST000964	8.872895201635192	GCST000964	21297633		drug	High	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000151834 at this locus (66059bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151834	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	4	46543306	4	46541289		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=26405		GCST000964	8.872895201635192	GCST000964	21297633		drug	Low	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000163285 at this locus (417235bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000163285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	4	46543306	4	46541289		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=3524		GCST003427	9.0	GCST003427	26830138		drug	Low	Ed Mountjoy	GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (213998bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151834	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	4	46691244	4	46689227		EFO_0000249	Alzheimer disease and age of onset [between families]	Alzheimer's disease
East Asian=4275		GCST001384	8.096910013008056	GCST001384	22291604		drug	Low	Ed Mountjoy	c-Jun N-terminal kinase 3 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000109339 at this locus (442619bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000109339	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	87958395	4	87037243		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=361141			9.056494107508188	NEALE2_20002_1262		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (25518bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	TA	T	4	90619732	4	89698581		EFO_0002508	Parkinsons disease | non-cancer illness code, self-reported	Parkinson's disease
European=334141		GCST003984	56.0	GCST003984	27182965		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	90626111	4	89704960		EFO_0002508	Parkinson's disease	Parkinson's disease
European=108990		GCST002544	72.39794000867204	GCST002544	25064009		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	90626111	4	89704960		EFO_0002508	Parkinson's disease	Parkinson's disease
European=417508		GCST004902	122.30102999566398	GCST004902	28892059		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	90626111	4	89704960		EFO_0002508	Parkinson's disease	Parkinson's disease
NR=4258		GCST001445	64.22184874961636	GCST001445_2	22438815		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	90637601	4	89716450		EFO_0002508	Parkinson's disease [EA]	Parkinson's disease
European=17352		GCST000959	46.69897000433602	GCST000959	21292315		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	90637601	4	89716450		EFO_0002508	Parkinson's disease	Parkinson's disease
East Asian=3509		GCST000530	16.154901959985743	GCST000530	19915576		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (5735bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	4	90639515	4	89718364		EFO_0002508	Parkinson's disease	Parkinson's disease
European=33050		GCST001126	18.69897000433602	GCST001126	21738487		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	90641340	4	89720189		EFO_0002508	Parkinson's disease	Parkinson's disease
European=3986		GCST002353	9.0	GCST002353_3	24511991		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	90641340	4	89720189		EFO_0002508	Parkinson's disease [Sporadic]	Parkinson's disease
European=8477		GCST001430	34.096910013008056	GCST001430	22451204		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	90641340	4	89720189		EFO_0002508	Parkinson's disease	Parkinson's disease
European=3986		GCST000772	10.522878745280337	GCST000772	20711177		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	90641340	4	89720189		EFO_0002508	Parkinson's disease	Parkinson's disease
European=6880		GCST000855	15.045757490560675	GCST000855	21044948		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	90641340	4	89720189		EFO_0002508	Parkinson's disease	Parkinson's disease
European=3023		GCST000874	7.522878745280337	GCST000874	21084426		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	90641340	4	89720189		EFO_0002508	Parkinson's disease	Parkinson's disease
European=3986		GCST002353	10.522878745280337	GCST002353	24511991		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	4	90641340	4	89720189		EFO_0002508	Parkinson's disease	Parkinson's disease
East Asian=14006		GCST003922	32.0	GCST003922	28011712		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (797bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	4	90644454	4	89723303		EFO_0002508	Parkinson's disease	Parkinson's disease
NR=17996		GCST007780	11.698970004336019	GCST007780	30957308		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	4	90666041	4	89744890		EFO_0002508	Parkinson's disease (age of onset)	Parkinson's disease
European=5691		GCST000528	15.698970004336019	GCST000528	19915575		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	90678541	4	89757390		EFO_0002508	Parkinson's disease	Parkinson's disease
NR=4258		GCST001445	10.301029995663981	GCST001445	22438815		drug	Low	Ed Mountjoy	Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (21437bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145335	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	4	90780902	4	89859751		EFO_0002508	Parkinson's disease [Asian]	Parkinson's disease
European=459000		GCST007072	14.096910013008056	GCST007072	30595370		drug	Medium	Ed Mountjoy	Microsomal triglyceride transfer protein inhibitor drug LOMITAPIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000138823 at this locus (245600bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000138823	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	4	100239319	4	99318162		EFO_0000319	Cardiovascular disease	cardiovascular system disease
East Asian=4168		GCST003154	8.301029995663981	GCST003154	26488411		drug	Low	Ed Mountjoy	Endothelin receptor ET-A antagonist drug ZIBOTENTAN is Phase II for the indiciation EFO_0004265 and targets the gene ENSG00000151617 at this locus (1251bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151617	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	4	148400819	4	147479667		EFO_0004265	Peripheral artery disease	peripheral arterial disease
European=1030836		GCST006414	10.878440155812498	GCST006414	30061737		drug	High	Ed Mountjoy	Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151623	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	4	148937537	4	148016386		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	13.221848749616356	GCST006061	29892015		drug	High	Ed Mountjoy	Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151623	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	4	148937537	4	148016386		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	10.878440155812498	GCST006414	30061737		drug	Low	Ed Mountjoy	Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151623	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	4	148937537	4	148016386		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	13.221848749616356	GCST006061	29892015		drug	Low	Ed Mountjoy	Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151623	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	4	148937537	4	148016386		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	12.154901959985743	GCST006061_3	29892015		drug	High	Ed Mountjoy	Mineralocorticoid receptor antagonist drug CANRENONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151623	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	4	148946690	4	148025539		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	12.154901959985743	GCST006061_3	29892015		drug	Low	Ed Mountjoy	Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000151623	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	4	148946690	4	148025539		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=459000		GCST007072	10.698970004336019	GCST007072	30595370		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (259540bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	4	156420605	4	155499453		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			8.636910992288339	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	156433308	4	155512156		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=361141			8.636910992288339	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	4	156433308	4	155512156		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
NR=296525		GCST005194	9.962972120244226	GCST005194	29212778		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	156436507	4	155515355		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	9.962972120244226	GCST005194	29212778		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	4	156436507	4	155515355		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	9.962972120244226	GCST005194	29212778		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	4	156436507	4	155515355		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	10.0	GCST005196	29212778		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	4	156436517	4	155515365		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	10.0	GCST005196	29212778		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	4	156436517	4	155515365		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	10.0	GCST005196	29212778		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	4	156436517	4	155515365		EFO_0000378	Coronary artery disease	coronary artery disease
NR=547261		GCST005195	14.0	GCST005195	29212778		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	4	156614184	4	155693032		EFO_0000378	Coronary artery disease	coronary artery disease
NR=547261		GCST005195	14.0	GCST005195	29212778		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	4	156614184	4	155693032		EFO_0000378	Coronary artery disease	coronary artery disease
NR=547261		GCST005195	14.0	GCST005195	29212778		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	4	156614184	4	155693032		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	22.476643793345207	GCST005194	29212778		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	156635309	4	155714157		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	21.397940008672037	GCST005196	29212778		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	4	156635309	4	155714157		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	21.397940008672037	GCST005196	29212778		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	4	156635309	4	155714157		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	21.397940008672037	GCST005196	29212778		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	4	156635309	4	155714157		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	22.476643793345207	GCST005194	29212778		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	4	156635309	4	155714157		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	22.476643793345207	GCST005194	29212778		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	4	156635309	4	155714157		EFO_0000378	Coronary artery disease	coronary artery disease
European, NR=63731		GCST004787	9.0	GCST004787	28714975		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	4	156638573	4	155717421		EFO_0000378	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	coronary artery disease
European, NR=63731		GCST004787	9.0	GCST004787	28714975		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	4	156638573	4	155717421		EFO_0000378	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	coronary artery disease
European, NR=63731		GCST004787	9.0	GCST004787	28714975		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	4	156638573	4	155717421		EFO_0000378	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	coronary artery disease
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	8.221848749616356	GCST003116	26343387		drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	4	156639888	4	155718736		EFO_0000378	Coronary artery disease	coronary artery disease
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	8.221848749616356	GCST003116	26343387		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	4	156639888	4	155718736		EFO_0000378	Coronary artery disease	coronary artery disease
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	8.221848749616356	GCST003116	26343387		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	4	156639888	4	155718736		EFO_0000378	Coronary artery disease	coronary artery disease
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	7.698970004336019	GCST003117	26343387		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000061918 at this locus (40257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	4	156639888	4	155718736		EFO_0000612	Myocardial infarction	myocardial infarction
European=408343	10.1038/s41588-018-0184-y		16.378823718224965	SAIGE_401			drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	4	156642884	4	155721732		EFO_0000537	Hypertension	hypertension
European=408089	10.1038/s41588-018-0184-y		16.32513885926219	SAIGE_401_1			drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	4	156642884	4	155721732		EFO_0000537	Essential hypertension	hypertension
European=408343	10.1038/s41588-018-0184-y		16.378823718224965	SAIGE_401			drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	4	156642884	4	155721732		EFO_0000537	Hypertension	hypertension
European=408089	10.1038/s41588-018-0184-y		16.32513885926219	SAIGE_401_1			drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	4	156642884	4	155721732		EFO_0000537	Essential hypertension	hypertension
European=408458	10.1038/s41588-018-0184-y		9.669586226650809	SAIGE_411			drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	4	156645513	4	155724361		EFO_0000378	Ischemic heart disease	coronary artery disease
European=408458	10.1038/s41588-018-0184-y		9.669586226650809	SAIGE_411			drug	Medium	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	4	156645513	4	155724361		EFO_0000378	Ischemic heart disease	coronary artery disease
European=408458	10.1038/s41588-018-0184-y		9.669586226650809	SAIGE_411			drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	4	156645513	4	155724361		EFO_0000378	Ischemic heart disease	coronary artery disease
European=459000		GCST007072	19.69897000433602	GCST007072	30595370		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (33805bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	4	156646340	4	155725188		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			15.293624498063002	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	4	156646340	4	155725188		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=361141			15.293624498063002	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	4	156646340	4	155725188		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
East Asian=50792		GCST007707	8.698970004336019	GCST007707	30487518		drug	Low	Ed Mountjoy	Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	A	4	156666991	4	155745839		EFO_0000537	Hypertension [East Asian]	hypertension
East Asian=50792		GCST007707	8.698970004336019	GCST007707	30487518		drug	High	Ed Mountjoy	Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000061918	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	4	156666991	4	155745839		EFO_0000537	Hypertension [East Asian]	hypertension
European=30659		GCST004347	65.52287874528034	GCST004347	28346443		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	1279790	5	1279675		EFO_0000326	Glioma	central nervous system cancer
African American or Afro-Caribbean=3749|European=5388		GCST001298	10.0	GCST001298	22037553		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	8.0	GCST004950	25751625		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=24381		GCST004349	73.09691001300806	GCST004349	28346443		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	1279790	5	1279675		EFO_0000326	Glioblastoma	central nervous system cancer
European=24381		GCST004349	73.09691001300806	GCST004349	28346443		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000326	Glioblastoma	central nervous system cancer
European=24009		GCST004348	16.0	GCST004348	28346443		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000326	Non-glioblastoma glioma	central nervous system cancer
European=22627		GCST001937	8.154901959985743	GCST001937	23535729		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=15566		GCST005075	15.397940008672037	GCST005075	29058716		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=24009		GCST004348	16.0	GCST004348	28346443		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	1279790	5	1279675		EFO_0000326	Non-glioblastoma glioma	central nervous system cancer
European=30659		GCST004347	65.52287874528034	GCST004347	28346443		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000326	Glioma	central nervous system cancer
European=139274		GCST004988	16.10874138309586	GCST004988	29059683		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=11582		GCST003228	19.397940008672037	GCST003228	26424050		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000326	Glioma	central nervous system cancer
European=22627		GCST001937	8.154901959985743	GCST001937	23535729		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=63347		GCST004415	7.522878745280337	GCST004415	28346442		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0001075	Invasive epithelial ovarian cancer	ovarian carcinoma
European=39387		GCST001930	11.301029995663981	GCST001930	23535733		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=39387		GCST001930	11.301029995663981	GCST001930	23535733		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	16.10874138309586	GCST004988	29059683		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=15566		GCST005075	15.397940008672037	GCST005075	29058716		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=11582		GCST003228	19.397940008672037	GCST003228	26424050		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	1279790	5	1279675		EFO_0000326	Glioma	central nervous system cancer
European=33864		GCST004950	8.0	GCST004950	25751625		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
African American or Afro-Caribbean=3749|European=5388		GCST001298	10.0	GCST001298	22037553		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1279790	5	1279675		EFO_0000305	Breast cancer	breast carcinoma
European=140254		GCST006085	51.39794000867204	GCST006085	29892016		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1280028	5	1279913		EFO_0001663	Prostate cancer	prostate carcinoma
European=19291		GCST003845	27.096910013008056	GCST003845	27117709		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (112882bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1280028	5	1279913		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	27.096910013008056	GCST003845	27117709		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1280028	5	1279913		EFO_0000305	Breast cancer	breast carcinoma
European=13560		GCST001148	23.522878745280337	GCST001148	21743467		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1280028	5	1279913		EFO_0001663	Prostate cancer	prostate carcinoma
European=407770	10.1038/s41588-018-0184-y		8.411168274405792	SAIGE_191_1			drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	5	1280830	5	1280715		EFO_0000326	Cancer of brain and nervous system	central nervous system cancer
European=407770	10.1038/s41588-018-0184-y		8.411168274405792	SAIGE_191_1			drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	5	1280830	5	1280715		EFO_0000326	Cancer of brain and nervous system	central nervous system cancer
European=19291		GCST003845	7.522878745280337	GCST003845	27117709		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110590bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1282319	5	1282204		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	7.522878745280337	GCST003845	27117709		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1282319	5	1282204		EFO_0000305	Breast cancer	breast carcinoma
European=123671		GCST003588	9.698970004336019	GCST003588_2	27197191		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (110495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1282414	5	1282299		EFO_0001075	Cancer (pleiotropy) [subset analysis]	ovarian carcinoma
European=123671		GCST003588	9.698970004336019	GCST003588_2	27197191		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1282414	5	1282299		EFO_0001663	Cancer (pleiotropy) [subset analysis]	prostate carcinoma
European=123671		GCST003588	9.698970004336019	GCST003588_2	27197191		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1282414	5	1282299		EFO_0000305	Cancer (pleiotropy) [subset analysis]	breast carcinoma
European=123671		GCST003588	9.698970004336019	GCST003588_2	27197191		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (110495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	1282414	5	1282299		EFO_0001071	Cancer (pleiotropy) [subset analysis]	lung carcinoma
European=123671		GCST003588	9.698970004336019	GCST003588_2	27197191		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1282414	5	1282299		EFO_0000305	Cancer (pleiotropy) [subset analysis]	breast carcinoma
European=7541		GCST002890	10.522878745280337	GCST002890	25939597		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1282414	5	1282299		EFO_0001663	Prostate cancer	prostate carcinoma
European=291407		GCST004142	11.154901959985743	GCST004142	28212542		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (108257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	1284653	5	1284538		EFO_0000756	Melanoma	melanoma
European=63347		GCST004415	9.154901959985743	GCST004415	28346442		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (106936bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1285974	5	1285859		EFO_0001075	Invasive epithelial ovarian cancer	ovarian carcinoma
European=361141			7.383947958952672	NEALE2_20002_1438		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000164362 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1285974	5	1285859		EFO_0002429	Polycythaemia vera | non-cancer illness code, self-reported	polycythemia vera
East Asian=5408		GCST001140	27.0	GCST001140	21725308		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	1286516	5	1286401		EFO_0001071	Lung cancer	lung carcinoma
European=4773		GCST001194	8.154901959985743	GCST001194	21827660		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
European=11582		GCST001058	14.0	GCST001058	21531791		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
European=7608		GCST002474	15.0	GCST002474	24908248		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1286516	5	1286401		EFO_0000326	Glioma (high-grade)	central nervous system cancer
European=5548		GCST000439	16.69897000433602	GCST000439	19578367		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
East Asian=10054		GCST001740	26.397940008672037	GCST001740	23143601		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	1286516	5	1286401		EFO_0001071	Lung cancer	lung carcinoma
European=4773		GCST001194	8.154901959985743	GCST001194	21827660		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
European=6811		GCST001633	8.397940008672037	GCST001633	22886559		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
European=7608		GCST002474	15.0	GCST002474	24908248		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	1286516	5	1286401		EFO_0000326	Glioma (high-grade)	central nervous system cancer
European=5548		GCST000439	16.69897000433602	GCST000439	19578367		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
European=11582		GCST001058	14.0	GCST001058	21531791		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
European=6811		GCST001633	8.397940008672037	GCST001633	22886559		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	1286516	5	1286401		EFO_0000326	Glioma	central nervous system cancer
African American or Afro-Caribbean=5339		GCST003775	8.522878745280337	GCST003775	27393504		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (105715bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	1287194	5	1287079		EFO_0001071	Lung cancer	lung carcinoma
European=5548		GCST000439	13.397940008672037	GCST000439	19578367		drug	Medium	Ed Mountjoy	Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	1288547	5	1288432		EFO_0000326	Glioma	central nervous system cancer
European=5548		GCST000439	13.397940008672037	GCST000439	19578367		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	1288547	5	1288432		EFO_0000326	Glioma	central nervous system cancer
European=139274		GCST004988	20.392866795608434	GCST004988	29059683		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (166bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	1295349	5	1295234		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	20.392866795608434	GCST004988	29059683		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (97561bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	1295349	5	1295234		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	13.522878745280337	GCST003845	27117709		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1297488	5	1297373		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	8.698970004336019	GCST004950	25751625		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1297488	5	1297373		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	8.698970004336019	GCST004950	25751625		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1297488	5	1297373		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	13.522878745280337	GCST003845	27117709		drug	Low	Ed Mountjoy	Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164362	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1297488	5	1297373		EFO_0000305	Breast cancer	breast carcinoma
European=3390		GCST000459	8.522878745280337	GCST000459	19654303		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (77250bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	1315660	5	1315545		EFO_0001071	Lung cancer	lung carcinoma
European=40187		GCST004749	16.522878745280337	GCST004749	28604730		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72773bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	1320136	5	1320021		EFO_0001071	Lung cancer in ever smokers	lung carcinoma
European=85716		GCST004748	31.69897000433602	GCST004748	28604730		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72663bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	1320247	5	1320132		EFO_0001071	Lung cancer	lung carcinoma
European=10422		GCST001267	7.522878745280337	GCST001267	21983787		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (70822bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1322087	5	1321972		EFO_0000756	Melanoma	melanoma
European=10295		GCST000257	8.096910013008056	GCST000257	18978787		drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (70822bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	1322087	5	1321972		EFO_0001071	Lung cancer	lung carcinoma
European=314072			10.406891232219362	NEALE2_20107_3		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (53019bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	1339890	5	1339775		EFO_0001071	Lung cancer | illnesses of father	lung carcinoma
European=360738			7.9587810673873625	NEALE2_1200		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Dopamine transporter inhibitor drug MODAFINIL is Phase IV for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	1442979	5	1442864		EFO_0004698	Sleeplessness / insomnia	insomnia
European=360738			7.9587810673873625	NEALE2_1200		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1442979	5	1442864		EFO_0004698	Sleeplessness / insomnia	insomnia
East Asian=4969		GCST000750	17.397940008672037	GCST000750	20676098		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1895829	5	1895715		EFO_0001663	Prostate cancer	prostate carcinoma
East Asian=7394		GCST003148	11.698970004336019	GCST003148	26443449		drug	Low	Ed Mountjoy	Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000142319	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	1895829	5	1895715		EFO_0001663	Prostate cancer	prostate carcinoma
European, NR=45975		GCST004133	8.104080454689985	GCST004133	28067908		drug	Low	Ed Mountjoy	Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (332548bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171522	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	40347469	5	40347367		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=27432		GCST003045	11.43486084803021	GCST003045	26192919		drug	Low	Ed Mountjoy	Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265131bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171522	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	40414886	5	40414784		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European=86475		GCST005537	74.0	GCST005537	26974007		drug	Low	Ed Mountjoy	Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265029bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171522	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	40414989	5	40414887		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=16753		GCST003097	10.096910013008056	GCST003097	26301688		drug	Low	Ed Mountjoy	Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (192747bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000171522	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	40487270	5	40487168		EFO_0000729	Pediatric autoimmune diseases	ulcerative colitis
European=83129		GCST006983	7.522878745280337	GCST006983	30610198		drug	Low	Ed Mountjoy	Growth hormone receptor agonist drug SOMATROPIN is Phase IV for the indiciation EFO_0003888 and targets the gene ENSG00000112964 at this locus (332768bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112964	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	43054747	5	43054645		EFO_0003888	Attention deficit hyperactivity disorder or cannabis use	attention deficit hyperactivity disorder
European=459000		GCST007072	7.3979400086720375	GCST007072	30595370		drug	Low	Ed Mountjoy	Serotonin 1a (5-HT1a) receptor agonist drug ERGOLOID is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000178394 at this locus (478140bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000178394	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	63736474	5	64440647		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=408878	10.1038/s41588-018-0184-y		15.436518914605589	SAIGE_272_1			drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000113161 at this locus (26934bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74605220	5	75309395		EFO_0003774	Hyperlipidemia	hyperlipidemia
European=406276	10.1038/s41588-018-0184-y		14.154901959985743	SAIGE_272_11			drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (26934bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74605220	5	75309395		HP_0003124	Hypercholesterolemia	Hypercholesterolemia
European=408961	10.1038/s41588-018-0184-y		15.410050398674292	SAIGE_272			drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74605220	5	75309395		Orphanet_309005	Disorders of lipoid metabolism	Disorder of lipid metabolism
European=408961	10.1038/s41588-018-0184-y		15.410050398674292	SAIGE_272			drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug LOVASTATIN is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	74605220	5	75309395		Orphanet_309005	Disorders of lipoid metabolism	Disorder of lipid metabolism
European=9618		GCST004045	11.045757490560675	GCST004045	27790247		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	74625487	5	75329662		EFO_0000275	Age-related diseases, mortality and associated endophenotypes	atrial fibrillation
European=9618		GCST004045	11.045757490560675	GCST004045	27790247		drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (6667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	74625487	5	75329662		EFO_0000712	Age-related diseases, mortality and associated endophenotypes	cerebrovascular accident
European=9618		GCST004045	11.045757490560675	GCST004045	27790247		drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	74625487	5	75329662		EFO_0000275	Age-related diseases, mortality and associated endophenotypes	atrial fibrillation
European=9618		GCST004045	11.045757490560675	GCST004045	27790247		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (6667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	74625487	5	75329662		EFO_0000311	Age-related diseases, mortality and associated endophenotypes	cancer
European=9618		GCST004045	11.045757490560675	GCST004045	27790247		drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (6667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	74625487	5	75329662		EFO_0003144	Age-related diseases, mortality and associated endophenotypes	heart failure
European=9618		GCST004045	11.045757490560675	GCST004045	27790247		drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (6667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	74625487	5	75329662		EFO_0000400	Age-related diseases, mortality and associated endophenotypes	diabetes mellitus
European=9618		GCST004045	11.045757490560675	GCST004045	27790247		drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (6667bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	74625487	5	75329662		EFO_0001645	Age-related diseases, mortality and associated endophenotypes	coronary heart disease
European=459000		GCST007072	8.301029995663981	GCST007072	30595370		drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000113161 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	74656539	5	75360714		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			42.19124767849288	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	74656539	5	75360714		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=9618		GCST004045	7.698970004336019	GCST004045	27790247		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	5	74759183	5	75463358		EFO_0000275	Age-related diseases, mortality and associated endophenotypes	atrial fibrillation
European=9618		GCST004045	7.698970004336019	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (101258bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	5	74759183	5	75463358		EFO_0001645	Age-related diseases, mortality and associated endophenotypes	coronary heart disease
European=9618		GCST004045	7.698970004336019	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	5	74759183	5	75463358		EFO_0000275	Age-related diseases, mortality and associated endophenotypes	atrial fibrillation
European=9618		GCST004045	7.698970004336019	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (101258bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	5	74759183	5	75463358		EFO_0000400	Age-related diseases, mortality and associated endophenotypes	diabetes mellitus
European=9618		GCST004045	7.698970004336019	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (101258bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	5	74759183	5	75463358		EFO_0000712	Age-related diseases, mortality and associated endophenotypes	cerebrovascular accident
European=9618		GCST004045	7.698970004336019	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (101258bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	5	74759183	5	75463358		EFO_0003144	Age-related diseases, mortality and associated endophenotypes	heart failure
European=9618		GCST004045	7.698970004336019	GCST004045	27790247		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (101258bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	5	74759183	5	75463358		EFO_0000311	Age-related diseases, mortality and associated endophenotypes	cancer
European=9618		GCST004045	7.522878745280337	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (221964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74879890	5	75584065		EFO_0001645	Age-related diseases, mortality and associated endophenotypes	coronary heart disease
European=9618		GCST004045	7.522878745280337	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74879890	5	75584065		EFO_0000275	Age-related diseases, mortality and associated endophenotypes	atrial fibrillation
European=9618		GCST004045	7.522878745280337	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (221964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74879890	5	75584065		EFO_0000712	Age-related diseases, mortality and associated endophenotypes	cerebrovascular accident
European=9618		GCST004045	7.522878745280337	GCST004045	27790247		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	74879890	5	75584065		EFO_0000275	Age-related diseases, mortality and associated endophenotypes	atrial fibrillation
European=9618		GCST004045	7.522878745280337	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (221964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74879890	5	75584065		EFO_0003144	Age-related diseases, mortality and associated endophenotypes	heart failure
European=9618		GCST004045	7.522878745280337	GCST004045	27790247		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (221964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	74879890	5	75584065		EFO_0000311	Age-related diseases, mortality and associated endophenotypes	cancer
European=9618		GCST004045	7.522878745280337	GCST004045	27790247		drug	Medium	Ed Mountjoy	HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (221964bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	74879890	5	75584065		EFO_0000400	Age-related diseases, mortality and associated endophenotypes	diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.522878745280337	GCST006867	30054458		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	75003678	5	75707853		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	14.698970004336019	GCST007515	29632382		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	75003678	5	75707853		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	11.301029995663981	GCST007517	29632382		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	75003678	5	75707853		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=204498		GCST001953	11.522878745280337	GCST001953_4	23563607		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (345752bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	75003678	5	75707853		EFO_0001073	Obesity [Obesity class I]	obesity
European=204498		GCST001953	8.397940008672037	GCST001953_3	23563607		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	5	75015242	5	75719417		EFO_0001073	Obesity [Obesity class II]	obesity
European=204498		GCST001953	8.0	GCST001953_5	23563607		drug	Low	Ed Mountjoy	HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113161	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	5	75015242	5	75719417		EFO_0001073	Obesity [Overweight]	obesity
European=116538		GCST007564	19.0	GCST007564	29785011		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	110142816	5	110807116		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=116538		GCST007564	19.0	GCST007564	29785011		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	110142816	5	110807116		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=102453		GCST007563	19.69897000433602	GCST007563	29785011		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	110142816	5	110807116		EFO_0000270	Allergic disease (asthma, hay fever or eczema)	asthma
European=102453		GCST007563	19.69897000433602	GCST007563	29785011		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	110142816	5	110807116		EFO_0000270	Allergic disease (asthma, hay fever or eczema)	asthma
European=401837	10.1038/s41588-018-0184-y		7.835647144215563	SAIGE_495			drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	110158844	5	110823145		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		7.835647144215563	SAIGE_495			drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	110158844	5	110823145		EFO_0000270	Asthma	asthma
European=91787			7.755663492560309	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	CA	C	5	110161473	5	110825774		EFO_0000270	Doctor diagnosed asthma	asthma
European=91787			7.755663492560309	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	CA	C	5	110161473	5	110825774		EFO_0000270	Doctor diagnosed asthma	asthma
European=361141			17.72690377259096	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	CA	C	5	110161473	5	110825774		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=361141			17.72690377259096	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	CA	C	5	110161473	5	110825774		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=360527			19.160999247384563	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	CA	C	5	110161473	5	110825774		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=72232			8.280520382028882	NEALE2_3761_raw		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (244289bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	CA	C	5	110161473	5	110825774		EFO_0000274	Age hay fever, rhinitis or eczema diagnosed	atopic eczema
European=360527			19.160999247384563	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	CA	C	5	110161473	5	110825774		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=127669		GCST006862	10.097453220686008	GCST006862	29273806		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	110198114	5	110862415		EFO_0000270	Asthma	asthma
European=127669		GCST006862	10.097453220686008	GCST006862	29273806		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	110198114	5	110862415		EFO_0000270	Asthma	asthma
European=36955			7.8621333944441085	NEALE2_3786_raw		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Age asthma diagnosed	asthma
European=127669		GCST006862	20.97469413473523	GCST006862	29273806		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=360527			36.21098861481695	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=157242		GCST003987	30.522878745280337	GCST003987	27182965		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=90853		GCST007562	19.69897000433602	GCST007562	29785011		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=36955			7.8621333944441085	NEALE2_3786_raw		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Age asthma diagnosed	asthma
European=90853		GCST007562	19.69897000433602	GCST007562	29785011		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=157242		GCST003987	30.522878745280337	GCST003987	27182965		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
African American or Afro-Caribbean=1612|European=2088|Hispanic or Latin American=1688		GCST001182	14.0	GCST001182	21804549		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=361141			37.65559397059892	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
African American or Afro-Caribbean=1612|European=2088|Hispanic or Latin American=1688		GCST001182	14.0	GCST001182	21804549		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=91787			21.00267741002066	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Doctor diagnosed asthma	asthma
European=116538		GCST007564	20.397940008672037	GCST007564	29785011		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=401837	10.1038/s41588-018-0184-y		26.016373712875467	SAIGE_495			drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=127669		GCST006862	20.97469413473523	GCST006862	29273806		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=116538		GCST007564	20.397940008672037	GCST007564	29785011		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=341215		GCST007798	41.0	GCST007798	30929738		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=20776		GCST002322	9.0	GCST002322	24388013		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma and hay fever	asthma
European=361141			37.65559397059892	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=341215		GCST007798	41.0	GCST007798	30929738		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=30810		GCST006911	21.69897000433602	GCST006911	30552067		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma (moderate or severe)	asthma
European=20776		GCST002322	9.0	GCST002322	24388013		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma and hay fever	asthma
East Asian=4836		GCST001183	16.0	GCST001183	21804548		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=28835		GCST007797	14.301029995663981	GCST007797	30929738		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma onset (childhood vs adult)	asthma
East Asian=4836		GCST001183	16.0	GCST001183	21804548		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		26.016373712875467	SAIGE_495			drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma	asthma
European=30810		GCST006911	21.69897000433602	GCST006911	30552067		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma (moderate or severe)	asthma
European=91787			21.00267741002066	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Doctor diagnosed asthma	asthma
European=360527			36.21098861481695	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	110401872	5	111066174		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=28835		GCST007797	14.301029995663981	GCST007797	30929738		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	110401872	5	111066174		EFO_0000270	Asthma onset (childhood vs adult)	asthma
African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398		GCST005212	25.045757490560675	GCST005212	29273806		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	110404999	5	111069301		EFO_0000270	Asthma	asthma
African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398		GCST005212	25.045757490560675	GCST005212	29273806		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	110404999	5	111069301		EFO_0000270	Asthma	asthma
European=127669		GCST006862	24.692503962086786	GCST006862	29273806		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	110404999	5	111069301		EFO_0000270	Asthma	asthma
European=127669		GCST006862	24.692503962086786	GCST006862	29273806		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	110404999	5	111069301		EFO_0000270	Asthma	asthma
European=361141			18.959010211096686	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	110406742	5	111071044		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=361141			18.959010211096686	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	110406742	5	111071044		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=360527			20.137288556960716	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	110406742	5	111071044		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=360527			20.137288556960716	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	110406742	5	111071044		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=20776		GCST002322	10.522878745280337	GCST002322	24388013		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	110467499	5	111131801		EFO_0000270	Asthma and hay fever	asthma
European=30810		GCST006911	12.522878745280337	GCST006911	30552067		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	110467499	5	111131801		EFO_0000270	Asthma (moderate or severe)	asthma
European=30810		GCST006911	12.522878745280337	GCST006911	30552067		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	110467499	5	111131801		EFO_0000270	Asthma (moderate or severe)	asthma
European=102453		GCST007563	19.30102999566398	GCST007563	29785011		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	110467499	5	111131801		EFO_0000270	Allergic disease (asthma, hay fever or eczema)	asthma
European=102453		GCST007563	19.30102999566398	GCST007563	29785011		drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	110467499	5	111131801		EFO_0000270	Allergic disease (asthma, hay fever or eczema)	asthma
European=20776		GCST002322	10.522878745280337	GCST002322	24388013		drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	110467499	5	111131801		EFO_0000270	Asthma and hay fever	asthma
European=401837	10.1038/s41588-018-0184-y		18.149353764816933	SAIGE_495			drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	110470137	5	111134439		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		18.149353764816933	SAIGE_495			drug	Medium	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	110470137	5	111134439		EFO_0000270	Asthma	asthma
European=72232			8.814540009081632	NEALE2_3761_raw		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (57494bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145777	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	110471218	5	111135520		EFO_0000274	Age hay fever, rhinitis or eczema diagnosed	atopic eczema
East Asian=20965		GCST001454	9.522878745280337	GCST001454	22446963		drug	Low	Ed Mountjoy	Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000164400 at this locus (18255bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164400	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131430118	5	132094425		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=27432		GCST003045	25.175982286576183	GCST003045	26192919		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (322795bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	5	131669161	5	132333468		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European=20883		GCST003044	46.705144404319334	GCST003044	26192919		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (322795bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	5	131669161	5	132333468		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=719047		GCST007443	8.0	GCST007443	30643255		drug	Low	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (200819bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	131676320	5	132340627		EFO_1000391	Nasal polyps	Nasal Cavity Polyp
European=393356	10.1038/s41588-018-0184-y		9.707743928643524	SAIGE_471			drug	Low	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (166739bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131710399	5	132374707		EFO_1000391	Nasal polyps	Nasal Cavity Polyp
European=20883		GCST003044	25.162379159732975	GCST003044	26192919		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (259500bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	5	131732456	5	132396764		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European, NR=40266		GCST004132	35.25274360255786	GCST004132	28067908		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	131770805	5	132435113		EFO_0000384	Crohn's disease	Crohn's disease
European=9541		GCST000207	17.69897000433602	GCST000207	18587394		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	131770805	5	132435113		EFO_0000384	Crohn's disease	Crohn's disease
European=86475		GCST005537	54.69897000433602	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (213503bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131778452	5	132442760		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=86475		GCST005537	54.69897000433602	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (213503bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131778452	5	132442760		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
European=86475		GCST005537	54.69897000433602	GCST005537	26974007		drug	Low	Ed Mountjoy	Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (366590bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164400	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131778452	5	132442760		EFO_0003898	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ankylosing spondylitis
European=86475		GCST005537	54.69897000433602	GCST005537	26974007		drug	Low	Ed Mountjoy	Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (366590bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164400	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131778452	5	132442760		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=21389		GCST000879	20.0	GCST000879	21102463		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	5	131784393	5	132448701		EFO_0000384	Crohn's disease	Crohn's disease
European=34366		GCST001729	19.496209316942817	GCST001729	23128233		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	5	131784393	5	132448701		EFO_0000384	Crohn's disease	Crohn's disease
European=27432		GCST003045	10.237794241945119	GCST003045	26192919		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (195033bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131796922	5	132461230		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European=127669		GCST006862	10.667561540084394	GCST006862	29273806		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (79591bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	131797547	5	132461855		EFO_0000270	Asthma	asthma
European=127669		GCST006862	10.667561540084394	GCST006862	29273806		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131797547	5	132461855		EFO_0000270	Asthma	asthma
European=127669		GCST006862	10.667561540084394	GCST006862	29273806		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	131797547	5	132461855		EFO_0000270	Asthma	asthma
European=127669		GCST006862	10.667561540084394	GCST006862	29273806		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (212132bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131797547	5	132461855		EFO_0000270	Asthma	asthma
European=33394		GCST005527	7.620391669707774	GCST005527	23143594		drug	Low	Ed Mountjoy	Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (387511bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164400	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	5	131799373	5	132463681		EFO_0000676	Psoriasis	psoriasis
European=30810		GCST006911	13.221848749616356	GCST006911	30552067		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma (moderate or severe)	asthma
European=360527			26.061318695302564	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=401837	10.1038/s41588-018-0184-y		9.563837352959244	SAIGE_495			drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma	asthma
European=360527			26.061318695302564	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=30810		GCST006911	13.221848749616356	GCST006911	30552067		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma (moderate or severe)	asthma
European=360527			26.061318695302564	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=30810		GCST006911	13.221848749616356	GCST006911	30552067		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131799626	5	132463934		EFO_0000270	Asthma (moderate or severe)	asthma
European=401837	10.1038/s41588-018-0184-y		9.563837352959244	SAIGE_495			drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131799626	5	132463934		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		9.563837352959244	SAIGE_495			drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	131799626	5	132463934		EFO_0000270	Asthma	asthma
European=361141			27.398007329534234	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=361141			27.398007329534234	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=361141			27.398007329534234	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=30810		GCST006911	13.221848749616356	GCST006911	30552067		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	131799626	5	132463934		EFO_0000270	Asthma (moderate or severe)	asthma
European=361141			27.398007329534234	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=401837	10.1038/s41588-018-0184-y		9.563837352959244	SAIGE_495			drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131799626	5	132463934		EFO_0000270	Asthma	asthma
European=360527			26.061318695302564	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	131799626	5	132463934		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=116538		GCST007564	9.301029995663981	GCST007564	29785011		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (68469bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	131808668	5	132472976		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=116538		GCST007564	9.301029995663981	GCST007564	29785011		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (201010bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131808668	5	132472976		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=116538		GCST007564	9.301029995663981	GCST007564	29785011		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	131808668	5	132472976		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=116538		GCST007564	9.301029995663981	GCST007564	29785011		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131808668	5	132472976		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=16753		GCST003097	8.698970004336019	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (180773bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131811182	5	132475490		EFO_0000384	Pediatric autoimmune diseases	Crohn's disease
European=16753		GCST003097	8.698970004336019	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (180773bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131811182	5	132475490		EFO_0000729	Pediatric autoimmune diseases	ulcerative colitis
European=16753		GCST003097	8.698970004336019	GCST003097	26301688		drug	Low	Ed Mountjoy	Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (399320bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164400	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131811182	5	132475490		EFO_0003898	Pediatric autoimmune diseases	ankylosing spondylitis
European=16753		GCST003097	8.698970004336019	GCST003097	26301688		drug	Low	Ed Mountjoy	Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (399320bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164400	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131811182	5	132475490		EFO_0000676	Pediatric autoimmune diseases	psoriasis
European=91787			11.05858795962645	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (50815bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	131826322	5	132490630		EFO_0000270	Doctor diagnosed asthma	asthma
European=91787			11.05858795962645	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	131826322	5	132490630		EFO_0000270	Doctor diagnosed asthma	asthma
European=91787			11.05858795962645	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (183357bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131826322	5	132490630		EFO_0000270	Doctor diagnosed asthma	asthma
European=91787			11.05858795962645	NEALE2_22127		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	131826322	5	132490630		EFO_0000270	Doctor diagnosed asthma	asthma
European=30810		GCST006911	14.698970004336019	GCST006911	30552067		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	131887986	5	132552294		EFO_0000270	Asthma (moderate or severe)	asthma
European=30810		GCST006911	14.698970004336019	GCST006911	30552067		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	131887986	5	132552294		EFO_0000270	Asthma (moderate or severe)	asthma
European=30810		GCST006911	14.698970004336019	GCST006911	30552067		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	131887986	5	132552294		EFO_0000270	Asthma (moderate or severe)	asthma
European=30810		GCST006911	14.698970004336019	GCST006911	30552067		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (121692bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	131887986	5	132552294		EFO_0000270	Asthma (moderate or severe)	asthma
European=157242		GCST003987	15.698970004336019	GCST003987	27182965		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	131901225	5	132565533		EFO_0000270	Asthma	asthma
European=157242		GCST003987	15.698970004336019	GCST003987	27182965		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (8696bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	131901225	5	132565533		EFO_0000270	Asthma	asthma
European=157242		GCST003987	15.698970004336019	GCST003987	27182965		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131901225	5	132565533		EFO_0000270	Asthma	asthma
European=157242		GCST003987	15.698970004336019	GCST003987	27182965		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (108454bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131901225	5	132565533		EFO_0000270	Asthma	asthma
European=341215		GCST007798	31.154901959985743	GCST007798	30929738		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	131916940	5	132581248		EFO_0000270	Asthma	asthma
European=361141			26.939774475605834	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=360527			28.044273294785736	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=341215		GCST007798	31.154901959985743	GCST007798	30929738		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma	asthma
European=360527			28.044273294785736	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=341215		GCST007798	31.154901959985743	GCST007798	30929738		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	5	131916940	5	132581248		EFO_0000270	Asthma	asthma
European=361141			26.939774475605834	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=28835		GCST007797	8.154901959985743	GCST007797	30929738		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma onset (childhood vs adult)	asthma
European=360527			28.044273294785736	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=361141			26.939774475605834	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=28835		GCST007797	8.154901959985743	GCST007797	30929738		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	131916940	5	132581248		EFO_0000270	Asthma onset (childhood vs adult)	asthma
European=28835		GCST007797	8.154901959985743	GCST007797	30929738		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma onset (childhood vs adult)	asthma
European=28835		GCST007797	8.154901959985743	GCST007797	30929738		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	5	131916940	5	132581248		EFO_0000270	Asthma onset (childhood vs adult)	asthma
European=360527			28.044273294785736	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
European=361141			26.939774475605834	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	131916940	5	132581248		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=341215		GCST007798	31.154901959985743	GCST007798	30929738		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131916940	5	132581248		EFO_0000270	Asthma	asthma
European=90853		GCST007562	11.0	GCST007562	29785011		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (84491bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131925187	5	132589495		EFO_0000270	Asthma	asthma
European=90853		GCST007562	11.0	GCST007562	29785011		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131925187	5	132589495		EFO_0000270	Asthma	asthma
European=90853		GCST007562	11.0	GCST007562	29785011		drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (32657bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	131925187	5	132589495		EFO_0000270	Asthma	asthma
European=90853		GCST007562	11.0	GCST007562	29785011		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131925187	5	132589495		EFO_0000270	Asthma	asthma
European=18190		GCST002740	17.69897000433602	GCST002740_3	25574825		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131952222	5	132616530		EFO_0000274	Inflammatory skin disease [Opposed]	atopic eczema
European=18190		GCST002740	17.69897000433602	GCST002740_3	25574825		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131952222	5	132616530		EFO_0000274	Inflammatory skin disease [Opposed]	atopic eczema
NR, European=212120		GCST006409	8.698970004336019	GCST006409	30013184		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	5	131955577	5	132619885		EFO_0005854	Allergic rhinitis	allergic rhinitis
NR, European=212120		GCST006409	8.698970004336019	GCST006409	30013184		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	TATATATATATAG	T	5	131955577	5	132619885		EFO_0005854	Allergic rhinitis	allergic rhinitis
NR, European=212120		GCST006409	8.698970004336019	GCST006409	30013184		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	TAGAG	T	5	131955577	5	132619885		EFO_0005854	Allergic rhinitis	allergic rhinitis
NR, European=212120		GCST006409	8.698970004336019	GCST006409	30013184		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	TAG	T	5	131955577	5	132619885		EFO_0005854	Allergic rhinitis	allergic rhinitis
NR, European=212120		GCST006409	8.698970004336019	GCST006409	30013184		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	TAA	T	5	131955577	5	132619885		EFO_0005854	Allergic rhinitis	allergic rhinitis
European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201		GCST003184	16.397940008672037	GCST003184	26482879		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131991085	5	132655393		EFO_0000274	Atopic dermatitis [EA, fixed effects]	atopic eczema
European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201		GCST003184	16.397940008672037	GCST003184	26482879		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131991085	5	132655393		EFO_0000274	Atopic dermatitis [EA, fixed effects]	atopic eczema
European=401837	10.1038/s41588-018-0184-y		15.5654310959658	SAIGE_495			drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	131991881	5	132656189		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		15.5654310959658	SAIGE_495			drug	High	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (99351bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	131991881	5	132656189		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		15.5654310959658	SAIGE_495			drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	131991881	5	132656189		EFO_0000270	Asthma	asthma
European=401837	10.1038/s41588-018-0184-y		15.5654310959658	SAIGE_495			drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (17797bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	131991881	5	132656189		EFO_0000270	Asthma	asthma
European=5617		GCST002100	16.69897000433602	GCST002100	23886662		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131995843	5	132660151		EFO_0000274	Atopic dermatitis	atopic eczema
European=5946		GCST002737	8.301029995663981	GCST002737	25574825		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	131995843	5	132660151		EFO_0000274	Atopic dermatitis	atopic eczema
European=5617		GCST002100	16.69897000433602	GCST002100	23886662		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131995843	5	132660151		EFO_0000274	Atopic dermatitis	atopic eczema
European=5946		GCST002737	8.301029995663981	GCST002737	25574825		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	131995843	5	132660151		EFO_0000274	Atopic dermatitis	atopic eczema
African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398		GCST005212	15.301029995663981	GCST005212	29273806		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398		GCST005212	15.301029995663981	GCST005212	29273806		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
European=127669		GCST006862	13.853871964321762	GCST006862	29273806		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
European=127669		GCST006862	13.853871964321762	GCST006862	29273806		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398		GCST005212	15.301029995663981	GCST005212	29273806		drug	Medium	Ed Mountjoy	Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
European=127669		GCST006862	13.853871964321762	GCST006862	29273806		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398		GCST005212	15.301029995663981	GCST005212	29273806		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
European=127669		GCST006862	13.853871964321762	GCST006862	29273806		drug	Medium	Ed Mountjoy	Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	131995964	5	132660272		EFO_0000270	Asthma	asthma
European=7565		GCST004866	8.301029995663981	GCST004866	25608926		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase II for the indiciation EFO_0004192 and targets the gene ENSG00000169194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	131996500	5	132660808		EFO_0004192	Alopecia areata	alopecia areata
European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201		GCST003184	11.154901959985743	GCST003184_2	26482879		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	132028858	5	132693166		EFO_0000274	Atopic dermatitis [conditional on rs6419573]	atopic eczema
European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201		GCST003184	11.154901959985743	GCST003184_2	26482879		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	132028858	5	132693166		EFO_0000274	Atopic dermatitis [conditional on rs6419573]	atopic eczema
European=11181		GCST003180	7.301029995663981	GCST003180	26542096		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	5	132030667	5	132694975		EFO_0000274	Atopic march	atopic eczema
European=11181		GCST003180	7.301029995663981	GCST003180	26542096		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	5	132030667	5	132694975		EFO_0000274	Atopic march	atopic eczema
European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201		GCST003184	10.0	GCST003184	26482879		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	132049027	5	132713335		EFO_0000274	Atopic dermatitis [EA, fixed effects]	atopic eczema
European=26171		GCST001363	7.3979400086720375	GCST001363	22197932		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	132049027	5	132713335		EFO_0000274	Atopic dermatitis	atopic eczema
European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201		GCST003184	10.0	GCST003184	26482879		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	132049027	5	132713335		EFO_0000274	Atopic dermatitis [EA, fixed effects]	atopic eczema
European=26171		GCST001363	7.3979400086720375	GCST001363	22197932		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	132049027	5	132713335		EFO_0000274	Atopic dermatitis	atopic eczema
European=36955			8.737359096244738	NEALE2_3786_raw		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	132056874	5	132721182		EFO_0000270	Age asthma diagnosed	asthma
European=36955			8.737359096244738	NEALE2_3786_raw		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	132056874	5	132721182		EFO_0000270	Age asthma diagnosed	asthma
European=36955			8.737359096244738	NEALE2_3786_raw		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (38505bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	132056874	5	132721182		EFO_0000270	Age asthma diagnosed	asthma
European=36955			8.737359096244738	NEALE2_3786_raw		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (164345bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	5	132056874	5	132721182		EFO_0000270	Age asthma diagnosed	asthma
European=116538		GCST007564	9.698970004336019	GCST007564	29785011		drug	Medium	Ed Mountjoy	Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (168054bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113525	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	132060583	5	132724891		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=116538		GCST007564	9.698970004336019	GCST007564	29785011		drug	Low	Ed Mountjoy	Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (42213bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	132060583	5	132724891		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=116538		GCST007564	9.698970004336019	GCST007564	29785011		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	132060583	5	132724891		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=116538		GCST007564	9.698970004336019	GCST007564	29785011		drug	Medium	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	132060583	5	132724891		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	7.698970004336019	GCST007692	30804561		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	5	132439010	5	133103318		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	7.698970004336019	GCST007692	30804561		drug	Low	Ed Mountjoy	Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	132439010	5	133103318		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	10.221848749616356	GCST006061_3	29892015		drug	Low	Ed Mountjoy	Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113580	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	142650404	5	143270839		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	11.0	GCST006061	29892015		drug	Low	Ed Mountjoy	Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113580	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	5	142650404	5	143270839		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	11.0	GCST006061	29892015		drug	High	Ed Mountjoy	Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113580	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	142650404	5	143270839		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	10.221848749616356	GCST006061_3	29892015		drug	High	Ed Mountjoy	Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113580	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	142650404	5	143270839		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=1030836		GCST006414	16.716472635138306	GCST006414	30061737		drug	High	Ed Mountjoy	Glucocorticoid receptor agonist drug METHYLPREDNISOLONE HEMISUCCINATE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113580	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	5	142880532	5	143500967		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	16.716472635138306	GCST006414	30061737		drug	Low	Ed Mountjoy	Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113580	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	5	142880532	5	143500967		EFO_0000275	Atrial fibrillation	atrial fibrillation
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	32.52287874528034	GCST007692	30804561		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	147854970	5	148475407		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	32.52287874528034	GCST007692	30804561		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor partial agonist drug CELIPROLOL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	147854970	5	148475407		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	32.52287874528034	GCST007692	30804561		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	147854970	5	148475407		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European, NR=58918|European=458554		GCST007611	13.0	GCST007611	30940143		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	147856333	5	148476770		EFO_0000341	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	chronic obstructive pulmonary disease
European, NR=58918|European=458554		GCST007611	13.0	GCST007611	30940143		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	147856333	5	148476770		EFO_0000341	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	chronic obstructive pulmonary disease
European, NR=58918|European=458554		GCST007611	13.0	GCST007611	30940143		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	147856333	5	148476770		EFO_0000341	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	chronic obstructive pulmonary disease
African American or Afro-Caribbean=3522|Hispanic or Latin American=600|European=47856|East Asian=6940		GCST004147	25.30102999566398	GCST004147	28166215		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	147856333	5	148476770		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
African American or Afro-Caribbean=3522|Hispanic or Latin American=600|European=47856|East Asian=6940		GCST004147	25.30102999566398	GCST004147	28166215		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	147856333	5	148476770		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European, NR=58918|European=458554		GCST007611	13.0	GCST007611	30940143		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor antagonist drug PROPRANOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (348475bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	147856333	5	148476770		EFO_0000537	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	hypertension
African American or Afro-Caribbean=3522|Hispanic or Latin American=600|European=47856|East Asian=6940		GCST004147	25.30102999566398	GCST004147	28166215		drug	Low	Ed Mountjoy	Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	147856333	5	148476770		EFO_0000341	Chronic obstructive pulmonary disease	chronic obstructive pulmonary disease
European=361141			8.715497077748008	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Beta-2 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (139293bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169252	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	148347543	5	148967980		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=88583		GCST007505	8.698970004336019	GCST007505	30429480		drug	Low	Ed Mountjoy	Macrophage colony stimulating factor receptor inhibitor drug VATALANIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000182578 at this locus (236621bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000182578	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	5	149196234	5	149816671		EFO_0000389	Nevus count or cutaneous melanoma	skin melanoma
European=88583		GCST007505	8.698970004336019	GCST007505	30429480		drug	Low	Ed Mountjoy	Platelet-derived growth factor receptor beta inhibitor drug DASATINIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113721	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	5	149196234	5	149816671		EFO_0000389	Nevus count or cutaneous melanoma	skin melanoma
European=88583		GCST007505	8.698970004336019	GCST007505	30429480		drug	Low	Ed Mountjoy	Platelet-derived growth factor receptor beta inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113721	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	5	149196234	5	149816671		EFO_0000389	Nevus count or cutaneous melanoma	skin melanoma
European=33394		GCST005527	10.388393510619363	GCST005527	23143594		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158669913	5	159242905		EFO_0000676	Psoriasis	psoriasis
European=33394		GCST005527	10.388393510619363	GCST005527	23143594		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	158669913	5	159242905		EFO_0000676	Psoriasis	psoriasis
European=2759		GCST000322	27.69897000433602	GCST000322	19169254		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	158717789	5	159290781		EFO_0000676	Psoriasis	psoriasis
European=6297		GCST003269	13.0	GCST003269	26626624		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	158717789	5	159290781		EFO_0000676	Cutaneous psoriasis	psoriasis
European=2759		GCST000322	27.69897000433602	GCST000322	19169254		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	158717789	5	159290781		EFO_0000676	Psoriasis	psoriasis
European=6297		GCST003269	13.0	GCST003269	26626624		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	158717789	5	159290781		EFO_0000676	Cutaneous psoriasis	psoriasis
East Asian=5134|European=8682		GCST002874	9.301029995663981	GCST002874_10	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	5	158749088	5	159322080		EFO_0000676	Psoriasis [conditional on rs7709212, rs4921493]	psoriasis
East Asian=5134|European=8682		GCST002874	9.301029995663981	GCST002874_10	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	5	158749088	5	159322080		EFO_0000676	Psoriasis [conditional on rs7709212, rs4921493]	psoriasis
East Asian=5134|European=8682		GCST002874	7.698970004336019	GCST002874_6	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	5	158749088	5	159322080		EFO_0000676	Psoriasis [EA, conditional on rs7709212, rs4921493]	psoriasis
East Asian=5134|European=8682		GCST002874	7.698970004336019	GCST002874_6	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	5	158749088	5	159322080		EFO_0000676	Psoriasis [EA, conditional on rs7709212, rs4921493]	psoriasis
European=7353		GCST000833	10.301029995663981	GCST000833	20953190		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	158750769	5	159323761		EFO_0000676	Psoriasis	psoriasis
East Asian=2271		GCST000321	25.522878745280337	GCST000321	19169255		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	158750769	5	159323761		EFO_0000676	Psoriasis	psoriasis
European=7353		GCST000833	10.301029995663981	GCST000833	20953190		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158750769	5	159323761		EFO_0000676	Psoriasis	psoriasis
East Asian=2271		GCST000321	25.522878745280337	GCST000321	19169255		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158750769	5	159323761		EFO_0000676	Psoriasis	psoriasis
European=398907	10.1038/s41588-018-0184-y		8.0268721464003	SAIGE_696_42			drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	158755845	5	159328837		EFO_0003778	Psoriatic arthropathy	psoriatic arthritis
European=18190		GCST002740	34.52287874528034	GCST002740_4	25574825		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	158759900	5	159332892		EFO_0000676	Inflammatory skin disease [Psoriasis]	psoriasis
European=1618		GCST000836	20.0	GCST000836	20953188		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	158759900	5	159332892		EFO_0000676	Psoriasis	psoriasis
European=1618		GCST000836	20.0	GCST000836	20953188		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	158759900	5	159332892		EFO_0000676	Psoriasis	psoriasis
European=18190		GCST002740	34.52287874528034	GCST002740_4	25574825		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	158759900	5	159332892		EFO_0000676	Inflammatory skin disease [Psoriasis]	psoriasis
East Asian=5134|European=8682		GCST002874	19.522878745280337	GCST002874_8	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis [EA]	psoriasis
East Asian=5134|European=8682		GCST002874	11.0	GCST002874_3	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis [Chinese]	psoriasis
East Asian=5134|European=8682		GCST002874	8.301029995663981	GCST002874_2	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis [Chinese, conditional on rs1990760]	psoriasis
East Asian=5134|European=8682		GCST002874	11.0	GCST002874_3	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis [Chinese]	psoriasis
East Asian=5134|European=8682		GCST002874	19.522878745280337	GCST002874_8	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis [EA]	psoriasis
East Asian=5134|European=8682		GCST002874	29.69897000433602	GCST002874	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis	psoriasis
East Asian=5134|European=8682		GCST002874	8.301029995663981	GCST002874_2	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis [Chinese, conditional on rs1990760]	psoriasis
East Asian=5134|European=8682		GCST002874	29.69897000433602	GCST002874	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158764177	5	159337169		EFO_0000676	Psoriasis	psoriasis
European=6880		GCST003270	24.0	GCST003270	26626624		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (6584bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158764478	5	159337470		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=361141			22.400348322298537	NEALE2_20002_1453		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	5	158766022	5	159339014		EFO_0000676	Psoriasis | non-cancer illness code, self-reported	psoriasis
European=361141			22.400348322298537	NEALE2_20002_1453		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	158766022	5	159339014		EFO_0000676	Psoriasis | non-cancer illness code, self-reported	psoriasis
European=2198		GCST007043	9.045757490560675	GCST007043	30552173		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (10470bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	158768365	5	159341357		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=20883		GCST003044	33.5271134750456	GCST003044	26192919		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	158771337	5	159344329		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=20883		GCST003044	33.5271134750456	GCST003044	26192919		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	158771337	5	159344329		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=27432		GCST003045	16.91802094893202	GCST003045	26192919		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158774965	5	159347957		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European, NR=45975		GCST004133	19.67571754470231	GCST004133	28067908		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158774965	5	159347957		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=21389		GCST000879	13.301029995663981	GCST000879	21102463		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	5	158787385	5	159360377		EFO_0000384	Crohn's disease	Crohn's disease
European=21389		GCST000879	13.301029995663981	GCST000879	21102463		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	5	158787385	5	159360377		EFO_0000384	Crohn's disease	Crohn's disease
European, NR=40266		GCST004132	19.061080187755227	GCST004132	28067908		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	158798075	5	159371067		EFO_0000384	Crohn's disease	Crohn's disease
European, NR=40266		GCST004132	19.061080187755227	GCST004132	28067908		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	5	158798075	5	159371067		EFO_0000384	Crohn's disease	Crohn's disease
European=361141			20.03839715731701	NEALE2_20002_1453		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158810793	5	159383785		EFO_0000676	Psoriasis | non-cancer illness code, self-reported	psoriasis
European=361141			20.03839715731701	NEALE2_20002_1453		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158810793	5	159383785		EFO_0000676	Psoriasis | non-cancer illness code, self-reported	psoriasis
European=9541		GCST000207	12.397940008672037	GCST000207	18587394		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	5	158814533	5	159387525		EFO_0000384	Crohn's disease	Crohn's disease
European=9541		GCST000207	12.397940008672037	GCST000207	18587394		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	158814533	5	159387525		EFO_0000384	Crohn's disease	Crohn's disease
European=11802		GCST001149	7.698970004336019	GCST001149	21743469		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (60850bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	5	158818745	5	159391737		EFO_0003898	Ankylosing spondylitis	ankylosing spondylitis
European=400436	10.1038/s41588-018-0184-y		13.292429823902063	SAIGE_696_4			drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158820061	5	159393053		EFO_0000676	Psoriasis	psoriasis
European=400436	10.1038/s41588-018-0184-y		13.292429823902063	SAIGE_696_4			drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158820061	5	159393053		EFO_0000676	Psoriasis	psoriasis
European=33394		GCST005527	13.017728766960431	GCST005527	23143594		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	5	158821917	5	159394909		EFO_0000676	Psoriasis	psoriasis
European=33394		GCST005527	13.017728766960431	GCST005527	23143594		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	5	158821917	5	159394909		EFO_0000676	Psoriasis	psoriasis
European=400492	10.1038/s41588-018-0184-y		20.714442690992225	SAIGE_696			drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	5	158826310	5	159399302		EFO_0000676	Psoriasis and related disorders	psoriasis
European=400492	10.1038/s41588-018-0184-y		20.714442690992225	SAIGE_696			drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	5	158826310	5	159399302		EFO_0000676	Psoriasis and related disorders	psoriasis
European=22647|East Asian=3117		GCST005529	7.522878745280337	GCST005529	23749187		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (68897bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158826792	5	159399784		EFO_0003898	Ankylosing spondylitis	ankylosing spondylitis
European, NR=45975		GCST004133	23.22951619056889	GCST004133	28067908		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158826792	5	159399784		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=26405		GCST000964	7.991399828238082	GCST000964	21297633		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158826792	5	159399784		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=27432		GCST003045	26.13838459401752	GCST003045	26192919		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158827769	5	159400761		EFO_0000729	Ulcerative colitis [EA]	ulcerative colitis
European=86475		GCST005537	42.52287874528034	GCST005537	26974007		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158827769	5	159400761		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=20883		GCST003044	40.64029045008325	GCST003044	26192919		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158827769	5	159400761		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=20883		GCST003044	40.64029045008325	GCST003044	26192919		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	158827769	5	159400761		EFO_0000384	Crohn's disease [EA]	Crohn's disease
European=86475		GCST005537	42.52287874528034	GCST005537	26974007		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	5	158827769	5	159400761		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=86475		GCST005537	42.52287874528034	GCST005537	26974007		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158827769	5	159400761		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
European=86475		GCST005537	42.52287874528034	GCST005537	26974007		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158827769	5	159400761		EFO_0003898	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ankylosing spondylitis
European=86475		GCST005537	42.52287874528034	GCST005537	26974007		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	158827769	5	159400761		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
European=86475		GCST005537	42.52287874528034	GCST005537	26974007		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	5	158827769	5	159400761		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
European=400436	10.1038/s41588-018-0184-y		19.950781977329818	SAIGE_696_4			drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	5	158829289	5	159402281		EFO_0000676	Psoriasis	psoriasis
European=400436	10.1038/s41588-018-0184-y		19.950781977329818	SAIGE_696_4			drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	5	158829289	5	159402281		EFO_0000676	Psoriasis	psoriasis
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158829294	5	159402286		EFO_0000729	Pediatric autoimmune diseases	ulcerative colitis
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	158829294	5	159402286		EFO_0000384	Pediatric autoimmune diseases	Crohn's disease
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158829294	5	159402286		EFO_0000384	Pediatric autoimmune diseases	Crohn's disease
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158829294	5	159402286		EFO_0003898	Pediatric autoimmune diseases	ankylosing spondylitis
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	5	158829294	5	159402286		EFO_0000676	Pediatric autoimmune diseases	psoriasis
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158829294	5	159402286		EFO_0000676	Pediatric autoimmune diseases	psoriasis
European, NR=40266		GCST004132	28.860120913598763	GCST004132	28067908		drug	Low	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	158829294	5	159402286		EFO_0000384	Crohn's disease	Crohn's disease
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	Low	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	5	158829294	5	159402286		EFO_0001359	Pediatric autoimmune diseases	insulin-dependent diabetes mellitus
European=16753		GCST003097	9.698970004336019	GCST003097	26301688		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158829294	5	159402286		EFO_0002690	Pediatric autoimmune diseases	systemic lupus erythematosus
European, NR=40266		GCST004132	28.860120913598763	GCST004132	28067908		drug	Medium	Ed Mountjoy	Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	5	158829294	5	159402286		EFO_0000384	Crohn's disease	Crohn's disease
European=361141			32.77779353908738	NEALE2_20002_1453		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	A	5	158829527	5	159402519		EFO_0000676	Psoriasis | non-cancer illness code, self-reported	psoriasis
European=1460		GCST000835	16.154901959985743	GCST000835	20953186		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	5	158829527	5	159402519		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=361141			32.77779353908738	NEALE2_20002_1453		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	5	158829527	5	159402519		EFO_0000676	Psoriasis | non-cancer illness code, self-reported	psoriasis
European=287323		GCST004346	83.52287874528034	GCST004346	28537254		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	5	158829527	5	159402519		EFO_0000676	Psoriasis	psoriasis
European=33394		GCST005527	12.669586226650809	GCST005527	23143594		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	A	5	158829527	5	159402519		EFO_0000676	Psoriasis	psoriasis
European=33394		GCST005527	12.669586226650809	GCST005527	23143594		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	5	158829527	5	159402519		EFO_0000676	Psoriasis	psoriasis
European=361141			11.735654492949907	NEALE2_20002_1477		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	5	158829527	5	159402519		EFO_0003778	Psoriatic arthropathy | non-cancer illness code, self-reported	psoriatic arthritis
European=287323		GCST004346	83.52287874528034	GCST004346	28537254		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	A	5	158829527	5	159402519		EFO_0000676	Psoriasis	psoriasis
European=398907	10.1038/s41588-018-0184-y		10.665546248849068	SAIGE_696_42			drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	5	158829527	5	159402519		EFO_0003778	Psoriatic arthropathy	psoriatic arthritis
European=7208		GCST005538	8.698970004336019	GCST005538	26051272		drug	Low	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000113302 at this locus (74382bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	5	158832277	5	159405269		Orphanet_797	Sarcoidosis [EA]	Sarcoidosis
East Asian=5134|European=8682		GCST002874	12.154901959985743	GCST002874_11	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158836107	5	159409099		EFO_0000676	Psoriasis [conditional on rs7709212]	psoriasis
East Asian=5134|European=8682		GCST002874	10.522878745280337	GCST002874_7	25903422		drug	High	Ed Mountjoy	Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	5	158836107	5	159409099		EFO_0000676	Psoriasis [EA, conditional on rs7709212]	psoriasis
East Asian=5134|European=8682		GCST002874	12.154901959985743	GCST002874_11	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158836107	5	159409099		EFO_0000676	Psoriasis [conditional on rs7709212]	psoriasis
East Asian=5134|European=8682		GCST002874	10.522878745280337	GCST002874_7	25903422		drug	Medium	Ed Mountjoy	Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113302	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	5	158836107	5	159409099		EFO_0000676	Psoriasis [EA, conditional on rs7709212]	psoriasis
European=351833			8.322648589788734	NEALE2_1980		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145863 at this locus (281691bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145863	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	CA	5	161411289	5	161984283		EFO_0005230	Worrier / anxious feelings	anxiety
European=351833			8.322648589788734	NEALE2_1980		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug ALPRAZOLAM is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000022355	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	CA	5	161411289	5	161984283		EFO_0005230	Worrier / anxious feelings	anxiety
European=351833			8.322648589788734	NEALE2_1980		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145864	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	CA	5	161411289	5	161984283		EFO_0005230	Worrier / anxious feelings	anxiety
European=351833			8.322648589788734	NEALE2_1980		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000022355	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	CA	5	161411289	5	161984283		EFO_0005230	Worrier / anxious feelings	anxiety
European=351833			8.322648589788734	NEALE2_1980		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113327	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	CA	5	161411289	5	161984283		EFO_0005230	Worrier / anxious feelings	anxiety
European=351833			8.322648589788734	NEALE2_1980		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug CLORAZEPIC ACID is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000113327	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	CA	5	161411289	5	161984283		EFO_0005230	Worrier / anxious feelings	anxiety
European=351833			8.322648589788734	NEALE2_1980		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	GABA-A receptor; anion channel positive allosteric modulator drug CLOMETHIAZOLE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000145864	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	CA	5	161411289	5	161984283		EFO_0005230	Worrier / anxious feelings	anxiety
European=10767		GCST003468	7.698970004336019	GCST003468	26956414		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137285 at this locus (255233bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	2969278	6	2969044		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
European=10767		GCST003468	7.698970004336019	GCST003468	26956414		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137267 at this locus (184622bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137267	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	2969278	6	2969044		EFO_0000095	Chronic lymphocytic leukemia	chronic lymphocytic leukemia
East Asian=7321		GCST007728	8.045757490560675	GCST007728_9	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [serous]	ovarian carcinoma
East Asian=7321		GCST007728	8.045757490560675	GCST007728_9	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [serous]	ovarian carcinoma
East Asian=7321		GCST007728	8.045757490560675	GCST007728_9	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137267	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [serous]	ovarian carcinoma
East Asian=7321		GCST007728	8.045757490560675	GCST007728_9	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137267	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [serous]	ovarian carcinoma
East Asian=7321		GCST007728	7.3979400086720375	GCST007728_2	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [HGSOC]	ovarian carcinoma
East Asian=7321		GCST007728	7.3979400086720375	GCST007728_2	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [HGSOC]	ovarian carcinoma
East Asian=7321		GCST007728	8.045757490560675	GCST007728_9	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [serous]	ovarian carcinoma
East Asian=7321		GCST007728	8.045757490560675	GCST007728_9	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137267	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [serous]	ovarian carcinoma
East Asian=7321		GCST007728	7.3979400086720375	GCST007728_2	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137267	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [HGSOC]	ovarian carcinoma
East Asian=7321		GCST007728	7.3979400086720375	GCST007728_2	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137267	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [HGSOC]	ovarian carcinoma
East Asian=7321		GCST007728	7.3979400086720375	GCST007728_2	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137267	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [HGSOC]	ovarian carcinoma
East Asian=7321		GCST007728	7.3979400086720375	GCST007728_2	30898391		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000137285	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	6	3581089	6	3580855		EFO_0001075	Epithelial ovarian cancer [HGSOC]	ovarian carcinoma
European=40187		GCST004749	12.154901959985743	GCST004749	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	30342753	6	30374976		EFO_0001071	Lung cancer in ever smokers	lung carcinoma
European=40187		GCST004749	12.154901959985743	GCST004749	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	30342753	6	30374976		EFO_0001071	Lung cancer in ever smokers	lung carcinoma
European=63053		GCST004750	13.522878745280337	GCST004750	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	30351348	6	30383571		EFO_0000708	Squamous cell lung carcinoma	squamous cell lung carcinoma
European=63053		GCST004750	13.522878745280337	GCST004750	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	30351348	6	30383571		EFO_0000708	Squamous cell lung carcinoma	squamous cell lung carcinoma
European=85716		GCST004748	17.397940008672037	GCST004748	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	30357294	6	30389517		EFO_0001071	Lung cancer	lung carcinoma
European=85716		GCST004748	17.397940008672037	GCST004748	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	30357294	6	30389517		EFO_0001071	Lung cancer	lung carcinoma
European=140254		GCST006085	8.221848749616356	GCST006085	29892016		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	30601232	6	30633455		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	8.221848749616356	GCST006085	29892016		drug	High	Ed Mountjoy	Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	30601232	6	30633455		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	8.221848749616356	GCST006085	29892016		drug	Low	Ed Mountjoy	Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	30601232	6	30633455		EFO_0001663	Prostate cancer	prostate carcinoma
European=85716		GCST004748	18.154901959985743	GCST004748	28604730		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	30864279	6	30896502		EFO_0001071	Lung cancer	lung carcinoma
European=85716		GCST004748	18.154901959985743	GCST004748	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	30864279	6	30896502		EFO_0001071	Lung cancer	lung carcinoma
European=63053		GCST004750	15.522878745280337	GCST004750	28604730		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	30882415	6	30914638		EFO_0000708	Squamous cell lung carcinoma	squamous cell lung carcinoma
European=63053		GCST004750	15.522878745280337	GCST004750	28604730		drug	Medium	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	30882415	6	30914638		EFO_0000708	Squamous cell lung carcinoma	squamous cell lung carcinoma
European=287323		GCST004346	324.22184874961636	GCST004346	28537254		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (223056bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	30916259	6	30948482		EFO_0000676	Psoriasis	psoriasis
European=120184|East Asian=5294		GCST007856	8.045757490560675	GCST007856	30510241		drug	Low	Ed Mountjoy	Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000196230 at this locus (316982bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31010185	6	31042408		EFO_0005842	Colorectal cancer or advanced adenoma	colorectal cancer
European=1712|African American or Afro-Caribbean=1233|Hispanic or Latin American=677		GCST000863	8.0	GCST000863	21051598		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (331606bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	31024808	6	31057031		EFO_0000180	HIV-1 control [AA]	HIV-1 infection
East Asian=1098		GCST001768	11.0	GCST001768	23001997		drug	Low	Ed Mountjoy	Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (364975bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31058178	6	31090401		EFO_0003780	Behcet's disease	Behcet's syndrome
East Asian=1098		GCST001768	11.0	GCST001768	23001997		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (485164bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	31058178	6	31090401		EFO_0003780	Behcet's disease	Behcet's syndrome
European=781		GCST000448	10.301029995663981	GCST000448	19620980		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000096 and targets the gene ENSG00000196230 at this locus (380827bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	6	31074030	6	31106253		EFO_0000096	Follicular lymphoma	neoplasm of mature B-cells
European=1048		GCST005541	26.096910013008056	GCST005541	26651848		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	6	31080016	6	31112239		Orphanet_797	Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	Sarcoidosis
European=1048		GCST005541	26.096910013008056	GCST005541	26651848		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	6	31080016	6	31112239		Orphanet_797	Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	Sarcoidosis
European=40187		GCST004749	15.301029995663981	GCST004749	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	31081205	6	31113428		EFO_0001071	Lung cancer in ever smokers	lung carcinoma
European=40187		GCST004749	15.301029995663981	GCST004749	28604730		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31081205	6	31113428		EFO_0001071	Lung cancer in ever smokers	lung carcinoma
European=8970|African American or Afro-Caribbean=2025		GCST003833	10.698970004336019	GCST003833	27611488		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (455197bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	31088145	6	31120368		EFO_0000270	Adult asthma	asthma
Other=978|European=1112		GCST006575	9.698970004336019	GCST006575_3	25604533		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (453635bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31089708	6	31121931		EFO_1001857	Takayasu arteritis [Turkish]	Takayasu arteritis
East Asian=1098		GCST001768	19.69897000433602	GCST001768	23001997		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (443766bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	31099577	6	31131800		EFO_0003780	Behcet's disease	Behcet's syndrome
East Asian=1098		GCST001768	19.69897000433602	GCST001768	23001997		drug	Low	Ed Mountjoy	Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (406375bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31099577	6	31131800		EFO_0003780	Behcet's disease	Behcet's syndrome
Other=1097|NR=150064		GCST003048	9.0	GCST003048	26198764		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (440378bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	31102964	6	31135187		EFO_0000692	Schizophrenia	schizophrenia
NR=150064|European=70017		GCST007257	9.698970004336019	GCST007257	30626913		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (437929bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	31105413	6	31137636		EFO_0003761	Broad depression or schizophrenia	unipolar depression
NR=150064|European=70017		GCST007257	9.698970004336019	GCST007257	30626913		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (437929bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	31105413	6	31137636		EFO_0000692	Broad depression or schizophrenia	schizophrenia
European=9641		GCST002140	10.0	GCST002140	23955597		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31107258	6	31139481		EFO_0001378	Multiple myeloma	multiple myeloma
European=9641		GCST002140	10.0	GCST002140	23955597		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	31107258	6	31139481		EFO_0001378	Multiple myeloma	multiple myeloma
East Asian=1310		GCST000529	66.39794000867204	GCST000529	19915573		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31111356	6	31143579		EFO_0000729	Ulcerative colitis	ulcerative colitis
East Asian=1310		GCST000529	66.39794000867204	GCST000529	19915573		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	31111356	6	31143579		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=241704		GCST004483	16.522878745280337	GCST004483	27363682		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31116526	6	31148749		EFO_0001378	Multiple myeloma	multiple myeloma
European=241704		GCST004483	16.522878745280337	GCST004483	27363682		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	31116526	6	31148749		EFO_0001378	Multiple myeloma	multiple myeloma
European=13560		GCST001148	7.522878745280337	GCST001148	21743467		drug	Low	Ed Mountjoy	Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	31118511	6	31150734		EFO_0001663	Prostate cancer	prostate carcinoma
European=13560		GCST001148	7.522878745280337	GCST001148	21743467		drug	Low	Ed Mountjoy	Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	6	31118511	6	31150734		EFO_0001663	Prostate cancer	prostate carcinoma
European=13560		GCST001148	7.522878745280337	GCST001148	21743467		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	6	31118511	6	31150734		EFO_0001663	Prostate cancer	prostate carcinoma
European=2305		GCST001181	7.698970004336019	GCST001181	21801394		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (406890bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31136453	6	31168676		EFO_0004775	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	toxic epidermal necrolysis
European=2305		GCST001181	7.698970004336019	GCST001181	21801394		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (406890bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	31136453	6	31168676		EFO_0004276	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	Stevens-Johnson syndrome
European=2305		GCST001181	7.522878745280337	GCST001181	21801394		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (401097bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	6	31142245	6	31174468		EFO_0004276	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	Stevens-Johnson syndrome
European=2305		GCST001181	7.522878745280337	GCST001181	21801394		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (401097bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	6	31142245	6	31174468		EFO_0004775	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	toxic epidermal necrolysis
European=1712|African American or Afro-Caribbean=1233|Hispanic or Latin American=677		GCST000863	15.397940008672037	GCST000863_2	21051598		drug	Low	Ed Mountjoy	Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (450379bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	6	31143582	6	31175805		EFO_0000180	HIV-1 control [EA]	HIV-1 infection
East Asian=2271		GCST000321	207.69897000433602	GCST000321	19169255		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	6	31155785	6	31188008		EFO_0000676	Psoriasis	psoriasis
East Asian=2271		GCST000321	207.69897000433602	GCST000321	19169255		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	6	31155785	6	31188008		EFO_0000676	Psoriasis	psoriasis
East Asian=2271		GCST000321	207.69897000433602	GCST000321	19169255		drug	Low	Ed Mountjoy	Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (462582bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196230	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	G	6	31155785	6	31188008		EFO_0000676	Psoriasis	psoriasis
European=1951		GCST001737	9.698970004336019	GCST001737_7	23144326		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	6	31240431	6	31272654		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [SP-D]	chronic obstructive pulmonary disease
European=1951		GCST001737	9.698970004336019	GCST001737_7	23144326		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	6	31240431	6	31272654		EFO_0000341	Chronic obstructive pulmonary disease-related biomarkers [SP-D]	chronic obstructive pulmonary disease
European=1460		GCST000835	71.69897000433602	GCST000835	20953186		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31241109	6	31273332		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=1460		GCST000835	71.69897000433602	GCST000835	20953186		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	31241109	6	31273332		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
Other=978|European=1112		GCST006575	9.0	GCST006575_2	25604533		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (301152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31242191	6	31274414		EFO_1001857	Takayasu arteritis [EA]	Takayasu arteritis
European=2759		GCST000322	100.0	GCST000322	19169254		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	31252925	6	31285148		EFO_0000676	Psoriasis	psoriasis
European=6880		GCST003270	98.69897000433602	GCST003270	26626624		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31252925	6	31285148		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=2759		GCST000322	100.0	GCST000322	19169254		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31252925	6	31285148		EFO_0000676	Psoriasis	psoriasis
European=1618		GCST000836	31.397940008672037	GCST000836	20953188		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	31252925	6	31285148		EFO_0000676	Psoriasis	psoriasis
European=1618		GCST000836	31.397940008672037	GCST000836	20953188		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31252925	6	31285148		EFO_0000676	Psoriasis	psoriasis
European=6880		GCST003270	98.69897000433602	GCST003270	26626624		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	31252925	6	31285148		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
East Asian=2546		GCST000692	32.69897000433602	GCST000692	20526339		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (284506bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31258837	6	31291060		EFO_0004208	Vitiligo	Vitiligo
European=2198		GCST007043	36.0	GCST007043	30552173		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	31265752	6	31297975		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=2198		GCST007043	36.0	GCST007043	30552173		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	31265752	6	31297975		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=8941		GCST003268	311.69897000433605	GCST003268	26626624		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000232810 at this locus (277252bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	31266090	6	31298313		EFO_1001494	Psoriasis vulgaris	psoriasis vulgaris
East Asian=2644		GCST003360	22.045757490560675	GCST003360	26891255		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (273649bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	31269693	6	31301916		EFO_0000384	Crohn's disease	Crohn's disease
European=7353		GCST000833	213.39794000867204	GCST000833	20953190		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31274555	6	31306778		EFO_0000676	Psoriasis	psoriasis
European=7353		GCST000833	213.39794000867204	GCST000833	20953190		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	31274555	6	31306778		EFO_0000676	Psoriasis	psoriasis
European=6297		GCST003269	206.39794000867204	GCST003269	26626624		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	31274555	6	31306778		EFO_0000676	Cutaneous psoriasis	psoriasis
European=737		GCST000173	38.69897000433602	GCST000173	18369459		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31274555	6	31306778		EFO_0000676	Psoriasis	psoriasis
European=737		GCST000173	38.69897000433602	GCST000173	18369459		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	31274555	6	31306778		EFO_0000676	Psoriasis	psoriasis
European=6297		GCST003269	206.39794000867204	GCST003269	26626624		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31274555	6	31306778		EFO_0000676	Cutaneous psoriasis	psoriasis
East Asian=2569		GCST006984	33.39794000867204	GCST006984	30498034		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (263125bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31280218	6	31312441		EFO_1001857	Takayasu arteritis	Takayasu arteritis
European=606		GCST000165	9.0	GCST000165	18364390		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	31312326	6	31344549		EFO_0000676	Psoriasis	psoriasis
European=606		GCST000165	9.0	GCST000165	18364390		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	6	31312326	6	31344549		EFO_0000676	Psoriasis	psoriasis
Other=1097|NR=150064		GCST003048	19.096910013008056	GCST003048	26198764		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (222075bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	6	31321267	6	31353490		EFO_0000692	Schizophrenia	schizophrenia
Other=1828|Greater Middle Eastern (Middle Eastern / North African / Persian)=1176		GCST007844	119.22184874961636	GCST007844_4	30946743		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (221214bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	6	31322129	6	31354352		EFO_0003898	Ankylosing spondylitis [Turkish]	ankylosing spondylitis
European=157242		GCST003987	16.0	GCST003987	27182965		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	31322197	6	31354420		EFO_0000270	Asthma	asthma
European=341215		GCST007798	59.69897000433602	GCST007798	30929738		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	31322197	6	31354420		EFO_0000270	Asthma	asthma
Other=1828|Greater Middle Eastern (Middle Eastern / North African / Persian)=1176		GCST007844	90.04575749056067	GCST007844_3	30946743		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (217409bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	31325933	6	31358156		EFO_0003898	Ankylosing spondylitis [Iranian]	ankylosing spondylitis
European=4806		GCST000961	8.0	GCST000961	21254220		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000289 and targets the gene ENSG00000232810 at this locus (215641bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	6	31327701	6	31359924		EFO_0000289	Bipolar disorder [addtive]	bipolar disorder
European=7193		GCST000563	303.30102999566395	GCST000563	20062062		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (207242bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	6	31336100	6	31368323		EFO_0003898	Ankylosing spondylitis	ankylosing spondylitis
East Asian=1098		GCST001768	9.698970004336019	GCST001768	23001997		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (206925bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	31336418	6	31368641		EFO_0003780	Behcet's disease	Behcet's syndrome
European=22647|East Asian=3117		GCST005529	100.0	GCST005529_3	23749187		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (198427bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31344916	6	31377139		EFO_0003898	Ankylosing spondylitis [EA]	ankylosing spondylitis
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	15.698970004336019	GCST007692_13	30804561		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31348519	6	31380742		EFO_0000341	Chronic obstructive pulmonary disease [conditional on rs2284174]	chronic obstructive pulmonary disease
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811		GCST007692	15.698970004336019	GCST007692_13	30804561		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	31348519	6	31380742		EFO_0000341	Chronic obstructive pulmonary disease [conditional on rs2284174]	chronic obstructive pulmonary disease
Other=978|European=1112		GCST006575	7.698970004336019	GCST006575_3	25604533		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (192130bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31351212	6	31383435		EFO_1001857	Takayasu arteritis [Turkish]	Takayasu arteritis
European=7156		GCST002357	8.045757490560675	GCST002357	24532677		drug	Low	Ed Mountjoy	TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (186502bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000226979	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31353329	6	31385552		EFO_0000685	Rheumatoid arthritis (ACPA-negative)	rheumatoid arthritis
European=7156		GCST002357	8.045757490560675	GCST002357	24532677		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug PLACULUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31353329	6	31385552		EFO_0000685	Rheumatoid arthritis (ACPA-negative)	rheumatoid arthritis
European=7156		GCST002357	8.045757490560675	GCST002357	24532677		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	31353329	6	31385552		EFO_0000685	Rheumatoid arthritis (ACPA-negative)	rheumatoid arthritis
Other=788|European=659		GCST006863	15.221848749616356	GCST006863	23830517		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	31354238	6	31386461		EFO_1001857	Takayasu arteritis	Takayasu arteritis
Other=978|European=1112		GCST006575	14.522878745280337	GCST006575_2	25604533		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	31354238	6	31386461		EFO_1001857	Takayasu arteritis [EA]	Takayasu arteritis
European=2930		GCST007361	17.30102999566398	GCST007361	25200001		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (183053bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	31360289	6	31392512		EFO_0003898	Acute anterior uveitis in ankylosing spondylitis	ankylosing spondylitis
European=1073		GCST002876	22.0	GCST002876	25936594		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	31364707	6	31396930		EFO_0001359	Type 1 diabetes and autoimmune thyroid diseases	insulin-dependent diabetes mellitus
European=1073		GCST002876	22.0	GCST002876	25936594		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31364707	6	31396930		EFO_0001359	Type 1 diabetes and autoimmune thyroid diseases	insulin-dependent diabetes mellitus
European=11802		GCST001149	200.0	GCST001149_2	21743469		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (177556bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	31365787	6	31398010		EFO_0003898	Ankylosing spondylitis [less than]	ankylosing spondylitis
European=2305		GCST001181	8.698970004336019	GCST001181	21801394		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (135514bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31407828	6	31440051		EFO_0004775	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	toxic epidermal necrolysis
European=2305		GCST001181	8.698970004336019	GCST001181	21801394		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (135514bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	31407828	6	31440051		EFO_0004276	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	Stevens-Johnson syndrome
European=737		GCST000173	25.69897000433602	GCST000173	18369459		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	31431780	6	31464003		EFO_0000676	Psoriasis	psoriasis
European=737		GCST000173	25.69897000433602	GCST000173	18369459		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	6	31431780	6	31464003		EFO_0000676	Psoriasis	psoriasis
European=6434		GCST003092	44.52287874528034	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (109011bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	A	6	31434331	6	31466554		EFO_0000783	Myositis	myositis
European=16582		GCST006052	75.22184874961636	GCST006052	26362759		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0003063 and targets the gene ENSG00000232810 at this locus (108976bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31434366	6	31466589		EFO_0003063	Polymyositis	polymyositis
European=6434		GCST003092	44.69897000433602	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108976bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31434366	6	31466589		EFO_0000783	Myositis	myositis
European=6434		GCST003092	44.69897000433602	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108721bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31434621	6	31466844		EFO_0000783	Myositis	myositis
European=6434		GCST003092	42.52287874528034	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (100560bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31442782	6	31475005		EFO_0000783	Myositis	myositis
South Asian=1225		GCST002453	14.698970004336019	GCST002453	24837172		drug	High	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	6	31448862	6	31481085		EFO_0000729	Ulcerative colitis	ulcerative colitis
South Asian=1225		GCST002453	14.698970004336019	GCST002453	24837172		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	6	31448862	6	31481085		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=6434		GCST003092	48.30102999566398	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (94366bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	6	31448976	6	31481199		EFO_0000783	Myositis	myositis
European=10564		GCST001436	7.698970004336019	GCST001436_2	22399527		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000195 and targets the gene ENSG00000232810 at this locus (94366bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	6	31448976	6	31481199		EFO_0000195	Metabolic syndrome [HDL]	metabolic syndrome
European=6434		GCST003092	49.0	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (91507bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31451836	6	31484059		EFO_0000783	Myositis	myositis
African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398		GCST005212	11.045757490560675	GCST005212	29273806		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (70622bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	6	31472720	6	31504943		EFO_0000270	Asthma	asthma
European=6434		GCST003092	47.39794000867204	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (66885bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	31476458	6	31508681		EFO_0000783	Myositis	myositis
East Asian=1005		GCST001239	7.698970004336019	GCST001239	21912425		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (37863bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	31505480	6	31537703		EFO_0004276	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	Stevens-Johnson syndrome
European=6434		GCST003092	48.52287874528034	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (37863bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31505480	6	31537703		EFO_0000783	Myositis	myositis
East Asian=1005		GCST001239	7.698970004336019	GCST001239	21912425		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (37863bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31505480	6	31537703		EFO_0004775	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	toxic epidermal necrolysis
European=6434		GCST003092	48.221848749616356	GCST003092	26291516		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (29095bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31514247	6	31546470		EFO_0000783	Myositis	myositis
European=21389		GCST000879	10.397940008672037	GCST000879	21102463		drug	High	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (1034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	31542308	6	31574531		EFO_0000384	Crohn's disease	Crohn's disease
European=1073		GCST002876	22.69897000433602	GCST002876	25936594		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31568469	6	31600692		EFO_0001359	Type 1 diabetes and autoimmune thyroid diseases	insulin-dependent diabetes mellitus
European=1073		GCST002876	22.69897000433602	GCST002876	25936594		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	31568469	6	31600692		EFO_0001359	Type 1 diabetes and autoimmune thyroid diseases	insulin-dependent diabetes mellitus
Other=978|European=1112		GCST006575	9.0	GCST006575_3	25604533		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (24557bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	31570670	6	31602893		EFO_1001857	Takayasu arteritis [Turkish]	Takayasu arteritis
European=69395		GCST001238	10.0	GCST001238	21909115		drug	High	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (70254bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	31616366	6	31648589		EFO_0000537	Hypertension	hypertension
East Asian=700		GCST001203	9.522878745280337	GCST001203	21844665		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug OZORALIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	6	31622606	6	31654829		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
East Asian=700		GCST001203	9.522878745280337	GCST001203	21844665		drug	Low	Ed Mountjoy	TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (80506bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000226979	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	6	31622606	6	31654829		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
East Asian=700		GCST001203	9.522878745280337	GCST001203	21844665		drug	High	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	6	31622606	6	31654829		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=3037		GCST000142	51.69897000433602	GCST000142	18204446		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (174921bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31721033	6	31753256		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=2734		GCST004053	8.301029995663981	GCST004053	28067912		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (187838bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	CAG	6	31733950	6	31766173		EFO_0000384	Poor prognosis in Crohn's disease	Crohn's disease
European=1048		GCST005541	31.397940008672037	GCST005541	26651848		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31749142	6	31781365		Orphanet_797	Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	Sarcoidosis
European=1048		GCST005541	31.397940008672037	GCST005541	26651848		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	31749142	6	31781365		Orphanet_797	Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	Sarcoidosis
East Asian=45528		GCST007201	19.30102999566398	GCST007201_2	30285260		drug	Medium	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (241055bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	31787167	6	31819390		EFO_0000692	Schizophrenia [EA]	schizophrenia
Other=1097|NR=150064		GCST003048	18.154901959985743	GCST003048	26198764		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (280592bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	31826705	6	31858928		EFO_0000692	Schizophrenia	schizophrenia
East Asian=2546		GCST000692	48.0	GCST000692	20526339		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (290954bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	31837066	6	31869289		EFO_0004208	Vitiligo	Vitiligo
European=3163		GCST002463	20.096910013008056	GCST002463	24871463		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (324214bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	31870326	6	31902549		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
European=13574|NR=2380		GCST004521	15.698970004336019	GCST004521	28540026		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (335197bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	31881309	6	31913532		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
European=3105		GCST004873	7.698970004336019	GCST004873	28881265		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001065 and targets the gene ENSG00000232810 at this locus (337844bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31883957	6	31916180		EFO_0001065	Endometriosis	endometriosis
South Asian=1225		GCST002453	13.301029995663981	GCST002453	24837172		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	31917540	6	31949763		EFO_0000729	Ulcerative colitis	ulcerative colitis
South Asian=1225		GCST002453	13.301029995663981	GCST002453	24837172		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	31917540	6	31949763		EFO_0000729	Ulcerative colitis	ulcerative colitis
European=1073		GCST002876	24.30102999566398	GCST002876	25936594		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	31918860	6	31951083		EFO_0001359	Type 1 diabetes and autoimmune thyroid diseases	insulin-dependent diabetes mellitus
European=1073		GCST002876	24.30102999566398	GCST002876	25936594		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	31918860	6	31951083		EFO_0001359	Type 1 diabetes and autoimmune thyroid diseases	insulin-dependent diabetes mellitus
European=2198		GCST007043	13.397940008672037	GCST007043	30552173		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	31936057	6	31968280		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
European=2198		GCST007043	13.397940008672037	GCST007043	30552173		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	6	31936057	6	31968280		EFO_0003778	Psoriatic arthritis	psoriatic arthritis
NR=150064|European=70017		GCST007257	12.0	GCST007257	30626913		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (401348bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	31947460	6	31979683		EFO_0000692	Broad depression or schizophrenia	schizophrenia
NR=150064|European=70017		GCST007257	12.0	GCST007257	30626913		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (401348bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	31947460	6	31979683		EFO_0003761	Broad depression or schizophrenia	unipolar depression
East Asian=5057|European=10995		GCST003622	100.69897000433602	GCST003622_3	27399966		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (483092bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	32029205	6	32061428		EFO_0002690	Systemic lupus erythematosus [EA]	systemic lupus erythematosus
European=18264|African American or Afro-Caribbean=5422|Hispanic or Latin American=3888		GCST005752	116.22184874961636	GCST005752	28714469		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (492437bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	32038550	6	32070773		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=9469		GCST002627	10.397940008672037	GCST002627	25249183		drug	Low	Ed Mountjoy	TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (498738bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000232810	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	32044851	6	32077074		EFO_0000537	Hypertension	hypertension
African American or Afro-Caribbean=2308		GCST006959	7.3979400086720375	GCST006959_3	30423114		drug	Low	Ed Mountjoy	MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112062	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	6	36355654	6	36387877		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	8.698970004336019	GCST006959	30423114		drug	Low	Ed Mountjoy	MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112062	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	6	36355654	6	36387877		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
East Asian=191764		GCST007847	13.397940008672037	GCST007847	30718926		drug	High	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	AAAAG	A	6	39039140	6	39071364		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	13.397940008672037	GCST007847	30718926		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	39039140	6	39071364		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	13.397940008672037	GCST007847	30718926		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	AAAAG	A	6	39039140	6	39071364		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	13.397940008672037	GCST007847	30718926		drug	High	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	39039140	6	39071364		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	13.397940008672037	GCST007847	30718926		drug	High	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	AG	A	6	39039140	6	39071364		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	13.397940008672037	GCST007847	30718926		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	AG	A	6	39039140	6	39071364		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	7.522878745280337	GCST003117	26343387		drug	High	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000112164 at this locus (65370bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	39124448	6	39156672		EFO_0000612	Myocardial infarction	myocardial infarction
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	7.698970004336019	GCST003116	26343387		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (75021bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	39134099	6	39166323		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	11.117418546445549	GCST005194	29212778		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	39174922	6	39207146		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	11.522878745280337	GCST005196	29212778		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	39174922	6	39207146		EFO_0000378	Coronary artery disease	coronary artery disease
East Asian=191764		GCST007847	9.0	GCST007847	30718926		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug LIXISENATIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	39282371	6	39314595		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	9.0	GCST007847	30718926		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	39282371	6	39314595		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=15000|South East Asian=2034|Asian unspecified=1783		GCST001351	7.698970004336019	GCST001351	22158537		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	6	39284050	6	39316274		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=15000|South East Asian=2034|Asian unspecified=1783		GCST001351	7.698970004336019	GCST001351	22158537		drug	Medium	Ed Mountjoy	Glucagon-like peptide 1 receptor agonist drug LIRAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112164	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	39284050	6	39316274		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=140254		GCST006085	7.522878745280337	GCST006085	29892016		drug	Low	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000112715 at this locus (43324bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	43694598	6	43726861		EFO_0001663	Prostate cancer	prostate carcinoma
NR=296525		GCST005194	11.39848321634999	GCST005194	29212778		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	43758873	6	43791136		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	11.698970004336019	GCST005196	29212778		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	43758873	6	43791136		EFO_0000378	Coronary artery disease	coronary artery disease
NR=547261		GCST005195	8.3767507096021	GCST005195	29212778		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	43758873	6	43791136		EFO_0000378	Coronary artery disease	coronary artery disease
European=33976		GCST003219	14.0	GCST003219_2	26691988		drug	Medium	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	43826627	6	43858890		EFO_0001365	Advanced age-related macular degeneration [EA]	age-related macular degeneration
European=55115|South Asian=229|East Asian=4150		GCST001884	15.045757490560675	GCST001884	23455636		drug	Medium	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	43826627	6	43858890		EFO_0001365	Age-related macular degeneration	age-related macular degeneration
European=33976		GCST003219	14.0	GCST003219_2	26691988		drug	Medium	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	43826627	6	43858890		EFO_0004683	Advanced age-related macular degeneration [EA]	wet macular degeneration
European=33976		GCST003219	14.0	GCST003219_2	26691988		drug	High	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	43826627	6	43858890		EFO_0004683	Advanced age-related macular degeneration [EA]	wet macular degeneration
European=33976		GCST003219	14.0	GCST003219_2	26691988		drug	High	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	43826627	6	43858890		EFO_0001365	Advanced age-related macular degeneration [EA]	age-related macular degeneration
European=55115|South Asian=229|East Asian=4150		GCST001884	15.045757490560675	GCST001884	23455636		drug	High	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	43826627	6	43858890		EFO_0001365	Age-related macular degeneration	age-related macular degeneration
European=6728		GCST001100	8.045757490560675	GCST001100	21665990		drug	Medium	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	43828582	6	43860845		EFO_0001365	Age-related macular degeneration	age-related macular degeneration
European=6728		GCST001100	8.045757490560675	GCST001100	21665990		drug	High	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug CONBERCEPT is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	43828582	6	43860845		EFO_0001365	Age-related macular degeneration	age-related macular degeneration
East Asian=7810		GCST002766	17.221848749616356	GCST002766	25629512		drug	Medium	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	43970827	6	44003090		EFO_0004683	Exudative age-related macular degeneration	wet macular degeneration
East Asian=7810		GCST002766	17.221848749616356	GCST002766	25629512		drug	Medium	Ed Mountjoy	Vascular endothelial growth factor A inhibitor drug AFLIBERCEPT is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112715	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	43970827	6	44003090		EFO_0004683	Exudative age-related macular degeneration	wet macular degeneration
East Asian=5683		GCST001681	15.0	GCST001681	23028356		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	44232920	6	44265183		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
East Asian=20965		GCST001454	18.221848749616356	GCST001454	22446963		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	44232920	6	44265183		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	7.522878745280337	GCST006959_3	30423114		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	44233921	6	44266184		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	18.69897000433602	GCST006959	30423114		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	44233921	6	44266184		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=58284|East Asian=22515		GCST002318	19.0	GCST002318	24390342		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	44233921	6	44266184		EFO_0000685	Rheumatoid arthritis	rheumatoid arthritis
European=58284|East Asian=22515		GCST002318	12.698970004336019	GCST002318_3	24390342		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	44233921	6	44266184		EFO_0000685	Rheumatoid arthritis [East Asian]	rheumatoid arthritis
European=58284|East Asian=22515		GCST002318	7.522878745280337	GCST002318_2	24390342		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	44233921	6	44266184		EFO_0000685	Rheumatoid arthritis [EA]	rheumatoid arthritis
African American or Afro-Caribbean=2308		GCST006959	12.045757490560675	GCST006959_4	30423114		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	44233921	6	44266184		EFO_0000685	Rheumatoid arthritis [East Asian]	rheumatoid arthritis
European=2406		GCST001659	7.301029995663981	GCST001659	22941190		drug	Low	Ed Mountjoy	Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000112759 at this locus (392271bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112759	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	44594159	6	44626422		EFO_0000712	Stroke (ischemic) [LAA]	cerebrovascular accident
European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=22156		GCST004963	178.0	GCST004963	28753643		drug	Medium	Ed Mountjoy	LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146070	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	6	46677098	6	46709361		EFO_0005672	Lipoprotein phospholipase A2 activity in cardiovascular disease	acute coronary syndrome
European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=10874		GCST004966	46.096910013008056	GCST004966	28753643		drug	Medium	Ed Mountjoy	LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146070	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	6	46677098	6	46709361		EFO_0005672	Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease	acute coronary syndrome
European=11181		GCST003180	7.698970004336019	GCST003180	26542096		drug	Low	Ed Mountjoy	Interleukin 17A inhibitor drug SECUKINUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000112115 at this locus (236700bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112115	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	52292136	6	52427338		EFO_0000274	Atopic march	atopic eczema
European=204641|East Asian=4262		GCST004549	7.3979400086720375	GCST004549	28537267		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	151816011	6	151494876		EFO_0001065	Endometriosis	endometriosis
European=204641|East Asian=4262		GCST004549	7.3979400086720375	GCST004549	28537267		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	151816011	6	151494876		EFO_0001065	Endometriosis	endometriosis
European=361141			8.287247628480976	NEALE2_20002_1065		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000091831 at this locus (67422bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	AAC	6	151910404	6	151589269		EFO_0000537	Hypertension | non-cancer illness code, self-reported	hypertension
European=22627		GCST001937	20.69897000433602	GCST001937	23535729		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	151914113	6	151592978		EFO_0000305	Breast cancer	breast carcinoma
European=22627		GCST001937	20.69897000433602	GCST001937	23535729		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	151914113	6	151592978		EFO_0000305	Breast cancer	breast carcinoma
European=22627		GCST001937	20.69897000433602	GCST001937	23535729		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	151914113	6	151592978		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	19.0	GCST003845	27117709		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	6	151918856	6	151597721		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	26.154901959985743	GCST004950	25751625		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	151918856	6	151597721		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	26.154901959985743	GCST004950	25751625		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	6	151918856	6	151597721		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	26.154901959985743	GCST004950	25751625		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	6	151918856	6	151597721		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	19.0	GCST003845	27117709		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	151918856	6	151597721		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	19.0	GCST003845	27117709		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	6	151918856	6	151597721		EFO_0000305	Breast cancer	breast carcinoma
European=688809		GCST006477	9.154901959985743	GCST006477	29942085		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	6	151925507	6	151604372		EFO_0003761	Depression	unipolar depression
European=688809		GCST006477	9.154901959985743	GCST006477	29942085		drug	High	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	6	151925507	6	151604372		EFO_0003761	Depression	unipolar depression
European=15566		GCST005075	11.522878745280337	GCST005075	29058716		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	6	151942194	6	151621059		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=15566		GCST005075	11.522878745280337	GCST005075	29058716		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	6	151942194	6	151621059		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=15566		GCST005075	11.522878745280337	GCST005075	29058716		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	6	151942194	6	151621059		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=19291		GCST003845	27.397940008672037	GCST003845	27117709		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	T	6	151946152	6	151625017		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	27.397940008672037	GCST003845	27117709		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	6	151946152	6	151625017		EFO_0000305	Breast cancer	breast carcinoma
European=19291		GCST003845	27.397940008672037	GCST003845	27117709		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	T	6	151946152	6	151625017		EFO_0000305	Breast cancer	breast carcinoma
European=39387		GCST001930	15.301029995663981	GCST001930	23535733		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
European=39387		GCST001930	15.301029995663981	GCST001930	23535733		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
East Asian=13905		GCST003520	14.154901959985743	GCST003520	27354352		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
East Asian=13905		GCST003520	14.154901959985743	GCST003520	27354352		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
East Asian=13905		GCST003520	14.154901959985743	GCST003520	27354352		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	23.221848749616356	GCST004950	25751625		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
European=2727		GCST001916	8.301029995663981	GCST001916	23544013		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	151948366	6	151627231		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=39387		GCST001930	15.301029995663981	GCST001930	23535733		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	23.221848749616356	GCST004950	25751625		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
European=33864		GCST004950	23.221848749616356	GCST004950	25751625		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
East Asian=3027		GCST000343	14.698970004336019	GCST000343	19219042		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
East Asian=3027		GCST000343	14.698970004336019	GCST000343	19219042		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
East Asian=3027		GCST000343	14.698970004336019	GCST000343	19219042		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	151948366	6	151627231		EFO_0000305	Breast cancer	breast carcinoma
European=2727		GCST001916	8.301029995663981	GCST001916	23544013		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	151948366	6	151627231		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=2727		GCST001916	8.301029995663981	GCST001916	23544013		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	151948366	6	151627231		EFO_0000305	Breast Cancer in BRCA1 mutation carriers	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		15.344861565188618	SAIGE_174			drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	6	151949806	6	151628671		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		15.344861565188618	SAIGE_174			drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	6	151949806	6	151628671		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		15.344861565188618	SAIGE_174			drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	6	151949806	6	151628671		EFO_0000305	Breast cancer	breast carcinoma
European=330828			12.785156151952302	NEALE2_20110_5		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	151952332	6	151631197		EFO_0000305	Breast cancer | illnesses of mother	breast carcinoma
European=330828			12.785156151952302	NEALE2_20110_5		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	6	151952332	6	151631197		EFO_0000305	Breast cancer | illnesses of mother	breast carcinoma
European=330828			12.785156151952302	NEALE2_20110_5		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	151952332	6	151631197		EFO_0000305	Breast cancer | illnesses of mother	breast carcinoma
European=139274		GCST004988	7.895171596346344	GCST004988	29059683		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	6	151952645	6	151631510		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	7.895171596346344	GCST004988	29059683		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	6	151952645	6	151631510		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	7.895171596346344	GCST004988	29059683		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	151952645	6	151631510		EFO_0000305	Breast cancer	breast carcinoma
Hispanic or Latin American=4710		GCST002662	17.045757490560675	GCST002662	25327703		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	151954834	6	151633699		EFO_0000305	Breast cancer	breast carcinoma
Hispanic or Latin American=4710		GCST002662	17.045757490560675	GCST002662	25327703		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	151954834	6	151633699		EFO_0000305	Breast cancer	breast carcinoma
Hispanic or Latin American=4710		GCST002662	17.045757490560675	GCST002662	25327703		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	151954834	6	151633699		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	53.54668165995296	GCST004988	29059683		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	151955914	6	151634779		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	53.54668165995296	GCST004988	29059683		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	151955914	6	151634779		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	53.54668165995296	GCST004988	29059683		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	151955914	6	151634779		EFO_0000305	Breast cancer	breast carcinoma
European=32530|African American or Afro-Caribbean=3748		GCST001683	9.698970004336019	GCST001683	22976474		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	6	151987357	6	151666222		EFO_0000305	Breast cancer	breast carcinoma
European=32530|African American or Afro-Caribbean=3748		GCST001683	9.698970004336019	GCST001683	22976474		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	151987357	6	151666222		EFO_0000305	Breast cancer	breast carcinoma
European=32530|African American or Afro-Caribbean=3748		GCST001683	9.698970004336019	GCST001683	22976474		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	6	151987357	6	151666222		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	18.080451241031152	GCST004988	29059683		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	A	6	152020390	6	151699255		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	18.080451241031152	GCST004988	29059683		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	A	6	152020390	6	151699255		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	18.080451241031152	GCST004988	29059683		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	A	6	152020390	6	151699255		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		7.47755576649368	SAIGE_174			drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	152034820	6	151713685		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		7.47755576649368	SAIGE_174			drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	152034820	6	151713685		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		7.47755576649368	SAIGE_174			drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	152034820	6	151713685		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	25.84893674664625	GCST004988	29059683		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	152432902	6	152111767		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	25.84893674664625	GCST004988	29059683		drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	152432902	6	152111767		EFO_0000305	Breast cancer	breast carcinoma
European=139274		GCST004988	25.84893674664625	GCST004988	29059683		drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	6	152432902	6	152111767		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		12.767003889607846	SAIGE_174			drug	High	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	152437016	6	152115881		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		12.767003889607846	SAIGE_174			drug	Low	Ed Mountjoy	Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	152437016	6	152115881		EFO_0000305	Breast cancer	breast carcinoma
European=401447	10.1038/s41588-018-0184-y		12.767003889607846	SAIGE_174			drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	152437016	6	152115881		EFO_0000305	Breast cancer	breast carcinoma
European=204641|East Asian=4262		GCST004549	7.698970004336019	GCST004549	28537267		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	6	152554014	6	152232879		EFO_0001065	Endometriosis	endometriosis
European=204641|East Asian=4262		GCST004549	7.698970004336019	GCST004549	28537267		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	6	152554014	6	152232879		EFO_0001065	Endometriosis	endometriosis
European=204641|East Asian=4262		GCST004549	7.698970004336019	GCST004549_2	28537267		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	6	152554014	6	152232879		EFO_0001065	Endometriosis [EA]	endometriosis
European=204641|East Asian=4262		GCST004549	7.698970004336019	GCST004549_2	28537267		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	6	152554014	6	152232879		EFO_0001065	Endometriosis [EA]	endometriosis
European=539925		GCST006462	23.045757490560675	GCST006462	30194396		drug	Medium	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000731 and targets the gene ENSG00000091831 at this locus (111518bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	6	152562271	6	152241136		EFO_0000731	Uterine fibroids	uterine fibroid
European=33181		GCST003962	7.3979400086720375	GCST003962	28072414		drug	Low	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (263852bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	6	152714606	6	152393471		EFO_0000289	Bipolar disorder	bipolar disorder
European=61220		GCST001877	8.397940008672037	GCST001877_3	23453885		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000091831 at this locus (339820bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	6	152790573	6	152469438		EFO_0000692	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]	schizophrenia
European=61220		GCST001877	8.397940008672037	GCST001877_3	23453885		drug	Low	Ed Mountjoy	Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (339820bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	6	152790573	6	152469438		EFO_0000289	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]	bipolar disorder
European=61220		GCST001877	8.397940008672037	GCST001877_3	23453885		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	152790573	6	152469438		EFO_0003761	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]	unipolar depression
European=61220		GCST001877	8.397940008672037	GCST001877_3	23453885		drug	Low	Ed Mountjoy	Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000091831	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	6	152790573	6	152469438		EFO_0003761	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]	unipolar depression
European=1027|African American or Afro-Caribbean=383		GCST004136	7.522878745280337	GCST004136	28115739		drug	Low	Ed Mountjoy	Mu opioid receptor agonist drug MORPHINE is Phase IV for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112038	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	154025139	6	153704004		EFO_0005611	Methadone dose in opioid dependence [AA]	opioid dependence
European=1027|African American or Afro-Caribbean=383		GCST004136	7.522878745280337	GCST004136	28115739		drug	Low	Ed Mountjoy	Mu opioid receptor agonist drug TRAMADOL is Phase III for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112038	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	154025139	6	153704004		EFO_0005611	Methadone dose in opioid dependence [AA]	opioid dependence
European=1027|African American or Afro-Caribbean=383		GCST004136	7.522878745280337	GCST004136	28115739		drug	Low	Ed Mountjoy	Mu opioid receptor antagonist drug NALDEMEDINE is Phase II for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000112038	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	6	154025139	6	153704004		EFO_0005611	Methadone dose in opioid dependence [AA]	opioid dependence
NR=296525		GCST005194	88.32422165832591	GCST005194	29212778		drug	Low	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (371740bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	6	160751531	6	160330499		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	30.522878745280337	GCST005196	29212778		drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	160911596	6	160490564		EFO_0000378	Coronary artery disease	coronary artery disease
European=408458	10.1038/s41588-018-0184-y		19.416801226031378	SAIGE_411			drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	160911596	6	160490564		EFO_0000378	Ischemic heart disease	coronary artery disease
European=388806	10.1038/s41588-018-0184-y		11.869666231504993	SAIGE_411_2			drug	Medium	Ed Mountjoy	Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	6	160911596	6	160490564		EFO_0000612	Myocardial infarction	myocardial infarction
European=388806	10.1038/s41588-018-0184-y		11.869666231504993	SAIGE_411_2			drug	Medium	Ed Mountjoy	Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	160911596	6	160490564		EFO_0000612	Myocardial infarction	myocardial infarction
NR=296525		GCST005194	31.75870261289001	GCST005194	29212778		drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	160911596	6	160490564		EFO_0000378	Coronary artery disease	coronary artery disease
NR=547261		GCST005195	28.657577319177793	GCST005195	29212778		drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	160911596	6	160490564		EFO_0000378	Coronary artery disease	coronary artery disease
European=15666		GCST006405	11.522878745280337	GCST006405	30003307		drug	Medium	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (126153bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	A	6	160997118	6	160576086		EFO_0000378	Coronary artery disease in diabetes	coronary artery disease
European=361141			28.71524000401907	NEALE2_20002_1075		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161005610	6	160584578		EFO_0000612	Heart attack/myocardial infarction | non-cancer illness code, self-reported	myocardial infarction
NR=296525		GCST005194	153.0096611452124	GCST005194	29212778		drug	Medium	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161005610	6	160584578		EFO_0000378	Coronary artery disease	coronary artery disease
European=408458	10.1038/s41588-018-0184-y		61.367542707815275	SAIGE_411			drug	Medium	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161005610	6	160584578		EFO_0000378	Ischemic heart disease	coronary artery disease
European=361141			28.71524000401907	NEALE2_20002_1075		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	161005610	6	160584578		EFO_0000612	Heart attack/myocardial infarction | non-cancer illness code, self-reported	myocardial infarction
European=388806	10.1038/s41588-018-0184-y		40.28149831113272	SAIGE_411_2			drug	Medium	Ed Mountjoy	Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161005610	6	160584578		EFO_0000612	Myocardial infarction	myocardial infarction
NR=547261		GCST005195	119.20065945054642	GCST005195	29212778		drug	Medium	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161005610	6	160584578		EFO_0000378	Coronary artery disease	coronary artery disease
European=388806	10.1038/s41588-018-0184-y		40.28149831113272	SAIGE_411_2			drug	Medium	Ed Mountjoy	Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	161005610	6	160584578		EFO_0000612	Myocardial infarction	myocardial infarction
NR=250736		GCST005196	153.52287874528034	GCST005196	29212778		drug	Medium	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161005610	6	160584578		EFO_0000378	Coronary artery disease	coronary artery disease
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	38.30102999566398	GCST003116	26343387		drug	Medium	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161005610	6	160584578		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	10.522878745280337	GCST005196	29212778		drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161006077	6	160585045		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	10.522878745280337	GCST005196	29212778		drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	6	161006077	6	160585045		EFO_0000378	Coronary artery disease	coronary artery disease
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	26.045757490560675	GCST003117	26343387		drug	Medium	Ed Mountjoy	Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	161010118	6	160589086		EFO_0000612	Myocardial infarction	myocardial infarction
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	26.045757490560675	GCST003117	26343387		drug	Medium	Ed Mountjoy	Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	161010118	6	160589086		EFO_0000612	Myocardial infarction	myocardial infarction
European, NR=63731		GCST004787	48.69897000433602	GCST004787	28714975		drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	161010118	6	160589086		EFO_0000378	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	coronary artery disease
NR=123388		GCST002287	11.698970004336019	GCST002287	24262325		drug	Medium	Ed Mountjoy	Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	161010118	6	160589086		EFO_0000712	Coronary artery disease or ischemic stroke	cerebrovascular accident
European=360420			27.967377210462196	NEALE2_6150_1		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	161010118	6	160589086		EFO_0000612	Heart attack | vascular/heart problems diagnosed by doctor	myocardial infarction
European=360420			27.967377210462196	NEALE2_6150_1		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	6	161010118	6	160589086		EFO_0000612	Heart attack | vascular/heart problems diagnosed by doctor	myocardial infarction
NR=123388		GCST002287	11.698970004336019	GCST002287	24262325		drug	Low	Ed Mountjoy	Plasminogen activator drug RETEPLASE is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	6	161010118	6	160589086		EFO_0000712	Coronary artery disease or ischemic stroke	cerebrovascular accident
NR=123388		GCST002287	11.698970004336019	GCST002287	24262325		drug	Medium	Ed Mountjoy	Plasminogen activator drug DESMOTEPLASE is Phase III for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	6	161010118	6	160589086		EFO_0000712	Coronary artery disease or ischemic stroke	cerebrovascular accident
NR=547261		GCST005195	76.85387196432177	GCST005195	29212778		drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	161013013	6	160591981		EFO_0000378	Coronary artery disease	coronary artery disease
European=388806	10.1038/s41588-018-0184-y		25.059981844992336	SAIGE_411_2			drug	Medium	Ed Mountjoy	Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	161013013	6	160591981		EFO_0000612	Myocardial infarction	myocardial infarction
European=361141			17.90926593057954	NEALE2_20002_1075		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	T	6	161013013	6	160591981		EFO_0000612	Heart attack/myocardial infarction | non-cancer illness code, self-reported	myocardial infarction
European=361141			17.90926593057954	NEALE2_20002_1075		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	161013013	6	160591981		EFO_0000612	Heart attack/myocardial infarction | non-cancer illness code, self-reported	myocardial infarction
European=408458	10.1038/s41588-018-0184-y		42.36957212497498	SAIGE_411			drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	161013013	6	160591981		EFO_0000378	Ischemic heart disease	coronary artery disease
European=388806	10.1038/s41588-018-0184-y		25.059981844992336	SAIGE_411_2			drug	Medium	Ed Mountjoy	Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	161013013	6	160591981		EFO_0000612	Myocardial infarction	myocardial infarction
NR=296525		GCST005194	9.409046764812015	GCST005194	29212778		drug	Medium	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (105907bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	6	161017363	6	160596331		EFO_0000378	Coronary artery disease	coronary artery disease
NR=250736		GCST005196	7.698970004336019	GCST005196	29212778		drug	High	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (35407bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	161087863	6	160666831		EFO_0000378	Coronary artery disease	coronary artery disease
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	23.69897000433602	GCST003117	26343387		drug	High	Ed Mountjoy	Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	C	6	161108144	6	160687112		EFO_0000612	Myocardial infarction	myocardial infarction
African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630		GCST003117	23.69897000433602	GCST003117	26343387		drug	Medium	Ed Mountjoy	Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	C	6	161108144	6	160687112		EFO_0000612	Myocardial infarction	myocardial infarction
European=360420			17.657683931817257	NEALE2_6150_1		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161111700	6	160690668		EFO_0000612	Heart attack | vascular/heart problems diagnosed by doctor	myocardial infarction
European=360420			17.657683931817257	NEALE2_6150_1		http://www.nealelab.is/uk-biobank	drug	Medium	Ed Mountjoy	Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	6	161111700	6	160690668		EFO_0000612	Heart attack | vascular/heart problems diagnosed by doctor	myocardial infarction
NR=250736		GCST005196	91.30102999566398	GCST005196	29212778		drug	High	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161111700	6	160690668		EFO_0000378	Coronary artery disease	coronary artery disease
NR=296525		GCST005194	96.70114692359029	GCST005194	29212778		drug	High	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	6	161111700	6	160690668		EFO_0000378	Coronary artery disease	coronary artery disease
European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323		GCST003116	31.69897000433602	GCST003116	26343387		drug	High	Ed Mountjoy	Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000122194	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	6	161123451	6	160702419		EFO_0000378	Coronary artery disease	coronary artery disease
European=361141			8.507692295087963	NEALE2_20002_1111		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000136244	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	AT	7	22783490	7	22743871		EFO_0000270	Asthma | non-cancer illness code, self-reported	asthma
European=360527			9.229103089046006	NEALE2_6152_8		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000136244	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	AT	7	22783490	7	22743871		EFO_0000270	Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	asthma
East Asian=191764		GCST007847	11.301029995663981	GCST007847	30718926		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (377278bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	7	44174857	7	44135258		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European, NR=735838		GCST007545	7.698970004336019	GCST007545	30525989		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (335997bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	7	44216137	7	44176538		EFO_0000378	Coronary artery disease and triglyceride levels (multivariate analysis)	coronary artery disease
East Asian=7696		GCST001965	9.522878745280337	GCST001965_2	23575436		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	7	44229068	7	44189469		EFO_0001360	Glycemic traits [2-hPG]	type II diabetes mellitus
East Asian=7696		GCST001965	17.30102999566398	GCST001965_3	23575436		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	7	44229068	7	44189469		EFO_0001360	Glycemic traits [FPG]	type II diabetes mellitus
East Asian=7696		GCST001965	8.522878745280337	GCST001965	23575436		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	7	44229068	7	44189469		EFO_0001360	Glycemic traits [1-hPG]	type II diabetes mellitus
European=10564		GCST001436	12.397940008672037	GCST001436	22399527		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (320918bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	T	7	44231216	7	44191617		EFO_0000195	Metabolic syndrome [GLU]	metabolic syndrome
European=655666|South Asian=3650		GCST006867	8.397940008672037	GCST006867	30054458		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (303306bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	7	44248828	7	44209229		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=10564		GCST001436	10.045757490560675	GCST001436	22399527		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	7	44259871	7	44220272		EFO_0000195	Metabolic syndrome [GLU]	metabolic syndrome
European=10564		GCST001436	10.045757490560675	GCST001436	22399527		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	7	44259871	7	44220272		EFO_0000195	Metabolic syndrome [GLU]	metabolic syndrome
European=459000		GCST007072	7.301029995663981	GCST007072	30595370		drug	High	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000015520 at this locus (1072bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	7	44581986	7	44542387		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=459000		GCST007072	7.301029995663981	GCST007072	30595370		drug	Low	Ed Mountjoy	Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196262 at this locus (254293bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196262	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	7	44581986	7	44542387		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=361141			14.154901959985743	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000015520 at this locus (3637bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	7	44584551	7	44544952		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=26405		GCST000964	9.097453220686008	GCST000964	21297633		drug	Medium	Ed Mountjoy	Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000196262 at this locus (224051bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000196262	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	7	44612229	7	44572630		EFO_0000729	Ulcerative colitis	ulcerative colitis
NR=296525		GCST005194	7.438898616350944	GCST005194	29212778		drug	Low	Ed Mountjoy	Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (497064bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000015520	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	7	45077978	7	45038379		EFO_0000378	Coronary artery disease	coronary artery disease
NR=15094		GCST006480	11.154901959985743	GCST006480_2	30152087		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma (age-stratified) [Below median age-at-diagnosis]	glioblastoma multiforme
NR=15094		GCST006480	15.397940008672037	GCST006480	30152087		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma (age-stratified) [Above median age-at-diagnosis]	glioblastoma multiforme
European=24381		GCST004349	33.30102999566398	GCST004349	28346443		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma	glioblastoma multiforme
NR=15094		GCST006480	11.154901959985743	GCST006480_2	30152087		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma (age-stratified) [Below median age-at-diagnosis]	glioblastoma multiforme
European=9218		GCST003220	10.221848749616356	GCST003220	26424050		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma	glioblastoma multiforme
European=24381		GCST004349	33.30102999566398	GCST004349	28346443		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma	glioblastoma multiforme
NR=15094		GCST006480	11.698970004336019	GCST006480_3	30152087		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma (age-stratified) [Median age-at-diagnosis]	glioblastoma multiforme
European=24381		GCST004349	33.30102999566398	GCST004349	28346443		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000326	Glioblastoma	central nervous system cancer
European=24009		GCST004348	7.698970004336019	GCST004348	28346443		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000326	Non-glioblastoma glioma	central nervous system cancer
NR=15094		GCST006480	15.397940008672037	GCST006480	30152087		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma (age-stratified) [Above median age-at-diagnosis]	glioblastoma multiforme
NR=15094		GCST006480	11.698970004336019	GCST006480_3	30152087		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma (age-stratified) [Median age-at-diagnosis]	glioblastoma multiforme
European=11582		GCST003228	10.698970004336019	GCST003228	26424050		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000326	Glioma	central nervous system cancer
European=30659		GCST004347	26.397940008672037	GCST004347	28346443		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	T	7	54916280	7	54848587		EFO_0000326	Glioma	central nervous system cancer
European=9218		GCST003220	10.221848749616356	GCST003220	26424050		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	T	7	54916280	7	54848587		EFO_0000519	Glioblastoma	glioblastoma multiforme
NR=15094		GCST006480	8.698970004336019	GCST006480_3	30152087		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	7	55134872	7	55067179		EFO_0000519	Glioblastoma (age-stratified) [Median age-at-diagnosis]	glioblastoma multiforme
European=24381		GCST004349	22.30102999566398	GCST004349	28346443		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	7	55134872	7	55067179		EFO_0000519	Glioblastoma	glioblastoma multiforme
European=24381		GCST004349	22.30102999566398	GCST004349	28346443		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	7	55134872	7	55067179		EFO_0000519	Glioblastoma	glioblastoma multiforme
NR=15094		GCST006480	10.698970004336019	GCST006480	30152087		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	7	55134872	7	55067179		EFO_0000519	Glioblastoma (age-stratified) [Above median age-at-diagnosis]	glioblastoma multiforme
NR=15094		GCST006480	10.698970004336019	GCST006480	30152087		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	7	55134872	7	55067179		EFO_0000519	Glioblastoma (age-stratified) [Above median age-at-diagnosis]	glioblastoma multiforme
European=24381		GCST004349	22.30102999566398	GCST004349	28346443		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	7	55134872	7	55067179		EFO_0000326	Glioblastoma	central nervous system cancer
NR=15094		GCST006480	8.698970004336019	GCST006480_3	30152087		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	7	55134872	7	55067179		EFO_0000519	Glioblastoma (age-stratified) [Median age-at-diagnosis]	glioblastoma multiforme
NR=15094		GCST006480	9.698970004336019	GCST006480	30152087		drug	Low	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	7	55159349	7	55091656		EFO_0000519	Glioblastoma (age-stratified) [Above median age-at-diagnosis]	glioblastoma multiforme
NR=15094		GCST006480	9.698970004336019	GCST006480	30152087		drug	Medium	Ed Mountjoy	Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000146648	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	7	55159349	7	55091656		EFO_0000519	Glioblastoma (age-stratified) [Above median age-at-diagnosis]	glioblastoma multiforme
NR=361315|European=446238		GCST007342	13.045757490560675	GCST007342	30718901		drug	Low	Ed Mountjoy	Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (381311bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000153956	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	7	82454404	7	82825088		EFO_0003761	Depression	unipolar depression
European=6507		GCST004486	7.522878745280337	GCST004486	28540843		drug	Low	Ed Mountjoy	Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000153956	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	A	7	82468374	7	82839058		EFO_0003761	Major depressive disorder	unipolar depression
European=6507		GCST004486	7.522878745280337	GCST004486	28540843		drug	Low	Ed Mountjoy	Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000153956	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	A	7	82468374	7	82839058		EFO_0003761	Major depressive disorder	unipolar depression
Other=1097|NR=150064		GCST003048	10.154901959985743	GCST003048	26198764		drug	Medium	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	86427626	7	86798310		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	9.397940008672037	GCST007201	30285260		drug	Medium	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	86427626	7	86798310		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	9.522878745280337	GCST007201_2	30285260		drug	Medium	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	86427626	7	86798310		EFO_0000692	Schizophrenia [EA]	schizophrenia
European=105318		GCST006803	13.397940008672037	GCST006803	29483656		drug	Medium	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	86427626	7	86798310		EFO_0000692	Schizophrenia	schizophrenia
European=82315|East Asian=5219		GCST002539	9.522878745280337	GCST002539	25056061		drug	Medium	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	86427626	7	86798310		EFO_0000692	Schizophrenia	schizophrenia
European=13574|NR=2380		GCST004521	10.0	GCST004521	28540026		drug	Medium	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	86427626	7	86798310		EFO_0000692	Autism spectrum disorder or schizophrenia	schizophrenia
East Asian=26026|European=82315		GCST004946	9.522878745280337	GCST004946	28991256		drug	Medium	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	86427626	7	86798310		EFO_0000692	Schizophrenia	schizophrenia
East Asian=45528		GCST007201	7.522878745280337	GCST007201	30285260		drug	Low	Ed Mountjoy	Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (305241bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000198822	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	T	7	86799441	7	87170125		EFO_0000692	Schizophrenia	schizophrenia
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Medium	Ed Mountjoy	Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (200123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	7	100287495	7	100689872		EFO_0000692	Pursuit maintenance gain in psychotic disorders [African]	schizophrenia
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Low	Ed Mountjoy	Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	7	100287495	7	100689872		EFO_0005411	Pursuit maintenance gain in psychotic disorders [African]	schizoaffective disorder
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Medium	Ed Mountjoy	Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (200123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	7	100287495	7	100689872		EFO_0000289	Pursuit maintenance gain in psychotic disorders [African]	bipolar disorder
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Medium	Ed Mountjoy	Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	7	100287495	7	100689872		EFO_0005411	Pursuit maintenance gain in psychotic disorders [African]	schizoaffective disorder
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Low	Ed Mountjoy	Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	7	100298984	7	100701361		EFO_0005411	Pursuit maintenance gain in psychotic disorders [African]	schizoaffective disorder
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Medium	Ed Mountjoy	Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (188633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	7	100298984	7	100701361		EFO_0000692	Pursuit maintenance gain in psychotic disorders [African]	schizophrenia
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Medium	Ed Mountjoy	Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (188633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	7	100298984	7	100701361		EFO_0000289	Pursuit maintenance gain in psychotic disorders [African]	bipolar disorder
African unspecified=224|European=367		GCST005028	8.0	GCST005028_2	29064472		drug	Medium	Ed Mountjoy	Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000087085	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	A	7	100298984	7	100701361		EFO_0005411	Pursuit maintenance gain in psychotic disorders [African]	schizoaffective disorder
European=139274		GCST004988	15.979638717352293	GCST004988	29059683		drug	Low	Ed Mountjoy	Serine/threonine-protein kinase B-raf inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000157764 at this locus (476824bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000157764	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	A	G	7	139942304	7	140242504		EFO_0000305	Breast cancer	breast carcinoma
European=1030836		GCST006414	10.674484336636851	GCST006414	30061737		drug	High	Ed Mountjoy	HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000055118	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	7	150661409	7	150964321		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	10.045757490560675	GCST006061_3	29892015		drug	Low	Ed Mountjoy	HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000055118	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	7	150661409	7	150964321		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	9.154901959985743	GCST006061	29892015		drug	High	Ed Mountjoy	HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000055118	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	7	150661409	7	150964321		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	9.154901959985743	GCST006061	29892015		drug	Low	Ed Mountjoy	HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000055118	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	7	150661409	7	150964321		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=1030836		GCST006414	10.674484336636851	GCST006414	30061737		drug	Low	Ed Mountjoy	HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000055118	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	7	150661409	7	150964321		EFO_0000275	Atrial fibrillation	atrial fibrillation
European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022		GCST006061	10.045757490560675	GCST006061_3	29892015		drug	High	Ed Mountjoy	HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000055118	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	7	150661409	7	150964321		EFO_0000275	Atrial fibrillation [EA]	atrial fibrillation
European=459000		GCST007072	48.69897000433602	GCST007072	30595370		drug	High	Ed Mountjoy	HERG blocker drug SOTALOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000055118 at this locus (14774bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000055118	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	7	150690176	7	150993088		EFO_0000319	Cardiovascular disease	cardiovascular system disease
European=241704		GCST004483	8.0	GCST004483	27363682		drug	Low	Ed Mountjoy	Cyclin-dependent kinase 5 inhibitor drug DINACICLIB is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000164885 at this locus (195958bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000164885	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	7	150950940	7	151253854		EFO_0001378	Multiple myeloma	multiple myeloma
European=33394		GCST005527	7.481235531320022	GCST005527	23143594		drug	Low	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (12463bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	9	4971927	9	4971927		EFO_0000676	Psoriasis	psoriasis
European=86475		GCST005537	42.30102999566398	GCST005537	26974007		drug	Low	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (2788bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	9	4981602	9	4981602		EFO_0000676	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	psoriasis
East Asian=5057|European=10995		GCST003622	16.69897000433602	GCST003622	27399966		drug	Medium	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	9	4984530	9	4984530		EFO_0002690	Systemic lupus erythematosus	systemic lupus erythematosus
East Asian=5057|European=10995		GCST003622	13.397940008672037	GCST003622_2	27399966		drug	Medium	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	C	G	9	4984530	9	4984530		EFO_0002690	Systemic lupus erythematosus [Chinese]	systemic lupus erythematosus
European=401535	10.1038/s41588-018-0184-y		16.707743928643524	SAIGE_200_1			drug	High	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	9	5049092	9	5049092		EFO_0002429	Polycythemia vera	polycythemia vera
European=401535	10.1038/s41588-018-0184-y		16.707743928643524	SAIGE_200_1			drug	Low	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	9	5049092	9	5049092		EFO_0002429	Polycythemia vera	polycythemia vera
European=361141			19.559482903933304	NEALE2_20002_1438		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	G	9	5049092	9	5049092		EFO_0002429	Polycythaemia vera | non-cancer illness code, self-reported	polycythemia vera
European=361141			19.559482903933304	NEALE2_20002_1438		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	9	5049092	9	5049092		EFO_0002429	Polycythaemia vera | non-cancer illness code, self-reported	polycythemia vera
European=3198		GCST002840	10.0	GCST002840	25849990		drug	Low	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	G	9	5063296	9	5063296		EFO_0004251	Myeloproliferative neoplasms	myeloproliferative disorder
European=3198		GCST002840	10.0	GCST002840	25849990		drug	Medium	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	G	9	5063296	9	5063296		EFO_0004251	Myeloproliferative neoplasms	myeloproliferative disorder
European=3323		GCST000357	19.397940008672037	GCST000357	19287384		drug	Medium	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	G	C	9	5070831	9	5070831		EFO_0004251	Myeloproliferative neoplasms	myeloproliferative disorder
European=3323		GCST000357	19.397940008672037	GCST000357	19287384		drug	Low	Ed Mountjoy	Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000096968	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	C	9	5070831	9	5070831		EFO_0004251	Myeloproliferative neoplasms	myeloproliferative disorder
European=86475		GCST005537	8.221848749616356	GCST005537	26974007		drug	High	Ed Mountjoy	Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000147955 at this locus (72455bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000147955	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	9	34710260	9	34710263		EFO_0000729	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	ulcerative colitis
European=86475		GCST005537	8.221848749616356	GCST005537	26974007		drug	High	Ed Mountjoy	Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000147955 at this locus (72455bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000147955	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	A	G	9	34710260	9	34710263		EFO_0000384	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]	Crohn's disease
European=116538		GCST007564	10.096910013008056	GCST007564	29785011		drug	Low	Ed Mountjoy	Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000147955 at this locus (251638bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000147955	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	G	9	34889444	9	34889447		EFO_0000270	Asthma or allergic disease (pleiotropy)	asthma
European=361141			14.698970004336019	NEALE2_20002_1473		http://www.nealelab.is/uk-biobank	drug	High	Ed Mountjoy	ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000165029 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000165029	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	9	107664301	9	104902020		HP_0003124	High cholesterol | non-cancer illness code, self-reported	Hypercholesterolemia
European=408878	10.1038/s41588-018-0184-y		7.73754891026957	SAIGE_272_1			drug	High	Ed Mountjoy	ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000165029 at this locus (0bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000165029	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	G	C	9	107665978	9	104903697		EFO_0003774	Hyperlipidemia	hyperlipidemia
European=38053		GCST000987	10.397940008672037	GCST000987	21383967		drug	High	Ed Mountjoy	Complement C5 inhibitor drug ECULIZUMAB is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000106804 at this locus (74113bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000106804	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	C	T	9	123640500	9	120878222		EFO_0000540	Celiac disease or Rheumatoid arthritis	immune system disease
European=314072			7.955550400347374	NEALE2_20107_3		http://www.nealelab.is/uk-biobank	drug	Low	Ed Mountjoy	Tyrosine-protein kinase ABL inhibitor drug IMATINIB is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000097007 at this locus (238206bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000097007	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	GT	9	133351128	9	130475741		EFO_0001071	Lung cancer | illnesses of father	lung carcinoma
European=1125		GCST000250	10.301029995663981	GCST000250	18849991		drug	Low	Ed Mountjoy	Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (252890bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	G	X	66510984	X	67291142		EFO_0004191	Male-pattern baldness	androgenetic alopecia
European=1198		GCST001297	21.522878745280337	GCST001297	22032556		drug	Low	Ed Mountjoy	Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	X	66563018	X	67343176		EFO_0004191	Male-pattern baldness	androgenetic alopecia
European=12806		GCST001548	90.69897000433602	GCST001548	22693459		drug	Low	Ed Mountjoy	Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	X	66563018	X	67343176		EFO_0004191	Male-pattern baldness	androgenetic alopecia
European=13560		GCST001148	8.0	GCST001148	21743467		drug	Medium	Ed Mountjoy	Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	X	67021550	X	67801708		EFO_0001663	Prostate cancer	prostate carcinoma
European=13560		GCST001148	8.0	GCST001148	21743467		drug	High	Ed Mountjoy	Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	X	67021550	X	67801708		EFO_0001663	Prostate cancer	prostate carcinoma
European=13560		GCST001148	8.0	GCST001148	21743467		drug	Low	Ed Mountjoy	Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	X	67021550	X	67801708		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	9.0	GCST006085	29892016		drug	High	Ed Mountjoy	Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	High	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_IV	Ed Mountjoy	drug|ChEMBL|ChEMBL_IV	T	C	X	67021550	X	67801708		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	9.0	GCST006085	29892016		drug	Low	Ed Mountjoy	Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	T	C	X	67021550	X	67801708		EFO_0001663	Prostate cancer	prostate carcinoma
European=140254		GCST006085	9.0	GCST006085	29892016		drug	Medium	Ed Mountjoy	Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Medium	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_III	Ed Mountjoy	drug|ChEMBL|ChEMBL_III	T	C	X	67021550	X	67801708		EFO_0001663	Prostate cancer	prostate carcinoma
European=43590		GCST005116	34.52287874528034	GCST005116	29146897		drug	Low	Ed Mountjoy	Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (413341bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000169083	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	G	A	X	67363801	X	68143959		EFO_0004191	Male-pattern baldness	androgenetic alopecia
European=16753		GCST003097	8.0	GCST003097	26301688		drug	Low	Ed Mountjoy	CD40 ligand inhibitor drug DAPIROLIZUMAB PEGOL is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000102245 at this locus (64575bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000102245	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	A	C	X	135665778	X	136583619		EFO_0002690	Pediatric autoimmune diseases	systemic lupus erythematosus
European=258962		GCST003390	12.154901959985743	GCST003390	26908601		drug	Low	Ed Mountjoy	Coagulation factor VIII inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000185010 at this locus (23583bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000185010	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	X	154278797	X	155050522		EFO_0003827	Thrombosis	pulmonary embolism
European=258962		GCST003390	12.154901959985743	GCST003390	26908601		drug	Low	Ed Mountjoy	Coagulation factor VIII inhibitor drug TB-402 is Phase II for the indiciation EFO_0004286 and targets the gene ENSG00000185010 at this locus (23583bp away).		ChEMBL - Open Targets Evidence 19.06	ENSG00000185010	Low	Gold-standard derived from drug-indication pairs in ChEMBL	2019-07-29	Ed Mountjoy	ChEMBL_II	Ed Mountjoy	drug|ChEMBL|ChEMBL_II	C	T	X	154278797	X	155050522		EFO_0004286	Thrombosis	venous thromboembolism
European=407701	10.1038/s41588-018-0184-y		8.20690839982342	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	12250620	10	12208621		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	26.096910013008056	GCST007847	30718926		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	12302607	10	12260608		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	16.69897000433602	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	9.42712839779952	GCST005413	29358691		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	13.397940008672037	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	12.0	GCST003400_2	26818947		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
East Asian=3712		GCST001666	8.154901959985743	GCST001666	22961080		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	8.522878745280337	GCST002352	24509480		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	28.522878745280337	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.522878745280337	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	12307894	10	12265895		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
East Asian=2729		GCST000796	8.0	GCST000796	20862305		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	10	12314997	10	12272998		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=10128		GCST000167	10.0	GCST000167	18372903		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000183049	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	10	12328010	10	12286011		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	8.522878745280337	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000122859	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	10	71273357	10	69513601		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	8.522878745280337	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000122859	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	71332301	10	69572545		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	8.073297505817354	GCST005413	29358691		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000122859	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	10	71465928	10	69706172		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	8.154901959985743	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000122859	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	10	71469514	10	69709758		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	10.522878745280337	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	10	80942631	10	79182874		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	9.698970004336019	GCST002352	24509480		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	10	80942631	10	79182874		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	19.69897000433602	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	10	80942631	10	79182874		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	9.619788758288394	GCST005047	22885922		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	10	80942631	10	79182874		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	7.522878745280337	GCST003400_2	26818947		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	10	80943841	10	79184084		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
European=459000		GCST007077	14.221848749616356	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	10	80952826	10	79193069		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		15.025949097207123	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	80954785	10	79195028		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	10.522878745280337	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000108175	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	80964975	10	79205218		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	10.698970004336019	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114737777	10	112978018		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=455607		GCST006868	10.397940008672037	GCST006868	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114737777	10	112978018		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=56799|African American or Afro-Caribbean=3571|East Asian=4735|Hispanic or Latin American=6499		GCST003619	52.221848749616356	GCST003619	27189021		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114754071	10	112994312		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		135.64397414280688	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114754071	10	112994312		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	22.522878745280337	GCST003400_2	26818947		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114754071	10	112994312		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
European=4862		GCST000025	48.0	GCST000025_2	17463249		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114754088	10	112994329		EFO_0001360	Type 2 diabetes [DGI+FUSION+WTCCC]	type II diabetes mellitus
East Asian=191764		GCST007847	48.52287874528034	GCST007847	30718926		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114754088	10	112994329		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=361141			28.732802449449522	NEALE2_20002_1223		http://www.nealelab.is/uk-biobank	functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114754784	10	112995025		EFO_0001360	Type 2 diabetes | non-cancer illness code, self-reported	type II diabetes mellitus
European=4862		GCST000277	15.221848749616356	GCST000277_2	19056611		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [obese]	type II diabetes mellitus
NR=60647		GCST001550	39.69897000433602	GCST001550	22693455		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [Lean]	type II diabetes mellitus
European=459000		GCST007077	202.52287874528034	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	74.10790539730952	GCST005047	22885922		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=1616		GCST001809	74.04575749056067	GCST001809_3	23300278		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [South Asian, East Asian, Europeans]	type II diabetes mellitus
European=997		GCST000049	7.301029995663981	GCST000049	17668382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=1616		GCST001809	34.52287874528034	GCST001809_5	23300278		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [South Asians]	type II diabetes mellitus
East Asian=26805		GCST002128	14.698970004336019	GCST002128	23945395		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
Hispanic or Latin American=7746		GCST004758	11.0	GCST004758	28254843		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=2128		GCST001759	35.0	GCST001759_2	23209189		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [Indo-European South Asians]	type II diabetes mellitus
African American or Afro-Caribbean=23827		GCST002560	93.39794000867204	GCST002560	25102180		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=10128		GCST000167	22.522878745280337	GCST000167	18372903		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	347.0	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=1616		GCST001809	21.221848749616356	GCST001809	23300278		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [All Punjabi]	type II diabetes mellitus
European=4805|African American or Afro-Caribbean=1683		GCST001326	14.698970004336019	GCST001326	22101970		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	93.92081875395237	GCST005413	29358691		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	183.69897000433602	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	74.09691001300806	GCST002352	24509480		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=1376		GCST000478	30.0	GCST000478	19734900		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
NR=60647		GCST001550	20.397940008672037	GCST001550_2	22693455		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [Obese]	type II diabetes mellitus
Hispanic or Latin American=8214		GCST002317	14.0	GCST002317	24390345		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
African American or Afro-Caribbean=23827		GCST002560	43.30102999566398	GCST002560_2	25102180		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [AA]	type II diabetes mellitus
European=2931		GCST000028	48.0	GCST000028	17463246		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=47117		GCST000712	50.69897000433602	GCST000712	20581827		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=1022		GCST000383	11.096910013008056	GCST000383	19401414		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=4862		GCST000277	29.045757490560675	GCST000277	19056611		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [non-obese]	type II diabetes mellitus
European=2335		GCST000024	8.0	GCST000024	17463248		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=1616		GCST001809	18.522878745280337	GCST001809_2	23300278		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [Punjabi Sikhs]	type II diabetes mellitus
European=1947		GCST007221	10.522878745280337	GCST007221	30470734		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=8686		GCST000027	9.698970004336019	GCST000027	17460697		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=1616		GCST001809	37.69897000433602	GCST001809_4	23300278		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [South Asians, East Asians]	type II diabetes mellitus
European=1275		GCST000012	33.69897000433602	GCST000012	17293876		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	22.522878745280337	GCST004894_3	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [South Asian]	type II diabetes mellitus
European=117775		GCST006801	44.15490195998574	GCST006801	26961502		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes [additive model]	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	219.0	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	10	114758349	10	112998590		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=390054	10.1038/s41588-018-0184-y		11.145693958198919	SAIGE_250_23			functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	T	10	114798893	10	113039134		EFO_0001360	Type 2 diabetes with ophthalmic manifestations	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	12.397940008672037	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114880342	10	113120583		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	8.397940008672037	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000148737	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	10	114880342	10	113120583		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
Hispanic or Latin American=8658		GCST006145	13.221848749616356	GCST006145	28838971		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	2161530	11	2140300		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
African American or Afro-Caribbean=23827		GCST002560	7.522878745280337	GCST002560_2	25102180		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	11	2178670	11	2157440		EFO_0001360	Type 2 diabetes [AA]	type II diabetes mellitus
European=459000		GCST007077	10.154901959985743	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	11	2197112	11	2175882		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	12.522878745280337	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	11	2197286	11	2176056		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	10.522878745280337	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	2213166	11	2191936		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	11.0	GCST003400	26818947		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	11	2215089	11	2193859		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	7.698970004336019	GCST003400_2	26818947		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	11	2215089	11	2193859		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
East Asian=191764		GCST007847	9.0	GCST007847_2	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000167244	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	11	2291050	11	2269820		EFO_0001360	Type 2 diabetes [Conditioned]	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		9.896196279044043	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408404	11	17386857		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	20.0	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	10.522878745280337	GCST002352	24509480		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	16.397940008672037	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	13.096910013008056	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=298957		GCST007518	21.30102999566398	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=69033		GCST005047	10.494850021680094	GCST005047	22885922		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	19.69897000433602	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=4862		GCST000025	10.301029995663981	GCST000025_2	17463249		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17408630	11	17387083		EFO_0001360	Type 2 diabetes [DGI+FUSION+WTCCC]	type II diabetes mellitus
European=2335		GCST000024	10.154901959985743	GCST000024_2	17463248		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes [DGI+FUSION+WTCCC]	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	21.221848749616356	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=2931		GCST000028	10.154901959985743	GCST000028	17463246		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	21.69897000433602	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=4862		GCST000277	9.0	GCST000277	19056611		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	11	17409572	11	17388025		EFO_0001360	Type 2 diabetes [non-obese]	type II diabetes mellitus
European=459000		GCST007077	11.698970004336019	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000187486	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	17411821	11	17390274		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	9.301029995663981	GCST007516	29632382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	11	72408055	11	72697010		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	7.301029995663981	GCST007515	29632382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	11	72408055	11	72697010		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	8.698970004336019	GCST007518	29632382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	11	72408055	11	72697010		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
East Asian=191764		GCST007847	11.0	GCST007847	30718926		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	11	72428172	11	72717127		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	16.522878745280337	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	11	72433098	11	72722053		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	24.045757490560675	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	11	72433098	11	72722053		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=47117		GCST000712	22.0	GCST000712	20581827		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	11	72433098	11	72722053		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	13.0	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	11	72433098	11	72722053		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=459000		GCST007077	16.522878745280337	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	A	11	72460762	11	72749717		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		8.269217724333611	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000214530	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	A	11	72460762	11	72749717		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	8.193820026016112	GCST005047	22885922		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000134640	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	11	92668975	11	92935809		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=47117		GCST000712	14.096910013008056	GCST000712	20581827		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000134640	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	11	92673828	11	92940662		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	17.397940008672037	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000134640	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	11	92708710	11	92975544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		9.154901959985743	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000134640	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	11	92708710	11	92975544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	29.221848749616356	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000134640	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	11	92708710	11	92975544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	15.698970004336019	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000134640	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	11	92708710	11	92975544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	15.522878745280337	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000134640	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	11	92708710	11	92975544		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=70127		GCST005413	8.870954940112043	GCST005413	29358691		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	4328521	12	4219355		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	7.522878745280337	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	12	4374373	12	4265207		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	7.698970004336019	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	12	4374373	12	4265207		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		9.65169513695184	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	12	4384696	12	4275530		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	30.69897000433602	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	12	4384844	12	4275678		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		24.4145392704915	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	12	4384844	12	4275678		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=361141			8.217634170939927	NEALE2_20002_1223		http://www.nealelab.is/uk-biobank	functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	12	4384844	12	4275678		EFO_0001360	Type 2 diabetes | non-cancer illness code, self-reported	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	9.698970004336019	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000118971	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	12	4406281	12	4297115		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	7.698970004336019	GCST007516	29632382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	27867727	12	27714794		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007517	8.698970004336019	GCST007517	29632382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	27867727	12	27714794		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	7.522878745280337	GCST007518	29632382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	27867727	12	27714794		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	11.0	GCST007515	29632382		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	27867727	12	27714794		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	13.154901959985743	GCST007847	30718926		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	12	27963507	12	27810574		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	11.045757490560675	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	12	27965150	12	27812217		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	16.0	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	12	27965150	12	27812217		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.698970004336019	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000087448	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	12	27965150	12	27812217		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
East Asian=191764		GCST007847	8.0	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000075035 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000075035	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	108613151	12	108219374		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	7.522878745280337	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000075035 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000075035	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	12	108618630	12	108224853		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	11.221848749616356	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	121327809	12	120890006		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
Hispanic or Latin American=2584		GCST001070	7.698970004336019	GCST001070	21573907		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	12	121402932	12	120965129		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	11.0	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	12	121416650	12	120978847		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	9.698970004336019	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	12	121416650	12	120978847		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=459000		GCST007077	7.698970004336019	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	12	121429194	12	120991391		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	13.698970004336019	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	G	12	121456616	12	121018813		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	8.522878745280337	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	T	12	121460686	12	121022883		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=47117		GCST000712	7.698970004336019	GCST000712	20581827		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	T	12	121460686	12	121022883		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.0	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000135100	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	T	12	121460686	12	121022883		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	8.698970004336019	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000150967 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000150967 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000150967 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000150967	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	12	123491572	12	123007025		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	8.0	GCST002352	24509480		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000150967 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000150967 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000150967 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000150967	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	12	123640853	12	123156306		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.698970004336019	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000205502	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	15	62383155	15	62090956		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	16.69897000433602	GCST007847	30718926		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000205502	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	15	62394264	15	62102065		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	8.301029995663981	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000205502	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	15	62396389	15	62104190		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=7541		GCST000787	13.045757490560675	GCST000787	20818381		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000205502	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	15	62396389	15	62104190		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	8.301029995663981	GCST003400_2	26818947		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000205502	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	15	62409070	15	62116871		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		7.627087997029894	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000177508 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000177508 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000177508 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000177508	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	16	54490811	16	54456899		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	17.69897000433602	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000050820	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	C	16	75243772	16	75209874		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		8.449771646944907	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000050820	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	16	75245937	16	75212039		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	13.397940008672037	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000050820	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	16	75246035	16	75212137		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.301029995663981	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000050820	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	16	75247245	16	75213347		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
East Asian=26805		GCST002128	12.096910013008056	GCST002128	23945395		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000174326	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	17	6940393	17	7037074		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
Hispanic or Latin American=8214		GCST002317	14.301029995663981	GCST002317	24390345		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000174326	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	G	17	6945087	17	7041768		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	10.096910013008056	GCST003400_2	26818947		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000174326	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	17	6945483	17	7042164		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
East Asian=191764		GCST007847	15.221848749616356	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000174326	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	17	6947453	17	7044134		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	13.301029995663981	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000166603	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	18	57838401	18	60171168		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.301029995663981	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000166603	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	18	57884750	18	60217517		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	11.522878745280337	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000166603	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	18	57884750	18	60217517		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	11.301029995663981	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000166603	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	18	57884750	18	60217517		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	7.522878745280337	GCST002352	24509480		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000166603	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	18	57884750	18	60217517		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	9.698970004336019	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000213996	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	19	19379549	19	19268740		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	14.522878745280337	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000213996	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	19	19379549	19	19268740		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	11.301029995663981	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000213996	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	19	19379549	19	19268740		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	12.0	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000213996	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	19	19379549	19	19268740		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	11.397940008672037	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000213996	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	19	19407718	19	19296909		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=56799|African American or Afro-Caribbean=3571|East Asian=4735|Hispanic or Latin American=6499		GCST003619	8.154901959985743	GCST003619	27189021		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000130203 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000130203 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000130203	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	19	45392254	19	44888997		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		7.72584215073632	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000010310	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	19	46147527	19	45644269		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	12.698970004336019	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000010310	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	19	46150182	19	45646924		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	15.522878745280337	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000010310	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	19	46158513	19	45655255		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	18.522878745280337	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000010310	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	19	46166604	19	45663346		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	11.522878745280337	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000010310	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	19	46172278	19	45669020		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	11.154901959985743	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000010310	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	19	46181392	19	45678134		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007518	11.522878745280337	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000010310	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	19	46181392	19	45678134		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007518	14.0	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27730940	2	27508073		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	24.30102999566398	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27730940	2	27508073		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	15.0	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27730940	2	27508073		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	15.0	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27730940	2	27508073		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	17.522878745280337	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27730940	2	27508073		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
East Asian=191764		GCST007847	14.397940008672037	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	2	27734972	2	27512105		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	16.69897000433602	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27741237	2	27518370		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	20.30102999566398	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27741237	2	27518370		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		11.072116589669292	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000084734	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	2	27742603	2	27519736		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=15000|South East Asian=2034|Asian unspecified=1783		GCST001351	11.0	GCST001351	22158537		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	20	42946966	20	44318326		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	7.698970004336019	GCST005047	22885922		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	20	42964514	20	44335874		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.397940008672037	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	20	42989267	20	44360627		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=20019		GCST001213	9.522878745280337	GCST001213	21874001		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	20	42989267	20	44360627		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	7.301029995663981	GCST002352	24509480		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	20	42989267	20	44360627		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	8.397940008672037	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	20	42989777	20	44361137		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.698970004336019	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	20	43001721	20	44373081		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	7.522878745280337	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	20	43042364	20	44413724		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	10.698970004336019	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	20	43042364	20	44413724		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	7.301029995663981	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000101076	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	20	43042364	20	44413724		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	10.522878745280337	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000100344	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	22	44324727	22	43928847		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007518	7.522878745280337	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000100344	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	22	44324727	22	43928847		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	9.698970004336019	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000100344	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	22	44324727	22	43928847		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	9.522878745280337	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000100344	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	22	44377442	22	43981562		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	11.0	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	3	12329783	3	12288284		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	8.795880017344075	GCST005047	22885922		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	3	12392272	3	12350773		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	16.0	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	17.0	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	13.698970004336019	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=298957		GCST007517	11.301029995663981	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	18.522878745280337	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	9.221848749616356	GCST002352	24509480		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	18.69897000433602	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	3	12393125	3	12351626		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	23.69897000433602	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	3	12394840	3	12353341		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	15.357832365595055	GCST005413	29358691		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000132170	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	3	12396913	3	12355414		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.698970004336019	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	The is a likely causal T2D variant (2C) for ENSG00000163581 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000163581 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000163581 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000163581	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	3	170766618	3	171048829		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	14.096910013008056	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6270056	4	6268329		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=1376		GCST000478	8.0	GCST000478	19734900		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6270056	4	6268329		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	15.0	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6270056	4	6268329		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	8.698970004336019	GCST002352	24509480		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	4	6289986	4	6288259		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		18.367542707815275	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	4	6299914	4	6298187		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	16.69897000433602	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6302519	4	6300792		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	20.154901959985743	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6302519	4	6300792		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=459000		GCST007077	17.522878745280337	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6302519	4	6300792		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	24.0	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6302519	4	6300792		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	19.154901959985743	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6302519	4	6300792		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	33.221848749616356	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	4	6303022	4	6301295		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=47117		GCST000712	7.522878745280337	GCST000712	20581827		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	4	6303022	4	6301295		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	8.366531544420413	GCST005047	22885922		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	4	6303955	4	6302228		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	7.698970004336019	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000109501	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	G	4	6333669	4	6331942		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=455607		GCST006868	8.397940008672037	GCST006868	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000154122	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	5	14751305	5	14751196		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		7.723538195826756	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000154122	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	5	14751305	5	14751196		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	12.522878745280337	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000154122	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	5	14768092	5	14767983		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	8.522878745280337	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000154122	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	5	14847331	5	14847222		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	14.698970004336019	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000152359	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	5	75003678	5	75707853		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.522878745280337	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000152359	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	5	75003678	5	75707853		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	11.301029995663981	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000152359	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	5	75003678	5	75707853		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	17.0	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	5	102100576	5	102764872		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	8.397940008672037	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	A	5	102247916	5	102912212		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		11.85078088734462	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	A	5	102331465	5	102995761		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=455607		GCST006868	13.397940008672037	GCST006868	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	5	102338739	5	103003035		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		11.021363051615525	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	5	102338739	5	103003035		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	12.397940008672037	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	5	102338811	5	103003107		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	14.154901959985743	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	5	102338811	5	103003107		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007517	11.221848749616356	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	5	102338811	5	103003107		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	16.0	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	5	102338811	5	103003107		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	15.397940008672037	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000145730	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	5	102422968	5	103087264		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	7.522878745280337	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	6	7226959	6	7226726		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	13.0	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	6	7231843	6	7231610		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	12.698970004336019	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	6	7231843	6	7231610		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	16.69897000433602	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	6	7231843	6	7231610		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957		GCST007517	11.698970004336019	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	6	7231843	6	7231610		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	14.698970004336019	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	6	7231843	6	7231610		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		8.844663962534938	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	6	7231843	6	7231610		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	9.0	GCST002352	24509480		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	6	7258617	6	7258384		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	10.522878745280337	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	6	7281654	6	7281421		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	7.698970004336019	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	6	7290437	6	7290204		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.0	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000124782	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	6	7290437	6	7290204		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	11.698970004336019	GCST004894_2	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	14898282	7	14858657		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	12.0	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	14898282	7	14858657		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	11.698970004336019	GCST007847	30718926		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	14898282	7	14858657		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	14.698970004336019	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	14898282	7	14858657		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	8.221848749616356	GCST005047	22885922		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	15053589	7	15013964		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	14.0	GCST007077	30595370		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	15063926	7	15024301		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		12.492144128304169	SAIGE_250_2			functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	15063926	7	15024301		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	18.522878745280337	GCST006867	30054458		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	G	7	15064255	7	15024630		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	9.0	GCST004894	28869590		functional observational	Medium	Ed Mountjoy	There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000136267	Medium	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	G	7	15064309	7	15024684		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	11.301029995663981	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106633 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000106633 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106633 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106633	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	T	7	44174857	7	44135258		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	8.397940008672037	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106633 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000106633 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106633 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106633	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	7	44248828	7	44209229		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=15000|South East Asian=2034|Asian unspecified=1783		GCST001351	10.301029995663981	GCST001351	22158537		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106331	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	7	127164958	7	127524904		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	9.096910013008056	GCST003400_2	26818947		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106331	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	7	127237312	7	127597258		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
East Asian=1639		GCST001919	9.698970004336019	GCST001919	23532257		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106331	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	7	127246903	7	127606849		EFO_0001360	Type 2 diabetes [East Asian]	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	12.397940008672037	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106331	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	127253550	7	127613496		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	11.698970004336019	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106331	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	127253550	7	127613496		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	73.39794000867204	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000106331	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	7	127253550	7	127613496		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	8.0	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000130675 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000130675 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000130675	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	7	156983847	7	157191153		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	8.154901959985743	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000175445 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000175445 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000175445 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000175445	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	8	19819724	8	19962213		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	7.522878745280337	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000175445 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000175445 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000175445 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000175445	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	C	8	19852310	8	19994799		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	7.522878745280337	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118024315	8	117012076		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=56799|African American or Afro-Caribbean=3571|East Asian=4735|Hispanic or Latin American=6499		GCST003619	11.0	GCST003619	27189021		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007517	29.221848749616356	GCST007517	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=1022		GCST000383	13.698970004336019	GCST000383	19401414		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007515	46.69897000433602	GCST007515	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=70127		GCST005413	14.522878745280337	GCST005413	29358691		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=298957		GCST007518	35.096910013008056	GCST007518	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	41.39794000867204	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	21.69897000433602	GCST004894_2	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes [EA]	type II diabetes mellitus
European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287		GCST007516	47.0	GCST007516	29632382		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes (adjusted for BMI)	type II diabetes mellitus
European=407701	10.1038/s41588-018-0184-y		19.041914151478913	SAIGE_250_2			functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=2335		GCST000024	7.301029995663981	GCST000024_2	17463248		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes [DGI+FUSION+WTCCC]	type II diabetes mellitus
East Asian=191764		GCST007847	29.522878745280337	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=4862		GCST000025	7.301029995663981	GCST000025_2	17463249		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes [DGI+FUSION+WTCCC]	type II diabetes mellitus
European=2931		GCST000028	7.301029995663981	GCST000028	17463246		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=41646		GCST003400	12.045757490560675	GCST003400_2	26818947		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	T	C	8	118184783	8	117172544		EFO_0001360	Type 2 diabetes [Japanese]	type II diabetes mellitus
European=459000		GCST007077	23.69897000433602	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	8	118185025	8	117172786		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=47117		GCST000712	8.0	GCST000712	20581827		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	8	118185025	8	117172786		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	51.69897000433602	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	8	118185025	8	117172786		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
NR=60647		GCST001550	7.3979400086720375	GCST001550	22693455		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	8	118185025	8	117172786		EFO_0001360	Type 2 diabetes [Lean]	type II diabetes mellitus
European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583		GCST002352	17.69897000433602	GCST002352	24509480		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	G	8	118185025	8	117172786		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	15.2518119729938	GCST005047	22885922		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000164756	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	T	8	118220270	8	117208031		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=15000|South East Asian=2034|Asian unspecified=1783		GCST001351	13.698970004336019	GCST001351	22158537		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000107249	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	9	4287466	9	4287466		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
South Asian=13532|European=20298|NR=149821		GCST004894	7.522878745280337	GCST004894	28869590		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000107249	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	G	A	9	4287466	9	4287466		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=191764		GCST007847	11.096910013008056	GCST007847	30718926		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000107249	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	A	C	9	4289050	9	4289050		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=69033		GCST005047	7.468521082957745	GCST005047	22885922		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000107249	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	G	9	4290085	9	4290085		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=459000		GCST007077	8.301029995663981	GCST007077	30595370		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000107249	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	9	4291928	9	4291928		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
European=655666|South Asian=3650		GCST006867	14.522878745280337	GCST006867	30054458		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000107249	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	9	4291928	9	4291928		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
East Asian=3712		GCST001666	11.221848749616356	GCST001666	22961080		functional observational	High	Ed Mountjoy	The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus.		Type 2 Diabetes Knowledge Portal Effector Genes	ENSG00000107249	High	Gold-standard derived from the list of effector genes at the T2D Knowledge Portal	2019-07-17	Ed Mountjoy	T2D Knowledge Portal 	Ed Mountjoy	T2D	C	A	9	4293150	9	4293150		EFO_0001360	Type 2 diabetes	type II diabetes mellitus
		GCST000760		GCST000760	20686565		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTLs in human liver, subcutaneous adipocytes, SORT1 expression arrays, EMSA|Original publication looked at variant rs12740374 using the following methods: Luciferase, siRNA, gene knockdown and overexpression, measuring lipids and lipoproteins	20686566|20686566		ENSG00000134243	High	Cohort: MDC-CC & PARC 	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	G	1	109818306	1	109275684		EFO_0000612	Myocardial infarction	myocardial infarction
		GCST000489		GCST000489	19767754		functional observational	Medium	Maya Ghoussaini	 3C prostate cancer	21814516		ENSG00000136997	Medium	Cohort: PRACTICAL 	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	8	128323181	8	127310936		EFO_0001663	Prostate carcinoma	prostate carcinoma
		GCST000489		GCST000489	19767754		functional observational	High	Maya Ghoussaini	ChIP-seq, 3C prostate cancer, expression	21814516		ENSG00000249859	High	Cohort: PRACTICAL	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	8	128323181	8	127310936		EFO_0001663	Prostate carcinoma	prostate carcinoma
		GCST004950		GCST004950	25751625		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C in breast cancer|Original publication looked at variant rs554219 using the following methods: Luciferase	23540573|23540573		ENSG00000110092	High	Cohort: BCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	C	11	69331642	11	69516874		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004950		GCST004950	25751625		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C in breast cancer|Original publication looked at variant rs78540526 using the following methods: Luciferase	23540573|23540573		ENSG00000110092	High	Cohort: BCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	11	69331418	11	69516650		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004950		GCST004950	25751625		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C in breast cancer|Original publication looked at variant rs75915166 using the following methods: Luciferase	23540573|23540573		ENSG00000110092	High	Cohort: BCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	C	11	69379161	11	69564393		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST000150		GCST000150	18245381		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	3C, ChIP-seq, allele-specific expression, TALENs|Original publication looked at variant rs1427407, rs7606173 using the following methods: reporter assays, transgenic mouse models	24115442|24115442		ENSG00000119866	High	Cohort: SCD	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	2	60720246	2	60493111		EFO_0004576	Fetal hemoglobin levels	fetal hemoglobin measurement
		GCST007039		GCST007039	30595370		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	4C-seq in mouse and zebrafish embryoe, 3C adult mouse brain, CHIA-PET ENCODE, human fibroblasts and MCF7, eQTL in brains, KO IRX3|Original publication looked at variant Not specified: they refer to region of association using the following methods: reporter assays of fragments to assess enhancer activity	24646999|24646999		ENSG00000177508	High	Cohort: GIANT	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	16	53800954	16	53767042		EFO_0001073	Obesity/T2D	obesity
		GCST004988		GCST004988	29059683		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C in breast cancer|Original publication looked at variant rs4442975 using the following methods: Luciferase	25248036|25248036		ENSG00000115461	High	Cohort: BCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	G	2	217920769	2	217056046		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST007039		GCST007039	30595370		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C, 4C, mouse work, epigenomic data in 127 cells, eQTLs|Original publication looked at variant rs1421085 using the following methods: CRISPR in patients samples and mice followed by cellular phenotyping, knockdown and overexpression	26287746|26287746		ENSG00000176842	High	Cohort: Obesity 	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	16	53800954	16	53767042		EFO_0001073	Obesity	obesity
		GCST007039		GCST007039	30595370		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C, 4C, mouse work, epigenomic data in 127 cells, eQTLs|Original publication looked at variant rs1421085 using the following methods: CRISPR in patients samples and mice followed by cellular phenotyping, knockdown and overexpression	26287746|26287746		ENSG00000177508	High	Cohort: Obesity 	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	16	53800954	16	53767042		EFO_0001073	Obesity	obesity
		GCST001445		GCST001445_2	22438815		functional observational	High	Maya Ghoussaini	Allele-specific qRT-PCR, Overlap with epigenetic marks, EMSA, SB, eQTL, Chip-qRT-PCR	27096366		ENSG00000145335	High	Cohort: PD	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	G	4	90637601	4	89716450		EFO_0002508	Parkinson's disease	Parkinson's disease
		GCST000750		GCST000750	20676098		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	allele-specific Chip-qPCR, RNA immunoprecip, Chromatin conformation capture, eQTL|Original publication looked at variant rs7463708 using the following methods: SiRNA, site-directed mutgenesis + reporter assays, mouse xenograft	27526323|27526323		ENSG00000253438	High	Cohort: PC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	8	128103937	8	127091692		EFO_0001663	Prostate carcinoma	prostate carcinoma
		GCST003845		GCST003845	27117709		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase	27601076|27601076		ENSG00000127220	High	Cohort: BCAC & OCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	C	19	17393925	19	17283116		EFO_0000305	Breast Cancer 	breast carcinoma
		GCST003845		GCST003845	27117709		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase	27601076|27601076		ENSG00000160117	High	Cohort: BCAC & OCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	C	19	17393925	19	17283116		EFO_0000305	Breast Cancer 	breast carcinoma
		GCST004462		GCST004462	28346442		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase	27601076|27601076		ENSG00000127220	High	Cohort: BCAC & OCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	19	17390291	19	17279482		EFO_0000305	Ovarian cancer	breast carcinoma
		GCST004462		GCST004462	28346442		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase	27601076|27601076		ENSG00000160117	High	Cohort: BCAC & OCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	19	17390291	19	17279482		EFO_0000305	Ovarian cancer	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, allele-specific qPCR, chromatin conformation caprure (3C), allele-specific 3C, overlap with epigenetics marks|Original publication looked at variant rs10941679 using the following methods: luciferase (no allele-specific effect), EMSA and supershift (allele-specific effect)	27640304|27640304		ENSG00000070193	High	Cohort: BCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	5	44706498	5	44706396		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL, allele-specific qPCR, chromatin conformation caprure (3C), allele-specific 3C, overlap with epigenetics marks|Original publication looked at variant rs10941679 using the following methods: luciferase (no allele-specific effect), EMSA and supershift (allele-specific effect)	27640304|27640304		ENSG00000112996	High	Cohort: BCAC	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	5	44706498	5	44706396		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST000760		GCST000760	20686565		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL|Original publication looked at variant rs2277862 using the following methods: CRISPR	28388432|28388432		ENSG00000214078	High	Cohort: PhLiPS Study	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	20	34152782	20	35564866		EFO_0004529	Blood lipid (HDL, LDL, TG, PP, â€¦)	lipid measurement
		GCST002221		GCST002221	24097068		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL|Original publication looked at variant rs10889356 using the following methods: CRISPR	28388432|28388432		ENSG00000116641	High	Cohort: PhLiPS Study	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	G	1	63145439	1	62679768		EFO_0004529	Blood lipid (HDL, LDL, TG, PP, â€¦)	lipid measurement
		GCST002221		GCST002221	24097068		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL|Original publication looked at variant rs10889356 using the following methods: CRISPR	28388432|28388432		ENSG00000132855	High	Cohort: PhLiPS Study	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	G	1	63145439	1	62679768		EFO_0004529	Blood lipid (HDL, LDL, TG, PP, â€¦)	lipid measurement
		GCST002221		GCST002221	24097068		functional observational|functional experimental	High|High	Maya Ghoussaini|Maya Ghoussaini	eQTL|Original publication looked at variant rs10872142 using the following methods: CRISPR	28388432|28388432		ENSG00000111816	High	Cohort: PhLiPS Study	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	G	6	116337503	6	116016340		EFO_0004529	Blood lipid (HDL, LDL, TG, PP, â€¦)	lipid measurement
		GCST004441		GCST004441	27989323		functional observational	High	Maya Ghoussaini	NLRC4-inflammasome hyperactivity causes infantile-onset Macrophage Activation Syndrome and enterocolitis with extraordinary serum IL-18 elevation (NLRC4-MAS). Herein, we report a critically ill infant with severe, refractory NLRC4-MAS who showed sustained response to treatment with experimental IL-18 inhibition.	27876626		ENSG00000091106	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	2	32489851	2	32264782		EFO_0004581	Interleukin-18 levels	interleukin 18 measurement
		GCST003845		GCST003845	27117709		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000171094	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	A	2	29119585	2	28896719		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000171681	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	G	12	14413931	12	14260997		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST005077		GCST005077	29058716		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000149311	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		GA	G	11	108345515	11	108474788		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000139618	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	A	13	32972626	13	32398489		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000064012	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	2	202123430	2	201258707		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000110092	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	11	69331418	11	69516650		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST005077		GCST005077	29058716		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000105173	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	19	30277729	19	29786822		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000183765	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	22	29272637	22	28876649		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST005077		GCST005077	29058716		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000005339	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	C	16	4106788	16	4056787		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000257923	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	G	7	101552440	7	101909160		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000119772	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	2	25129473	2	24906604		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000091831	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	6	151955914	6	151634779		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000066468	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	GC	10	123340431	10	121580917		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000107485	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	TG	10	9088113	10	9046150		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST003845		GCST003845	27117709		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000102554	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	13	73957681	13	73383544		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000095015	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	5	56027240	5	56731413		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000136997	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	8	128372172	8	127359926		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000196712	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	C	17	29180996	17	30853978		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000152217	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	G	18	42411803	18	44831838		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000135111	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		A	C	12	115106688	12	114668883		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000168769	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	A	4	106073509	4	105152352		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000163513	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		T	C	3	30684907	3	30643415		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000185650	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		C	T	14	68979835	14	68513118		EFO_0000305	Breast carcinoma	breast carcinoma
		GCST004988		GCST004988	29059683		functional observational	High	Maya Ghoussaini	Breast cancer driver genes	00000000		ENSG00000183779	High	Cohort: Breast cancer driver genes	2019-11-08	Maya Ghoussaini	otg_curated_191108	Maya Ghoussaini		G	C	8	36849946	8	36992428		EFO_0000305	Breast carcinoma	breast carcinoma
East Asian=1999		GCST006137	18.397940008672037	GCST006137	29953918		expert curated	High	Eric Fauman	enzyme involved in folate metabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000177000	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	1	11856378	1	11796321		EFO_0005111	metabolite: folate	folic acid measurement
European=404196	10.1038/s41588-018-0184-y		10.97061622231479	SAIGE_594_1			expert curated	High	Eric Fauman	phosphatase		Eric Fauman's Twitter list based on biological plausability	ENSG00000162551	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	A	1	21904374	1	21577881		EFO_0004253	calculus of kidney and ureter	nephrolithiasis
European=215551|African American or Afro-Caribbean=57332|Hispanic or Latin American=24743		GCST006612	256.52287874528037	GCST006612	30275531		expert curated	High	Eric Fauman	PCSK9 regulates LDL via LDLR		Eric Fauman's Twitter list based on biological plausability	ENSG00000169174	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	G	1	55505647	1	55039974		EFO_0004611	treatment: statin use	low density lipoprotein cholesterol measurement
European=359241			7.33164017904141	NEALE2_6151_5		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	important function in bone marrow cells in the regenerative response of bone and cartilage after injulry		Eric Fauman's Twitter list based on biological plausability	ENSG00000116678	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	1	66110284	1	65644601		EFO_0009515	wrist fracture	wrist fracture
European=393873		GCST007091	14.397940008672037	GCST007091	30664745		expert curated	High	Eric Fauman	collagen gene, involved in ossification		Eric Fauman's Twitter list based on biological plausability	ENSG00000060718	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	1	103572927	1	103107371		EFO_1000786	arthrosis of hip	osteoarthritis, hip
European=25708		GCST000679	70.20616772397125	GCST000679	20453842		expert curated	High	Eric Fauman	PTPN22 encodes a protein tyrosine phosphatase involved in immune response		Eric Fauman's Twitter list based on biological plausability	ENSG00000134242	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	1	114377568	1	113834946		EFO_0000685	rheumatoid arthritis	rheumatoid arthritis
European=80003		GCST007638	13.096910013008056	GCST007638	30837465		expert curated	High	Eric Fauman	PHDGH encodes an enzyme involved in de novo serine biosynthesis		Eric Fauman's Twitter list based on biological plausability	ENSG00000092621	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	1	120254506	1	119711883		EFO_0009767	metabolite: glycine	glycine measurement
European=344728			307.6526555685888	NEALE2_30260_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	SPTA1 encodes spectrin, a cytoskeleton protein that helps define the cell shape		Eric Fauman's Twitter list based on biological plausability	ENSG00000163554	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	G	1	158596438	1	158626648			reticulocyte volume	
European=204402		GCST007614	522.3979400086721	GCST007614	30388399		expert curated	High	Eric Fauman	gene for the measured protein		Eric Fauman's Twitter list based on biological plausability	ENSG00000132693	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	1	159678816	1	159709026		EFO_0004458	CRP levels	C-reactive protein measurement
European=360527			182.1308557348547	NEALE2_6152_5		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	Factor V Leiden mutation		Eric Fauman's Twitter list based on biological plausability	ENSG00000198734	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	1	169519049	1	169549811		EFO_0003907	Blood clot in the leg, DVT	deep vein thrombosis
European=393873		GCST007091	9.221848749616356	GCST007091	30664745		expert curated	High	Eric Fauman	collagen galactosyltransferase		Eric Fauman's Twitter list based on biological plausability	ENSG00000198756	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	1	183906245	1	183937111		EFO_1000786	arthrosis of hip	osteoarthritis, hip
European=91787			8.362829604311715	NEALE2_22504		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	MUC5AC encodes one of the principal mucins in lung.  This is the protein portion of mucus.		Eric Fauman's Twitter list based on biological plausability	ENSG00000215182	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	11	1113133	11	1119225		EFO_0009824	bring up phlegm/sputum/mucus on most days	bringing up phlegm, sputum or mucus on most days, self-reported
European=360527			19.56919957537582	NEALE2_6152_5		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	encodes thrombin, the final step in the clotting cascade, converting fibrinogen to fibrin		Eric Fauman's Twitter list based on biological plausability	ENSG00000180210	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	11	46761055	11	46739505		EFO_0003907	Blood clot in the leg, DVT	deep vein thrombosis
European=361141			7.81005233185522	NEALE2_20002_1331		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	TCN1 encodes an intrinsic factor which transports vitamin B12		Eric Fauman's Twitter list based on biological plausability	ENSG00000134827	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	C	11	59623378	11	59855905		EFO_0005576	pernicious anemia	pernicious anemia
European=346527			7.720768937672716	NEALE2_2000		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	GRM5 encodes a glutamate metabotropic receptor		Eric Fauman's Twitter list based on biological plausability	ENSG00000168959	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	11	88732956	11	88999788		EFO_0009589	worry too long	worry measurement
European=356530			307.6526555685888	NEALE2_1717		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	pigmentation gene		Eric Fauman's Twitter list based on biological plausability	ENSG00000077498	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	11	89017961	11	89284793		EFO_0003784	malignant neoplasms of skin	skin pigmentation
European=356530			307.6526555685888	NEALE2_1717		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	enzyme in melanin synthesis pathway		Eric Fauman's Twitter list based on biological plausability	ENSG00000077498	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	11	89017961	11	89284793		EFO_0003784	skin color	skin pigmentation
European=401024	10.1038/s41588-018-0184-y		15.23807216157947	SAIGE_361			expert curated	High	Eric Fauman	AT3 is an atypical cadherin in brain, important for neurite outgrowth and establishment of polarity in the retina.		Eric Fauman's Twitter list based on biological plausability	ENSG00000165323	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	11	92607866	11	92874700		EFO_0005773	retinal detachment	retinal detachment
European=105318		GCST006803	11.698970004336019	GCST006803	29483656		expert curated	High	Eric Fauman	DRD2 encodes a dopamine receptor which is the site of action for many antipsychotics		Eric Fauman's Twitter list based on biological plausability	ENSG00000149295	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	11	113392994	11	113522272		EFO_0000692	schizophrenia	schizophrenia
European=393873		GCST007091	24.0	GCST007091	30664745		expert curated	High	Eric Fauman	hormone regulating bone development		Eric Fauman's Twitter list based on biological plausability	ENSG00000087494	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	G	12	28014970	12	27862037		EFO_1000786	arthrosis of hip	osteoarthritis, hip
European=407648	10.1038/s41588-018-0184-y		7.954677021213342	SAIGE_594			expert curated	High	Eric Fauman	TNFS11 may influence circulating calcium levels via bone resorption		Eric Fauman's Twitter list based on biological plausability	ENSG00000120659	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	A	13	42701739	13	42127603		EFO_1000839	urolithiasis	bladder calculus
European=329134			12.835647144215564	NEALE2_1319		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	OR10G3 probably encodes an olfactory receptor.  Could it relate to enjoyment from smelling and eating fruit?		Eric Fauman's Twitter list based on biological plausability	ENSG00000169208	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	14	22038125	14	21569994		EFO_0008111	dried fruit intake	diet measurement
European=205327		GCST007020	13.397940008672037	GCST007020	30573740		expert curated	High	Eric Fauman	GSC, Goosecoid Homeobox, an important regulator of pattern formation and Wnt signaling		Eric Fauman's Twitter list based on biological plausability	ENSG00000133937	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	14	95237215	14	94770878		EFO_0007825	male balding pattern	balding measurement
European=408823	10.1038/s41588-018-0184-y		9.1331221856625	SAIGE_172			expert curated	High	Eric Fauman	pigmentation gene		Eric Fauman's Twitter list based on biological plausability	ENSG00000104044	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	15	28230247	15	27985101		EFO_0009259	malignant neoplasms of skin	skin carcinoma
European=356530			314.5809997598978	NEALE2_1717		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	tyrosine transporter		Eric Fauman's Twitter list based on biological plausability	ENSG00000104044	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	15	28534777	15	28289631		EFO_0003784	skin color	skin pigmentation
European=392109	10.1038/s41588-018-0184-y		16.609064892896622	SAIGE_241_2			expert curated	High	Eric Fauman	growth factor involved in thyroid gland development and thyroid hormone production		Eric Fauman's Twitter list based on biological plausability	ENSG00000140285	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	15	49706417	15	49414220		MONDO_0000334	non-toxic goitre	multinodular goiter
European=406659	10.1038/s41588-018-0184-y		9.385102783966865	SAIGE_351			expert curated	High	Eric Fauman	SMAD6 encodes a transcription factor important for cartilage and bone development		Eric Fauman's Twitter list based on biological plausability	ENSG00000137834	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	15	67034812	15	66742474		EFO_0009387	nerve, nerve root and plexus disorders	peripheral nervous system disease
European=334659			115.46487811249987	NEALE2_1498		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	caffeine metabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000140465	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	15	75027880	15	74735539		EFO_0004330	coffee intake	coffee consumption
European=334659			115.46487811249987	NEALE2_1498		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	caffeine metabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000140465	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	15	75027880	15	74735539		EFO_0004330	coffee intake	coffee consumption
European=334659			115.46487811249987	NEALE2_1498		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	caffeine metabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000140505	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	15	75027880	15	74735539		EFO_0004330	coffee intake	coffee consumption
European=406659	10.1038/s41588-018-0184-y		7.510041520575165	SAIGE_351			expert curated	High	Eric Fauman	ADAMTS17 encodes a extracellular matrix metaloprotease.  By analogy with ADAMTS10, ADAMTS17 may also play a role in the maturation of microfibril arrays which may contribute to structures in the carpal tunnel of the wrist driving risk of carpal tunnel syndrome, the most common plexus disorder		Eric Fauman's Twitter list based on biological plausability	ENSG00000140470	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	15	100692953	15	100152748		EFO_0009387	Nerve, nerve root and plexus disorders	peripheral nervous system disease
European=191843		GCST003997	62.69897000433602	GCST003997	27182965		expert curated	High	Eric Fauman	RBFOX1 encodes a transcription factor involved in eye development		Eric Fauman's Twitter list based on biological plausability	ENSG00000078328	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	T	16	7459347	16	7409346		HP_0000545	6 mm strong meridian angle	Myopia
European=404196	10.1038/s41588-018-0184-y		18.7594507517174	SAIGE_594_1			expert curated	High	Eric Fauman	uromodulin is a highly expressed kidney specific protein.		Eric Fauman's Twitter list based on biological plausability	ENSG00000169344	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	16	20366507	16	20355185		EFO_0004253	calculus of kidney and ureter	nephrolithiasis
European=80003		GCST007638	41.0	GCST007638	30837465		expert curated	High	Eric Fauman	GCSH encodes a component of the glycine cleavage system		Eric Fauman's Twitter list based on biological plausability	ENSG00000140905	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	16	81110903	16	81077298		EFO_0009767	metabolite: glycine	glycine measurement
European=350471			36.053639123304855	NEALE2_30090_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	"In addition to GATA1 and GATA2, there are hits for the so-called ""Friends of GATA"" or FOG.  These are additional TFs that heterodimerize with GATA1 and GATA2 encoded by ZFPM2 and ZFPM1"		Eric Fauman's Twitter list based on biological plausability	ENSG00000179588	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	16	88559699	16	88493291		EFO_0007985	platelet crit	plateletcrit
European=299651		GCST006986	307.69897000433605	GCST006986	30531825		expert curated	High	Eric Fauman	melanin production switch		Eric Fauman's Twitter list based on biological plausability	ENSG00000258839	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	C	16	89985918	16	89919510		EFO_0003924	red hair	hair color
European=353697			307.6526555685888	NEALE2_1727		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	melanin production switch		Eric Fauman's Twitter list based on biological plausability	ENSG00000258839	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	G	16	89986546	16	89920138			Skin changes due to chronic exposure to nonionizing radiation	
European=353697			307.6526555685888	NEALE2_1727		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	melanin production switch		Eric Fauman's Twitter list based on biological plausability	ENSG00000258839	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	G	16	89986546	16	89920138			skin color	
European=350471			52.04034387198277	NEALE2_30090_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	PAF is a lipid signaling molecule mediating platelet aggregation. PAF-AH deactivates PAF. PAFAH1B1 encodes the regulatory subunit of PAF-AH		Eric Fauman's Twitter list based on biological plausability	ENSG00000007168	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	17	1958536	17	2055242		EFO_0007985	platelet crit	plateletcrit
European=408823	10.1038/s41588-018-0184-y		21.008330992620053	SAIGE_172			expert curated	High	Eric Fauman	tumor suppressor		Eric Fauman's Twitter list based on biological plausability	ENSG00000141510	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	T	17	7571752	17	7668434		EFO_0009259	malignant neoplasms of skin	skin carcinoma
European=426795		GCST006980	40.30102999566398	GCST006980	30598549		expert curated	High	Eric Fauman	negative regulator of bone growth via wnt signaling pathway		Eric Fauman's Twitter list based on biological plausability	ENSG00000167941	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	G	17	41798855	17	43721487		EFO_0003931	wrist fracture	bone fracture
European=446000		GCST007066	94.0	GCST007066	30595370		expert curated	High	Eric Fauman	transcription factor involved in limb development		Eric Fauman's Twitter list based on biological plausability	ENSG00000121075	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	17	59023998	17	60946637		EFO_0009270	arthrosis of hip	heel bone mineral density
European=446000		GCST007066	150.0	GCST007066	30595370		expert curated	High	Eric Fauman	regulator of bone structure and function		Eric Fauman's Twitter list based on biological plausability	ENSG00000177150	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	18	13719510	18	13719511		EFO_0009270	wrist fracture	heel bone mineral density
European=354736			81.07626495694595	NEALE2_23120_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	MC4R is a well-known BMI gene.  It influences feeding behavior.		Eric Fauman's Twitter list based on biological plausability	ENSG00000166603	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	GTCT	18	57850927	18	60183694		EFO_0004995	arm fat mass (right)	lean body mass
European=394929		GCST006433	29.096910013008056	GCST006433	30048462		expert curated	High	Eric Fauman	TNFRSF11A encodes RANK, a key receptor regulating bone growth		Eric Fauman's Twitter list based on biological plausability	ENSG00000141655	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	A	18	60054857	18	62387624		EFO_0009270	treatment with alendronate	heel bone mineral density
European=406659	10.1038/s41588-018-0184-y		10.721246399047171	SAIGE_351			expert curated	High	Eric Fauman	ADAMTS10 encodes a extracellular matrix metaloprotease which plays a role in the maturation of microfibril arrays which may contribute to structures in the carpal tunnel of the wrist driving risk of carpal tunnel syndrome, the most common plexus disorder		Eric Fauman's Twitter list based on biological plausability	ENSG00000142303	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	19	8670147	19	8605262		EFO_0009387	Nerve, nerve root and plexus disorders	peripheral nervous system disease
European=215551|African American or Afro-Caribbean=57332|Hispanic or Latin American=24743		GCST006612	300.0	GCST006612	30275531		expert curated	High	Eric Fauman	LDLR is involved in lipoprotein regulation		Eric Fauman's Twitter list based on biological plausability	ENSG00000130164	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	C	19	11187324	19	11076648		EFO_0004611	treatment: statin use	low density lipoprotein cholesterol measurement
European=360291			11.684659523372712	NEALE2_1428_3		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	APOE drives LDL-cholesterol levels, perhaps leading to a dietary choice to switch from butter to margarine		Eric Fauman's Twitter list based on biological plausability	ENSG00000130203	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	19	45411941	19	44908684		EFO_0008111	margarine intake	diet measurement
European=361141			78.44592291862462	NEALE2_20003_1140861958		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	APOE involved in lipoprotein regulation		Eric Fauman's Twitter list based on biological plausability	ENSG00000130203	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	G	19	45413233	19	44909976		CHEBI_9150	treatment: statin use	simvastatin
European=91787			9.45496765241607	NEALE2_22504		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	FUT2 encodes a fucosyltransferase, responsible for the glycosylation portion of mucus		Eric Fauman's Twitter list based on biological plausability	ENSG00000176920	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	19	49206417	19	48703160		EFO_0009824	bring up phlegm/sputum/mucus on most days	bringing up phlegm, sputum or mucus on most days, self-reported
European=350061			20.08594099932527	NEALE2_30530_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	FGF21 encodes a growth factor that acts on the brain to increase reward associated with eating sugar		Eric Fauman's Twitter list based on biological plausability	ENSG00000105550	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	19	49259529	19	48756272		HP_0012603	sodium in urine	Abnormal urine sodium concentration
European=360468			14.522878745280337	NEALE2_1349		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	FGF21 encodes a growth factor that acts on the brain to increase reward associated with eating sugar		Eric Fauman's Twitter list based on biological plausability	ENSG00000105550	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	19	49259529	19	48756272		EFO_0008111	processed meat intake	diet measurement
European=406659	10.1038/s41588-018-0184-y		7.886056647693163	SAIGE_351			expert curated	High	Eric Fauman	EFEMP1 encodes fibulin-3, an extracellular matrix protein with a role in elastic fiber production which could directly contribute to the properties of the carpal ligament or other structures in the carpal tunnel		Eric Fauman's Twitter list based on biological plausability	ENSG00000115380	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	C	2	56009382	2	55782247		EFO_0009387	Nerve, nerve root and plexus disorders	peripheral nervous system disease
European=360806			9.227682694932648	NEALE2_1418_6		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	LCT encodes lactase, necessary for break down of lactose		Eric Fauman's Twitter list based on biological plausability	ENSG00000115850	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	2	136707982	2	135950412		EFO_0008111	milk intake	diet measurement
European=80003		GCST007638	1631.5228787452804	GCST007638	30837465		expert curated	High	Eric Fauman	CPS1 encodes an enzyme acting on the breakdown products of glycine catabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000021826	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	2	211543055	2	210678331		EFO_0009767	metabolite: glycine	glycine measurement
East Asian=110207		GCST005980	1254.5228787452804	GCST005980	29403010		expert curated	High	Eric Fauman	the UGT1A1 encodes an enzyme which has UDP-glucuronosyltransferase activity against bilirubin		Eric Fauman's Twitter list based on biological plausability	ENSG00000241635	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	G	2	234671462	2	233762816		EFO_0004570	total bilirubin	bilirubin measurement
European=354798			10.226191621507935	NEALE2_23114_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	bone morphogenic protein, growth factor influencing bone growth		Eric Fauman's Twitter list based on biological plausability	ENSG00000125845	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	20	6709838	20	6729191		EFO_0004995	leg predicted mass (right)	lean body mass
European=392109	10.1038/s41588-018-0184-y		10.661543506395395	SAIGE_241_2			expert curated	High	Eric Fauman	transcription factor important for thyroid endoderm development		Eric Fauman's Twitter list based on biological plausability	ENSG00000125798	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	20	22625447	20	22644809		MONDO_0000334	non-toxic goitre	multinodular goiter
European=121296		GCST005897	315.0	GCST005897	29739929		expert curated	High	Eric Fauman	MC1R antagonist		Eric Fauman's Twitter list based on biological plausability	ENSG00000101440	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	20	32665748	20	34077942		EFO_0004279	Skin changes due to chronic exposure to nonionizing radiation	suntan
European=121296		GCST005897	315.0	GCST005897	29739929		expert curated	High	Eric Fauman	MC1R antagonist		Eric Fauman's Twitter list based on biological plausability	ENSG00000101440	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	20	32665748	20	34077942		EFO_0004279	skin color	suntan
European=360527			9.184008739942152	NEALE2_6152_5		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	protein C receptor, involved in clotting response		Eric Fauman's Twitter list based on biological plausability	ENSG00000101000	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	GAA	20	33724557	20	35136754		EFO_0003907	Blood clot in the leg, DVT	deep vein thrombosis
European=354798			111.76709786992673	NEALE2_23114_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	GDF5 encodes a growth factor involved in limb and joint development		Eric Fauman's Twitter list based on biological plausability	ENSG00000125965	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	20	34025756	20	35437976		EFO_0004995	leg predicted mass (right)	lean body mass
European=350471			153.24222071603972	NEALE2_30090_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	TUBB1 which contributes to the structure of the microtubules which are important for forming platelets from the megakaryocytes. Rare TUBB1 mutations cause congenital macrothrombocytopenia		Eric Fauman's Twitter list based on biological plausability	ENSG00000101162	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	G	20	57597971	20	59022916		EFO_0007985	platelet crit	plateletcrit
European=350471			22.632124355053705	NEALE2_30090_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	One nifty analysis in Enrichr is finding upstream transcription factors that are enriched for the implicated genes. The top 3 TFs are GATA1 (upstream of 75 GWAS genes), GATA2 (67 genes) and RUNX1 (91 genes). *All 3 of these TFs are themselves GWAS hits!*https://		Eric Fauman's Twitter list based on biological plausability	ENSG00000159216	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	G	21	36393747	21	35021450		EFO_0007985	platelet crit	plateletcrit
European=404196	10.1038/s41588-018-0184-y		12.095825631715837	SAIGE_594_1			expert curated	High	Eric Fauman	a kidney-specific protein inivolved in calcium reabsorption		Eric Fauman's Twitter list based on biological plausability	ENSG00000159261	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	21	37818871	21	36446573		EFO_0004253	calculus of kidney and ureter	nephrolithiasis
European=7824		GCST002443	177.30102999566398	GCST002443_58	24816252		expert curated	High	Eric Fauman	metabolite is a product of the encoded enzyme		Eric Fauman's Twitter list based on biological plausability	ENSG00000093010	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	22	19951271	22	19963748		EFO_0005664	metabolite: methylascorbic acid	blood metabolite measurement
European=334659			10.55425572432335	NEALE2_1498		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	response to caffeine		Eric Fauman's Twitter list based on biological plausability	ENSG00000128271	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	A	22	24771955	22	24375987		EFO_0004330	coffee intake	coffee consumption
European=402950	10.1038/s41588-018-0184-y		23.554395796726403	SAIGE_571			expert curated	High	Eric Fauman	PNPLA3 encodes a triacylglycerol lipase with high expression in the liver		Eric Fauman's Twitter list based on biological plausability	ENSG00000100344	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	22	44324730	22	43928850		EFO_0001421|EFO_0001422	disease of liver	liver disease
European=7824		GCST002443	17.154901959985743	GCST002443_44	24816252		expert curated	High	Eric Fauman	ARSA encodes the enzyme arylsulfatase A		Eric Fauman's Twitter list based on biological plausability	ENSG00000100299	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	22	51063477	22	50625049		EFO_0005664	metabolite: O-sulfo-tyrosine	blood metabolite measurement
European=80003		GCST007638	30.0	GCST007638	30837465		expert curated	High	Eric Fauman	ALDH1L1 encodes an enzyme involved in the folate cycle		Eric Fauman's Twitter list based on biological plausability	ENSG00000144908	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	3	125910381	3	126191538		EFO_0009767	metabolite: glycine	glycine measurement
European=350471			10.522430206021097	NEALE2_30090_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	One nifty analysis in Enrichr is finding upstream transcription factors that are enriched for the implicated genes. The top 3 TFs are GATA1 (upstream of 75 GWAS genes), GATA2 (67 genes) and RUNX1 (91 genes). *All 3 of these TFs are themselves GWAS hits!*https://		Eric Fauman's Twitter list based on biological plausability	ENSG00000179348	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	3	128201889	3	128483046		EFO_0007985	platelet crit	plateletcrit
European=350471			139.91119437332395	NEALE2_30090_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	THPO encodes thrombopoietin, a growth factor driving platelet production		Eric Fauman's Twitter list based on biological plausability	ENSG00000090534	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	3	184090242	3	184372454		EFO_0007985	platelet crit	plateletcrit
European=79366		GCST005367	307.6526555685888	GCST005367	29343764		expert curated	High	Eric Fauman	GC encodes the vitamin D binding protein		Eric Fauman's Twitter list based on biological plausability	ENSG00000145321	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	G	4	72614267	4	71748550		EFO_0004631	metabolite: vitamin D	vitamin D measurement
European=941280		GCST007461	307.69897000433605	GCST007461	30643251		expert curated	High	Eric Fauman	alcohol metabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000196616	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	4	100239319	4	99318162		EFO_0007878	average weekly red wine intake	alcohol consumption measurement
European=941280		GCST007461	307.69897000433605	GCST007461	30643251		expert curated	High	Eric Fauman	encodes alcohol dehydrogenase, regulating clearance rate for alcohol		Eric Fauman's Twitter list based on biological plausability	ENSG00000196616	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	4	100239319	4	99318162		EFO_0007878	alcohol consumption	alcohol consumption measurement
European=360527			23.63941415920316	NEALE2_6152_5		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	Factor XI, a protease in the clotting cascade		Eric Fauman's Twitter list based on biological plausability	ENSG00000088926	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	T	4	187188094	4	186266940		EFO_0003907	Blood clot in the leg, DVT	deep vein thrombosis
European=356530			307.6526555685888	NEALE2_1717		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	melanocyte-specific transporter		Eric Fauman's Twitter list based on biological plausability	ENSG00000164175	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	C	5	33951693	5	33951588		EFO_0003784	skin color	skin pigmentation
European=215551|African American or Afro-Caribbean=57332|Hispanic or Latin American=24743		GCST006614	93.15490195998575	GCST006614	30275531		expert curated	High	Eric Fauman	HMGCR encodes an enzyme in the cholesterol biosynthetic pathway		Eric Fauman's Twitter list based on biological plausability	ENSG00000113161	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	5	74656539	5	75360714		EFO_0004574	treatment: statin use	total cholesterol measurement
Other=1097|NR=150064		GCST003048	9.0	GCST003048	26198764		expert curated	High	Eric Fauman	Glutamate receptor involved in synaptic transmissions		Eric Fauman's Twitter list based on biological plausability	ENSG00000155511	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	5	152608619	5	153229059		EFO_0000692	schizophrenia	schizophrenia
European=205327		GCST007020	266.39794000867204	GCST007020	30573740		expert curated	High	Eric Fauman	EBF1 contributes to hair growth through regulation of adipocyte maturation in the skin		Eric Fauman's Twitter list based on biological plausability	ENSG00000164330	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	5	158343969	5	158916961		EFO_0007825	hair.balding pattern 4	balding measurement
European=6880		GCST003270	24.0	GCST003270	26626624		expert curated	High	Eric Fauman	cytokine involved in immune response		Eric Fauman's Twitter list based on biological plausability	ENSG00000113302	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	5	158764478	5	159337470		EFO_0003778	psoriatic arthropathy	psoriatic arthritis
European=404196	10.1038/s41588-018-0184-y		12.014124642691606	SAIGE_594_1			expert curated	High	Eric Fauman	a kidney specific sodium/phosphate transporter		Eric Fauman's Twitter list based on biological plausability	ENSG00000131183	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	5	176799992	5	177372991		EFO_0004253	calculus of kidney and ureter	nephrolithiasis
European=121296		GCST005897	581.0	GCST005897	29739929		expert curated	High	Eric Fauman	IRF4 encodes a transcription factor involved in skin pigmentation		Eric Fauman's Twitter list based on biological plausability	ENSG00000137265	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	6	396321	6	396321		EFO_0004279	melanocytic naevi	suntan
European=354798			24.351119148082883	NEALE2_23114_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	bone morphogenic protein, growth factor influencing bone growth		Eric Fauman's Twitter list based on biological plausability	ENSG00000153162	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	6	7706004	6	7705771		EFO_0004995	leg predicted mass (right)	lean body mass
European=23986		GCST002679	96.52287874528034	GCST002679	25352340		expert curated	High	Eric Fauman	HFE encodes the hemochromatosis		Eric Fauman's Twitter list based on biological plausability	ENSG00000010704	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	6	26093141	6	26092913		EFO_0004461|EFO_0006332	hemochromatosis	iron biomarker measurement
European=393873		GCST007091	8.522878745280337	GCST007091	30664745		expert curated	High	Eric Fauman	bone morphogenic protein, involved in ossification		Eric Fauman's Twitter list based on biological plausability	ENSG00000112175	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	6	55636940	6	55772142		EFO_1000786	arthrosis of hip	osteoarthritis, hip
European=287323		GCST004346	41.69897000433602	GCST004346	28537254		expert curated	High	Eric Fauman	receptor involved in immune response		Eric Fauman's Twitter list based on biological plausability	ENSG00000056972	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	G	6	111929862	6	111608659		EFO_0000676	psoriatic arthropathy	psoriasis
European=426795		GCST006980	64.04575749056067	GCST006980	30598549		expert curated	High	Eric Fauman	activator of wnt signaling pathway, regulator of angiogenesis		Eric Fauman's Twitter list based on biological plausability	ENSG00000146374	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	A	6	127468274	6	127147129		EFO_0003931	wrist fracture	bone fracture
European=334659			94.49028415733696	NEALE2_1498		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	regulation of caffeine metabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000106546	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	7	17284577	7	17244953		EFO_0004330	coffee intake	coffee consumption
European=334659			94.49028415733696	NEALE2_1498		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	regulation of caffeine metabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000106546	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	7	17284577	7	17244953		EFO_0004330	coffee intake	coffee consumption
European=440328|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20687|Asian unspecified=555|Hispanic or Latin American=1247		GCST005843	13.045757490560675	GCST005843	29531354		expert curated	High	Eric Fauman	TWIST1 is a transcription factor involved in cranial development and cerebral vein formation		Eric Fauman's Twitter list based on biological plausability	ENSG00000122691	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	7	19049388	7	19009765		HP_0002140	stroke	Ischemic stroke
European=80003		GCST007638	33.15490195998574	GCST007638	30837465		expert curated	High	Eric Fauman	PSPH encodes an enzyme involved in de novo serine biosynthesis		Eric Fauman's Twitter list based on biological plausability	ENSG00000146733	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	C	T	7	56079094	7	56011401		EFO_0009767	metabolite: glycine	glycine measurement
European=346635			9.289347081400459	NEALE2_2247_1		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	SLC26A5 encodes prestin, a critical outer hair cell membrane protein essential for mechanical signal transduction		Eric Fauman's Twitter list based on biological plausability	ENSG00000170615	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	7	103061825	7	103421378		EFO_0004238	hearing loss	hearing loss
European=394929		GCST006433	1699.1549019599856	GCST006433	30048462		expert curated	High	Eric Fauman	WNT16 encodes a signaling protein involved in regulation of bone growth		Eric Fauman's Twitter list based on biological plausability	ENSG00000002745	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	7	120962164	7	121322110		EFO_0009270	wrist fracture	heel bone mineral density
European=394929		GCST006433	1699.1549019599856	GCST006433	30048462		expert curated	High	Eric Fauman	WNT16 encodes a signaling protein involved in regulation of bone growth		Eric Fauman's Twitter list based on biological plausability	ENSG00000002745	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	7	120962164	7	121322110		EFO_0009270	heel bone mineral density	heel bone mineral density
European=394929		GCST006433	1699.1549019599856	GCST006433	30048462		expert curated	High	Eric Fauman	WNT16 encodes a signaling protein involved in regulation of bone growth		Eric Fauman's Twitter list based on biological plausability	ENSG00000002745	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	7	120962164	7	121322110		EFO_0009270	Fracture of ankle	heel bone mineral density
European=367725		GCST006946	9.698970004336019	GCST006946	29500382		expert curated	High	Eric Fauman	GRM8 encodes a glutamate metabotropic receptor		Eric Fauman's Twitter list based on biological plausability	ENSG00000179603	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	A	7	126378842	7	126738788		EFO_0009589	worry too long	worry measurement
European=257773			15.933081750658816	NEALE2_1568		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	receptor for bitter taste		Eric Fauman's Twitter list based on biological plausability	ENSG00000257138	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	C	7	141673345	7	141973545		EFO_0007878	average weekly red wine intake	alcohol consumption measurement
European=348284			43.29265980539296	NEALE2_1309		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	OR2A7 encodes an olfactory receptor that may respond to sweet smells		Eric Fauman's Twitter list based on biological plausability	ENSG00000243896	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	7	143723137	7	144026044		EFO_0008111	fresh fruit intake	diet measurement
European=350471			80.9294929792367	NEALE2_30090_raw		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	"In addition to GATA1 and GATA2, there are hits for the so-called ""Friends of GATA"" or FOG.  These are additional TFs that heterodimerize with GATA1 and GATA2 encoded by ZFPM2 and ZFPM1"		Eric Fauman's Twitter list based on biological plausability	ENSG00000169946	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	A	8	106581528	8	105569300		EFO_0007985	platelet crit	plateletcrit
European=80003		GCST007638	39.69897000433602	GCST007638	30837465		expert curated	High	Eric Fauman	GLDC encodes an enzyme involved glycine catabolism		Eric Fauman's Twitter list based on biological plausability	ENSG00000178445	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	9	6550024	9	6550024		EFO_0009767	metabolite: glycine	glycine measurement
European=356530			218.9201208247617	NEALE2_1717		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	BNC2 encodes a transcription factor involved in skin pigmentation		Eric Fauman's Twitter list based on biological plausability	ENSG00000173068	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	G	9	16885017	9	16885019		EFO_0003784	melanocytic naevi	skin pigmentation
NR=296525		GCST005194	222.0545314148682	GCST005194	29212778		expert curated	High	Eric Fauman	locus associated with increased risk of heart disease		Eric Fauman's Twitter list based on biological plausability	ENSG00000147889	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	9	22098574	9	22098575		EFO_0000378	treatment with nicorandil	coronary artery disease
NR=296525		GCST005194	222.0545314148682	GCST005194	29212778		expert curated	High	Eric Fauman	locus associated with increased risk of heart disease		Eric Fauman's Twitter list based on biological plausability	ENSG00000147883	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	9	22098574	9	22098575		EFO_0000378	treatment with nicorandil	coronary artery disease
European=392109	10.1038/s41588-018-0184-y		22.543633966870956	SAIGE_241_2			expert curated	High	Eric Fauman	transcription factor exclusively expressed in thyroid, involved in thyroid development		Eric Fauman's Twitter list based on biological plausability	ENSG00000178919	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	G	A	9	100538470	9	97776188		MONDO_0000334	non-toxic goitre	multinodular goiter
European=393873		GCST007091	11.522878745280337	GCST007091	30664745		expert curated	High	Eric Fauman	transcription factor involved in limb development		Eric Fauman's Twitter list based on biological plausability	ENSG00000136944	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	9	129386860	9	126624581		EFO_1000786	arthrosis of hip	osteoarthritis, hip
European=360527			68.43321497559869	NEALE2_6152_5		http://www.nealelab.is/uk-biobank	expert curated	High	Eric Fauman	blood type is a risk factor for blood clots		Eric Fauman's Twitter list based on biological plausability	ENSG00000175164	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	T	C	9	136143372	9	133267960		EFO_0003907	Blood clot in the leg, DVT	deep vein thrombosis
European=205327		GCST007020	282.52287874528037	GCST007020	30573740		expert curated	High	Eric Fauman	AR encodes the androgen receptor, important for regulation of hair follicles		Eric Fauman's Twitter list based on biological plausability	ENSG00000169083	High		2019-07-30	Ed Mountjoy	Eric Fauman Twitter	Eric Fauman	Fauman|Biological plausability	A	C	X	66670566	X	67450724		EFO_0007825	hair.balding pattern 4	balding measurement
